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Abstract
Chapter one is an introduction to aldol and Mannich reactions -  tools used to 
access natural products containing di-functional amino and hydroxy 
carbonyl motifs. A discussion of the recent catalytic and asymmetric 
developments of these reactions is included. In addition the concept of soft 
enolisation is addressed through examples in the literature. An outline of the 
project's goals is disclosed which includes the development of new catalytic 
asymmetric processes encompassing the in situ generation and trapping of 
chiral enolates through soft enolisation.
Chapter two describes the synthetic work carried out. The first part describes 
the development of a direct catalytic enantioselective synthesis of protected 
jS-hydroxy-a-amino acids. The second part describes the application of the 
developed asymmetric catalysis to natural product synthesis -  vancomycin's 
AA-6 amino acid. The third part describes the extension of the developed 
aldol reaction to an asymmetric Mannich variant which delivers protected 
a,jS-diamino acids as products. The fourth and final part describes a direct 
diastereoselective synthesis of protected n,jS-dihydroxy ketones employing 
similar conditions as developed in previous syntheses.
Chapter three provides detailed experimental procedures.
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The work in this thesis describes the development of a new 
methodology for the generation and trapping of chiral enolates via soft 
enolisation and their use in aldol type processes and Mannich reactions. A 
vast array of natural products include an a-amino or n-hydroxy carbonyl 
moiety in addition to either a /?-amino or /3-hydroxy substituent; functionality 
reached through either the aldol or Mannich reaction, which has been 
demonstrated herein for all such analogues. Recent examples of such natural 
products are illustrated below. In order to access such products synthetically, 
techniques that can effectively control the stereochemical outcome of the 
synthetic route are a necessity.
The background of the aldol reaction and issues of stereochemical 
outcome are briefly described, followed by an inclusion of the development 
of the Mukaiyama aldol reaction and selected others, which invoke high 
stereoselectivity. This leads to the further discovery and development of 
more versatile direct catalysts for the aldol reaction, mainly bimetallic 
species. The emergence of organocatalysis in the aldol reaction is 
highlighted. Current asymmetric Darzens reactions and asymmetric 
Mannich reactions are discussed briefly -  two topics of importance within 
the work described. Finally, the concept of soft enolisation is discussed 
within an introduction to the proposed work towards an asymmetric 
catalytic aldol and Mannich reaction. This section is not intended to be a 
comprehensive review of the aldol and Mannich reaction. Its purpose is to 




I 1 Analogous a,/?-(amino and hydroxy) carbonyl motifs
in natural products and designed molecules
I 1.1 The a-amino-/?-hydroxy carbonyl unit
The n-amino-jS-hydroxy carbonyl unit is ubiquitous in many naturally 
occurring molecules. Their biological activities are widespread and include 
antibiotic and antifungal functions,1 anti-inflammatory activity,2 and cellular 
transport functions.3 In addition designed molecules have also been 
implicated in functions such as hypotension.4 Aryl-substituted variants are 
an important sub-class; vancomycin 1 (Figure l),1 ristocetin A,1 and 
biphenomycin A 2 (Figure l)5 are cyclic peptides that display significant 
antibiotic activity. Vancomycin 1 is described in more detail in section (II 2). 
Ristocetin A is structurally related to vancomycin and exhibits similar 
antibiotic activity although its clinical use was discontinued owing to 
fatalities.6 Biphenomycin 2 is a simpler cyclic tripeptide isolated from the 
culture broths of Streptomyces filipinensis and S. griseoruuginosus.5 This 
compound exhibits potent activity against Gram-positive bacteria such as 
Streptococcus aureus and Enterococcus faecalis. The cyclomarins display 
significant anti-inflammatory properties.2 Cyclomarin A 3 is a novel cyclic 
peptide isolated from the marine bacterium Streptomyces sp., which contains 
four structurally very unusual amino acids (Figure 1). Exochelins are a class 
of a-amino-|3-hydroxy carbonyls that play a crucial role in cellular iron(III) 
transport of mycobacteria.3 Exochelin MN 4 (Figure 1) was isolated from 
culture broths of M. neoaureum and can transport iron into M. leprae cells 
which are causative of leprosy.7
2
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Figure 1. Examples of |3-hydroxy-a-amino acid natural products.
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I 1.2 The afi-diamino carbonyl template8
The nonproteinogenic n,jS-diamino acid motif, which holds valuable 
biological properties makes it an interesting target for the synthetic chemist. 
The a,/?-diamino carbonyl unit is abundant in nature and many examples 
show antibiotic activity.9 The bleomycins, isolated from Streptomyces 
verticillus are peptides containing a,/J-diamino acid residues which are 
clinical antitumor agents used for the treatment of Hodgkin's lymphoma.10 
Also isolated from the same cultures is the amino glycoside antibiotic 
capreomycin IA 5 (Figure 2) which is used to treat tuberculosis.11 An
3
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interesting example, discovered through routine screening focused on 
detecting active antitumor agents, and isolated from marine sponge 
Psammocinia sp. is cyclocinamide A 6 (Figure 2) which is an unusual 
halogenated hexapeptide containing both 5-bromoindole and 4-chloro-N- 
methylpyrrole fragments.12














Apart from naturally formed products the a,/J-diamino carbonyl 
template is found in synthetically produced therapeutic drugs such as the 2- 
carboxypiperazine containing drug indinavir 7 (Figure 2).13 This drug is an 
effective HIV protease inhibitor and one of the most important to date to 
treat the HIV virus.
a,p~Diamino carbonyl compounds in a protected form are useful 
precursors to a-amino-jS-lactam antibiotics. Examples are the 
carbacephalosporin antibiotics, and one which is currently on the market to 
treat paediatric ear infections is loracarbef 8 (Figure 3).14 A final example of a
4
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natural product in which a total synthesis utilises a protected a,/?-diamino 
carbonyl precursor is the antifungal cyclic peptide rhodopeptin B5 9 (Figure 
3).15
Figure 3. Natural products utilising a,/J-diamino carbonyl precursors.
O
il 9 H
I H H > - (C H 2)4NH2 
(H3C)HC(H2C)9"' ^
M e ^ M e  
9
Rhodopeptin B5Loracarbef
I 1.3 The a,/5-dihydroxy carbonyl unit
In addition to the a-amino-^-hydroxy carbonyl unit obtained by the 
aldol reaction, a-hydroxy substituted enolate components can provide access 
to a,jS-dihydroxy carbonyl units which are ubiquitous in natural products. A 
recent example has been reported by Boeckman, in the enantioselective total 
synthesis of bengamide B 10 (Figure 4).16 The natural product, isolated from 
an Australian halichondrid sponge, shows potential anti-proliferation 
activity and could be indicated as a therapeutic for drug resistant solid 
tumours. The side chain last connected to the caprolactam was obtained by 
two subsequent aldol reactions using n-etherate substituted enolates. 
Rubransarol A 11 (Figure 4), another example, is a precursor to the antibiotic 
rubradirin A which interferes with ribosomal functions related to enzymatic 
peptide chain initiation.17 Antitumor agent TMC-95A 12 (Figure 4), also a a- 
amino-jS-hydroxy carbonyl species related to biphenomycin (Section I 1.1), 
contains the a,/1-dihydroxy carbonyl moiety.18 A final example is potassium
5
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aeshynomate 13, which was identified as a leaf-opening substance in a 
nyctinastic plant, Aeshynomene indica L.19
NMe






















I 1.4 The /5-amino-a-hydroxy carbonyl template
The final member of the di-functional aldol products we will consider 
is the jS-amino-a-hydroxy carbonyl motif. An interesting example is the 
potent renin inhibitor used in antihypertension therapy, KRI1314 14 (Figure 
5), which is a tripeptide containing a cyclohexylnorstatine residue.20 Finally 
bestatine2115 (Figure 5) a potent aminopeptidase B inhibitor is included as a 
drug molecule example although there are many others in the literature such 




Figure 5. /3-amino-a-hydroxy carbonyls in designed therapeutics.
KRI 1314 Bestatine
These few examples (Section I I )  illustrate how the /?-(hydroxy or 
amino)-a-(hydroxy or amino) carbonyl motifs feature in numerous natural 
products and accordingly their synthesis has become important. The specific 
synthesis of vancomycin is explored later (Section II 2). The aldol and 
Mannich reactions are excellent methodologies for this purpose and gives 
direct access to these moieties. In the next section, the background of the 
aldol reaction will be briefly exposed.
I 2 The aldol reaction
I 2.1 Acid or base catalysis -  enol or enolate
The aldol reaction, in which an a-carbon of one aldehyde or ketone 
adds to a carbonyl carbon of another via an enolate or enol, is one of the most 
important organic reactions. This is because the carbon-carbon bond forming 
reaction can produce highly functionalised compounds with up to two new 
adjacent stereocentres simultaneously. The acid-catalysed reaction proceeds 
via an enol tautomer, which then reacts with an acid-activated electrophilic
7
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carbonyl (Scheme 1). The product obtained is an a-hydroxy aldehyde or 
ketone. The retro reaction is also feasible, regenerating starting materials. In 
addition, the product can undergo further reaction via dehydration, forming 
an a,f$-conjugated carbonyl which is irreversible.
Scheme 1. Acid catalysed aldol reaction and dehydration.
enol tautomer
The more common base-catalysed reaction proceeds via the formation 
of an enolate (Scheme 2). A base abstracts an a-proton from the carbonyl 
substrate and this activated nucleophile then adds to an electrophilic 
carbonyl to form the aldol adduct. As in the acid catalysed process, this 
reaction is reversible. Moreover, if a second a-deprotonation is possible, this 
may lead to elimination of water and the production of an enone or enal.
Scheme 2. Base catalysed aldol reaction.
enolate
However, the outcome of the reaction can easily be a mixture of 
different products and starting materials, especially if there is more than one 
a-proton involved. Not only can chemo- and regioselectivity become issues, 
in addition, depending on the R-groups involved, different diastereomers 
and enantiomers can be formed. Therefore, the controlled formation of one 
product over another has been a quest for many years.
8
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I 2.2 Stereochemical issues of the aldol reaction
To become synthetically useful, the stereochemistry of the products of 
the aldol reaction must be predictable. One of the first attempts to account 
for stereochemistry came from Zimmerman and Traxler in 1957.24 An 
observation was that the addition reaction of preformed magnesium dianion 
16 to benzaldehyde 17 was fltth-selective (Scheme 3). Consequently, it was 
proposed that the reaction proceeded via a cyclic chair-like 6-membered 
transition state, a so-called ' Zimmerman-Traxler' transition state, depicted 
below (Scheme 3). Zimmerman and Traxler suggested that both the oxygen 
of the aldehyde and one from the carboxylate, chelate to one of the two 
magnesium cations. In order to minimise steric congestion, the two phenyl- 
substituents occupy equatorial positions of the 6-membered cycle, and 
thereby preferentially form anti-18.













i l  JL anti-18





H O ^ Y " P h  24% 
Ph
Later in 1967, Dubois et al exposed kinetic and thermodynamic control 
in the aldol reaction.2526 Solvent and temperature effects on the equilibrium 
of the products syn-21 and anti-16 were studied (Scheme 4). Dubois et al 
observed that the (E)-enolate obtained from cyclopentanone 19 treated with 
KOH in MeOH, added to acetaldehyde 20 to afford preferentially syn-21 
under thermodynamic conditions (4 h at 5 °C). However, under kinetic
9
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conditions (15 s at -20 °C) the (E)-enolate afforded preferentially the opposite 
an fr’-diastereomer.
Scheme 4. Kinetic and thermodynamic control in the aldol reaction.
O
*Al
9 KOH ?K 20 N 9H 9 0H
+
19 (E)-e nolate anti- 21 syn-21
kinetic product thermodynamic 
product
In kinetically controlled aldol processes, the reaction usually proceeds 
via a Zimmerman-Traxler transition state, which is structured around a metal 
centre. The largest substituent of the electrophile adopts the equatorial 
position to minimise steric interactions.27 Consequently, an (E)-enolate would 
normally give access to an an h-diastereomer whereas a (Z)-enolate would 
give access to a syn-diastereomer (Scheme 5).
Scheme 5. Zimmerman-Traxler transition states of (£)- and (Z)- 
enolates and stereochemical outcome.
(Eye  nolate anti- diastereomer (Z)-e nolate syn- diastereomer
In 1980, Heathcock studied the diastereoselectivity of the aldol 
reaction.28 The survey correlated the ratio of syn- and anfz-diastereomers 
afforded from the reactions of preformed lithium enolates with 
benzaldehyde 17 to the ratio of the starting enolate (Table 1).
10
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The diastereomeric ratios were determined by trapping the enolate 
mixtures with TMSCI. Complete kinetic stereoselection was observed for 
bulky R substituents. Entries 1 and 2 showed a good correlation between the 
enolate geometry and the stereochemistry of the aldol product. The (Z)- 
enolate provided the syn-aldol product (Entry 1) while the (E)-enolate 
provided preferentially the anti-aldol product (Entry 2). However, for 
ketbnes or esters with smaller substituents, such as a methyl ester (Entry 3), 
the stereoselectivity either decreased or disappeared. Many examples of 
aldol reactions support the concept of chair-like transition states but in this 
case, some other less controlled pathway is taking place. It is evident that the 
presence of other coordinating sites or the nature of the Lewis acid involved 
can have a dramatic effect on the nature of the transition state; not only a 
different closed transition state perhaps even an open one. One fact is certain, 
the geometry of the enolate whether (E) or (Z) has a considerable effect on 
the selectivity of the reaction and its formation must be controlled as much as 
possible. Small R substituents generally form (E)-enolates whereas increasing 
the substituent's size increases the amount of (Z)-enolate. However, a bulky 
base for example affords predominantly the (E)-enolate. To shortcut the
11
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problem of enolate stereochemistry, Mukaiyama ingenuously reported the 
use of silyl enol ethers as latent enolates. The fixed stereochemistry involved 
provides useful results and is described below.
I 2.3 The achiral Mukaiyama aldol reaction
In 1974, Teruaki Mukaiyama reported the nucleophilic addition of 
latent enolates such as enol silanes to aldehydes or ketones activated by a 
Lewis acid. This was a milestone in the development of the aldol reaction.29 It 
was discovered that titanium tetrachloride promoted the reaction of silyl 
enol ether 22 with benzaldehyde 17, to yield under kinetic control, the aldol 
adduct, /J-hydroxyketone 23 (92%) after subsequent hydrolysis. A reasonable 
degree of diastereoselectivity was achieved (symanti = 25:75) (Scheme 6).
Scheme 6. Mukaiyama aldol reaction.
The lewis acid, TiCk was found to be optimal and in addition, good 
yields of up to 80% were attained when only 13 mol% of TiCk was employed. 
This reaction was examined with other aldehydes, such as alkyl aldehydes 
but higher temperatures were necessary to achieve reaction and 








I 3 Stoichiometric chiral component asymmetric aldol 
reactions
I 3.1 The use of boron enolates
In 1981, the groups of Masamune30 and Evans31 concurrently reported 
extremely stereoselective asymmetric aldol reactions utilising chiral boron 
enolates. Masamune employed chiral n-silyloxyketones such as 24 and bulky 
boron Lewis acids to give syn-aldols exclusively in the reactions of achiral 
aldehydes, for example 26 (Scheme 7). This indicated the complete formation 
of the (Z)-boron enolate 25.
Scheme 7. Masamune's chiral boron enolate.
In the transition state proposed for the reaction the substituents 
attached to the chiral centre of the enolate are oriented such that steric 
congestion is minimised. Therefore, the chirality dictates the approach of the 
enolate with respect to the aldehyde, which is translated into the absolute 













Evans utilised chiral 2-oxazolidinones as in 28 as recyclable chiral 
auxiliaries for carboxylic acids in aldol reactions via boron enolates, which 
were again syn-selective (Scheme 8).31 The employment of di-n-butylboryl 
triflate gave the (Z)-enolate with a diastereomeric ratio Z:E > 100:1. The syn- 
selection observed was as high as 500:1 depending on the aldehyde. The 
chiral auxiliary attached aldols, when transformed to their corresponding 
methyl esters gave optical purities > 99% in all cases. The chiral auxiliaries 
can easily be prepared from optically active amino alcohols and have been 
widely used in organic synthesis.
Scheme 8. Evans's chiral oxazolidinone boron enolate.
I 3.2 Chiral diamines in the aldol reaction
Mukaiyama made a further advancement with the asymmetric aldol 
reaction in 1982 through incorporation of a chiral ligand component.32 The 
group reported highly enantioselective reactions of achiral tin(II) enolates, 
formed from Sn(OTf)2, N-ethylpiperidine as a base, and a stoichiometric 
amount of the chiral diamine 32 acting as the ligand, which added to achiral 
aldehydes (Scheme 9). This was the first reported example where significant 
selectivity could be induced through the formation of a metal enolate, which 
was generated in situ from a ketone. For example phenyl ethyl ketone 31 
produced syn-33 in 80% ee.
1. /7-Bu2BOTf 
DIPEA 






Scheme 9. Asymmetric induction via stoichiometric chiral diamines.
1 . Sn(OTf)2
N-Et
O '— /  O OH
DCM'~7 8 °C syrr.anti = 6:1






I 3.3 Titanium(IV) versus tin(II) enolates
In 1990, the employment of titanium tetrachloride as used in the 
Mukaiyama aldol reaction described above was also utilised by Evans in 
aldol reactions with chiral oxazolidinones (Scheme 10).33 At the same time, 
Evans disclosed the same reaction could be carried out with tin(II) triflate, 
although a different stereochemical outcome was observed (Scheme 10).33 It 
was proposed that the all-syn adduct 35 derived from the Ti(IV) enolate 
consisted of a transition state whereby the acyl oxazolidinone 34 coordinated 
to the titanium centre. Conversely, in the Sn(II) case which afforded 36 such 
coordination did not occur and a non-chelation controlled reaction pathway 
followed dominated by the methyl bearing stereocentre.
15
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Scheme 10. Ti(IV) versus Sn(II) enolates; opposite syn-selectivity.
7 N Et
^ ^  Me 
Bn
ii) 17 (1.1 equiv.) 
-78 °C, 30 min 
-40 °C, 1 h
i) TiCI4 (1.1 equiv.) 
'Pr2EtN (1.1 equiv.) 
DCM, -10 °C, 1 h
i) Sn(OTf)2 (1.05 equiv.) 
TEA (1.05 equiv.) 
DCM, -20 °C, 1 h
r°  *
Bn N 0
^ ^  Me 
Bn _
ii) 17 (1.1 equiv.) 
-78 °C, 30 min
More recently, Crimmins further investigated Ti(IV) enolates, 
including the use of different chiral auxiliaries and (-)-sparteine 40 as a weak 
base.34 Depending on the auxiliary, N-acyl oxazolidinone 37, 
oxazolidinethione 38, or thiazolidinethione 39, either the 'Evans' or 'non- 
Evans' syn-adducts were produced (Scheme 11).
Scheme 11. Crimmin's asymmetric aldol addition.
Bn
’Evans’ syn
37: X = Y = O 
38: X = S, Y = O 








The fact that thiazolidinethiones produce non-Evans syn-aldols, can be 
attributed to a highly ordered chelated transition state. The thiocarbonyl of 
thiazolidinethiones is more nucleophilic than the oxazolidinone carbonyl or 
the oxazolidinethione carbonyl, thus has a higher affinity to chelate to the 
Ti(TV) centre.
I 4 Catalytic asymmetric aldol reactions35'36'37'38
I 4.1 The catalytic asymmetric Mukaiyama aldol reaction
A major problem encountered during the development of stereo- 
controlled versions of the Mukaiyama aldol reaction was that of release of 
TMSC1 as a by-product. TMSC1 is able to act as a stereorandom aldol 
catalyst.39 However, Mukaiyama, Kobayashi and co-workers developed a 
system for the reaction of silyl ketene acetals of thioesters with aldehydes.4041 
Excellent diastereo- and enantioselection was obtained using chiral diamines 
coordinated to Sn(II) triflate and tributyltin fluoride (Bu3SnF) . 42'43 In the 
absence of BusSnF products were obtained as racemates, which suggested 
that a stoichiometric amount of this additive was suppressing the competing 
trimethylsilyl triflate catalysed reaction.44 This reaction was developed into a 
catalytic variant with similar results (Scheme 12), although the aldehyde had 
to be added very slowly to the prepared catalyst system of Sn(OTf)2  and 
chiral diamine 43 in propionitrile. Aldol adduct 44 for example, was isolated 
in 81% yield and 92% ee.45
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Scheme 1 2 . Catalytic asymmetric Mukaiyama aldol reaction.





Y = 81% 
ee = 92%
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This process was applied to a range of aldehydes which gave good 
yields and enantioselection. The success was attributed to the coordination of 
the metal centre by the solvent, increasing the electron density around the tin 
alkoxide. The reactivity of this metal alkoxide towards silylation was 
therefore accelerated. The TMSOTf was trapped faster, regenerating the 
active catalyst, increasing turnover and hence the stereoselectivity of the 
reaction.
Carreira delivered a solution to stereorandom catalysis in the aldol 
reaction.46'4748 The design of the catalysis involved accelerating the silylation 
of the metal alkoxide species, thereby regenerating the active catalyst more 
rapidly. A mechanism of intramolecular shuttling of the trimethylsilyl 
moiety sufficed, which the Ti(IV)-Schiff base complex 45 provided (Scheme
13); the secondary ligand, 3,5-di-f-butylsalicyclic acid, acting as the silyl 
shuttle. The catalyst gave excellent yields for aliphatic and aromatic 
aldehydes reacting with silyl enol ethers or silyl dienolates. Reactions 
conducted-at -10 °C in diethyl ether with as little as 0.5 mol% of catalyst
I 4.2 Carreira's Ti(IV) catalyst
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afforded yields of up to 99% and high levels of asymmetric induction (8 8 - 
99% ee).
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I 4.3 Evans' Cu(II) and Sn(II) catalysts
Evans reported, in 1996 for Cu(II) and shortly after in 1997 for Sn(II), 
highly efficient enantioselective Mukaiyama aldol reactions with 
complementary syn- and anti-selection.49'50 One of the efficient copper 
catalysts employed consisted of a tridentate bis(oxazolinyl)pyridine (PyBOx) 
ligand chelated to copper(II) hexafluoroantimonate 49 (Scheme 14). Five 
mol% of the catalyst was sufficient for the addition of the silyl ketene acetal 
47 (1.2 equiv.) to benzyloxyacetaldehyde 48 (1 equiv.). The syn-aldol adduct 
50 was obtained in quantitative yield and 99% ee. The reaction was found to 
be general with respect to the silyl ketene acetal but the requirement for a 
chelating substituent on the aldehyde was critical to catalyst selectivity.
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Indeed, bulkier etheric aldehydes gave lower ee's and non-chelating 
aldehydes led to racemates. In addition, the use of n-substituted silyl ketene 
acetals afforded preferentially the syn-aldol, regardless of the geometry of the 
nucleophile (diastereoselectivities ranging from 95:5 to 97:3 with ee's > 95%). 
This was rationalised by the attack of the silyl ketene acetal via an open 
transition state on the si face of the chelated aldehyde minimising the 
number of repulsive gauche interactions.
Scheme 14. Complementary Cu(II)- and Sn(II)-catalysed 
enantioselective Mukaiyama aldol reactions.
OTMS
OBn
i) 49 (5 mol%) 
DCM, -78 °C
47 48
ii) 1 N HCI
(1 equiv.)
OH O
- Bn° v A A s * .
50
Y = 100%
2+ ee = 99%
2 SbF6-
OTMS
^"S'BU+ M e ^ Y ° Me 
Me O
i) 53 (10 mol%) 
DCM, -78 °C MeO
Me, <DH°







Y = 94% 
ee = 99% 
d.r = 99:1
The Sn(II) system offered a complementary extension to glyoxylate 
and pyruvate esters, both bi-coordinating electrophiles, delivering adducts
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with high an//-selectivity. The catalyst composed of a tridentate 
bis(oxazolinyl)pyridine (PyBOx) ligand chelated to tin(II) triflate 53 (Scheme
14) afforded adducts, for example 54 in up to 99% ee and a d.r. of 99:1 
(antiisyn).
I 4.4 Kobayashi's anti-selective Zr catalyst
Kobayashi recently reported a highly an t/-selective catalytic 
Mukaiyama aldol reaction promoted by a zirconium Lewis acid (Table 2) . 5152  
Initially, they developed an effective enantioselective catalytic system, 
furnishing aldol adducts in good yield and enantioselectivity. The catalyst 
was formed from zirconium tetra-ferf-butoxide (Zr(OBu)4), (R)-3,3'-diiodo- 
1,1 '-binaphthalene-2,2'-diol ((R)-3 ,3 '-l2BINOL) and a primary alcohol to act as 
a proton source to aid in the regeneration of the catalyst. In addition, it was 
later discovered that the addition of a small amount of water increased the 
activity of the catalyst and improved reproducibility. From NMR 
experiments, the assumption was made that the water was taking part in the 
formation of the complex 56, the active catalyst species (Table 2). With this 
catalyst, anh-diastereoselectivity was obtained, regardless of the geometry of 
the starting silyl ketene acetal (Entries 1 and 2, Table 2). Reactions of 
mixtures enriched in either the (E)- or (Z)-silyl ketene acetal 55 (1.2 equiv.) 
with benzaldehyde 17 (1 equiv.) furnished the aldol adduct 57. Yields 
achieved were greater than 63%. The diastereoselectivity attained was in the 
order of 8:92 in favour of the flnh’-diastereomer with ee's greater than 95%. 
The catalytic cycle was proposed to proceed via activation of the aldehyde by 
the Lewis acid 58 (Scheme 16). The an //-selectivity was postulated to be a 
result of steric repulsions between the n-alkyl substituent of the nucleophile
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and the Lewis acid in an open transition state (Scheme 15). After carbon- 
carbon bond formation, the ligand is then silylated. The primary alcohol 
traps the trimethyl silyl species, regenerating the active catalyst and 
furnishing the a-hydroxy carbonyl.








Zr(OfBu)4 (10 mol%) 
(R)-3,3'-l2BINOL (12 mol%) 
EtOH (80 mol%)
H20  (20 mol%)
PhMe, 0 °C, 18 h
O OH
EtS
Entry E:Z ratio Yield (%) Syn.anti ee  (%)
1 88:12 63 9:91 95
2 7:93 77 7:93 98
































I 4.5 Denmark's Lewis base approach
The group of Denmark have developed the use of chiral Lewis bases, 
which is a conceptually different latent enolate approach than the above­
described methodologies. Phosphoramides have been used to efficiently 
promote the reaction of trichlorosilyl enolates with aldehydes53 and more 
recently ketones by employment of bis-N-oxide catalysts (Scheme 17).54 
Replacement of chlorine by coordination of the catalyst's oxygen atoms to 
silicon appears to lead to a cationic silicon enolate intermediate species that 
subsequently binds to the electrophilic carbonyl to effect aldolisation.
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I 5 Direct metallic asymmetric catalysis36'37'38
I 5.1 Ito and Hayashi's Au(I) catalyst
All the reactions described so far entail chiral auxiliaries/substrates, 
preformed enolates, or stoichiometric chiral ligands. Ito and Hayashi 
reported an early example of a direct catalytic asymmetric aldol reaction in 
1986.55 Chiral ferrocenylphosphine(67)-gold(I) complexes were used to 
catalyse the reaction of an zsocyanoacetate, for example 60, with achiral 
aldehydes to produce optically active oxazoline-carboxylates 6 8  (Scheme 18). 
These products are useful synthetic intermediates to optically active fi- 
hydroxyamino acids. The high efficiency of the gold catalyst, which is 
employed at loadings as low as 1  mol%, has been attributed to a transition
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state that utilises the terminal amino group to deprotonate an n-proton of the 
zsocyanoacetate, coordinated to the gold, thus forming an ion pair. This 
interaction permits a favourable stereodefined arrangement of the enolate 
and aldehyde (Scheme 18).
Scheme 18. Gold-catalysed asymmetric aldol reaction.
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I 5.2 Noyori's calcium (II) catalyst
Several metallic catalysts have recently been developed for the direct 
asymmetric aldol reaction. Noyori reported a protocol employing a simple 
diol containing-calcium catalyst that provided reasonable enantioselectivity 
(Scheme 19).56 For example, the reaction of acetophenone 62 and pivaldehyde 
69 was promoted by the catalyst system composed of Ca[N{Si(CH3)3}2]2THF2 
70, (S,S)-hydrobenzoin 71, and KSCN, in a respective ratio of (1:3:1), to 
provide /J-hydroxyketone 72 in 74% yield and 89% ee. However, a large
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excess of ketone, 1 0  equivalents, was crucial in obtaining the aldol adducts in 
reasonable yield and with a satisfactory ee.
Scheme 19. Noyori's Ca-hydrobenzoin direct asymmetric catalysis.
70 (3 mol%):71:KSCN 
(1:3:1)
72
Y = 74% 








I 5.3 Shibasaki's LLB catalyst
The design of low molecular weight catalysts that mimic enzymes has 
been an approach for the development of aldol reactions of unmodified 
ketones by certain groups. Shibasaki, for example has employed the 
heterobimetallic complex LaLi3tris(binaphthoxide) (LLB) 75 which is 
bifunctional in having both Lewis acid and Bronsted basic sites (Scheme 20). 
The reaction has been conducted with methyl ketones57 and more recently a- 
hydroxy ketones58 with aldehydes. The use of additives KN(SiMe3)2 and H2O 
generating KOH in-situ has lead to a much more active heteropolymetallic 
species reducing reaction times and catalyst loadings. The reaction of a- 
hydroxy ketones is anti-selective, and with 10 mol% LLB, 9 mol% KHMDS, 
and 20 mol% H2O, reaction times are approximately 24 h with adducts 
afforded in up to 95% ee (Scheme 20).
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Scheme 20. Shibasaki's direct catalytic asymmetric aldol reaction.
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I 5.4 Shibasaki's EhZn/linked BINOL complex
Shibasaki has also reported a practical complementary synthesis of 
syn-l,2-diols using a Zn-Zn-linked-BINOL 79 complex.59 The reaction of 2- 
hydroxy-2'-methoxyacetophenone 77 as a starting material proceeds 
smoothly using as little as 1 mol% of the dinuclear catalyst. High yields, syn- 
selectivity, and high ee's are reported making this one of the most efficient 
asymmetric aldol catalysts to date (Scheme 21). The syn-selectivity is 
attributed to steric congestion induced from the approach of the aldehyde to 




Scheme 2 1 . Shibasaki's dinuclear zinc syn-selective direct catalytic 
asymmetric aldol reaction.
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I 5.5 Trost's bimetallic Zn catalysts
In addition to Shibasaki's zinc catalyst, Trost has reported the 
use of a bimetallic zinc catalyst for the direct asymmetric aldol reaction.60 The 
semicrown Zn(II) complex 82 has been designed on the basis of the 
recognition ability of crown compounds and the behaviour of aldolase II- 
type enzymes.61 The complex works very efficiently in the reaction of aryl 
ketones with aliphatic a-branched aldehydes with loadings as low as 5
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mol%. The addition of a weak coordinating agent for zinc, 
triphenylphosphine sulfide, helped in terms of turnover and ee. The reaction 
was not at all atom economic with employment of an aldehyde:ketone ratio 
of 1:10. Trost's more recent publication discloses a much more atom 
economic catalysis and employs a-hydroxyketones as donors .62 A 1.5:1 ratio 
of hydroxyketone to aldehyde is used along with a low catalyst loading of 2.5 
mol% (Scheme 23). Trost has also developed this reaction for acetone as a 
donor.63
Scheme 23. Trost's dinuclear zinc catalysed direct asymmetric aldol 
reaction.
u u
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I 5.6 Evans' salen-Al catalyst
Evans has utilised salen-aluminium complex 85 to promote the 
catalytic synthesis of ds-oxazoles, for example 8 6 , synthetic equivalents of a- 
amino-jS-hydroxy acids (Scheme 24).64 The reaction of 5-methoxyoxazole 84 (1
o
equiv.) with benzaldehyde 17 (1 . 2  equiv.) in the presence of 5 mol% of 85, 3 A 
MS, and 20 mol% of LiClCh delivered the ds-oxazole 8 6  in a 94% yield, with a
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cisitrans ratio of 95:5 and an ee of 99%. The LiClCh additive was proposed to 
promote the breakdown of the aluminium alkoxide aldolate intermediate.
The scope of the aldehyde was studied and extended to a wide range 
of aromatic compounds. The yields were all higher than 93%, with 
diastereomeric ratios of the order, 90:10 in favour of the ds-oxazole, and ee's 
were all higher than 91%.








UCI04 (20 mol%) 
PhMe, 3 A MS, 25 °C 
20 h 
Y = 94% 
cis:trans = 95:5 
ee = 99%
c/s- 86
Surprisingly, aliphatic aldehydes were found to be unreactive under 
the standard reaction conditions. An advantage of the ds-product outcome 
was that epimerisation at the n-centre to trans- 8 6  could be achieved through 
the treatment of a catalytic amount of DBU (cisitrans = 5:95, ee > 99%).
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I 5.7 Evans' Ni(II) bis(oxazoline) catalyst
Evans has recently reported the first example of a direct catalytic
asymmetric aldol reaction of simple carboxylic acid derivatives.65 The Ni(II) 
bis(oxazoline) 8 8  as the Lewis acid catalyst promotes the 2,6-lutidine based 
soft-enolisation of thiazolidinethiones (Scheme 25). On this occasion TMSOTf 
is used as an additive, but a conceived Mukaiyama pathway was ruled out 
based on the experimental evidence that when the aldehyde component was 
excluded from the reaction no silylketene acetal was observed. A role in the 
catalytic cycle of silylation of the Ni(II) alkoxide intermediate is proposed for 
TMSOTf hence aiding product decomplexation and eventual catalyst 
turnover. Very high enantioselectivity was achieved irrespective of the 
aldehyde component for the major syn-diastereomer.
Scheme 25. Ni(II) bis(oxazoline)-catalysed syn-aldol reaction.









Y = 81 % 
d.r. = 94:6 
ee  = 97%
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I 6 Asymmetric Organocatalysis66'67'68
Catalysis via small chiral organic molecules -  organocatalysis, has 
emerged as a prominent field in asymmetric synthesis over the past few 
years. (L)-Proline for example has shown to be an excellent organocatalyst for 
the aldol reaction and is highlighted in this section along with other 
examples.
I 6.1 List's proline catalyst
Recently, List and co-workers discovered a novel catalytic reaction 
that uses a simple optically active amine-based catalyst in the direct aldol 
addition of acetone 90 and a variety of aldehydes (Scheme 26).69 70 It has been 
identified that (L)-proline 91 works well as a class I aldolase mimic in this 
reaction and there is no requirement for any metal intervention. The reaction 
has the advantages of being direct, water tolerant and conducted at RT.
Scheme 26. (L)-Proline catalysed aldol reaction.
O OH
Me Me H /Pr DMSORT
90 65 92
Y = 97% 
ee = 96%
Under optimised conditions, a 30 mol% loading of (L)-proline 
promotes the reaction, via an enamine type mechanism (Scheme 27). The 
resultant enantioselectivity can be attributed to a metal free Zimmerman-
Chapter I Introduction
Traxler transition state 93 comprising a tricyclic hydrogen bonded 
framework. The drawback of this catalysis is the need for the ketone 
component to be in high excess -  acetone was used as a co-solvent.
Scheme 27. List's proposed enamine mechanism. 
Ox
O Me MeMeMX N  
° ^ 0 ^ °
R^ T  ]TL




I 6.2 MacMillan's aldehyde cross aldol reaction
The reaction of two aldehydes, one acting as the nucleophilic 
component and the other acting as the electrophilic partner, which is a 
difficult process to control, has been successfully achieved through (L)- 
proline organocatalysis. MacMillan and co-workers have realised that under 
slow addition of the donor aldehyde to a mixture of (L)-proline ( 1 0  mol%) 
and the acceptor aldehyde in DMF at 4 °C, cross aldol adducts of up to 99% 
ee can be reached . 71 For example propionaldehyde 26 (2 equiv.) and 
isobutyraldehyde 65 (1 equiv.) afford /3-hydroxyaldehyde 94 in 82% yield 
and 99% ee (d.r. = 24:1 in favour of the anti-aldol) (Scheme 28). In this process, 
a respectable excess of the nucleophilic component aldehyde can be
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employed. More recently, MacMillan has extended the scope of the acceptor 
aldehyde to a-thioacetal aldehydes generating adducts in up to 99% ee.72
Scheme 28. MacMillan's aldehyde cross aldol reaction.
91 1
ho2c
(10 mol%) O OH Y = 82% 
d.r. = 24:1 




(2 equiv.) (1 equiv.)
I 6.3 Chiral ammonium salts as organocatalysts
Maruoka and co-workers have employed phase transfer catalysis in 
synthesising jS-hydroxy-a-amino acid derivatives.73 The chiral ammonium 
salt 97, derived from binaphthyls, is able to catalyse the reaction of glycine 
Schiff bases and aldehydes to afford aldol adducts in good yield and in very 
high ee (Scheme 29).
Scheme 29. Phase-transfer organocatalysis.
PhMe, NaOH/H20
O
Ph 0 °C, 2 h NH2 98
95 96 Y = 72% 







The biphasic catalysis employs only 2 mol% of the phase-transfer 
catalyst and yields the free jS-hydroxy-a-amino moiety under the reaction 
conditions.
I 7 Most recent developments
The group of Shibasaki has recently developed a process involving 
new bis(diphenylphospholane) ligands to aid in the Cu(I)-catalysed 
enantioselective aldol reaction of ketones. 74 The use of ketene trimethylsilyl 
acetal 99 generates the corresponding copper enolate (the actual nucleophilic 
species) through a transmetalation between silicon and copper atoms, which 
facilitates the addition reaction of ketones (Scheme 30).75 Chiral phosphine 
ligand 101 generated the most enantioselective Cu(I) catalyst, affording f>- 
hydroxyester 102 in 78% yield and 6 6 % ee after 43 h in DME from 
dialkylketone 1 0 0 .
Scheme 30. Shibasaki's new phosphine-Cu(I) enolate addition to
ketones.
n
1. CuF-3Ph3P-2EtOH (2.5 mol%) 
101 (5 mol%), (EtO)3SiF (1.2 eq.) OH O
99 100 ee = 66%
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The Cu(I) catalyst derived from CuF-3 Ph3P-2 EtOH was employed at 
the low loading of 2.5 mol% and the system required a stoichiometric 
amount of the additive, (EtO^SiF, to aid in catalyst turnover. Although ee is 
moderate, this is the most enantioselective reaction to date using aliphatic 
ketones.
Trost has recently extended the scope of the dinuclear zinc catalyst 82 
to include the reaction of methyl vinyl ketone 103 (a highly functionalised 
nucleophile) with a variety of aldehydes (Scheme 31).76 This is the first 
general asymmetric aldol reaction to date of the highly useful bifunctional 
building block -  methyl vinyl ketone, which due to its base instability has 
had hampered development in aldol processes. Products could be obtained 
in up to 98% ee and yields of up to 74% depending on the aldehyde, solvent 
and temperature employed.







Y = 53% 
ee = 92%
Organocatalysis has developed rapidly very recently, and many 
groups have seized the opportunity to develop this field especially in the 
asymmetric aldol reaction. Only in the last year have several novel (L)-proline 
derivatives been synthesised by numerous groups and applied to the
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reaction of acetone and various aldehydes with high degrees of 
enantioselection (Scheme 32).77'78'79'80'81
Scheme 32. Derivatised (L)-proline catalysts for the acetone/aldehyde 
aldol reaction.
A final inclusion of an asymmetric organocatalytic process and in 
particular a utilisation of (L)-proline is that of carbohydrate synthesis. The 
group of MacMillan have devised a two-step synthesis of protected glucose, 
allose, and mannose stereoisomers from an initial enantioselective self- 
aldolisation reaction catalysed by 10 mol% (L)-proline.82 The second 
carbohydrate-forming step involves a Mukaiyama aldol addition-cyclisation 
reaction catalysed by either MgBn-OEh or TiCk (Scheme 33). The a- 
oxyaldehyde dimerisation in step one of the two-step tandem reaction 
produces adducts in 95% ee (antiisyn = 4:1) (Scheme 33). Adducts of the first 
step, ^-hydroxy aldehydes, are inert to further enamine addition therefore 
require alternative mediation to continue the process. The outcome of the




20 °C, 24 h 
up to 92% ee 




-40 °C, 24 h
up to 99% ee 
Y = up to 88%
10 mol% up to 98% ee 
-35 °C, 24 h Y = up to 88%
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Lewis acid mediated second step including cyclisation i.e. whether a glucose, 
allose, or mannose derivative is produced is dependent on the Lewis acid 
and solvent used. Hexoses are produced in up to 97% yield, up to a d.r. of > 
19:1, and no loss in ee (95%).
Scheme 33. (L)-Proline catalysed carbohydrate synthesis.
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1 1  95% ee
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I 8 The asymmetric Darzens reaction83
An aldol reaction in which a post aldol cyclisation occurs at the a- 
centre to bring about epoxide formation -  the Darzens reaction, is an 
interesting modification. A direct asymmetric catalytic process involving 
metallic species is an attractive methodology to pursue but has remained 
elusive.
In 1982 Mukaiyama showed that under stoichiometric soft-enolisation 
conditions cis-a,/?-epoxyketones could be synthesized via a 2-step Darzens 
route stereoselectively.84 The cross aldol reaction between a-bromoketone 116 
and benzaldehyde 17 is mediated by Sn(OTf)2, and triethylamine. The major
38
Chapter I Introduction
syn-aldol adduct 117 is then treated with KF/dicyclohexyl-18-crown-6 as an 
HBr captor to allow formation of the correct cis-epoxide 118 without 
epimerisation of the n-centre (Scheme 34).
Scheme 34. Stoichiometric Sn(II)-mediated Darzens reaction of a- 
bromoketones.
Sn(OTf)2 0  OH KF O
Vr o  Et3N M |  18-Crown-6 f-Bu.
+ - X  f - B u ^ N f ' P h  ^  N 1r-BU H Ph THF I n
Br
Ph„  ^ r-ou ■ rn  n
 Ph T F 
0°C
116 17 117 118
d.r.> 95:5 (cis.trans) 
Y = 64%
Asymmetric Darzens reactions are scarce. The reaction is dominated 
by the use of phase transfer catalysis although Pridgen et al have employed 
Evans' chiral oxazolidinone protocol to initially prepare enantioenriched a- 
halo aldol adducts from various metal enolates.85 The anf z-bromohy drins 
afford stereospecifically fnms-benzyl-a,/J-epoxy esters upon treatment with 
lithium benzyloxide (Scheme 35). Again, this is a modified two-step 
procedure of the Darzens reaction.
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O -  (CH2)8Ph
Me 121 122 ee = 99.7%
Y = 65% 
d.r. = 87:13 (anti:syn) 
e.r. = 79:8 (anti)
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The group of Shiori has made considerable progress in the 
development of catalytic asymmetric Darzens reactions via phase transfer 
catalysis.86 A reactive and soluble ammonium halide (QX) can be transformed 
into a chiral active species in the presence of an inorganic base (MOH), which 
leads to an effective catalytic cycle (Scheme 36).
Scheme 36. PT catalytic cycle for the asymmetric Darzens reaction.
Shiori initially worked on a-chloroketones with various aldehydes 
and found that N-(4-trifluoromethylbenzyl)cinchonium bromide 124 and 
LiOH worked well as a catalyst system in di-w-butyl ether at 4 °C. The 
reaction of phenacyl chloride 123 with aliphatic aldehydes proceeded 
smoothly to give the corresponding epoxides with good stereocontrol and 
yield under the mild conditions (Scheme 37). Mechanistic studies discarded 
the reasonable assumption that the stereocontrol is derived from the reaction 
of the aldehyde with the chiral ammonium enolate. Instead, studies showed 
that stereoselectivity is controlled by a retro-aldol reaction and kinetic 
resolution.
R2CHO
MX X = Hal X
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A final example is that of Bako and co-workers who have described 
the use of chiral crown ethers derived from D-glucose and D-galactose as 
effective phase transfer catalysts in the Darzens condensation (Scheme 38).87
Scheme 38.15-Crown-5 PT-catalysed Darzens condensation.










Ph—^  A  H Y = 49% 
ee  = 71% 
\  d.r. = 98%
The reaction of phenacyl chloride 123 with benzaldehyde 17 in the 
presence of 5 mol% chiral crown ether catalyst 126 and 30% NaOH produced 
a,/J-epoxyketone 127 in 71% ee. Other nitrogen fragments resulted in much 
lower ee's especially those without the added hydroxyl side-arm. In all cases 
the trans-diastereomer was obtained in excellent de (> 98 %).
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I 9 The asymmetric Mannich reaction88
The final reaction to mention is the Mannich reaction where an imine 
electrophile takes the place of the electrophilic carbonyl component in the 
aldol reaction. The Mannich or imine-aldol reaction has taken similar 
developmental paths as the aldol reaction in terms of catalytic asymmetric 
methodologies. Described herein are a few of the latest developments of the 
asymmetric Mannich reaction -  a means to highlight the vast array of 
catalyses to be found in the current literature for a C-C bond forming 
reaction that synthetically reaches important products such /3-amino acids.
A highly enantioselective example of a latent enolate metal mediated 
catalysis is that of Kobayashi's zirconium-tridentate BINOL derivative 
system .89 The addition of ketene silyl acetals such as 129 to benzaldimines 
such as 128 proceeded smoothly under the reactions conditions of Zr(OfBu)4  
(10 mol%), ligand 130 (15 mol%), and N-methylimidazole (NMI) (20 mol%) in 
toluene (Scheme 39).
Scheme 39. Kobayashi's zirconium catalysed asymmetric Mannich 
reaction.
.OHZr(OfBu)4 (10 mol%) 
130 (15 mol%) 
NMI (30 mol%)
Y = 92% 
ee = 91%
OSiMe3











The high design of the BINOL derived ligand stemmed from an 
assumed 2:1 (R)-6 ,6 '-Br2-BINOL:Zr transition state structure from previous
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work on asymmetric Mannich reactions.90 Tridentate-BINOL derivative 130 
has superseded (R)-6 ,6 '-Br2-BINOL as a ligand with increased 
enantioselection and yields across the substrate range. The newly developed 
catalyst could also be conducted at room temperature with little loss in ee 
(Scheme 39). N-methylimidazole is believed to play an important role of 
dissociating oligomeric Zr-species and regulating the structure of the Zr
A recent example of a direct metal mediated catalyst system comes 
from the group of Trost.91 The dinuclear zinc catalyst 82, already mentioned 
as an effective catalyst in aldol reactions (Sections I 5.5 and I 7), has been 
utilised in the Mannich reaction of a-hydroxy ketones with N-protected
controlled by the type of N-protection incorporated into the starting imine. 
Diphenylphosphinoyl (Dpp) imines provided access to anti-adducts whereas 
Boc-imines provided syrc-adducts (Scheme 40).
Scheme 40. Trost's dinuclear Zn-catalyst in asymmetric Mannich
complex.








R = Dpp 132 
R= Boc 133
H THF, 4 A MS 
-30 °C(132)/5 °C (133) 
up to 24 h R = Dpp anti-134
Y = 86% 
d.r. = 5:1 
ee -  94%
Y = 77% 
d.r. = 5:1 




Yields of up to 8 6 %, d.r/s of up to 6:1 and ee's of up to > 99% have 
been achieved for a range of aliphatic imines and aryl ketones through 
employment of as little as 3.5% of catalyst 82 (Scheme 40). Modifications of 
the ligand were made but did not fulfil any improvement of the original 
dinuclear zinc catalyst.
Asymmetric organocatalytic methods have emerged as an effective 
protocol in many reactions as seen in the aldol reaction above (Sections I 6  
and I 7). The Mannich reaction has not escaped such developments. The 
groups of Barbas III, and Tanaka have recently disclosed an arch-selective 
amino acid catalysed Mannich reaction whereas (L)-proline is syrc-selective 
(Scheme 41).92/93
Scheme 41. Amino acid catalysed Mannich reactions.
2 10 mol% O HN'
C 02Et DMSO H ' ^ x ^ C 0 2Et
PMP = p-methoxyphenyl
Y = 80% 
d.r. = > 10:1 





O N 5 mol% O HN"
Y = 85% 
d.r. = 98:2 
ee  = 99%
The organocatalyst 5-Methyl-3-pyrrolinecarboxylic acid 139 provides 
the arch-adducts in up to 99% ee and 98:2 d.r. for the reaction of aldehydes
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and p-methoxyphenyl protected imines. The reason for the opposite 
stereochemical outcome compared to (L)-proline is portrayed in the above
enamine based mechanisms (Scheme 41). The stereoselective formation of the 
fltth-product necessitates a reversal in the facial selectivity of the enamine, 
which the 5-methyl substituent of 139 facilitates.
To end this section, other organocatalysts have been developed to 
mediate Mannich reactions. For example Jacobsen and co-workers have 
developed chiral thiourea catalysts such as 141 (Figure 6 ) for the reaction of 
ketene silyl acetals and Boc-protected imines, 94 whereas the group of 
Shibasaki have developed chiral phase transfer catalysts such as 142 (Figure 
6 ) for the reaction of glycine Schiff bases and various N-protected imines. 95
Figure 6 . Chiral organic molecules as catalysts for the asymmetric 
Mannich reaction.





I 10 Outline of the project
Introduction
Enolate-electrophile bond constructions are among the most efficient 
and general strategies for the stereoselective formation of carbon-carbon 
bonds in organic synthesis. The aldol addition reaction and imine variant 
being the most utilised. Accordingly, there are many examples of 
diastereoselective aldol/Mannich reactions that employ stoichiometric chiral 
controllers to ultimately deliver enantiomerically enriched adducts as 
discussed. Examples of catalytic enantioselective reactions are scarcer; 
however, several research groups have enjoyed considerable success in 
developing catalytic enantioselective variants of the Mukaiyama reaction. In 
such reactions, which employ a latent enolate equivalent, the 
enantioselectivity originates from the use of a chiral Lewis acid catalyst. The 
catalyst functions via the formation of a transient chiral electrophile (i.e., 
complexation of the Lewis acid to the carbonyl or imine group) and mediates 
only the bond-forming process. The formation of the enolate equivalent takes 
place in a separate operation. A more attractive strategy is to deliver the 
same bond construction by an aldol/Mannich reaction incorporating enolate 
generation as an integral part of the catalytic cycle. This results in the catalyst 
mediating both enolisation and subsequent bond formation. Such reactions 
proceed via the catalytic formation of a chiral nucleophile (Scheme 42). 
Denmark's enantioselective aldol system (Section 14.5) which employs chiral 
base catalysts does not fit well into either of the scenarios described above 
because the chiral base formed actually originates from a preformed enolate 
equivalent.
As detailed (Scheme 42) there is a requirement for the use of a 'chiral 
base' as the asymmetric catalyst; one approach towards obtaining such a base 
is to exploit 'soft enolisation' conditions produced by the combination of a
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Lewis acid and a weak base. In this process the Lewis acid first coordinates 
to the carbonyl oxygen for example, thus activating the a-hydrogen atoms to 
deprotonation. Crucially, by using this protocol a much weaker base than 
usual can be employed for the deprotonation step.
Scheme 42. Generation of chiral electrophiles and nucleophiles.
OTMS
R’ + E











The idea of soft enolisation has been seen throughout the introduction 
section but a few examples are discussed here to address the concept. 
Danishefsky and co-workers reported an impressive example of the use of 
soft enolisation.96 In search of different functionalities and oxidation levels of 
dienes for the Diels-Alder reaction, 1,3-dialkoxybutadienes were sought 
after. Pyrolysis of 1,1,3,3-tetramethoxybutane gave unsatisfactory results. 
However, reaction of 143 with TMSC1 in the presence of triethylamine and 
zinc chloride at 40 °C gave a 6 8 % yield of fnms-l-methoxy-3- 
trimethylsilyloxybuta-l,3-diene 144 (Scheme 43). Importantly, in the absence 
of the zinc chloride Lewis acid, enolisation of 143 did not occur.
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Scheme 43. Danishef sky's diene formation.
ZnCI2 (3 mol%)
J ^ N  (2.1 equiv.) Me3s i O ^  
TMSCI (2.0 equiv.) 3
benzene ]
OMe 40 °C OMe
Y = 68%
143 144
More recently the group of Evans has employed soft enolisation 
conditions in magnesium halide-catalysed anti-aldol reactions of chiral N- 
acyloxazolidinones (Scheme 44) . 97 Although the enantioselectivity is derived 
from the auxiliary, i.e. no chiral catalyst is involved, the reaction is catalytic 
with respect to the magnesium halide Lewis acid (10 mol %). The weak base 
used is triethylamine and although TMSCI is used as an additive, the 
reaction does not proceed via a Mukaiyama aldol pathway.
Scheme 44. Soft enolisation portrayed in Evans' magnesium catalysed 
anti-aldol reaction of chiral N-acyloxazolidinones.
1. MgCI2 (10 mol%) 
y ft Et3N, TMSCI U N ?
+ PhCHO  ^ A c  „  0 ^ N ^ Y ^ Ph hV  9<J?1
Me 2. MeOH, TFA \ _ ^  ‘ 8 d r - 32-1
Bn Bn
145 17 146
Jorgensen et al have applied catalytic enolisation conditions to the 
nitro-Mannich reaction.98 The reaction involves the catalytic addition of nitro 
compounds to imines to give /Lnitro-n-amino esters. A Cu(II) bis(oxazoline) 
148 catalyst is utilised, and triethylamine as the weak base (Scheme 45).
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Scheme 45. Catalytic asymmetric enolisation nitro-Mannich reaction.
Me Me 148<vv>\^ N  N-V
pfi' Cu(OTf)2 p h ^ V 0M e
(20 mol%) JL I)II NO, Et3N Y = 81%
+ r  ------------- ------------- T f . dr. = 95:5
J J *  DCM, 0 °C E t O j C ^ Y  ee  = 97%
H C 02Et N 02
137 147 149
The recent work of both Lygo and Corey using phase-transfer- 
catalysts in enantioselective alkylations" can also be rationalised by 
involving catalytic chiral enolates along with the work of Shibasaki's mixed- 
metal-BINOL catalysts already mentioned in this section. Ji and Barnes have 
applied soft enolisation conditions to the enantioselective conjugate addition 
of /3-keto esters to nitroalkenes (Scheme 46).100




Mg(OTf)2 (5 mol%) 0  Ph
0  + 15J NMM (6 mol%) MeA A ^ N° 2
CHCI3, mol. sieves C 02Et
n ° 2  1 5 3
151 91% selectivity
96% conversion
Treatment of 5 mol% of the Lewis acid, obtained by the combination 
of bis(oxazoline) 152 and Mg(OTf)2, together with N-methyl morpholine as a 
base produced a chiral enolate good enough to undergo selective addition to 
nitrostyrene. The adducts were furnished in good yield and with good
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selectivity at the carbon centre f> to the nitro group. Unfortunately, the ester- 
bearing stereogenic centre was produced without selectivity.
The lack of selectivity at the a-carbon arose because the pKa of the
A solution to this problem would be to tune the selectivity of the base 
so that a small difference in acidity between the substrate and the product a- 
protons would be sufficient to limit product deprotonation. Usually the 
difference is too small and an alternative solution is to derivatise the product 
in-situ so that the pKa of the proton a  to the carbonyl group in the product is 
less acidic. This requires an #-substituent that can be modified post carbon- 
carbon bond formation; most likely by reaction with the alkoxide oxygen 
(Scheme 48).55 Incorporating the newly formed hydroxyl group in a cyclic 
structure would also reduce the opportunity of product inhibition that could 
occur with a free jS-hydroxy-carbonyl unit.
Scheme 48. Product derivatisation.
substrate and product were similar allowing enolisation of the product and 
subsequently epimerisation (Scheme 47).
Scheme 47. Epimerisation of the or-carbon centre.
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The catalytic cycle for an aldol bond construction for example 
employing an aldehyde and an enolisable carbonyl compound conducted 
under soft-enolisation conditions is depicted below (Scheme 49). In order for 
the cycle to be effective several criteria must be achieved; most importantly 
the "chiral base" produced by the combination of the Lewis acid and amine 
base must be capable of facilitating enolisation. Ideally the aldehyde 
component will be unaffected by these conditions. Finally, the system must 
be able to turnover. The alkoxide adduct must be able to deprotonate the 
ammonium salt and thus regenerate the free base. Careful selection of the 
Lewis acid, base component, and a-substituent on the carbonyl should allow 
these criteria to be fulfilled.
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Scheme 49. Catalytic cycle for a chiral enolate aldol addition.
Chiral Enolate
O 'M ^ '
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/sothiocyanate substituted N-acyl oxazolidinone 154 satisfies many of 
the required design criteria (Scheme 50). The zsothiocyanate significantly
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attenuates the pKa of the substrate, whilst following carbon-carbon bond 
formation, reaction with the newly generated alkoxide to form an 
oxazolidinethione is possible. 101 The or-proton present in the final product will 
have an attenuated pKa to that of the starting substrate 154. The basicity of 
the metal coordinated thiooxazolidinone intermediate should be sufficient to 
regenerate the free base thus allow the use of catalytic amounts of Lewis acid 
and base.
Scheme 50. Proposed zsothiocyanatoacetate substituted aldolisation.
*Ln-1
/ MS
A n ' JA n c s m *l " + n r 3 J L X ^ n c s  r c h o  A  A  r - 1\ ► O N  "  O N y ^ R
*154 (Z)-enolate
o °  R 9 9 ?A..A X  A( f  y ' V ' o   ---------  O N '  N Q ,
—^ / HN-^ N -(
v_ cS SM*Ln.-|
One of the key objectives in establishing such a catalytic cycle is that 
the enolates produced are effective in transferring the chiral information 
from the catalyst to the incipient bond. N-acyloxazolidinones are known to 
selectively form (Z)-enolates. 102 This, together with their bidentate nature 
results in rigid structurally well-defined enolates. Finally and of crucial 
importance is that the ultimate products of the catalytic cycle are 
synthetically useful stereo-defined products. In order to achieve efficient 
transfer of stereochemical information, incorporation of chiral ligands would 
be expected to form rigid enolate complexes. This could be achieved by 
combining the bidentate oxazolidinone substrate 154 with bi- and tridentate 
chiral ligands. Possible ligand candidates include bisoxazolines (BOx),
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dibenzofuran (bis)oxazolines (DBFOx), bisimines and pyridine 
(bis)oxazolines (PyBOx) (Figure 7).
Figure 7. Potential chiral ligand selections.
combinations that would effect deprotonation and allow completion of the 
catalytic cycle. In selecting these combinations, it was essential that the Lewis 
acid and the amine base did not form an irreversible adduct.
What is described in the following section is an account of the work 
carried out to establish such an aldol catalysis centred around soft 
enolisation. The commencement of an achiral system and development to an 
enantioselective variant are described. The application to a natural product 
synthesis -  one of vancomycin's amino acid fragments is also disclosed. The 
extension of the developed aldol catalysis is extended to a Mannich variant 
and other types of direct enolate reactions centred around the formation of 
analogous a,/?-difunctional carbonyl products. Finally, the same soft 






Early studies focussed on identifying suitable Lewis acid and base
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II Results and Discussion
Results & Discussion
II 1 A direct catalytic enantioselective route to /?- 
hydroxy-a-amino acids
II 1.1 Introduction
The jS-Hydroxy-a-amino acid motif described previously (Section I I )  
is highly significant in natural products and biologically active molecules. 
The attractive route to such a unit by employment of a glycine equivalent in 
a catalytic soft enolisation aldol process is demonstrated in this section. 
Herein the development of an achiral diastereoselective process is described 
followed by the extension of this system to a highly enantioselective variant. 
Early work within the Willis group carried out by V. J.-D. Piccio on the 
achiral system focussed on the glycine equivalent, a-isothiocyanate 
substituted ethyl ester 155 for the initial screening of the soft enolisation 
catalysis, which is previously proposed and laid-out in Section I (Scheme 51). 
This readily available starting material was used to differentiate the pKa 
between the substrate and of adducts formed under soft enolisation 
conditions, which included a cyclisation post aldol addition. Initially 
benzaldehyde 17 was elected as a non-enolisable electrophile.
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Scheme 51. Initial screening for the soft enolisation.






The employment of both these substrates with various weak amine 
bases and several metal ions with differing counter ions were screened. The 
solvent, differing promotional additives and other reaction parameters were 
also included in this initial evaluation. After much effort excellent catalytic
were found to be Mg(C104)2 (10 mol%) and TEA (20 mol%). A crucial 
additive, 2,2/-bipyridine 157 (10 mol%) was discovered for this catalysis 
which acts as an external ligand and accelerates the reaction rate (Figure 8 ). 
Interestingly, the group of Watanabe had reported a cross aldol reaction of 
a,jS-unsaturated ketones that were catalysed by a one to one complex of 
cobaltous acetate with the same achiral ligand 2 ,2 /-bipyridine. 103' 104
Figure 8 .2,2'-bipyridine.
This method was found to be general to a range of aromatic aldehydes and 
delivered adducts in excellent yields and moderate syw-selectivity (Table 
3) . 105 The need for an external ligand to form an active catalyst was 
encouraging for the following part of the project which was the development 
of an asymmetric version of this process utilising enantiomerically enriched 
ligands.
conditions were discovered. The optimal combination of Lewis acid and base
157
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Table 3. Racemic reaction scope of aromatic aldehydes.3
Mg(CI04)2 O R  O r
O O bipyridineX NCS + X TEA + 0O Y 'o
E tO ''^ - '  H R  ► H N -y  H N ^ /
155 THF’ ° ”C S \
sy/7-aldol anti- aldol
Entry R Product Time (h) SynAntP Yield (%)c
1 c 6h5 156 21 65:35 86
2 4-N02-C6H4 158 25 70:30 70
3 4-CN-C6H4 159 22 75:25 85
4 2-Br-C6H4 160 23 65:35 84
5 3-Br-C6H4 161 21 65:35 88
6 4-Br-C6H4 162 21 70:30 84
7 2,6-diCI-C6H3 163 25 70:30 49
8 4-MeO-C6H4 164 23 60:40 67
9 2-Naphthyl 165 21 60:40 89
a All reactions: ester (1.0 equiv.), aldehyde (1.1 equiv.), 
Mg(CI04)2 (10 mol%), bipyridine (10 mol%), TEA (20 mol%). 
b Determined by 1H NMR. 
c Combined yield of the isolated diastereomers.
II 1.2 Enantioselective variant
The next phase of events carried out by V. J.-D. Piccio, which involved 
exchange of bipyridine for a range of enantiomerically pure C2-symmetric 
nitrogen-containing ligands, determined that ethyl ester 155 was not a good 
choice of substrate to bind effectively to the Lewis acid and allow for 
asymmetric induction. Therefore, a two-point binding nucleophile
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oxazolidinone 154 was prepared in the expectation of generating a more 
ordered enolate and used to develop the asymmetric process (Scheme 52). Its 
preparation, initially performed by V. J.-D. Piccio, and later improved, 
followed the procedure for the synthesis of a chiral zsothiocyanatoacetyl- 
Oxazolidinone reported by Evans.106





1. nBuLi (1.0 equiv.) 




-78 °C to RT, 45 min. 
Y = 95%



















« A ^ ncs
C _7 1
154
To circumvent the difficulties due to low solubility of oxazolidin-2- 
one 167, larger amounts of solvent were employed (Section El 2). After 
addition of n-BuLi and chloroacetyl chloride 168, the chlorocarbamate 169 
was isolated in 95% yield. After nucleophilic substitution of NaN3 the 
azidocarbamate 170 was obtained in 84% yield. The zsothiocyanatocarbamate 
154 was furnished in 69% yield through the reaction of azidocarbamate 170 
and triphenylphosphine in THF and carbon disulfide via 
phosphoazocarbamate 171.
A meticulous screening of bases, solvents, chiral ligands and 
temperatures with benzaldehyde 17, carried out by V. J.-D. Piccio, created 
excellent conditions for the asymmetric catalytic aldol reaction.107 The key
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chiral ligands examined in the asymmetric development are presented below 
(Figure 9) and their selectivities under optimised base and solvent conditions 
are detailed in Table 4. To aid in the determination of ee values of the 
products, the direct adducts were treated immediately with a solution of 
magnesium methoxide to yield the corresponding methyl ester derivatives.106




r ° >R2^-N N ^ r2 
R1 R1
148: R1 = Ph; R2 = H 
173: R1 = Bn; R2 = H 
174: R1 = H; R2 = *Bu
176
177: R1 = R3 = Ph; R2 = H
178: R1 = R3 = H; R2 = Bn
"'"Y-R3 179: R1 = Me; R2 = H; R3 = Ph
n ^ / r2 180: R1 = R3 = H; R2 = 'Bu
181: R1 = Ph; R2 = R3 = H
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Table 4. Chiral ligand screen.3
1. Mg(CI04)2
Ligand 0  Ph
O n DIPEA II I
A A ^ n c s *  X  DCM| ~78 °C, MeQA - A o
U J  H Ph 2. (MeO)MgBr







1 172 26 80:20 40 69
2 (4R,5S)-152 20 60:40 5 36
3 148 22 55:45 12 30
4 173 24 55:45 13 43
5 1749 24 65:35 7 65
6 175 19 50:50 16 52
7 176 21 60:40 67 70
8 177 18 90:10 73 69
9 1789 22 70:30 45 53
10 179 19 80:20 55 71
11 180 21 35:65 44e 51
12 181 20 75:25 83 71
13f 181 23 80:20 90 86
3 Conditions: isothiocyanate (1.0 equiv.), aldehyde (1.1 equiv.), 
Mg(CI04)2 (10 mol%), DIPEA (20 mol%) and ligand (10 mol%). 
b Determined by 1H NMR.
c Enantiomeric excess determined by chiral HPLC using a 
Chiracel OD column.
d Combined yield of the isolated diastereomers. 
e Enantiomeric excess corresponds to antf-aldol. 
f 4 A MS present.
9 Enantiomeric excess corresponds to opposite enantiomer.
The optimised reaction conditions comprised of Mg(ClC>4)2 (10 mol%), 
and Hiinig's base (20 mol%) as opposed to TEA in the achiral bipyridine 
system. The use of DCM as a solvent and lower temperatures of -78 °C
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offered higher diastereo- and enantioselectivity. Bidentate bis(oxazolines) as 
ligands generated poorly selective catalysts (entries 1 to 5). The most 
selective was.(4R,5S)-indBOx, (4R,5S)-172 (eesyn = 40%, d.r. = 80:20, entry 1). 
This was also the case for dibenzofuran bis(oxazoline) (R,R)-175 (eesyn = 16%, 
d.r. = 50:50, entry 6). However, the switch to a pyridine bis(oxazoline) 
(PyBOx) ligand generated a catalyst that delivered the product with a much 
improved selectivity (entries 7 to 12). Variation of ligand substituents was 
used to tune selectivity of the catalyst. Benzyl and ferf-butyl substituents 
attached to the PyBOx (entries 9 and 11 respectively) achieved the 
predominant aldol diastereomer with ee's of 44% and 45% respectively. The 
highest ee attained was from the catalyst composed of phenyl-substituted 
PyBOx (R,R)-181 (entry 12). An ee of 83% was observed with this tridentate 
ligand and a respectable d.r. of 75:25 achieved with the syn-aldol 
predominating. This was the same preferred diastereomeric outcome as in 
the achiral bipyridine system. As a precaution against degradation of the 
hygroscopic Mg(C104)2, activated molecular sieves were added to the system 
and an increase in selectivity to an impressive 90% ee was observed (entry 
13). The addition of 20 mol% water to the system resulted in a significant 
reduction in the enantioselectivity of the process (50 to 60% ee depending on 
the exact reaction).
II 1.3 Aldehyde scope
With optimised conditions and the project now fully transferred to the 
author's hands, the scope of the process was then explored with respect to 
the aryl aldehyde component (Table 5). To aid in the determination of ee 
values of the products, the direct adducts were this time treated immediately
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with a solution of magnesium ethoxide to yield the corresponding ethyl ester 
derivatives. A wide variety of heteroatom, alkyl, and aryl substituents were 
readily accommodated in the para position of the aldehyde with observed 
enantioselectivities of up to 94% ee (entries 1, 2 and 5 to 9). In all cases the 
syn-aldol adduct was obtained as a major diastereomer with selectivities of 
up to 91:9 (d.r.) achieved. Substitution in the meta position was tolerated well 
(eesyn = 86%, d.r. = 82:18, entry 3), however the presence of a more hindered 
ortho substituent resulted in a 50:50 ratio of diastereomers, although the anti- 
aldol was generated in 89% ee (entry 4).
Moving towards more electron-withdrawing substitution in the para 
position diminished enantioselectivity (entries 10 to 12). These electron 
deficient examples gave the minor anh-diastereomer in higher ee than the 
predominant syw-aldol, although diastereoselection was comparable to their 
electron-rich counterparts (up to 74:26 d.r.) and high yields were still 
achieved (71 to 79% depending upon the exact example), p- 
Cyanobenzaldehyde with a strongly electron-deficient aryl system showed 
considerable loss of enantioselectivity as well as diminished 
diastereoselectivity, although the yield was again very good (71%, entry 12). 
The last example, 2-naphthaldehyde, was found to be a good substrate with 
the required aldol adduct obtained in 87% ee and a d.r. of 72:28 in favour of 
the syn-aldol (entry 13).
The absolute configuration of the major syn-adduct of benzaldehyde 
was confirmed previously by the Willis group through X-ray crystallography 
to be (4S,5R). Another example syn-227 described later (Section II 2) was also 
confirmed to have (4S,5R) configuration through X-ray crystallography. The 




Table 5. Aldehyde scope/
Results & Discussion
DIPEA 
DCM, 4 A MS
A n^ ncs + hA
-78 °C, 24 h
EtO
154





Entry Ar Product Syrr.antP G&syn-GQanti (%-%)C Yield (%)d
1 Ph 156 79:21 86:72 79
2 4-Me-C6H4 183 88:12 92:62 88
3 3-Me-C6H4 184 82:18 85:73 84
4 2-Me-C6H4 185 50:50 62:89 88
5 4-Et-C6H4 186 91:9 90:60 95
6 4-MeO-C6H4 164 85:15 86:53 69
7 4-EtO-C6H4 187 87:13 93:60 85
8 4-MeS-C6H4 188 85:15 94:62 64
9 4-Biphenyl 189 71:29 85:61 73
10 4-F3CO-C6H4 190 74:26 52:63 78
11 4-Br-C6H4 162 73:27 46:59 79
12 4-CN-C6H4 159 66:34 3:37 71
13 2-Naphthyl 165 72:28 85:71 64
a Conditions: isothiocyanate (1.0 equiv.), aldehyde (1.1 equiv.), Mg(CI04)2 (10 
mol%), DIPEA (20 mol%) and ligand (10 mol%), 4 A MS present. 
b Determined by 1H NMR.
c Enantiomeric excess determined by chiral HPLC using a Chiracel OD column. 
d Combined yield of the isolated diastereomers.
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II 1.4 Epimerisation and selectivity issues
The fact that for electron-deficient aldehydes, poorer selectivities were 
observed (the more electron-deficient the aldehyde the lower the ee of the 
major syn-aldol), it is plausible that epimerisation was taking place during 
ethanolysis for such examples. Examination of this process previously by the 
Willis group, via isolation of syn-and anfr'-oxazolidinones for benzaldehyde 
adducts and then subjection to both methanolysis and ethanolysis conditions 
had shown that no epimerisation at the a-centre was taking place. In addition 
diastereomeric ratios determined by 1H NMR for both aldol and alkanolysis 
steps showed no differentiation.
To examine this hypothesis further i.e. with an electron-deficient 
example, initially formed syn- and anh-oxazolidinones from 4- 
bromobenzaldehyde 192 were isolated. Their subjection to ethanolysis 
conditions confirmed that no epimerisation was taking place in either 
diastereomer (Scheme 53). This result was also supported by diastereomeric 
ratios determined by NMR for this example and others, which again 
showed no differentiation before and after ethanolysis.
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Scheme 53. Ethanolysis of syn- and anh'-oxazolidinone 191.
sy/7-191 S
O O
A rO N ^
\— 1 HN-^
anf/-191 S
MeMgBr (1.1 equiv.) 
EtOH (70 equiv.)
THF, 0 °C, 3 min.
MeMgBr (1.1 equiv.) 
EtOH (70 equiv.)








The question remained therefore why the lack of selectivity in 
electron-deficient systems -  could product epimerisation have occurred 
during the soft enolisation reaction? The isolated 4-bromo syn- and anti- 
oxazolidinones 191 were resubjected to the soft enolisation conditions and no 
apparent epimerisation was observed. An interesting observation was made 
by the Willis group that the aldol reaction of oxazolidinone 154 and 
benzaldehyde 17 in the presence of no Lewis acid or ligand produced 
minimal reaction (39%) in the presence of Hiinig's base alone after 22 h at -78 
°C. Therefore, a system containing a more activated, electron-deficient 
aldehyde could undergo a faster background reaction than the Lewis acid 
catalysed reaction. A reduction in ee is expected therefore, especially if 
coordination of the aldehyde to a Lewis acid species is required. Moreover, 
aldehydes that are electron-deficient and therefore more electrophilic would 
have more difficulty coordinating to the Lewis acid. This is believed to be the 
reason for this trend of lowered enantioselectivity with regards to more 
electrophilic aldehydes.
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II 1.5 Evidence for chelation -  stereo-differentiating 
experiments
The fact that monodentate substrate ethyl ester 155 failed to achieve 
successful enantioselection whereas bidentate oxazolidinone 154 succeeded 
suggests the existence of a more ordered enolate chelation. In order to obtain 
a better understanding mechanistically of the developed asymmetric 
catalysis for the preparation of protected jS-hydroxy-a-amino acids, it was 
envisaged that double stereo-differentiating experiments where the 
zsothiocyanate substrate contained a chiral fragment as a blocking group 
would influence the outcome of the reaction and therefore give further 
insight into chelation events and the enolate involved.108 Preparation of both 
(R)- and (S)-zsothiocyanate substrates bearing benzyl substituted 
oxazolidinone fragments was achieved following the procedure described by 
Evans (Figure 10).106
Figure 10. (R)- and (S)-benzyl-oxazolidinones 193.
Experiments were performed with p-tolualdehyde 196 under the 
standard reaction conditions (Table 6). The combination of (S)-benzyl 
oxazolidinone (S)-193 and (R,R)-Ph-PyBOx 181 (eesyn = 90%, entry 1) 
generated an enolate that produced a comparable result to the unsubstituted
0A n^ ncs 0A nX^ncs
O o o o
(Ry 193
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oxazolidinone 154 (eesyn = 92%, entry 2) -  the matched case. On the other 
hand, the combination of (R)-benzyl oxazolidinone (R)-193 and (R,R)-Ph- 
PyBOx 181 gave a slower reaction and therefore lower yielding product of 
lower ee and of the opposite configuration (eesyn = 64%, entry 3) -  the 
unmatched case. In the cases where no PyBOx ligand was employed, similar 
results followed that of the unmatched case (entry 2) in terms of the major 
enantiomer produced, ee, d.r., and yield (entries 4 and 5). In an attempt to 
achieve a better understanding of these results an unsubstituted PyBOx 
ligand 195 (Scheme 54) was synthesised which would allow for a similar 
coordination behaviour as the chiral PyBOx example. Hydroxy amide 194 
was prepared according to the method described by Kumar and 
subsequently treated with excess boron trifluoride diethyletherate at reflux to 
attain the cyclised product 195 in 54% yield.109110






120 °C, 4 hO O
194 195
54%
This ligand employed with (S)-benzyl oxazolidinone (S)-193 and p -  
tolualdehyde 196 achieved a much more selective process (eesyn = 83%, entry 
6). In addition the yield improved to 87% and the major diastereomer was 
assigned (4S,5R). Although the diastereomeric ratio remained static 
compared to the non-ligand examples it was important to realise the extent 
of the ligand effect on enantioselectivity, reaction rate and the 4S absolute 
configuration. The last entry (entry 7) shows the lack of reactivity associated
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with a non-Lewis acid promoted system where base alone could mediate the 
reaction.
Table 6. Double stereo-differentiating reactions.3
,1
196 Me
1. Mg(CI04)2, ligand, 
DIPEA, DCM
4 A MS, -78 °C, 24 h
2. EtMgBr, EtOH, 0 °C
Et02C
Entry R1 (config.) R2 Syrr.antP eesyn (%)c (config.) Yield (%)d
1 Bn (S) Ph 91:9 90 (4S.5R) 88
2 H Ph 88:12 92 (4S.5R) 88
3 Bn (R) Ph 81:19 64 (4R.5S) 74
4® Bn (S) - 80:20 68 (4S,5R) 72
5® Bn {R) - 81:19 67 (4R.5S) 71
6 Bn (S) H 81:19 83 (4S.5R) 87
7f Bn (S) - - - 0
a Conditions: isothiocyanate (1.0 equiv.), aldehyde (1.1 equiv.), Mg(CI04)2 (10 
mol%), DIPEA (20 mol%) and ligand (11 mol%), 4 A MS present. 
b Diastereomeric ratio determined by 1H NMR.
c Enantiomeric excess determined by chiral HPLC using a Chiracel OD column. 
d Combined yield of diastereomers. 
e No ligand used. 
f No ligand or Lewis acid used.
To explain the aforementioned stereo-differentiating experimental 
results a working model was postulated for the favoured enolate generated 
and the product outcome during the catalysis. We had postulated that a six- 
coordinate Mg(II) species was involved and to account for the absolute
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configuration of the major aldol adduct (4S,5R), the preferentially formed 
(Z)-enolate is hindered by the (4R)-phenyl substituent on the chiral ligand 
(R,R)-181 at the re face; enolate 197 (Figure 11). The attack from the si face of 
the (Z)-enolate to the aldehyde furnishes the 4S absolute configuration. The 
remaining apical octahedral coordination site presumably occupied by the 
reacting aldehyde would therefore be adjacent to the enolate, the oxygen of 
which coordinating to the equatorial site in the plane of the PyBOx ligand, 
and so forms a closed transition state bearing one Mg2+ centre. However, the 
likely distance between the two reacting carbon atoms resulting from such 
coordination seems too far for this cyclic transition state to occur.
Figure 11. Chelated enolate geometries as working models.
C ^ -A p ^ Ph 0^!<Qr}>Ph
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matched case 198
1*<P~^ >Ph X>-^Ph>=Nk S=nT^NjT
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L = aldehyde or solvent
In addition, the same six-coordinate enolate geometry, adapted to (R)- 
benzyl oxazolidinone (R)-193, enolate 198 (Figure 11) would result in a 
(4S,5R) productive matched combination of substrate and ligand. The 
experimental observation was however that this combination is in fact a
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mismatched case. Therefore, it was postulated that the enolate oxygen is 
coordinating an apical site and that the oxazolidinone carbonyl coordinates 
in the ligand plane, enolate 199. This geometry would account for (S)-benzyl 
oxazolidinone (S)-193 as the matched productive case. A five-coordinate 
trigonal bipyrimidal species is not out of the question as depicted by enolate 
200. This also predicts (S)-benzyl oxazolidinone (S)-193 as a matched case 
although the aldehyde no longer coordinates the same Mg2+ centre as the 
enolate. This outcome is however not a concern due to the fact it supports the 
more plausible hypothesis of a more complicated bimetallic transition state 
where the aldehyde is activated by a second Mg2+ species.
What has not been explained is the fact that the mismatched 
combination of (R)-benzyl oxazolidinone (R)-193 and (R,R)-Ph-PyBOx 181 is 
still productive of the opposite (4R,5S) enantiomer although at a slower 
reaction rate and the benzyl fragments of oxazolidinone 193 do not hinder 
the generation of productive absolute configuration. The outcome of 
reactions catalysed by Mg(ClC>4)2 alone seems to be that of Evan's auxiliary 
control. The opposite absolute configuration is achieved through minimising 
dipole-dipole interactions between oxazolidinone carbonyl and enolate 
moieties. In the case of (R,R)-Ph-PyBOx 181 and (S)-benzyl oxazolidinone (S)- 
193 (the matched combination) this should not occur because a 'good fit' is 
achieved and may be overriding to a conformation arising from the 
minimisation of any dipole-dipole interactions that would result from a non­
coordinating oxazolidinone carbonyl. Such dipole-dipole interactions are 
also minimised through the Mg2+ cation, and control of si addition from the 
PyBOx ligand is therefore dominating. The mismatched case on the other 
hand, due to the steric hindrance of benzyl and phenyl groups, may override 
a two-point binding enolate and thus the reaction can proceed via Evan's 
auxiliary control. The result from the reaction employing unsubstituted 
PyBOx ligand 195 seems to be comparative to the ligand omitted Evan's
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auxiliary controlled reactions in respect to the absolute configuration in the 
final product. Although, the reaction is more selective in terms of 
enantioselectivity than a non-ligand system, where a singly bound oxygen 
enolate species may be more ordered in this case (Figure 12).
Figure 12. Unsubstituted PyBOx ligand model.
II 1.6 Evidence for chelation -  X-ray crystallography 
experiments
X-ray crystallography would surely bring light to such matters as 
coordination geometry of the enolate involved. Many attempts failed to
coordinated to Mg(C104)2 for X-ray crystallography. This was also the case 
for attempts at crystallising the actual enolate species. However, crystals 
were gathered from such attempts, of a stable species containing Mg(ClC>4)2 
and two (R,R)-Ph-PyBOx ligands (Section III 7). The X-ray crystal structure of 
[Mg((R,R)-phenyl-bis(oxazolinyl)pyridine)2](C104)2 201 depicted below 
(Figure 13) is an octahedral species with slight distortions to accommodate 
the tridentate PyBOx ligand. The opposing phenyl groups from each PyBOx 
ligand seem to be able to orientate themselves so that minimal steric 
hindrance occurs even though they are both of (R)-configuration. The failure 
to form crystals of a Mg(II) species containing oxazolidinone 154 chelating
O
produce crystals of the chiral PyBOx ligand and starting materials
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via two carbonyls suggests that such a species is unstable existing as an 
equilibrium between the free and chelated oxazolidinone. It was envisaged 
that a temperature dependent ]H NMR study would bring some light to this 
matter.
Figure 13. X-ray crystal structure of [Mg((R,R)-phenyl- 
bis(oxazoliny l)py ridine)2] (004)2 201.
Ph, | 2+
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II 1.7 Evidence for chelation -  temperature dependent 
NMR study
NMR spectroscopy is a tool that has previously been used to 
provide evidence for the structure of catalysts complexed to substrates.111 
Low temperature ^  NMR was used to study our catalyst system of 
Mg(C104)2 and (R,R)-Ph-PyBOx 181 combined with the substrate 
oxazolidinone 154. Molar equivalents of each material were stirred in 
deuteriodichloromethane at room temperature and then transferred to an 
NMR tube. At room temperature (Figure 14, 2) there is a transition between 
free and complexed (R,R)-Ph-PyBOx due to two separate ligand species 
signals (compare ^  NMR spectrum of (R,R)-Ph-PyBOx, Figure 14, 1). The 
oxazolidinone substrate 154 (referred to as OxAcNCS, Figure 14) is observed 
as a free species at room temperature possibly exchanging very rapidly with 
a complexed species. At lower temperature (-78 °C) the PyBOx ligand is now 
fully complexed although there is still no separation between a free or 
complexed oxazolidinone species, which would signify the low stability of 
such a complex (Figure 14, 3). At a temperature of -78 °C a molar equivalent 
of DIPEA was added (Figure 14, 4a) and as a result, although not conclusive, 
the proton spectrum shows a separate oxazolidinone species forming -  
possibly an enolate species, although the enolate proton chemical shift range 
is too congested to specify (Figure 14,4b).
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Figure 14. Temperature dependent NMR study.
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II 1.8 Nonlinear effects
Results & Discussion
Nonlinear effects can provide useful insight into both the behaviour of 
enantioselective catalyst systems and the mechanisms of the processes they 
mediate.112 Consequently, experiments were performed to determine if 
nonlinear effects were operative in the Mg(II) PyBOx-catalysed aldol reaction 
under investigation. Indeed, when the aldol reaction was conducted with the 
catalyst [Mg(Ph-PyBOx)](ClC>4)2 202 (10 mol%) with ligand of reduced 
enantiomeric excess a strong positive nonlinear effect was observed (Figure 
15). For example, employment of a catalyst of 25% ee afforded the aldol 
adduct in 57% ee, and a catalyst of 50% ee afforded the aldol adduct in 77% ee.
To rationalise this significant nonlinear effect it is postulated that 
either (i) the transition state is of a bimetallic nature i.e. two chiral units are 
involved in the stereochemical rate-determining step of the reaction, one Mg- 
(R,R)-Ph-PyBOx coordinated to the bidentate enolate and another Mg-(R,R)- 
Ph-PyBOx coordinated to the reacting aldehyde or (ii) formation of a stable 
[Mg((S,S)-Ph-PyB0x)((R,R)-Ph-PyB0x)](C104)2 2:1 ligand:metal complex 
serves as a catalytically inactive reservoir for the minor (R,R)-Ph-PyBOx 
ligand, consequently enriching the enantiomeric excess of the remaining Mg- 
(R,R)-Ph-PyBOx catalyst. The fact that a more hindered 2:1 ligand:metal 
complex of (R,R)-Ph-PyBOx and Mg(C104)2 has been isolated through 
crystallisation suggests the latter reasoning plausible. Conversely, a 
bimetallic catalyst is a likely outcome through these findings and other 
experiments performed including stereo-differentiation and working model 
postulation. Time has precluded a conclusive rationale for the above 
described (+)-nonlinear effect.
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Figure 15. Nonlinear effect in the Mg(II)-PyBOx catalysed aldol 
reaction.
DIPEA (20 mol%)
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II 1.9 Conclusion
In summary, a simple catalyst system assembled from an 
enantiomerically pure tridentate ligand, a Lewis acidic metal, and an amine 
base, efficiently generates a chiral glycine enolate derived from 
oxazolidinone 154. The preferentially formed (Z)-enolate undergoes
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enantioselective addition to a range of aryl aldehydes to provide protected 
aryl jS-hydroxy-a-amino acids in good yields with high enantioselectivities. 
Importantly, all of the catalyst components are commercially available and 
reactions are simple to perform. The catalysis has been probed 
mechanistically through stereo-differentiating experiments, X-ray 
crystallography, temperature dependent NMR studies, and nonlinear effect 
studies. Although time has precluded any concrete conclusion, evidence 
leans towards a complex bimetallic catalysis where both enolate and 
aldehyde are coordinated to separate chiral Lewis acids in the transition 
state.
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II 2 Synthesis of a building block for the total synthesis 
of vancomycin -  AA6
II 2.1 Introduction
Vancomycin 1 (Figure 16) is referred to as an antibiotic of last resort 
towards the highly drug resistant staphylococcus aureum bacterium -  the so 
called "hospital superbug' responsible for MRS A. Vancomycin belongs to the 
glycopeptide family of antibiotics and was discovered as the first member in 
1956 from an Indonesian soil sample as a product from the streptomyces 
orientalis bacterium. Since then the family has grown to thousands of 
members, particularly after determination of its crystal structure and 
mechanism of action. 113 Vancomycin's potency against all gram-positive 
bacteria is derived from its capability of being able to inhibit cell wall 
biosynthesis by inhibiting a crucial amide-based cross linking event during 
cell wall assembly. This has the effect of weakening the target bacterium's 
cell wall causing the cell to lyse. The cross linking event involves the docking 
of the D-Ala-D-Ala dipeptide terminus of a peptidoglycan precursor to a 
transpeptidase enzyme; vancomycin also has this D-Ala-D-Ala recognition 
site and through five strong hydrogen bonds can thus block the enzymes 
mode of action.
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It has been reported that even such a potent antibiotic as vancomycin 
can become less effective towards certain strains of bacteria. Both 
vancomycin-resistant enterococci (VRE) which causes a rare form of 
meningitis and vancomycin-resistant staphylococcus aureus (VRSA) bacteria 
have been described. 114115 These bacteria have become resistant via a mutation 
which causes a change in the D-Ala-D-Ala dipeptide terminus of adjoining 
peptidoglycan chains. The terminus has become a D-Ala-D-Lac amino acid 
series which offers the possibility of only four hydrogen bonds . 116 New 
antibiotics have come onto the market to combat such strains but they are not 
without severe side effects. So the search continues to find an all conquering 
antibiotic for the so called 'superbugs' of today and their mutations of 
tomorrow and with many libraries of antibiotic derivatives already in place 
we are one step closer to achieving this goal. Because of its already observed 
potency, vancomycin's core framework has become an important target for 
derivative synthesis and thus easy, rapid, and convergent synthetic
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methodology of such an entity has become a necessity for efficient screening 
of the drugs of tomorrow for diseases such as MRSA.
II 2.2 Retrosynthetic issues of vancomycin
All glycopeptide antibiotics are structurally highly related and fall 
into one of the sub-categories: vancomycins, ritocetins, teicoplanins, and 
avoparcins. Their core structure consists of a cyclic polypeptide framework 
with a variety of substituents giving the molecule its characteristics. 
Vancomycin for example comprises amino, hydroxy, amido, carboxylic, 
phenolic, and chloro functionality. Vancomycin has a strained heptapeptide 
framework or aglycon and another disaccharide-containing segment made 
up of an L-vancosamine unit linked to a D-glucose unit through an a- 
glycoside bond. The aglycon is fused to the L-vancosamine section via a 
phenolic /3-glycoside linkage. The heptapeptide aglycon unit can be broken 
down retrosynthetically to its seven base amino acids (AA 1-7). There are five 
aromatic components (A-E) and eight stereocentres within these seven amino 
acids and they make up the three macrocycles of the heptapeptide; in 
addition the structure therefore inherently contains three sites of 
atropisomerism (Scheme 55) . 117118
The amino acid building blocks themselves present a formidable 
challenge to the synthetic chemist due to the stereochemistry and 
functionality involved. Amino acids AA-4, 5, and 7 (206, 207, and 209 
respectively) are examples of aryl glycines, AA-2 and 6  (204, and 208) are /3- 
hydroxytyrosine derivatives, AA-1 203 is a protected N-methyl leucine and 
AA-3 205 is an asparagine derivative. Both Evans and Nicolaou have 
completed the total synthesis. 119120 The syntheses differ overly in their build­
up of the three macrocycles AB, C-O-D and D-O-E. Evans commenced with
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the AB macrocycle, followed by the C-O-D and D-O-E aryl ether linkages. 
Nicolaou on the other hand found success by beginning with the C-O-D 
macrocycle and to append AB and D-O-E units accordingly. Once these 
appendages were complete, further functional group interconversions were 
necessary.





Me02C ^ N H 2
AA-4
206
One key aspect of the total structure of vancomycin is that of 
atropisomerism. The three macrocycles must be constructed in their specific 
conformations due to the fact that rotation about the C-O and C-C bonds 
within the macrocycles is in fact an energetic barrier. Evans more 
convincingly introduces this selectivity via a nucleophilic aromatic 
substitution of a fluoro species as a 5:1 ratio in favour of the correct
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atropisomer. Nicolaou on the other hand settles for a lack of selectivity with 
regards to the correct atropisomer utilising a triazene driven copper 
mediated reaction.
Returning to the seven amino acid building blocks, any synthetic 
route that may be envisaged must be facile and efficient in providing the 
degree of stereoselectivity required that is inherent in these sub-structures.
The asymmetric catalysis methodology that was described previously 
(Section II 1) has potential for such a synthesis of one of these key building 
blocks of vancomycin. The same stereochemical information portrayed in the 
enantioselective aldol reaction is inherent in the amino acid AA- 6  208, a )5- 
hydroxytyrosine derivative. The synthesis of AA- 6  208 incorporating this 
methodology as the key step is described in due course after briefly 
examining previous enantioselective syntheses of AA- 6  208.
II 2.3 Previous asymmetric syntheses of vancomycin's 
building block AA-6
Described in the four part report on the total synthesis of vancomycin, 
Nicolaou targets a Sharpless asymmetric aminohydroxylation step as key to 
AA-6 's synthesis. 117 The synthesis is carried out over six linear steps starting 
from the commercially available 4-hydroxy benzaldehyde 210 (Scheme 56). 
The overall synthesis generates AA- 6  in 31% and the key enantioselective 
step delivers the correct enantiomer in 87% ee but in a poor yield of 45%.
4-hydroxy benzaldehyde 210 is first benzylated before a Homer- 
Wadsworth-Emmons reaction with (Et0 )2(0 )PCH2C0 2 Et to yield trans-a,fi- 
unsaturated ester 211. This sets up the Sharpless asymmetric 
aminohydroxylation to give 212 in 45% yield and 87% ee. The low yield is 
attributed to a regioselectivity issue governed by the type of ligand
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incorporation, PHAL or AQN but Nicolaou omits any description of the 
actual regioselectivity observed. Subsequent protection/deprotection steps to 
furnish the free amino ester 213 swiftly follow this step. To finish the 
synthesis reaction of 213 with SO2CI2 provides the 3-chloro adduct 214 in 80% 
yield.
Scheme 56. Nicolaou's synthesis of AA-6 .













Reagents: (a) BnBr, K2C 03i Kl, 98%; (b) (Et0 )2(0 )PCH2C0 2 Et) KOH, 95%; 
(c) NaOH, NH2C 02Bn, fBuOCI, (DHQD)AQN, K2[0 s 0 2(0H)4], nPrOH:H20  (1:1), 
45% (87% ee); (d) TBSOTf, 2,6-lutidine, 98%; (e) H2, Pd(OH)2/C, 95%; 
(f) S 0 2CI2, Et20 , 80%.
In the Evans's synthesis of vancomycin the Evans auxiliary is called 
upon to build the AA- 6  sub-unit (Scheme 57) . 119 A chiral glycine derivative 
(S)-193 involving the oxazolidinone auxiliary is partnered with aldehyde 215 
in a tin(II) triflate mediated aldol condensation. A 95:5 diastereoselectivity in 
favour of the desired syn-aldol was attained. The AB macrocycle is then duly 
developed before further manipulation has taken place on the AA- 6  portion. 
Later in the synthesis of the AB macrocycle, the oxazolidinone is ring opened 
with LhCCb in MeOH and even further along the synthesis, after the C-O-D
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linkage step which employs the aryl fluoride functionality, the nitro group is 
removed with Zn°, HO Ac, and EtOH.
Scheme 57. Evans's construction of the AA- 6  portion.
Cl
b, c 0 2N
215 h
Reagents: (a) Sn(OTf)2, /V-ethylpiperidine; (b) Boc20 , DMAP, then 




Rama Rao et al have also synthesised a protected form of AA- 6  
starting from a chiral tyrosine amino acid. The inherent (S)-stereocentre of 
the amino acid was used as a platform to introduce the second stereocentre 
via a silver nitrate promoted displacement of epimeric /J-bromo intermediate 
219 (Scheme 58).113
Scheme 58. Synthesis of AA- 6  from (S)-tyrosine.
o 1. AgN03l2. MeOH, HCI H q  j
H02C ^ N H 2 3. S 0 2CI2 MeOzC^NPht 2 2TBSOTf Me0 2Cvy*NPht
4. AczO 3- Na0Me
5.NBS.AIBN Br T T  TBSO T  j f
53% 0Ac 49%, 80% de 0H
218 219 220
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One final mention to synthetic methods of AA- 6  is that of the Genet's 
group in which asymmetric catalytic hydrogenation takes centre stage. Genet 
commences from the aryl-jS-ketoester 2 2 1  and after two steps the racemic a- 
ketoamide 2 2 2  is treated with an optically active ruthenium catalyst under 
140 bar of hydrogen to incorporate the correct configuration at both 
stereocentres (Scheme 59) . 113
Scheme 59. Synthesis of AA- 6  by asymmetric catalytic hydrogenation.
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II 2.4 A direct catalytic enantioselective synthesis of AA-6
The handful of syntheses just described are the few in the literature 
that bias any enantioselective route to the jS-hydroxy-a-amino acid AA- 6  to 
date. Others either give poor diastereoselectivities or generate the anti- 
adduct as a major product rather than the desired syn-aldol. 113 The desire for 
high enantio- as well as diastereo-control means that finding an effective 
strategy is difficult. The direct catalytic enantioselective route to protected 
syn-^-hydroxy-a-amino acids as previously described (Section II 1) qualifies 
as such a route due to the fact that the key asymmetric step is early in the 
synthesis and quickly and directly gives a protected form of AA-6 . All one 
has to do after the key C-C bond formation is to deprotect the necessary 
functionality. A retrosynthetic view is given in Scheme 60.
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Scheme 60. Retrosynthetic analysis of AA-6 .
asymmetric 












As seen previously (Section II 1) the combination of a tridentate 
PyBOx ligand, magnesium perchlorate and Hiinig's base allows the catalytic 
generation of a chiral glycine-enolate that undergoes a highly 
enantioselective addition to a range of aryl aldehydes.
II 2.5 The key enantioselective step: in search of a 
protected aldehyde
It was now time to extend this aldehyde range to an appropriate 
aldehyde that contained the correct 3-chloro and 4-hydroxyl substitution 
pattern in order to reach the final amino acid of vancomycin. 3-Chloro-4- 
hydroxy benzaldehyde is commercially available and was tested in the 
standard reaction (Section I I 1) but the free hydroxyl moiety suppressed any 
reactivity. Therefore, a range of protected aldehydes at the 4-hydroxyl 
position were prepared and screened under the normal reaction conditions. 
The procedure also included the second step removal of the oxazolidinone 
for the ethyl ester derivative for ease of HPLC analysis. It was evident from 
the examples chosen that those, which had a more electron-rich aryl system, 
fared better (Table 7). The protecting groups examined were TBS (entry 2), 
MEM (entry 3), MTM (entry 4) and finally PMB (entry 5) respectively. 
Although encouraging results were obtained with the middle three entries it 
was not until the PMB group was explored that the true nature of an electron
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rich system was realised. In fact, an excellent diastereoselectivity and 
enantioselectivity was observed with this example, 93:7 d.r. and 95% ee. This 
was the best result to date and for a structure with such implications towards 
natural product synthesis beckoning (this was a good day).












DCM, 4 A MS I f l-78 °C, 24 h
2. (EtO)MgBr
T
B 0 2C ^ \
THF, 0 °C
h H s
Entry P Product Syn-.anti0 Yield (%) ®®syn (%)°
1 H - - 0 -
2 TBS 224 75:25 80 74
3 MEM 225 77:23 79 72
4 MTM 226 93:7 63 82
5 PMB 227 93:7 77 95
a All reactions: isothiocyanate (1.0 equiv.), aldehyde (1.1 equiv.), 
Mg(CI04)2 (10 mol%),DIPEA (20 mol%) and ligand (11 mol%). 
b Diastereomeric ratio determined by 1H NMR. 
c Enantiomeric excess determined by Chiral HPLC using a Chiracel OD 
column.
The absolute configuration of the syn-227 aldol adduct was confirmed 
by X-ray crystallography (Appendix A) as being (4S,5R) as required for AA- 6  
(Figure 17).
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II 2.6 The racemic route: a lesson in deprotection/
protection chemistry
Now that a successful aldehyde candidate had been found for the key 
enantioselective step in the synthesis of AA-6 all that was required in order 
to reach the target molecule were a few deprotection and protection steps. 
Already a synthetic method was established to exchange the oxazolidinone 
for an ester appendage, which was required for the synthesis of AA-6 (Table
(4S,5R)-227
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7). The following description of events proceeded with the chosen syrc-aldol 
adduct 227 as a racemate (see Section III 11) in order to examine the 
feasibility of onward syntheses. In turn, it was necessary to deprotect the 
oxazolidinethione ring. Attempts at doing this directly failed in both acidic 
and basic media -  reactions gave complex reaction mixtures (Scheme 61).
It was deemed necessary to first N-protect and then transform the 
oxazolidinethione into oxazolidinone 229 via a peroxide oxidation.121 This 
methodology was successfully achieved in one pot (Scheme 62) employing 
B0 C2O and H2O2/HCO2H as reagents. The oxazolidinone functionality later 
proved to be easier to ring open.
Scheme 62. Manipulation of the oxazolidinethione ring.
Scheme 61. Direct oxazolidinethione deprotection. 
OPMB







1. B0 C2O, DMAP 
DCM, RT, 45 min.






Protection of the nitrogen as the N -Boc species and displacement of 
sulfur for oxygen gave a much more accessible ring towards deprotection. 
Treatment of 229 with a catalytic amount of CS2CO3 in ethanol gave a 25%
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yield of the desired ring opened material although this chemistry was far 
from optimal. The major drawback with this reaction was that of a major 
elimination side reaction (Scheme 63). The (Z)-configuration was assigned by 
analogy to the methyl ester analogue 237 via NOESY experiment (appendix 
F) -  see later (Scheme 67).















BocHN ^ A opMB 
231
As an aside, it was envisaged that by replacing the Boc for a CBz N- 
protecting group on the oxazolidinethione ring the number of steps could be 
reduced in the synthesis of AA- 6  by allowing a double PMB and CBz 
deprotection step via hydrogenation. The N -CBz protected adduct was 
obtained in 74% yield (Scheme 64). On treatment with cesium carbonate in 
ethanol a complicated mixture of products was observed; again the 
elimination product predominated, but also the CBz group was removed and 
further transesterification occurred. Therefore this route was terminated.
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1. CBz20 , DMAP 
DCM, RT, 45 min.
2. H20 2, HC02H Et02C 




Returning to the original problem, this was eventually remedied 
through the exploration of various solvents. If the afore mentioned reaction 
was carried out in methanol the outcome was, as a major product, the 
desired deprotected oxazolidinone rather than the elimination side-product. 
In fact, a different problem now arose. Due to the utilisation of the ethyl ester 
a mixture of methyl and ethyl transesterification products were attained 
when the reaction was conducted in methanol. Therefore the initial 
oxazolidinone formed directly from the asymmetric aldol addition was 
necessarily transformed to the corresponding methyl ester 234 via reaction 
with (MeO)MgBr in THF with very similar results as in the preparation of 
ethyl ester analogue 227 (Scheme 65).
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DCM, 4 A MS 
-78 °C, 24 h
OPMB
2. (MeO)MgBr MeOzC^^^A*
Cl THF' ° ° C 234 h’H
s
OPMB
Y = 78%, d.r.b = 93:7, eec = 94%
a Reaction conditions: isothiocyanate (1.0 equiv.), aldehyde (1.1 
equiv.), Mg(CI04)2 (10 mol%), DIPEA (20 mol%) and ligand (11 
mol%).
b Diastereomeric ratio determined by 1H NMR. 
c Enantiomeric excess determined by Chiral HPLC using a Chiracel 
OD column.
With the methyl ester analogue in hand the same procedure of N -Boc 
protection and sulfur displacing oxidation again utilising racemic material 
(see Section III 11) could now be carried out. This reaction gave similar 
results to the ethyl ester giving a high yield (73%) for the one-pot process 
(Scheme 6 6 ).
Scheme 6 6 . Manipulation of the oxazolidinethione ring (methyl ester).
Me02C
OPMB
1. BoCzO, DMAP 
DCM, RT, 45 min.





The key step of ring opening the oxazolidinone was then performed 
under careful conditions and produced the desired hydroxy-carbamate 236
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successfully in 60% yield unavoidably giving a small amount of the 
elimination by-product 237 (Scheme 67).
Scheme 67. Ring opening of the oxazolidinone functionality (methyl 
ester 235).
With this ring-opened material in hand, the scene was set to embark 
on the final deprotection chemistry. It was decided to remove the PMB group 
last, therefore it was necessary to deprotect the N-Boc moiety. Finally to give 
a direct comparison to Nicolaou's AA-6 compound 214, the protection of the 
free hydroxyl as a TBS ether was necessary.
It was envisioned that these last two steps could be incorporated into 
one single reaction step by the use of the reagent TBSOTf. This reagent, 
commonplace in the literature as a silylating agent, has also been used to 
deprotect N-Boc groups in the presence of 2,6-lutidine.122 Utilisation of 2.6 
equivalents of TBSOTf and excess 2,6-lutidine was enough to complete both 
the hydroxyl protection and N-Boc deprotection. On basic work-up 
employing a solution of K2CO3 in MeOH/water, any remaining base labile N- 
CO2TBS species was cleaved to give the free amino alcohol in quantitative 
yield (Scheme 68). Without a basic work-up only 44% yield of the desired 
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Scheme 6 8 . One-pot double TBS protection and N-Boc deprotection.
OH o RjutiHino i'k a 2A \ OTBS
M6O2C 
BocHN
TBSOTf (2.6 eq.) 
2,6-lutidine (3.5 eq.)
DCM, RT, 1h Me02C
236





The final step of the racemic synthesis was to cleave the PMB group to 
furnish the free o-chloro phenol. In the literature it has been demonstrated 
that o-Cl-OBn protected phenols can be cleaved utilising classical palladium 
based hydrogenation . 123 Pearlman's catalyst, 20% Pd(OH)2 on carbon was 
employed as the palladium source and treatment with hydrogen under 
vigorous stirring accomplished the de-p-methoxybenzylation. Yields of 60% 
were achieved, after column chromatography, of the desired AA- 6  analogue 
239 (Scheme 69). Reassuringly in this reaction only one product was 
observed and the Cl-group and more hindered benzyl fragment of the 
compound were left intact.





H2, Pd(OH)2/C Me0 2Cv^






II 2.7 The asymmetric route to AA-6
Now that the chemistry and synthetic route to the AA- 6  analogue had 
been proven, the synthesis could be taken through with asymmetric material 
from the initial key enantioselective aldol reaction. This was subsequently 
achieved with similar results to the racemic synthesis over all steps. The final
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hydrogenation step was improved slightly generating the final product 
(4S,5R)-239 in 69% yield. The overall scheme of synthetic events is provided 
below (Scheme 70).
Scheme 70. Asymmetric synthesis of AA- 6  methyl ester analogue.
1.
O o
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(2S,3/?)-238 100% (2S,3R)-239 ^
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The overall yield for this asymmetric synthesis was 23% over 6  steps 
commencing from the enantioselective key aldol step. The ethyl ester adduct 
syn-227 was shown to have the correct configuration true to AA- 6  through X- 
ray crystallography and later steps of the synthesis with methyl ester 
derivatives 234, 235, 236, 238, and 239 generated no apparent epimerisation 
products. The final AA- 6  analogue 239 gave polarimetry parameters of the 
same sign ([a]D20 = -11.0 (c = 1.0, DCM)) to the final ethyl ester 214 ( [ c i J d 22 =  -  
17.9 (c = 0.98, EtOAc)) as in Nicolaou's AA- 6  synthesis.
II 2.8 Conclusion
What must be noted in this section is the fact that, although further 
protection and deprotection steps were found to be necessary in this formal 
synthesis of vancomycin's AA- 6  building block, the elementary idea of the 
application of a direct catalytic enantioselective route with a high degree of 
stereoselectivity to such a target has been accomplished. The asymmetric key 
steps in syntheses of AA- 6  to date have been limited in the degree of 
enantioselectivity achieved. Nicolaou's very impressive synthesis although 
very short (32% in 6  steps) encompasses a low yielding (45%) asymmetric 
aminohydroxylation that achieves a respectable 87% ee. The asymmetric 
synthesis described in this section allows for a high yielding 
diastereoselectivity (93:7 d.r.) and excellent enantioselectivity (94-95% ee) and 
incorporates this stereochemistry early on. A key problem encountered was 
the difficulty in deprotecting the oxazolidinethione moiety directly and 
therefore further manipulation was deemed necessary. With starting 
materials in hand, the zsothiocyanate 154 and aldehyde 233 were taken 
through to the methyl ester analogue of AA- 6  in 6  steps and an overall yield 
of 23%.
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II 3 A direct catalytic enantioselective route to afi- 
diamino acids
II 3.1 Introduction
A key aspect of the project was to further develop and expand the 
scope of electrophiles utilised in the bifunctional enantioselective catalysis 
already developed for aryl aldehydes. The addition of oxazolidinone 154 to 
imines proved attractive due to the fact that products of such a Mannich type 
reaction would deliver protected a,/3-diamino acids in the form of cyclic 
thioureas. This type of Mannich reaction with post addition cyclisation of the 
zsothiocyanate substituent has been reported by Volkmann. 124 The protected 
a:,/3-diamino acid moiety has important potential applications, including the 
formation of /3-lactams, scaffolds for some of the most important 
antibiotics. 125 The formation of an imidazolidinethione should prevent the 
epimerisation at the n-carbon. The proposed reaction is illustrated below 
(Scheme 71).
Scheme 71. Proposed Mannich reaction.
The transition from zsothiocyanato ethyl ester 155 to oxazolidinone 154 
in the achiral catalytic aldol reaction showed increases in reactivity. The 
former substrate depended more on the bipyridine complexed Mg catalyst 
for maximised yields. Therefore, exploration of a catalytic Mannich reaction
S
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commenced with oxazolidinone 154. The imine partner, N-tosylimine 240 
was selected as an activated imine source due to literature precedent of 
readily undergoing imine-aldol reactions. 126127 It was soon realised that N- 
tosylimine 240 utilising similar catalytic conditions; Mg(ClC>4)2 (10 mol%) and 
DIPEA (20 mol%) readily underwent the addition reaction in DCM at -78 °C 
employing two equivalents of tosylimine (Scheme 72). It was a surprise to 
observe that the reaction was in fact flnh-selective and delivered the adduct 
in high yield. The next stage of development addressed the application of 
this catalysed reaction to an enantioselective reaction employing C2- 
symmetric ligands as in the asymmetric aldol reaction.
Scheme 72. Achiral Mannich reaction.
Me
Mg(CI04)2 (10 mol%) 
DIPEA (20 mol%)
NCS + Ocro
DCM, -78 °C 
24 h \__ /
241
Me
154 240 Y = 80%
syrr.anti= 14:86
II 3.2 Asymmetric induction
The C2-symmetric ligands elected for the asymmetric induction screen 
are presented below (Figure 18). Again a range of bidentate bis(oxazolines) 
were examined (entries 1 to 4, Table 8 ) and all produced the predominant 
fltth-imidazolidinethione adducts in relatively poor ee. The highest 
enantioselectivity was achieved by (4R)-benzyl substituted bis(oxazoline) 242 
(1eeanti = 39%, entry 3). A vast array of tridentate pyridine bis(oxazolines) 
(PyBOx) ligands were also examined in the screen. All of these ligands
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produced the imidazolidinethione adducts in high yield and anfz-selectivities 
of up to 86:13 (entries 6  to 11). The (4S)-benzyl substituted PyBOx 178 gave 
the poorest enantioselectivity of this ligand type (eeanti = 8 % , entry 8 ). The 
successfully employed (4R)-phenyl substituted PyBOx 181 with regards to 
the asymmetric aldol reaction (Sections II 1 and II 2) delivered the anti- 
product in only 45% ee (entry 11). The highest enantioselectivity from a 
PyBOx ligand was achieved by employing (4R)-zsopropyl PyBOx 244 (eeanti = 
70%, entry 7). The last ligand variety explored was the tridentate 
dibenzofuran bis(oxazoline) (DBFOx) that comprises a central oxygen 
coordinating atom.
Figure 18. C2-symmetric ligands.
(4R5S)-152
242: R1 = Bn; R2 = H 
243: R1 = H; R2 = 'Bu
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1 172 24 25:75 82 10
2 152 24 20:80 100 4
3 242 24 33:67 97 39
4 243® 24 40:60 83 4
5 175 24 13:87 94 96
6 176 24 22:78 100 63
7 244 24 14:86 100 70
8 178e 24 31:69 100 8
9 179e 24 39:61 82 19
10 180e 24 20:80 100 43
11 181 24 37:63 100 45
aConditions: isothiocyanate (1.0 equiv.), tosylimine (2.0 equiv.), 
Mg(CI04)2 (10 mol %), DIPEA (20 mol %) and ligand (11 mol %). 
b Diastereomeric ratio determined by 1H NMR. 
c Isolated yield of both diastereomers. 
d Enantiomeric excess determined by Chiral HPLC using a 
Chiracel OD column.
e Enantiomeric excess corresponds to opposite enantiomer.
This ligand, (R,R)-Ph-DBFOx (R,R)-175, gave poor selectivity in the 
aldol reaction but the switch from aldehyde to a tosylimine electrophile 
furnished the flntz-imidazolidinethione adduct in high yield and with an ee of 




II 3.3 Tosylimine scope
Results & Discussion
Now that a highly selective ligand had been discovered, which 
invoked high enantioselection and diastereoselection, it was time to explore 
the scope of the tosylimine component (Table 9). To aid in the determination 
of ee values of certain products, the direct adducts were treated with a 
solution of magnesium ethoxide to yield the more soluble corresponding 
ethyl ester derivatives (entries 11 to 14) (Section III 17). As with the 
asymmetric aldol reaction, a wide variety of substitution on the aryl imine 
was readily accommodated. Both electron rich and electron poor substitution 
in the ipara and meta positions delivered adducts in high ee, for example the 
anti-adducts from 4-bromo tosylimine 247 (eeanti = 98%, d.r. = 83:17, entry 3), 4- 
cyano tosylimine 258 (eeanti = 99%, d.r. = 67:33, entry 14) and 3-methyl 
tosylimine 249 (eeanti = 99%, d.r. = 86:14, entry 5). This degree of electrophile 
scope, employing electron-rich and poor systems, is in contrast to that of the 
comparable aldol reaction. The reaction could also be applied to a wide range 
of tosylimines other than aryl species such as heterocyclic, alkenyl, and alkyl 
imines with a high degree of enantioselection, for example where R = 
cyclohexyl 251 (eeanti = 99%, d.r. = 67:33, entry 7), R = (E)-cinnamyl 254 (eeanti =  
97%, d.r. = 78:22, entry 9) and R = thiophenyl 255 (eeanti = 90%, d.r. = 50:50, 
entry 11). This was not achieved in the aldol variant. One last example, 
where R = n-pentyl 252 (entry 8 ) although produced in lower yield and 
diastereoselectivity was furnished in 84% ee.
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Entry R Product • Anti:synb Yield (%)c eeanti (%)d
1 Ph 241 87:13 94 96
2 2-Naphthyl 246 93:7 100 98
3 4-Br-C6H4 247 83:17 86 98
4 4-F-C6H4 248 75:25 98 93
5 3-Me-C6H4 249 86:14 91 99
6 4-fBu-C6H4 250 82:18 96 99
7 Cy 251 67:33 98 99
8 C5H11 252 67:33 40 84
9 (E)-cinnamyl 253 78:22 97 97
10 2 -furyl 254 50:50 92 _e,f
11 2 -thiophenyl 255 50:50 94 90®
12 4-Me-C6H4 256 83:17 96 99e
13 4-MeO-C6H4 257 76:24 86 97e
14 4-CN-C6H4 258 67:33 85 99e
Conditions: isothiocyanate (1.0 equiv.), tosylimine (2.0  equiv.), Mg(CI04)2 
(10 mol%), DIPEA (20 mol%) and (R,R)-Ph-DBFOx 175 (11 mol%). 
b Diastereomeric ratio determined by 1H NMR. 
c Isolated yield corresponds to combined diastereomers. 
d ee  determined by chiral HPLC on a Chiralcel OD column. 
e ee  corresponds to the derivatised ethyl ester. 
f Enantiomers could not be separated by Chiral HPLC.
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II 3.4 Absolute configuration -  Xray crystallography 
experiments
The absolute configuration of the major anti-adducts was confirmed 
by X-ray crystallography of two of the above examples; b e n z y l and 
cyclohexyl adducts, anti-241, and anti-251 respectively to be (4S,5S) (Figures 
21 and 22). The other examples reported have been assigned by analogy. The 
same (4S)-configuration is observed in the product as in the asymmetric aldol 
reaction which implies the same si face attack from the enolate species to the 
electrophilic component albeit with a different C2-symmetric ligand. The fact 
that the anfr'-diastereomer of (5S)-configuration, is formed preferentially, is 
believed to be due to the nature of the tosylimines coordination to the Lewis 
acid. The steric hindrance due to the much larger spatial occupancy of the N- 
tosyl group compared to that of an aldehyde is responsible for a change in 
orientation of the coordinating electrophile i.e. the metal would lie cis to the 
R-group of the imine, and lie trans to the R-group of an aldehyde (Figure 20). 
This difference in orientation would transfer to the transition state and 
therefore inherently determine the diastereomeric outcome of the reaction.
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Figure 2 2 . Imidazolidinethione (4S,5S)-251 and X-ray crystal structure.
II 3.5 C onclusion
The extension of an asymmetric catalytic aldol process involving soft 
enolisation to reach other electrophiles in particular tosylimines (a Mannich 
variant) has been accomplished. The discovery of (R,R)-Ph-DBFOx 175 as an 
effective enantioselective ligand for the reaction of tosylimines with 
oxazolidinone 154 was crucial in this development. The other commercially 
available catalyst components remained the same, the Lewis acid, Mg(C104)2 
and amine base, DIPEA. The characteristics of this imine-aldol reaction out 
perform those of the aldol reaction in that higher enantioselectivity is 
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with alkyl substitution. The observed an t/-selectivity, which is unusual in 
such an addition, is the reverse of the aldol process and has been achieved in 
ratios of up to 93:7 for the 2-naphthyl analogue 246. Time constraints have 
not allowed any probing of the mechanism although it is believed to be 
similar to the aldol process aforementioned (Section I I 1) with the tosylimine 
adopting a different orientation of coordination to the Mg centre.
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II 4 A direct catalytic and diastereoselective route to 
protected a,/?-dihydroxyketones
II 4.1 Introduction
To supplement the direct catalytic asymmetric synthesis of jS-hydroxy- 
a-amino and a,j8 -diamino moieties it was envisaged that employment of an 
n-oxygenated carbonyl in our system would add to aldehydes to yield a,f$- 
dihydroxy adducts. This third class of functionality is ubiquitous in a variety 
of natural products and biologically active molecules and examples of such 
are described in section (II).
Accordingly, there are a number of methods available to prepare this 
structural motif128 but one of the most attractive strategies is the use of an a- 
oxygenated enolate addition to an aldehyde which features a single step 
formation of both a carbon-carbon bond and two hydroxyl stereocentres. 
Direct catalytic examples that deliver high diastereoselectivity and 
enantioselectivity are rare and present a formidable challenge.
One problem that was envisioned in applying our catalytic system to 
the synthesis of poly-hydroxylated adducts was the possibility of product 
inhibition due to binding between an alkoxy intermediate and Lewis acid. To 
limit this an a-carbonate substituent was chosen that should allow in situ 
protection of the newly formed hydroxyl group via carbonate transfer 
(Scheme 73). This strategy of incorporating the newly formed hydroxyl 
group in a cyclic structure follows suit to that of the zsothiocyanate variant of 
the proposed reaction.
106
Chapter II Results & Discussion
Scheme 73. Direct catalytic aldol route to protected 1,2-diols.
O O
n  n p i A  catalyst
° Y ° R + H R2 ------------- *
o
Me
R1 = — Me — Et
259 260 261
II 4.2 Initial studies
A selection of phenyl ketones with various a-carbonate substituents; 
methyl 259, ethyl 260, z-propenyl 261 and phenyl 262 were prepared from 
phenacyl alcohol and the corresponding chloroformate for initial study 
(Section III 18).129 The choice of an aryl ketone was believed to be a good 
starting point. The increased acidity of a-protons compared to that of 
ester/amide analogues would allow for more facile deprotonation since the 
reactivity was unclear for these substrates in a soft-enolisation system. 
Benzaldehyde 17 was elected as the initial electrophilic component due to its 
non-enolisable nature. Catalyst conditions employed in the enolisation of a- 
isothiocyanate substituted esters for the synthesis of protected /Lhydroxy-a- 
amino acids, previously developed in our group, were investigated in this 
reaction. The catalyst components of this system were Mg(ClC>4)2 (10 mol%), 
bipyridine (10 mol%), and triethylamine (20 mol%). The -carbonates were 
initially reacted with sub-stoichiometric (50 mol%) loadings of Lewis acid 
component and a stoichiometric amount of tertiary amine base in order to 
gain insight into the reactivity of the addition reaction (Table 1 0 ).
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Table 10. a-Carbonate variation.3
Mg(CI04)2
O  O  h in\/ T E A  O  ■ h  O
O 17 263 o - ^  264 O
O




1 Ethyl 48 49 12
2 Methyl 48 62 23
3 Phenyl 48 38 50
4 /-Propenyl 48 50 50
a All reactions: carbonate (1.0 equiv.), aldehyde (1.1 
equiv.), Mg(CI04)2 (50 mol%), bipy (50 mol%), TEA (100 
mol%).
b Conversion measured by 1H NMR.
Under conditions of high Lewis acid loading the cyclic carbonate 
product 263 was found to be unstable and readily underwent elimination to 
generate a 1,2-dicarbonyl by-product 264. The use of methyl carbonate 259 
(entry 2 ) gave greater conversion to the cyclic carbonate than ethyl carbonate 
260 (entry 1) and z-propenyl carbonate 261 (entry 4) reacted fastest under the 
high Lewis acid loading. The phenyl carbonate 262 (entry 3) proved to be 
unstable under the reaction conditions and was soon discarded from the 
investigation. The elimination that occurs is depicted in scheme 74 and was 
later found to be easily controlled under conditions of lower Lewis acid 
loading.
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Scheme 74. Generation of 1,2-dicarbonyl by-product.
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II 4.3 Employment of additives
Under lower loadings of the Lewis acid magnesium perchlorate (10 
mol%) the generation of 1,2-dicarbonyl 264 had completely diminished 
(Table 11) but yields of the desired cyclic carbonate 263 were low (entry 1) 
even after extended reaction times. In order to increase yields the addition of 
4 A MS was found to be beneficial with methyl carbonate 259 (entry 3). The 
reason for this was initially believed to be due to removal of methanol 
introduced into the system, which could potentially deactivate the Lewis 
acid. It was later observed that z-propenyl carbonate 261 which generates 
acetone rather than an alcohol into the system also gave an increased yield
o
with the addition of 4 A MS (entry 7). The more obvious reason for this 
increased reactivity lies in the hygroscopic nature of Mg(C104)2, in that 
weighing and charging was not carried out in an anhydrous atmosphere and
o
4 A MS act to activate the Lewis acid catalyst. The exclusion of either 
bipyridine or 4 A MS resulted in minimal reaction (entries 1 and 2 ). In order 
to achieve greater yields and turnover of the catalyst an alcohol could also 
act as a proton source and thus z'-PrOH (entry 4) and 2,2,2-trifluoroethanol
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(entry 5) were examined in the system . 130 These additives gave no beneficial 
turnover of catalyst.
Table 11. Effects of additives.3
Ph
o
OR + . A
Mg(CI04)2 
bipy, TEA O Ph
Y  " H Ph THF.RT Ph 
O additive
17
O + Ph' y  'Ph
<H  °
263 °  264
Entry R Additived Time (h) Yield 263 Yield 264 
(%)b (%)b
1 Methyl - 96 13 0
2° Methyl 4 A MS 72 16 0
3 Methyl 4 A MS 48 57 0
4 Methyl 4 A MS, 'PrOH 48 51 0
5 Methyl 4 A MS, CF3CH2OH 48 52 0
6 'Propenyl - 48 16 0
7 'Propenyl 4 A MS 48 62 0
a All reactions: carbonate (1.0 equiv.), aldehyde (1.1 equiv.), Mg(CI04)2 (10 
mol%), bipy (10 mol%), TEA (100 mol%). 
b Conversion measured by 1H NMR. 
c No bipy employed.
d 'PrOH and CF3CH2OH (I.Oequiv.), 4 A MS (200 mg/mmol of carbonate).
II 4.4 Other preliminary variables
At this point in the development of the a-carbonate addition, it was 
deemed necessary to investigate such variables as equivalents of reagents, 
temperature, and solvent systems. Under the conditions of Mg(C104)2 (10 
mol%), bipyridine (10 mol%) in THF at RT the excesses of tertiary amine 
base, aldehyde and carbonate were examined to see whether the reaction 
could be driven to completion (Table 1 2 ).
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TEA (200 mol%, entry 2), aldehyde (2.2 equivalents, entry 3), and 
carbonate (2.0 equiv., entry 4) were employed but none of these conditions 
enhanced reaction efficiency. The effect of temperature was also briefly 
examined. At attenuated reaction temperatures (entry 6 ) the reaction started 
to become a complex mixture of products and lowering the temperature to 0  
°C inhibited the reactivity of the catalyst (entry 7).
Table 1 2 . Effect of reagent stoichiometry and temperature .3
Mg(CI04)2
°  °  bipy, TEA °  PI
+ H Ph THF P i l ' Y o
O 4AMS 0-4
17 263 O
Entry R Time (h) T(°C) Yield 263 
(%)b
1 Methyl 48 RT 57
2° Methyl 48 RT 56
3d Methyl 48 RT 47
4® Methyl 48 RT 50
5f 'Propenyl 48 RT 16
6f 'Propenyl 48 35 22
7f 'Propenyl 48 0 0
a All reactions: carbonate (1.0 equiv.), aldehyde (1.1 
equiv.), Mg(CI04)2 (10 mol%), bipy (10 mol%), TEA 
(100 mol%), 4 A MS (200 mg/mmol of carbonate). 
b Conversion measured by 1H NMR. 
c TEA (200 mol%). 
d Aldehyde (2.2 equiv.). 
e Carbonate (2.0 equiv.). 
f No 4 A MS used.
The effects of several solvents were also examined in this reaction 
(Table 13). In changing the solvent, a reduction in the difference in pKa 
between the substrate coordinated to Mg2+ and tertiary amine base may be
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achieved therefore increasing the rate of enolisation. It is also possible that a 
change in solvent could accelerate the turnover of catalyst. The polarity of 
the solvent could affect stabilisation of any transition state involved and/or 
products generated which would alter rates of forward/retro aldol reactions.
Table 13. Solvent screening.3
Mg(CI04)2
9 9 bipy, TEA 9 ?h
P f r ^ ° Y ° Me + H Ph solvent P h ^ Y ^ O  
O RT ^
259 17 263 O
Entry Solvent Time (h) Yield 263 
(%)b
1 THF 48 13
2 DCM 48 1
3 Toluene 48 1
4 MeCN 48 0
5 DME 48 14
6 1,4-Dioxane 48 13
a All reactions: carbonate (1.0 equiv.), aldehyde (1.1 
equiv.), Mg(CI04)2 (10 mol%), bipy (10 mol%), TEA (100 
mol%).
b Conversion measured by 1H NMR.
The reaction carried out in acetonitrile (entry 4) gave no reaction and 
can be attributed to the solvents polarity and strong coordination to the 
magnesium cation. Less polar solvents like toluene (entry 3) and DCM (entry 
2) gave minimal reaction. Etheric solvents like DME (entry 5), 1,4-dioxane 
(entry 6 ), and THF (entry 1) provide some solvating function and gave the 




II 4.5 Lewis acid screening
Results & Discussion
Although magnesium has been a focal point of the project, it was 
deemed necessary to screen at least some of the well-known Lewis acids 
employed in catalyses in combination with an amine base. Varying the metal 
centre of the catalyst would allow insight into Lewis acid activity for the 
system under investigation.
Commercially available triflate salts of various metals were utilised 
(Table 14). Sn(II) and Cu(II) triflates (entries 3 and 4 respectively) produced 
no reaction whereas Zn(II) and Sc(III) triflates resulted in complex reaction 
mixtures. The use of Mg(II) triflate produced minimal reaction compared to 
its perchlorate counterpart (entry 2 ).
Table 14. Lewis acid screening.3
Lewis acid
o o bipyi TEA O Ph
y  H Ph THF’RT \ °o o -^
159 17 263 o
Entry Lewis acid Time (h) Yield 263 
<%)b
1 Mg(CI04)2 48 62
2 Mg(OTf)2 48 35
3 Sn(OTf)2 48 0
4 Cu(OTf)2 48 0
5C Zn(OTf)2 48 -
6C Sc(OTf)3 48 -
a All reactions: carbonate (1.0 equiv.), aldehyde (1.1 
equiv.), Lewis acid (50 mol%), bipy (50 mol%), TEA 
(100  mol%).
b Conversion measured by 1H NMR. 
c Complex reaction mixture resulted.
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From the few metal Lewis acids examined Mg(C104)2 offered the most 
active catalyst component and was therefore employed in the following 
screening of tertiary amine bases.
II 4.6 Base screening
In an attempt to increase the yield of the catalytic addition reaction a 
number of non-nucleophilic bases were screened. It is essential that the 
Lewis acid and amine base combination do not form an irreversible adduct. 
Thus bases deemed suitable were elected having a p K a  in water of 
approximately 5 to 12 (Table 15).131 Bases having a p K a  below 7 for example 
bipyridine (entry 1 ) and diethylaniline (entry 2 ) gave no reaction; a stronger 
base was required in order for the ketone to be deprotonated. The fact that 
bipyridine employed at a stoichiometric loading was unable to carry out the 
deprotonation heeds well for the function of bipyridine being that of an 
external ligand. Bases having a p K a  value of 11.0 and above gave little or no 
reaction. Quinuclidine (entry 8 ) and DBU (entry 10) afforded no reaction and 
this may be attributed to an irreversible Lewis acid base complex formation. 
DIPEA produced the cyclic carbonate in very low yield and poor selectivity 
(27%, entry 9).
The screening of amine bases allowed the selectivity of the soft- 
enolisation and addition to be examined. In all cases the syn-aldol adduct 
leading to the fnms-cyclic carbonate was the major diastereomer and it was 
in the p K a  range of 7.4 to 10.8 that the diastereoselectivity and yield of the 
catalysis became fruitful. Although DABCO (entry 4) and NEP (entry 5) 
afforded the cyclic carbonates as a 15:1 mixture of diastereomers the yields 
were particularly lower (31% and 45% respectively) than when TEA (62%, 
entry 6 ) was employed as the base. This is quite a surprising result since the
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p K a 's  of both DABCO and NEP lie between the p K a  range of NMM and TEA. 
NMM (entry 3) having a pKa  of 7.4 furnished the cyclic carbonate adduct in 
74% yield -  the highest yield achieved so far. This positive result was 
dampened somewhat by the low diastereoselectivity attained of 7:1 in favour 
of the syrc-aldol.
Table 15. Screening of amine bases.3
Mg(CI04)2
O O him/ O Ph O Ph
ph^ O Y C Me ,  HA ph^  * phA ^ o
O *' 4 A MS O - ^  O - ^
161 17 trans-263 O c/s-263 O
Entry Base pxad Time (h) SyrrAntP Yield 263 
(%)c
1 2,2'-Bipyridine 4.5 48 - 0
2 /V,A/-Diethylaniline 6.5 48 - 0
3 /V-Methylmorpholine 7.4 48 7:1 74
4 DABCO 8.8 48 15:1 31
5 Af-Ethylpiperidine 10.5 48 15:1 45
6 Triethylamine 10.8 48 13:1 62
7 Tri-n-butylamine 10.9 48 9:1 42
8 Quinuclidine 11.0 48 - 0
9 di-/-propylethylamine 11.4 48 2:1 27
10e DBU 12 48 - 0
a All reactions: carbonate (1.0 equiv.), aldehyde (1.1 equiv.), Mg(CI04)2 (10 mol%), 
bipy (10 mol%), base (100 mol%), 4 A MS (200 mg/mmol of carbonate). 
b dr measured by 1H NMR. 
c Conversion measured by 1H NMR. 
d pKa of protonated nitrogen in H20  at RT.131 
e pKa of protonated nitrogen in DMSO at RT.131
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The choice of carbonate for this study in the selection of amine base 
was later examined and will be described in the next sub-section. The choice 
between z-propenyl 161 and methyl 159 carbonates for further development 
was yet to be decided since similar results were gathered for these substrates.
II 4.7 Further optimisation
The initial focus of the use of z-propenyl carbonate 161 was to avoid 
the introduction of an alcohol into the system, which could potentially 
deactivate the Lewis acid. However, reaction of methyl carbonate 159 in 
combination with Mg(C104)2 employed at 20 mol% and NMM (Table 16) 
delivered the cyclic carbonate in almost identical conversion and an isolated 
yield of 72% along with an increased diastereoselectivity (10:1, entry 4). The 
utilisation of Mg at 20 mol% increased turnover and therefore yield of the 
reaction without the occurrence of 1 ,2 -dicarbonyl by-product formation 
observed earlier. The use of 20 mol% Lewis acid also allowed the reaction 
time to be reduced to 24 hours. The yield could be further increased to 91% 
by raising the equivalents of carbonate from 1.0 to 2.0 (entry 5). A 50 mol% 
loading of NMM was found to be optimal with lower loadings resulting in 
reduced yields (entries 5 and 6 ).
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Table 16. Final optimisation.3
Mg(CI04 )2
9 9 bipy, NMM 9 ? h 9 ?h
A  , o .  , o r  + A  -------------------  A  A  + A  X
ph H Ph THF.RT P t v Y l o  P I Y T f \ )
O 4 A MS O -^





Time (h) Syrr.Antib Yield 263 
(%)c
1 /-Propenyl 10 100 48 7:1 74
2 /-Propenyl 20 100 24 7:1 81
3d /-Propenyl 20 100 24 4
4 Methyl 20 100 24 10:1 72s
5f Methyl 20 50 24 10:1 91®
6 Methyl 20 20 24 11:1 78
7 Methyl 0 50 24 0
8 Methyl 20 0 24 0
99 Methyl 20 50 24 11:1 17
a All reactions: carbonate (1.0 equiv.), aldehyde (1.1 equiv.), bipy (as Mg), 4 A MS 
(200  mg/mmol of carbonate). 
b dr measured by 1H NMR. 
c Conversion measured by 1H NMR. 
d Mg(OTf)2. 
e Isolated yield. 
f 2 .0  equivalents of carbonate.
9 No bipy used.
To conclude the optimisation process, Mg(OTf)2 was also re-examined 
and produced minimal reaction (entry 3). It was established that both Lewis 
acid (entry 7) and amine base (entry 8 ) were necessary in order to achieve 
reaction and finally that bipyridine plays an important role as an external 
ligand and accelerates the reaction rate (entry 9).
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II 4.8 Ketone and aldehyde variation
With optimised conditions in hand, the scope of aldehydes that could 
be successfully employed in the reaction was investigated (Table 17). The 
catalyst system generated from Mg(C104)2 ( 2 0  mol%), bipyridine ( 2 0  mol%) 
and NMM (50 mol%) was used to promote the addition of carbonate 159 (2.0 
equiv.) to a range of aromatic aldehydes (1.0 equiv.). All reactions were 
conducted at RT in THF in the presence of 4 A molecular sieves. The 
benzaldehyde derived adduct was obtained in 91% yield as a 10:1 mixture of 
diastereomers (entry 1). Electron rich aldehydes such as p-tolualdehyde 
(97%, 16:1, entry 2) and p-anisaldehyde (8 6 %, 11:1, entry 3) also performed 
well, albeit after longer reaction times. Conversely, electron poor aldehydes 
gave quicker reaction times with p-trifluoromethyl- and p- 
cyanobenzaldehyde furnishing the cyclic carbonate adducts in 65% and 76% 
respectively (entries 4 and 5).
The phenyl ketone portions were then changed to the corresponding
2-naphthyl analogues (Section III 18) and the same trends broadly followed 
although less of an excess of carbonate 274 could be employed effectively. 
The benzaldehyde derived adduct was delivered in 79% as an 8:1 mixture of 
diastereomers (entry 6 ). p-Anisaldehyde (72%, 14:1, entry 8 ) delivered the 
required adduct in increased diastereoselectivity to the phenyl counterpart. 
This was also the case for electron poor aldehydes for example p- 
cyanobenzaldehyde (69%, 16:1, entry 10).
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J k . O v . O M e  +
4 AMS
Ar
Entry Ar R Product Time (h) SymAntP Yield
(%)c
1 Ph H 263 24 10:1 91
2 Ph Me 265 48 16:1 97
3 Ph OMe 266 48 11:1 86
4 Ph CO
LLO 267 24 9:1 65
5 Ph CN 268 18 9:1 76
6d 2-Naphthyl H 269 24 8:1 79
7d 2-Naphthyl Me 270 48 8:1 75
8d 2-Naphthyl OMe 271 48 14:1 72
9e 2-Naphthyl CO
LLO 272 24 15:1 97
10e 2-Naphthyl CN 273 18 16:1 69
a All reactions: carbonate (2.0  equiv.), aldehyde (1.0 equiv.), Mg(CI04)2 (20 mol%), 
bipy (20 mol%), NMM (50 mol%), 4 A MS (200 mg/mmol of carbonate). 
b dr measured by 1H NMR. 
c Isolated yields of combined diastereomers. 
d Carbonate (1.0 equiv.). 
e Carbonate (1.5 equiv.).
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II 4.9 Diastereoselectivity issues
Results & Discussion
In all examples that have been studied, the trans-cyclic carbonate has 
been isolated as the major diastereomer and selectivities of up to 16:1 have 
been achieved. An investigation into how these useful levels of 
diastereoselection arise has been conducted. The trapping of enolates 
produced under the catalytic conditions has been carried out using TMSC1. 
From aH NMR experiment The ratio of E:Z silyl enol ethers formed was 
found to be 1:1 (Scheme 75). Hence, an initial unselective aldol addition is 
believed to occur. This is then followed by a rapid cyclisation of the syn-aldol 
adduct to give the trans-cyclic carbonate. Cyclisation of the anti-aldol 
intermediate (which would provide the cz's-carbonate) is slow and 
preferentially reverts to starting materials (Scheme 76). This has been shown 
experimentally by preparative isolation of the initial anti-aldol adduct 
(Section III 20) and resubjection to the reaction conditions. Isolation of the 
syw-aldol adduct was not possible due to the rapid cyclisation step. Isolated 
cis and trans-cyclic carbonates have also been resubjected to the reaction 
conditions and have shown no signs of epimerisation.










Scheme 76. Origin of diastereoselectivity.
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II 4.10 Synthetic utility
tf,j8 -Dihydroxylated ketones are established intermediates in organic 
synthesis and specifically for the above direct catalytic route comprise 
electron rich analogues. The inclusion of an aromatic ketone substituent 
allows the amenable synthesis of aryl esters. Baeyer-Villager oxidation of 
both phenyl and 2 -naphthyl adducts was found to be straightforward when 
phosphate buffered m-CPBA was employed (Scheme 77).
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Scheme 77. Baeyer-Villiger oxidations.
O Ph m-CPBA o  Ph
H  Ho o
Ar = 2-Naphthyl 277, 87%
Ar = Ph 276, 67%
The oxidation of phenyl ketone trans-263 produced the aryl ester trans- 
276 as the major product and in reasonable yield (67%) although as an 8:1 
mixture of regioisomers. 2-Naphthyl ketone trans-269 delivered the 
corresponding aryl ester trans-277 in high yield (87%) without the 
complication of regioisomer formation.
II 4.11 Enantioselective variant
The next stage of development was to examine the replacement of 
bipyridine with a chiral ligand. The need for a ligand to generate an active 
catalyst was encouraging for this part of the project and it was hoped a chiral 
ligand would allow for asymmetric induction. Although chiral bipyridines 
were not commercially available and the few synthetic routes already 
reported were lengthy, the success of pyridine (bis)oxazolines in the 
zsothiocyanate additions reported earlier was deemed a good starting 
point. 132 133 134 As well as the phenyl ketone 259 a two-point binding substrate 
was also considered in this investigation. This would allow a more rigid, 
structurally defined enolate, which may be required to furnish a more 
efficient asymmetric process. An o-SMe moiety on the phenyl ketone was 
selected to provide the bidentate binding in the enolate and the synthesis of 
such a substrate is demonstrated in scheme 78. The a-carbonate 282 was 
reached through the same chemistry as in other a-carbonate preparations
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once the o-SMe group had been incorporated (Section III 18). This was 
accomplished through direct displacement of 2'-bromoacetophenone 278 
with NaSMe. Acetophenone 279 was then a-brominated with the addition of 
bromine and a catalytic amount of AlCh. The a-bromo species 280 was 
treated with betaine followed by basic work-up to give a-hydroxy ketone 281 
and finally reacted with methyl chloroformate to furnish the corresponding 
a-carbonate 282 in 81% yield.
Scheme 78. Preparation of bidentate a-carbonate.
With this new starting material in hand, the asymmetric catalysis was 
investigated. The o-SMe phenyl ketone 282 was first subjected to the original 
conditions employing Mg(ClC>4)2 (20 mol%), bipyridine (20 mol%), NMM (50
this species. An 8:1 mixture of diastereomers in favour of the trans-product 
was achieved and a yield of 75% of the trans-carbonate 283 was attained 
(Table 18, entry 2). The bipyridine ligand was then exchanged for (R,R)- 
PhPyBOx 181 and experiments were conducted utilising bidentate carbonate 
282 and the original methyl carbonate 259 (entries 3 and 4). Surprisingly the 
yields were very low (7% conversion in both cases) and ee values were not 
gathered. Another ligand (4R,5R)-4-Me-5-PhPyBOx 179 was also examined 
but this gave no improvement (entries 5 and 6 ). The solvent was changed to
NaSMe
Br
Et3N+ C 02‘ MeS O
OH
CIC02Me
pyridine rYWOMe280 EtOH 




0 °C, 2 h 
Y = 81%
282 O
mol%) in THF with 4A MS at RT in order to gain insight into the reactivity of
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DCM and the same results were obtained (entries 7 and 8 ). Finally another 
ligand type was tried and (4R,5S)-indBOx 152 gave the same levels of 
reaction in both carbonate cases (entries 9 and 10).
Table 18. Screening of chiral ligands. 3 6
O




THF, RT Ar 
4 A MS
Entry Ar Ligand Time (h) Syn:Anti° Yield 263/ 
283 (%)c
1 Ph 2 ,2 -bipy 24 10:1 9 l f
2 2-MeS-C6H4 2 ,2 -bipy 24 00 -v
l on
, (b
3 Ph (RR)-PhPyBOx 24 7
4 2-MeS-C6H4 (/?,R)-PhPyB0x 24 7
5 Ph (4R,5R)-4-Me-5-PhPyBOx 24 6
6 2-MeS-C6H4 (4R,5R)-4-Me-5-PhPyBOx 24 6
7d Ph (R,R)-PhPyBOx 24 7
8 d 2-MeS-C6H4 (R,R)-PhPyBOx 24 7
9 Ph (4R,5S)-indBOx 24 8
10 2-MeS-C6H4 (4R,5S)-indBOx 24 7
a All reactions: carbonate (2.0 equiv.), aldehyde (1.0 equiv.), Mg(CI04)2 (20 mol%),
ligand (20 mol%), NMM (50 mol%), 4 A MS (200 mg/mmol of carbonate).
b dr measured by 1H NMR.
c Conversion measured by 1H NMR.
d DCM used.
e ees were not recorded.
f Isolated yield. gof trans-carbonate only.
Unfortunately, time precluded a full screening of ligands including 
those having a bipyridine core in order to achieve a successful
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enantioselective catalysis. From these initial results, it is clear that some 
ligand types have a dramatic effect on reactivity. Whether or not bulk is the 
major factor is a topic for further study.
II 4.12 /^Amino-a-hydroxy-ketones
As part of future work, it was envisaged that to complete the set of 
four amino/hydroxy analogues, the final /2-amino-a-hydroxy carbonyl 
(highlighted in Figure 23) could be reached if tosylimines were employed in 
the a-carbonate addition. As with zsothiocyanatocarbamates, this was 
possible and the exchange of aldehyde for imine gave a reversal in the 
selectivity of the reaction products.
Figure 23. The four amino/hydroxy analogous set.
NHP NHP
befa-hydroxy-a/p/za-amino alpha, befa-diamino
O OP O NPo
A J k  A AX Wr X Y' "Ar
OP OP
alpha, befa-dihydroxy befa-amino-a/pfra-hydroxy
Reaction of methyl carbonate 259 with tosylimine 240 delivered the 
Mannich adduct without cyclisation under the conditions of Mg(ClC>4)2 (20 
mol%), bipy (20 mol%), NMM (50 mol%) in THF and in the presence of 4 A 
MS at RT (Scheme 79). As with the zsothiocyanatocarbamate-imine additions, 
antz-selectivity was observed.
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Scheme 79. a-Carbonate Mannich reaction.
Mg(CI04)2 (20  mol%)
O NHTs O NHTs
i^ Y ^ P h  + P h ^ Y ^ P h
OC02Me OC02Me259 0  240
anf/'-284 anti.syn, 5:1 sy/7-284 
Y = 70%
A respectable yield (70%) and diastereoselectivity in favour of the anti- 
aldol was achieved (5:1). The reversal of diastereoselectivity in this reaction 
as with the addition of zsothiocyanatocarbamates to tosylimines (Section I I 3), 
compared to aldehydes, can again be explained in terms of steric hindrance 
of the much larger spatial occupancy of the N-tosyl group forfeiting a 
different orientation in the coordination of substrate to Lewis acid and 
eventual opposite diastereomeric outcome. The reason that no cyclisation 
had occurred can be assumed on steric grounds. Formation of a czs-cyclised 
product is unfavoured and is therefore a very slow step. Again, time 
constraints have precluded any further investigation of scope and 
optimisation of this reaction.
II 4.13 In search of a Darzens reaction
Much time has been spent preparing substrates for a catalytic Darzens 
variant of the previously described reactions (Section III 23). In the Darzens 
process as illustrated in scheme 80, it is necessary to have a stoichiometric 
amount of amine base and for this process, the difference in pKa between the 
substrate and product is expected to be large enough to prohibit product 
epimerisation.
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Scheme 80. Potential catalytic Darzens reaction.
JL x MLn ? ML v r2cho || ? M L n- 1 _ O r 2
r1 n r3 R1^  r ' ^ y ^ r 2 n r 3 Ri ^ < i
Y + 0
h r 3n + l* a
h r 3n+x-
A large number of a-substituted substrates were prepared in order to 
screen for a possible Darzens closure (Scheme 81). Up until now, only 5-exo­
trig ring closures were observed. In order for a Darzens reaction to proceed, a
3-exo-tet ring closure would need to occur.
Scheme 81. Substrate variation for the Darzens reaction.
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Lewis acids: Mg(CI0 4)2, Mg(OTf)2.
Amine bases: NMM, TEA, DIPEA, 
TMP, PMP, proton sponge, DBU.
Unfortunately, no combination of substrate employed with aryl 
aldehydes delivered epoxide products under various Lewis acid and amine 
base conditions. Certain substrates did bring about reaction with 
benzaldehydes, acting in a 5-exo-trig fashion, as in a-methyl carbonate 259 
described previously (Section II 4) and the O-imidazoyl substrate 287b, 
delivering cyclic carbonate species. Oxazolidinone 286f and methyl ester
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285e analogues of such a-substituents did not achieve reaction -  the piC of a- 
protons is believed to be too low in these examples. a-Triflate 287g reacted 
with amine bases such as TEA to form a quaternary nitrogen salt whereas 
bulkier amines such as DBU gave no reaction. The quaternary nitrogen salts 
formed in these reactions were also investigated, in hope that via an N-ylide 
the catalysis would proceed. Under solvating conditions (THF was replaced 
with acetonitrile), these substrates again failed to show reactivity. a-Chloro 
phenyl ketone 287c provided limited conversion to initial aldol adducts even 
at stoichiometric levels of Lewis acid (Section III 24). All other substrates 
including a-mesylate 287h, and a-oxalate 286d and 287d gave no reaction, 
which is surprising considering some of these examples have attenuated a- 
proton acidity.
In the case of phenacyl methyl oxalate 287d, it was believed that the 
responsible factor for lack of reactivity lied in the oxalate moiety. The oxalate 
portion could act as a bidentate ligand to the Lewis acid rendering the metal 
centre inactive. It was envisaged that incorporation of an o-SMe group in the 
phenyl ring would allow a stronger binding site at the necessary carbonyl for 
the catalysis to proceed. Unfortunately, the prepared substrate 288 (Section 
III 23) again showed no reactivity.
An interesting last example examined for this reaction was that of 
cyclic anhydride 289, which would hopefully lead to the generation of 
glycidic acids under soft enolisation conditions (Scheme 82). Again, this 
substrate failed to give the desired products and was found to be unstable 
under the reaction conditions.
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Scheme 82. Plausible glycidic acid synthesis.
soft enolisation HO 
conditions \
II 4.14 Conclusion
The a,/3-dihydroxy unit is an important class of functionality to the 
organic chemist. There are numerous examples of this motif in biologically 
active synthetic targets and their synthesis is attractive. Protected a,f$- 
dihydroxy ketones have been accessed through the development of a direct 
catalytic aldol route, combining strategies of soft enolisation and post aldol 
cyclisation, to prohibit product epimerisation and allow turnover of the 
catalytic species. The optimised catalyst components comprise of Mg(ClC>4)2, 
bipyridine, N-methylmorpholine and 4 A MS and all are commercially 
available. A wide range of aromatic aldehydes can be employed in the 
catalysis and excellent yields and high levels of diastereoselectivity have 
been achieved. The origins of the high diastereoselectivity have been 
investigated and evidence points to an initial unselective enolate formation. 
The selectivity results from a slow anti-aldol cyclisation step and relatively 
fast syn-aldol cyclisation step. The products of the reaction have been further 
utilised synthetically and the synthesis of ester analogues has been 
successfully demonstrated. The extension of this system to an 
enantioselective synthesis of a,/3-dihydroxy ketones has been examined albeit 
with no success although much work needs to be done evaluating ligands 
further. Synthesis of protected a-hydroxy-/3-amino compounds has been 
accomplished through the same catalysis which concludes the set of four 
amino/hydroxy analogous targets: /3-hydroxy-a-amino, a,/3-diamino, a-
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hydroxy-/J-amino, and n,jS-dihydroxy moieties. To this end, an investigation 
of a Darzens type reaction under catalytic soft enolisation conditions has 





III 1 General information
All reactions were performed under an inert atmosphere of nitrogen, 
in oven or flame dried glassware unless otherwise stated. Nitrogen was 
passed through a Drierite®-filled drying-tube before use.
The solvents used in the reactions were distilled prior to use from the 
relevant drying agent. Toluene, n-hexane, diethyl ether and THF were 
distilled from sodium metal. DCM, chloroform, and acetonitrile were 
distilled from calcium hydride. Light petroleum refers to petroleum spirit 
(bp 40-60 °C).
Analytical thin layer chromatography was carried out using precoated 
aluminium-backed silica plates (Merck Kieselgel 6 OF254). Plates were 
visualised under ultraviolet light (254 nm) or by staining with KMnCX Flash 
column chromatography was carried out using Merck Kieselgel 6 0H  silica. 
Pressure was applied at the column head via hand bellows.
Melting points were determined using a Biichi 535 melting point 
apparatus and are reported uncorrected. Infrared measurements were 
carried out as liquid films on NaCl discs or as a KBr disc using a Perkin- 
Elmer 1600 series FTIR spectrometer with internal calibration in the range 
4000-500 cm 1. Mass spectrometry was carried out on a Micromass Quattro II 
and Finnegan MAT 95XP by the EPSRC mass spectrometry service at the 
University of Wales, Swansea. Elemental analysis was performed on an 
Exeter Analytical CE440 Elemental Analyser at the University of Bath.
JH, 13C and 19F nuclear magnetic resonance experiments were carried 
out using a Bruker AC-300 MHz or AC-400 MHz NMR spectrometer. 
Chemical shifts were reported in parts per million from tetramethylsilane for
131
Chapter III Experimental
JH and 13C experiments. The residual solvent peak was used as an internal 
standard. The multiplicities of the spectra are reported as follows: singlet (s), 
doublet (d), triplet (t), quartet (q) and multiplet (m). Sometimes apparent 
multiplicities (app.) were observed. Coupling constants (J) are given in Hz.
Optical rotations were performed on an Optical Activity LTD: AA-10 
automatic polarimeter.
Analytical high performance liquid chromatography was carried out 
using Thermo Separation Products (TSP) spectra SERIES P200, using the 
Chiralcel® OD00CE-IJ033 column. The loading loop was 20 pL. The eluant 
employed was an isocratic mixture of n-hexane and IPA (80:20 respectively) 
at a flow of 1 mL.min1. A TSP spectra SERIES UV100 detector was fitted to 
the outlet of the column and indicated the absorption at 254 nm, r = 0.0005. 
Retention times are reported in minutes. The enantiomeric excess was 
calculated from the integration of the absorption peaks at 254 nm.
All chemicals were purchased from Acros, Aldrich, Alfa Aesar or 
Strem chemical companies and were used after distillation for liquids but 
without further purification for solids.
2,6-Bis-[(4'R)-4'-phenyloxazolin-2'-yl]-pyridine 181,135 4,6-
dibenzofurandiyl-2,2/-bis[4-(R)-phenyl-l,3-oxazoline] 175,136 pyridine-2,6 - 
dicarboxylic acid bis-[(2-hydroxy-ethyl)-amide] 194,109 4-benzyl-3-(2-
zsothiocyanatoacetyl)oxazolidin-2-one 193,106 N-tosylbenzaldimines, 137 N- 
tosyl-2-naphthaldimine 309,137 (furan-2-yl)-N-tosylmethanimine 322,138 
(thiophen-2-yl)-N-tosylmethanimine 324,139 cyclohexyl-N-tosylmethanimine 
314,140 N-tosylhexan-l-imine 315,140 (£)-3-phenyl-N-tosylprop-2-en-l-imine 
313,137 2-hydroxy-l-(naphthalen-2-yl)ethanone 327,141 2-bromo-l-(2'-
(methylthio)phenyl)ethanone 280,142 5-methyl-[l,3]dioxolane-2,4-dione 289,143 
trifluoromethanesulfonic acid 2-oxo-2-phenyl-ethyl ester 287g,144 
methanesulfonic acid 2-oxo-2-phenyl-ethyl ester 287h,137 and l-phenyl-2-
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(pyridin-2-yloxy)ethanone 287j145 were prepared as described in the 
literature.
Ill 2 Preparation of 3-(2-isothiocyanatoacetyl)-oxazolidin- 
2-one 154
Preparation of 3-(2-chloroacetyl)-oxazolidin-2-one 169
0  O °  oJL,U + I n  ----- «A.X^CIO NH O N
v u  a  v u
167 168 169
A solution of n-BuLi (2.5 M in n-hexane, 8.00 mL, 20.0 mmol) was added 
drop-wise to a solution of oxazolidine-2-one 167 (1.74 g, 20.0 mmol) in dry 
THF (300 mL) at -78 °C and the reaction was stirred for an additional 15 min. 
The temperature was allowed to reach RT for 2.5 h and then the mixture was 
cooled to -78 °C for 15 min. Chloroacetyl chloride 168 (1.75 mL, 22.0 mmol) 
was added slowly to the reaction mixture. After 15 min, the light yellow 
solution was warmed to RT for a further 30 min. The reaction was quenched 
with saturated aqueous ammonium chloride solution (10 mL). The mixture 
was concentrated under reduced pressure, taken up in water (10 mL) and 
extracted with DCM (3 * 40 mL). The organic portions were dried (MgS04) 
and concentrated under reduced pressure. The chlorocarbamate 169 (3.14 g, 
96%) was obtained as a white solid. An analytical sample was prepared by 
recrystallisation from DCM; mp 61 °C (DCM); Rf(SiC>2, DCM) 0.19; 
Unax(KBr)/cm1 2966 (CH), 2928 (CH), 1782 (C=0), 1720 (C=0); <fc(400 MHz; 
CDCb) 4.74 (2H, s, CH2CI), 4.51 (2H, t, /  = 8.0, OCH2), 4.09 (2H, t, /  = 8.0,
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NCH2); &(100 MHz; CDCh) 165.7, 152.9, 62.7, 43.3, 42.5; HRMS (ES+): 
C5H 635C 1N 0 3 , M+requires 163.0036. Found 163.0038.
Preparation of 3-(2-azidoacetyl)-oxazolidin-2-one 170 
O o  O o
c A ^ cl --------   oA n^ N3vu \ /
169 170
A solution of sodium azide (6.50 g, 100 mmol) in water (20 mL) was added to 
a solution of chlorocarbamate 169 (3.14 g, 19.2 mmol) in DCM (20 mL). The 
biphasic system was stirred vigorously and tetrabutylammonium hydrogen 
sulfate (0.68 g, 2.00 mmol) was added. After 1.5 h at RT, the organic layer 
was separated and concentrated under reduced pressure. The residue was 
filtered through silica using DCM as the mobile phase. After concentration, 
the azidocarbamate 170 (2.70 g, 83%) was obtained as a colourless oil; Rf(SiC>2, 
DCM) 0.18; vwtneatycm1 2926 (C H ), 2210 (Ns), 1786 (CO ), 1714 (CO); <5h 
(400 MHz; CDCh) 4.52 (2H, t, /  = 8.1, OCH2), 4.51 (2H, s, CH2N3), 4.09 (2H, t, /  
= 8.1, NCH2); <5c(100 MHz; CDCh) 167.5,153.0, 62.9, 52.3,42.1.
Preparation of 3-(2-isothiocyanatoacetyl)-oxazolidin-2-one 154 
O °  O o
oA n^ N3 ------   oA n ^ ncs
\ / vu
170 154
Triphenylphosphine (3.32 g, 12.7 mmol) was added to a solution of the 
azidocarbamate 170 (1.96 g, 11.5 mmol) in CS2 (15 mL) and THF (15 mL) in a 
500 mL round bottom flask fitted with a condenser. After evolution of 
nitrogen, the solution gently self-refluxed and was left overnight. After
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concentration under reduced pressure, the residue was purified by flash 
chromatography (SiC>2, DCM) to yield the isothiocyanate 154 (1.49 g, 69%), as a 
white solid which was recrystallised from DCM-n-hexane; mp 99 °C (DCM- 
n-hexane); Rf(Si02, DCM) 0.26; vw(KBr)/cm1 2928 (CH), 2064 (NCS), 1786 
(C=0), 1721 (C=0); <5k(400 MHz; CDCh) 4.85 (2H, s, CH2NCS), 4.54 (2H, t, /  =
8.1, OCH2), 4.11 (2H, t, /  = 8.1, NCH2); <5c(100 MHz; CDCh) 165.7,153.4, 140.0,
63.6, 49.6, 42.8; HRMS (ES+): C6H6N2O3S, M+ requires 186.0099. Found 
186.0099.
Ill 3 Preparation of (4S*,5R*)-2-thioxo-5-p-tolyl- 
oxazolidine-4-carboxylic acid ethyl ester syn-183 and (4R*,5.R*)- 
2-thioxo-5-p-tolyl-oxazolidine-4-carboxylic acid ethyl ester anti- 
183; to serve as a typical experimental procedure for the racemic 
preparation of derivatised adducts of aromatic aldehydes and 3- 
(2-isothiocyanatoacetyl)-oxazolidin-2-one 154
Me Me
syn-183 S anti-183 S
A mixture of Mg(C104)2 (15 mg, 0.07 mmol), 2,2'-bipyridine (12 mg, 0.08 
mmol) and 3-(2-zsothiocyanatoacetyl)-oxazolidin-2-one 154 (128 mg, 0.69
o
mmol) was stirred in dry THF (15 mL) with activated powdered 4 A MS (200 
mg) under nitrogen at 0 °C. After 15 min, p-tolualdehyde 196 (90 pL, 0.76 
mmol) and triethylamine (20 pL, 0.14 mmol) were added and the mixture 
was stirred for a further 3 h. The reaction was quenched with saturated
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aqueous ammonium chloride (5 mL). The organic layer was separated and 
the aqueous layer extracted with DCM (3 * 10 mL). The organic portions 
were combined, washed with brine (5 mL), dried (MgSC>4) and concentrated 
under reduced pressure. The residue was dissolved in dry THF (15 mL) and 
cooled to 0 °C. A solution of methyl magnesium bromide (3 M in diethyl 
ether, 0.30 mL, 0.89 mmol) was added to ethanol (3.3 mL) at 0 °C and 
subsequently added to the previous solution via cannula transfer. After 3 
min. the reaction was quenched by addition of an aqueous pH 7 phosphate 
buffer (5 mL). The mixture was concentrated under reduced pressure, taken 
up in aqueous HC1 (1 M, 10 mL) and DCM (10 mL). The organic layer was 
separated and the aqueous layer extracted with DCM (3 * 10 mL). The 
organic portions were combined, dried (MgSCh) and concentrated under 
reduced pressure. The residue was purified by flash chromatography (SiC>2, 
DCM:EtOAc, 98:2) to provide the title compounds, in order of elution, 
oxazolidinethione syn-183 (140 mg, 75%), as a colourless oil; Kf(SiC)2, 
DCM:EtOAc, 98:2) 0.43; ^ (n e a ty c m 1 3176 (NH), 2983 (CH), 1736 (C=0), 
1491 (NHC=S), 1162 (CO), 1095 (CO); &(300 MHz; CDCh) 7.83 (1H, s, NH), 
7.22-7.31 (4H, m, ArH), 5.93 (1H, d, /  = 6.0, ArCH), 4.47 (1H, d, /  = 6.0, 
EtO(CO)CH), 4.25-4.40 (2H, m, CH2CH3), 2.38 (3H, s, ArCHa), 1.35 (3H, t, /  =
7.2, CH2CH3); <5c(100 MHz; CDCb) 188.5, 167.5, 139.2, 133.3, 129.3, 125.2, 85.3,
64.1, 62.5, 20.8, 13.6; HRMS (ES+): C13H 16NO3S, [M+H]+ requires 266.0845. 
Found 266.0842. C13H 15NO3S requires C, 58.9; H, 5.70; N, 5.28%. Found C, 
59.0; H, 5.63; N, 5.09%; and oxazolidinethione anti-183 (19 mg, 12%), as a white 
solid; mp 137 °C (DCM:EtOAc, 98:2); Kf(Si02, DCM:EtOAc, 98:2) 0.22; 
Unax(KBr)/cm1 3253 (NH), 2922 (CH), 1738 (C=0), 1472 (NHC=S), 1163 (CO), 
1087 (CO); <5h(300 MHz; CDCh) 7.18-7.22 (5H, m, ArH & NH), 6.05 (1H, d, /  =
9.9, ArCH), 4.87 (1H, d, /  = 9.9, EtO(CO)CH), 3.67-3.86 (2H, m, CH2CH3), 2.35 
(3H, s, ArCHs), 0.85 (3H, t, /  = 7.2, CH2CH3); <5c(100 MHz; CDCh) 189.6,166.5,
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139.3, 129.7, 128.7, 126.1, 84.9, 62.2, 61.6, 20.8, 13.0; HRMS (ES+): CisHieNOaS, 
[M+H]+ requires 266.0845. Found 266.0844.
Preparation of (4S*,5R*)-5-(4-ethoxy-phenyl)-2-thioxo-oxazolidine-4- 
carboxylic acid ethyl ester syn-187 and (4R*,5R*)-5-(4-ethoxy-phenyl)-2- 
thioxo-oxazolidine-4-carboxylic acid ethyl ester anti-187
OEt OEt
hnH  hH
syn-187 S anti-187 S
The reaction was carried out according to the experimental procedure above 
(Section III 3) with 4-ethoxybenzaldehyde 291 (106 pL, 0.76 mmol) and 
provided, in order of elution, oxazolidinethione syn-187 (145 mg, 72%), as a 
pale yellow solid; mp 66 °C (DCM:EtOAc, 98:2) Rf(Si02/ DCM:EtOAc, 98:2) 
0.28; u„ax(K B r)/cm 1 3313 (NH), 2985 (CH), 1731 (C=0), 1469 (NHC=S), 1155 
(CO), 1020 (CO); <5k(300 MHz; CDCh) 7.65 (1H, s, NH), 7.32 (2H, d, /  = 9.0, 
ArH), 6.93 (2H, d, /  = 9.0, ArH), 5.90 (1H, d, /  = 6.2, ArCH), 4.48 (1H, d, /  = 6.0, 
EtO(CO)CH), 4.25-4.40 (2H, m, (C=0)0CH2CH3), 4.05 (2H, q, /  = 6.9, 
OCH2CH3), 1.43 (3H, t, /  = 6.9, OCH2CH3), 1.34 (3H, t, /  = 7.2, 
(C=0)0CH2CH3); &(100 MHz; CDCh) 189.0, 168.0, 160.0, 128.4, 127.5, 115.0,
86.9, 64.5, 63.6, 62.9, 14.7, 14.1; HRMS (ES+): C14H 18NO4S, [M+H]+ requires 
296.0951. Found 296.0956; and oxazolidinethione anti-187 (15 mg, 8%), as a 
white solid; mp 100 °C (DCM:EtOAc, 98:2); Rf(Si02, DCM:EtOAc, 98:2) 0.17; 
Mnax(KBr)/cm1 3168 (NH), 2977 (CH), 1730 (C=0), 1515 (NHC=S), 1161 (CO), 
1085 (CO); <5h(300 MHz; CDCh) 7.48 (1H, s, NH), 7.22 (2H, d, /  = 9.0, ArH), 
6.86 (2H, d, /  = 9.0, ArH), 6.03 (1H, d, /  = 9.8, ArCH), 4.87 (1H, d, /  = 9.8, 
EtO(CO)CH), 4.01 (2H, q, /  = 7.2, OCH2CH3), 3.65-3.90 (2H, m, 
(C=0)0CH2CH3), 1.40 (3H, t, /  = 6.9, OCH2CH3), 0.88 (3H, t, J = 7.2,
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(C=0)0CH2CH3); &(100 MHz; CDCh) 190.0, 167.1, 160.0, 128.2, 125.1, 114.5,
85.3, 63.6, 62.7, 62.2, 14.7, 13.6; m/z (EI+) 295 (37%, M+); HRMS (ES+): 
C14H 18NO4S, [M+H]+ requires 296.0951. Found 296.0955.
Preparation of (4S*,5R*)-5-(4-methylsulfanyl-phenyl)-2-thioxo-oxazolidine-
4-carboxylic acid ethyl ester syn-188 and (4R*,5R*)-5-(4-methylsulfanyl-
phenyl)-2-thioxo-oxazolidine-4-carboxylic acid ethyl ester anti-188
SMe SMe
O
syn-188 S anti-188 S
The reaction was carried out according to the experimental procedure above 
(Section III 3) with 4-(methylthio)benzaldehyde 292 (101 pL, 0.76 mmol) and 
provided, in order of elution, oxazolidinethione syn-188 (100 mg, 49%), as a 
yellow solid; mp 75 °C (DCM:EtOAc, 98:2) Rf(Si02, DCM:EtOAc, 98:2) 0.33; 
Mnax(KBr)/cm :l 3299 (NH), 2980 (CH), 1736 (CO ), 1489 (NHC=S), 1169 (CO), 
1088 (CO); <5h(300 MHz; CDCh) 7.56 (1H, s, NH), 7.27-7.35 (4H, m, ArH), 5.92 
(1H, d, /  = 6.3, ArCH), 4.45 (1H, d, /  = 6.3, EtO(CO)CH), 4.25-4.40 (2H, m, 
CH2CH3), 2.50 (3H, s, SCHa), 1.35 (3H, t, J = 7.2, CH2CH3); <5c(100 MHz; CDCh)
188.4, 167.3, 140.4, 132.7, 126.2, 125.7, 85.0, 64.0, 62.5, 15.0, 13.6; m/z (EI+) 297 
(57%, M+), 151 (51%, CsHtOS); HRMS (ES+): C13H 16NO3S2, [M+H]+ requires 
298.0566. Found 298.0564. C13H15NO3S2 requires C, 52.5; H, 5.08; N, 4.71%. 
Found C, 52.1; H, 5.07; N, 4.78%; and oxazolidinethione anti-188 (11 mg, 5%), as 
a white solid; mp 132 °C (DCM:EtOAc, 98:2); Rf(Si02, DCM:EtOAc, 98:2) 0.18; 
Mnax(KBr)/cm1 3151 (NH), 2982 (CH), 1739 (CO ), 1475 (NHC=S), 1172 (CO), 
1093 (CO); <5h(300 MHz; CDCh) 7.23 (4H, m, ArH), 7.19 (1H, s, NH), 6.04 (1H, 
d, /  = 9.8, ArCH), 4.88 (1H, d, J = 9.8, EtO(CO)CH), 3.70-3.90 (2H, m,
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CH2CH3), 2.48 (3H, s, SCHa), 0.88 (3H, t, J = 7.2, CH2CH3); &(100 MHz; CDCh)
189.4, 166.4, 140.6, 129.2, 126.6, 125.5, 84.5, 62.1, 61.7, 29.2, 14.9, 13.1; HRMS 
(ES+): C13H 16NO3S2, [M+H]+ requires 298.0566. Found 298.0569.
Preparation of (4S*,5R*)-2-thioxo-5-ra-tolyl-oxazolidine-4-carboxylic acid 
ethyl ester syn-184 and (4R*,5R*)-2-thioxo-5-ra-tolyl-oxazolidine-4- 




*0 Et0" Y  'o
syn-184 S anti-184 S
The reaction was carried out according to the experimental procedure above 
(Section III 3) with m-tolualdehyde 293 (90 pL, 0.76 mmol) and provided, in 
order of elution, oxazolidinethione syn-184 (115 mg, 63%), as a colourless oil; 
Rf(Si02, DCM:EtOAc, 98:2) 0.45; Unax(neat)/cm'1 3182 (NH), 2982 (CH), 1736 
(C=0), 1488 (NHC=S), 1168 (CO), 1094 (CO); <5k(300 MHz; CDCh) 7.39 (1H, s, 
NH), 7.18-7.35 (4H, m, ArH), 5.94 (1H, d, /  = 6.0, ArCH), 4.46 (1H, d, J = 6.0, 
EtO(C=0)CH), 4.25-4.40 (2H, m, CH2CH3), 2.38 (3H, s, ArCHs), 1.35 (3H, t, /  =
7.2, CH2CH3); <5c(100 MHz; CDCh) 188.5, 167.5, 138.6, 136.3, 129.8, 128.6,
125.7, 122.3, 85.3, 64.1, 62.5, 20.9, 13.6; HRMS (ES+): CisHieNOsS, [M+H]+ 
requires 266.0845. Found 266.0847; C13H15NO3S requires C, 58.8; H, 5.70; N, 
5.28%. Found C, 58.8; H, 5.71; N, 5.41% and oxazolidinethione anti-184 (23 mg, 
13%), as a colourless oil; Rf(Si02, DCM:EtOAc, 98:2) 0.29; vtna^neatycnr1 3147 
(NH), 2983 (CH), 1741 (C=0), 1491 (NHC=S), 1163 (CO), 1092 (CO); <5h(300 
MHz; CDCh) 7.72 (1H, s, NH), 7.10-7.30 (4H, m, ArH), 6.05 (1H, d, J = 9.8, 
ArCH), 4.90 (1H, d, J = 9.8, EtO(C=0)CH), 3.65-3.85 (2H, m, CH2CH3), 2.34 
(3H, s, ArCFh), 0.83 (3H, t, J = 7.2, CH2CH3); &(100 MHz; CDCh) 190.1,167.2,
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138.4, 133.1, 130.4, 128.5, 127.2, 123.9, 85.4, 62.8, 62.1, 21.3, 13.4; HRMS (ES+): 
C13H16NO3S, [M+H]+ requires 266.0845. Found 266.0846.
Preparation of (4S*,5R*)-5-biphenyl-4-yl-2-thioxo-oxazolidine-4-carboxylic 
acid ethyl ester syn-189 and (4R*,5R*)-5-biphenyl-4-yl-2-thioxo- 
oxazolidine-4-carboxylic acid ethyl ester anti-189
sy/7-189 anti-189
The reaction was carried out according to the experimental procedure above 
(Section III 3) with biphenyl-4-carboxaldehyde 294 (138 mg, 0.76 mmol) and 
provided, in order of elution, oxazolidinethione syn-189 (118 mg, 52%), as a 
pale yellow solid; mp 145 °C (DCM:EtOAc, 98:2) Rf(SiC>2, DCM:EtOAc, 98:2) 
0.37; Mnax(KBr)/cm1 3252 (NH), 2978 (CH), 1738 (C O ), 1485 (NHC=S), 1161 
(CO), 1087 (CO); &(300 MHz; CDCh) 7.75 (1H, s, NH), 7.65 (2H, m, ArH), 
7.58 (2H, m, ArH), 7.37-7.50 (5H, m, ArH), 6.02 (1H, d, J = 6.2, ArCH), 4.53 
(1H, d, J = 6.2, EtO(CO)CH), 4.30-4.40 (2H, m, CH2CH3), 1.37 (3H, t, J = 7.2, 
CH2CH3); &(100 MHz; CDCh) 188.5, 167.5, 142.1, 139.6, 135.2, 128.4, 127.4, 
127.3, 126.7, 125.7, 85.0, 64.1, 62.6, 13.7; HRMS (ES+): CisHisNOsS, [M+H]+ 
requires 328.1002. Found 328.0998. C18H 17NO3S requires C, 66.0; H, 5.23; N, 
4.28%. Found C, 65.7; H, 5.14; N, 4.47%; and oxazolidinethione anti-189 (32 mg, 
14%), as a white solid; mp 183 °C (DCM:EtOAc, 98:2); Rf(Si02, DCM:EtOAc, 
98:2) 0.21; ^ (K B ^ /c m 1 3154 (NH), 2985 (CH), 1735 (CO ), 1486 (NHC=S), 
1172 (CO), 1083 (CO); <5h(300 MHz; CDCh) 7.55-7.62 (4H, m, ArH), 7.38-7.45 
(5H, m, ArH), 7.16 (1H, s, NH), 6.13 (1H, d, J = 9.5, ArCH), 4.92 (1H, d, J = 9.5,
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EtO(CO)CH), 3.70-3.90 (2H, m, CH2CH3), 0.83 (3H, t, /=  7.2, CH2CH3); &(100 
MHz; CDCb) 189.6, 166.5, 142.2, 139.6, 131.6, 128.4, 127.4, 126.8, 126.7, 126.6,
84.6, 62.2, 61.7, 13.0; HRMS (ES+): CisHisNOsS, [M+H]+ requires 328.1002. 
Found 328.1005.
Preparation of (4S*,5R*)-5-(4-ethyl-phenyl)-2-thioxo-oxazolidine-4- 
carboxylic acid ethyl ester syn-186 and (4R*,5R*)-5-(4-ethyl-phenyl)-2- 
thioxo-oxazolidine-4-carboxylic acid ethyl ester anti-186
The reaction was carried out according to the experimental procedure above 
(Section III 3) with 4-ethylbenzaldehyde 295 (104 pL, 0.76 mmol) and 
provided, in order of elution, oxazolidinethione syn-186 (155 mg, 80%), as a 
white solid; mp 74 °C (DCM:EtOAc, 98:2) Rf(Si02, DCM:EtOAc, 98:2) 0.39; 
Mnax(KBr)/cm1 3315 (NH), 2967 (CH), 1739 (CO ), 1492 (NHC=S), 1214 (CO), 
1165 (CO); <5k(300 MHz; CDCh) 7.46 (1H, s, NH), 7.32 (2H, d, /  = 8.4, ArH), 
7.26 (2H, d, /  = 8.4, ArH), 5.94 (1H, d, J = 6.0, ArCH), 4.47 (1H, d, /  = 6.0, 
EtO(CO)CH), 4.25-4.40 (2H, m, (CO)OCH2CH3), 2.67 (2H, q, J = 7.8, 
CH2CH3), 1.35 (3H, t, /  = 7.2, (CO)OCH2CH3), 1.24 (3H, t, /  = 7.8, CH2CH3)} 
<5c(100 MHz; CDCh) 189.0, 168.0, 146.0, 134.0, 128.7, 125.8, 85.8, 64.5, 63.0,
28.6, 15.5, 14.1; HRMS (ES+): CuHisNOsS, [M+H]+ requires 280.1002. Found 
280.0999. C14H 17NO3S requires C, 60.2; H, 6.13; N, 5.01%. Found C, 60.1; H, 
6.20; N, 4.94%; and oxazolidinethione anti-186 (10 mg, 5%), as a white solid; mp 
120 °C (DCM:EtOAc, 98:2); Rf(Si02, DCM:EtOAc, 98:2) 0.23; M ,ax(KBr)/cm 1 
3163 (NH), 2974 (CH), 1736 (CO), 1486 (NHC=S), 1163 (CO), 1088 (CO);
Et Et
syn-186 ® anti-186 ^
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<5h (300 MHz; CDCh) 7.20-7.26 (4H, m, ArH), 7.08 (1H, s, NH), 6.05 (1H, d, /  =
9.5, ArCH), 4.86 (1H, d, J = 9.5, EtO(CO)CH), 3.67-3.83 (2H, m, 
(C=0)0CH2CH3), 2.64 (2H, q, J = 7.5, CH2CH3), 1.20 (3H, t, /  = 7.5, CH2CH3), 
0.81 (3H, t, J = 7.2, (C=0)0CH2CH3); <5c(100 MHz; CDCh) 190.1, 167.0, 146.2,
130.5, 128.1, 126.7, 85.4, 62.6, 62.1, 28.7, 15.6, 13.4; HRMS (ES+): CuHisNChS, 
[M+H]+ requires 280.1002. Found 280.0998.
Preparation of (4S*,5R*)-2-thioxo-5-(4-trifluoromethoxy-phenyl)- 
oxazolidine-4-carboxylic acid ethyl ester syn-190 and (4R*,5^*)-2-thioxo-5- 
(4-trifluoromethoxy-phenyl)-oxazolidine-4-carboxylic acid ethyl ester anti- 
190
O C F 3  O C F 3
S S
syn-190 anti-190
The reaction was carried out according to the experimental procedure above 
(Section III 3) with 4-(trifluoromethoxy)benzaldehyde 296 (108 pL, 0.76 
mmol) and provided, in order of elution, oxazolidinethione syn-190 (128 mg, 
56%), as a colourless oil; Rf(SiC>2, DCMrEtOAc, 98:2) 0.37; Unax(neat)/cm1 3183 
(NH), 2986 (CH), 1740 (C=0), 1510 (NHC=S), 1371 (CF3), 1210 (CO), 1152 
(CO); <5h (300 MHz; CDCh) 7.47 (2H, d, J = 8.1, ArH), 7.42 (1H, s, NH), 7.29 
(2H, d, /  = 8.1, ArH), 5.99 (1H, d, /  = 6.3, ArCH), 4.44 (1H, d, /  = 6.3, 
EtO(CO)CH), 4.25-4.40 (2H, m, (C=0)0CH2CH3), 1.36 (3H, t, J = 72, 
(C=0)0CH2CH3); <5c (100 MHz; CDCh) 188.7, 167.7, 150.0, 135.4, 127.3, 121.7,
120.4 (q, Vcf = 258.5), 84.6, 64.5, 63.2,14.1; HRMS (ES+): C13H 13F3NO4S, [M+H]+ 
requires 336.0512. Found 336.0509. C13H 12F3NO4S requires C, 46.6; H, 3.61; N, 
4.18%. Found C, 46.3; H, 3.67; N, 4.11%; and oxazolidinethione anti-190 (50 mg,
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22%), as a white solid; mp 112 °C (DCM:EtOAc, 98:2); Rf(SiCh, DCM:EtOAc, 
98:2) 0.22; v^ax(KBr)/cm-1 3158 (NH), 2995 (CH), 1736 (C=0), 1494 (NHC=S), 
1380 (CF3), 1152 (CO), 1082 (CO); <5h(300 MHz; CDCh) 7.35-7.40 (3H, m, NH
requires 336.0512. Found 316.0514.
Preparation of (4S*,5R*)-2-thioxo-5-o-tolyl-oxazolidine-4-carboxylic acid 
ethyl ester syn-185 and (4R*,5R*)-2-thioxo-5-o-tolyl-oxazolidine-4- 
carboxylic acid ethyl ester anti-185
The reaction was carried out according to the experimental procedure above 
(Section III 3) with o-tolualdehyde 297 (88 pL, 0.76 mmol) and provided, in 
order of elution, oxazolidinethione syn-185 (92 mg, 50%), as a colourless oil; 
Rf(Si02, DCM:EtOAc, 98:2) 0.23; ^ (n e a ty c m 1 3184 (NH), 2985 (CH), 1740 
(C=0), 1510 (NHC=S), 1210 (CO), 1152 (CO); <5h (400 MHz; CDCh) 7.69 (1H, s, 
NH), 7.21-7.34 (4H, m, ArH), 6.23 (1H, d, J = 4.0, ArCH), 4.44 (1H, d, /  = 4.0, 
EtO(CO)CH), 4.25-4.40 (2H, m, (C=0)0CH2CH3), 2.42 (3H, s, ArCH3), 1.35 
(3H, t, /=  8.0, (C=0)0CH2CH3); &(100 MHz; CDCh) 189.2, 168.1, 135.1, 134.7,
131.2,129.5, 126.9, 125.7, 83.5, 64.0, 63.0, 19.1, 14.1; HRMS (ES+): CisHieNOsS, 
[M+H]+ requires 266.0845. Found 266.0844; and oxazolidinethione anti-185 (65 
mg, 35%), as a white solid; Rf(Si02, DCM:EtOAc, 98:2) 0.14; v5nax(KBr)/cm1 
3158 (NH), 2995 (CH), 1738 (C=0), 1495 (NHC=S), 1152 (CO), 1082 (CO);
& ArH), 7.23-7.26 (2H, m, ArH), 6.10 (1H, d, /  = 9.6, ArCH), 4.91 (1H, d, J =
9.6, EtO(CO)CH), 3.72-3.82 (2H, m, (C=0)0CH2CH3), 0.83 (3H, t, J = 7.2, 
(C=0)0CH2CH3); <5c (100 MHz; CDCh) 189.8, 166.8, 150.1, 132.0, 128.5, 121.2, 
120.3 (q, Vcf = 258.0), 84.2, 62.6, 62.4,13.4; HRMS (ES+): Ci3H i3F3N 0 4S, [M+H]+
syn-185 S anf/-185 S
143
Chapter III Experimental
<5k(400 MHz; CDCh) 7.38 (1H, m, ArH), 7.17-7.27 (4H, m, NH & ArH), 6.31 
(1H, d, /  = 10.0, ArCH), 4.87 (1H, d, /  = 10.0, Et0(C=0)CH), 3.58-3.66 (1H, m, 
(C=0)0CHaHbCH3), 3.72-3.80 (1H, m, (C=0)0CHaHbCH3), 2.36 (3H, s, 
ArCH3), 0.79 (3H, t, /  = 8.0, (C=0 )0 CH2CH3); &(100 MHz; CDCh) 190.3,167.2,
135.1, 131.5, 130.2, 129.4, 126.5, 125.9, 82.8, 62.2, 61.6, 19.2, 13.4; HRMS (ES+): 
Ci3Hi6N 0 3S, [M+H]+ requires 266.0845. Found 266.0839.
Preparation of 3-(4S*/5R*)-[5-(4-bromo-phenyl)-2-thioxo-oxazolidine-4- 
carbonyl]-oxazolidin-2-one syn-191 and 3-(4R*,5R*)-[5-(4-bromo-phenyl)-2- 
thioxo-oxazolidine-4-carbonyl]-oxazolidin-2-one anti-191
Br Br
syn-191 S anti-191 S
A mixture of Mg(C104)2 (120 mg, 0.54 mmol), 2,2'-bipyridine (85 mg, 0.54 
mmol) and 3-(2-isothiocyanatoacetyl)-oxazolidin-2-one 154 (1.00 g, 5.37 
mmol) in dry THF (20 mL) was stirred for 15 min. under nitrogen at 0 °C. 
Triethylamine (150 pL, 1.07 mmol) was added and 5 min. later followed by 4- 
bromobenzaldehyde 192 (1.09 g, 5.91 mmol). After 3 h the reaction was 
deemed complete (TLC) and quenched with sat. aqueous ammonium 
chloride solution (20 mL). The organic layer was separated and the aqueous 
layer extracted with DCM (3 x 40 mL). The organic portions were combined 
and washed with CuS04 (20 mL) and brine (20 mL), dried (MgSCh) and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography (SiO, DCM:EtOAc, 90:10) to provide, in order of elution, 
oxazolidinethione syn-191 (840 mg, 42%), as white crystals; mp 177 °C (DCM-n- 
hexane); Rf(Si02, DCM:EtOAc, 98:2) 0.08; Mnax(KBr)/cm1 3309 (NH), 1792
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(CO ), 1683 (CO ), 1485 (NHC=S), 1193 (CO); <5k(300 MHz; DMSO) 10.53 (1H, 
s, NH), 7.66 (2H, d, J = 8 .6 , ArH), 7.33 (2H, d, J = 8 .6 , ArH), 6.08 (1H, d, /  = 2.7, 
ArCH), 5.42 (1H, d, J = 2.7, N(CO)CH), 4.46 (2H, t, OCH2), 3.95 (2H, t, 
NCH2); <5c(75 MHz; DMSO) 189.4,168.5, 154.1, 137.7, 132.0, 128.9, 122.6, 83.9,
63.8, 63.3, 43.0; HRMS (EI+): Ci3Hii79BrN2 0 4S, [M]+ requires 369.9617. Found 
369.9617. Ci3HnBrN2 0 4S requires C, 42.0; H, 2.99; N, 7.55%. Found C, 41.9; H, 
2.94; N, 7.46%; and oxazolidinethione anti-191 (222 mg, 11%), as white crystals; 
mp 189 °C (DCM); Rf(Si02, DCM:EtOAc, 90:10) 0.06; Mnax(KBr)/cm1 3340 
(NH), 2913 (CH), 1773 (CO ), 1674 (CO), 1503 (NHC=S), 1174 (CO); <5h(300 
MHz; DMSO) 10.57 (1H, s, NH), 7.63 (2H, d, J = 8.3, ArH), 7.09 (2H, d, /  = 8.3, 
ArH), 6.25 (1H, d, /  = 10.1, ArCH), 5.87 (1H, d, /  =10.1, N(CO)CH), 4.27 (1H, 
m, OCHaHb), 3.94 (1H, m, OCHaHb), 3.72 (1H, m, NCHcHd), 3.10 (1H, m, 
NCHcHd); <5c(75 MHz; DMSO) 188.8, 167.3, 153.3, 133.9, 131.7, 129.4, 123.1,
83.4, 63.7, 62.8, 42.5; HRMS (EI+): Ci3Hn79BrN204S, [M]+ requires 369.9617. 
Found 369.9617.
Preparation of (4S*,5R*)-2-thioxo-5-(4-bromo-phenyl)-oxazolidine-4- 
carboxylic acid ethyl ester syn-162
Br Br
o „ 0
O-VVS, ~  EtO
—^ 1 HN~^ H N ^
sy/7-191 S syr?-162 S
A solution of methyl magnesium bromide (3 M in ether, 0.15 mL, 0.39 mmol) 
was added to ethanol (2.5 mL) at 0 °C and subsequently added via cannula 
transfer to a suspension of the oxazolidinethione syn-191 (130 mg, 0.35 mmol, 
de = 99%) dissolved in dry THF (7.5 mL) cooled to 0 °C. 3 min. later the 
reaction was quenched by addition of an aqueous pH 7 phosphate buffer (7.5
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mL). The mixture was concentrated under reduced pressure, taken up in 
aqueous HC1 (1 M, 7.5 mL) and DCM (15 mL). The organic layer was 
separated and the aqueous layer extracted with DCM (3 * 10 mL). The 
organic portions were combined, dried (MgSCh) and concentrated under 
reduced pressure. The residue was purified by flash chromatography (SiCh, 
DCM:EtOAc, 98:2) to provide oxazolidinethione syn-162 (92 mg, 80%, de = 
99%) as white crystals; mp 112 °C (DCM-light petroleum (bp 40-60 °C)); 
Rf(SiC>2, DCM:EtOAc, 98:2) 0.23; vbax(KBr)/cm1 3424 (NH), 2935 (CH), 1750 
(C=0), 1596 (Ar), 1490 (NHC=S), 1174 (CO); <5k(400 MHz; CDCb) 7.95 (1H, s, 
NH), 7.58-7.55 (2H, m, ArH), 7.31-7.26 (2H, m, ArH), 5.93 (1H, d, J = 6.2, 
ArCH), 4.43 (1H, d, J = 6.2, (CO)CH), 4.39-4.27 (2H, m, CH2), 1.35 (3H, t, /  =
7.2, CH3); &(100 MHz; CDCb) 188.4, 167.5, 135.6, 132.2, 127.2, 123.6, 84.8,
64.5, 63.2, 14.2; HRMS (EI+): CnHu^BrNOsS, [M]+ requires 328.9721. Found 
328.9733; CuH^BrNCbS requires C, 43.7; H, 3.65; N, 4.2%. Found: C, 43.6; H, 
3.6; N, 4.3%.
Preparation of (4R*,5R*)-2-thioxo-5-(4-bromo-phenyl)-oxazolidine-4- 
carboxylic acid ethyl ester anti-162
A solution of methyl magnesium bromide (3 M in ether, 0.11 mL, 0.29 mmol) 
was added to ethanol (1.9 mL) at 0 °C and subsequently added via cannula 
transfer to a suspension of the oxazolidinethione anti-191 (98 mg, 0.26 mmol, 
de = 99%) dissolved in dry THF (5.5 mL) cooled to 0 °C. 3 min. later the 




mL). The mixture was concentrated under reduced pressure, taken up in 
aqueous HC1 (1 M, 5.5 mL) and DCM (10 mL). The organic layer was 
separated and the aqueous layer extracted with DCM (3 * 10 mL). The 
organic portions were combined, dried (MgSCh) and concentrated under 
reduced pressure. The residue was purified by flash chromatography (SiCh, 
DCM:EtOAc, 98:2) to provide oxazolidinethione anti-162 (67 mg, 78%, de = 
99%) as white crystals; mp 122 °C (DCM-light petroleum (bp 40-60 °C)); 
Rf(SiC>2, DCM:EtOAc, 98:2) 0.11; iw(DCM, 0.05 MVcm1 3424 (NH), 2935 
(CH), 1749 (C=0), 1595 (Ar), 1492 (NHC=S); <&(400 MHz; CDCb) 7.58 (1H, s, 
NH), 7.53-7.50 (2H, m, ArH), 7.23-7.18 (2H, m, ArH), 6.04 (1H, d, J = 9.8, 
ArCH), 4.90 (1H, d, /  = 9.8, (C=0)CH), 3.85 (1H, dq, /  = 10.8, 7.2, CHaHb), 3.74 
(1H, dq, J = 10.8, 7.2, CHaHb), 0.89 (3H, t, J = 7.2, CHa); <5c(100 MHz; CDCb)
189.8, 166.9, 132.4, 132.0, 128.6, 124.2, 84.7, 62.9, 62.7, 14.0; HRMS (ES+): 
Ci2Hi279BrN03S, [M]+ requires 328.9721. Found 328.9707.
Ill 4 Asymmetric preparation of (4S,5.R)-5-phenyl-2- 
thioxo-oxazolidine-4-carboxylic acid ethyl ester syn-156; to serve 
as a typical experimental procedure for the asymmetric 




A mixture of Mg(ClC>4)2 (15 mg, 0.07 mmol), 2,6-bis((R)-4,5-dihydro-4- 
phenyl-2-oxazolyl)pyridine 181 (28 mg, 0.08 mmol) and 3-(2-
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zsothiocyanatoacetyl)-oxazolidin-2-one 154 (128 mg, 0.69 mmol) was stirred 
for 1 h in dry DCM (15 mL) with activated powdered 4 A MS (200 mg) under 
nitrogen at RT. The temperature was then lowered to -78 °C. After 15 min, 
benzaldehyde 17 (77 pL, 0.76 mmol) and dizsopropylethylamine (24 pL, 0.14 
mmol) were added and the mixture was stirred for a further 24 h at -78 °C. 
The reaction was quenched with saturated aqueous ammonium chloride (5 
mL). The organic layer was separated and the aqueous layer extracted with 
DCM (3 x 10 mL). The organic portions were combined, washed with brine (5 
mL), dried (MgSOi) and concentrated under reduced pressure. The residue 
was dissolved in dry THF (15 mL) and cooled to 0 °C. A solution of methyl 
magnesium bromide (3 M in diethyl ether, 0.30 mL, 0.89 mmol) was added to 
ethanol (3.3 mL) at 0 °C and subsequently added to the previous solution via 
cannula transfer. After 3 min. the reaction was quenched by addition of an 
aqueous pH 7 phosphate buffer (5 mL). The mixture was concentrated under 
reduced pressure, taken up in aqueous HC1 (1 M, 10 mL) and DCM (10 mL). 
The organic layer was separated and the aqueous layer extracted with DCM 
(3 x 10 mL). The organic portions were combined, dried (MgSCh) and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography (SiC>2, DCM:EtOAc, 98:2) to provide, in order of elution, the 
title compound and zmfz-diastereomer (137 mg, 79%), symanti = 79:21, eesyn = 
86%, [ a ] D 21 = +44.0 (c = 1.0, DCM), eeanti = 72%; oxazolidinethione syn-156 (108 
mg, 62%), as white crystals; mp 107 °C (EtOAc-light petroleum (bp 40-60 
°C)); Rf(SiC>2, CHCkEtOAc, 75:25) 0.53; Unax^BrJ/cm1 3426 (NH), 2952 (CH), 
1748 (C=0), 1486 (NHC=S), 1177 (CO); <5h(400 MHz; CDCh) 7.94 (1H, s, NH), 
7.46-7.38 (5H, m, ArH), 5.98 (1H, d, J = 6.1, ArCH), 4.49 (1H, d, /  = 6.1, 
EtO(CO)CH), 4.40-4.26 (2H, m, CH2), 1.40 (3H, t, /  = 7.0, CH3); <5c(100 MHz; 
CDCh) 189.9, 168.2, 137.0, 129.7, 129.3, 125.9, 85.9, 64.9, 63.4, 14.5; and 
oxazolidinethione anti-156 (29 mg, 17%), as white crystals; mp 114 °C 
(EtOAc-light petroleum (bp 40-60 °C)); Rf(Si02, CHCkEtOAc, 75:25) 0.38;
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Mnax(CHCl3, 0.05 MJ/on'1 3426 (NH), 2964 (C H ), 1749 (C=0), 1486 (NHC=S), 
1176 (CO); <5h(400 MHz; CDCh) 7.59 (1H, s, NH), 7.42-7.20 (5H, m, ArH), 6.09 
(1H, d, J = 9.8, ArCH), 4.91 (1H, d, J = 9.8, EtO(CO)CH), 3.80 (1H, dq, J = 10.7,
7.2, CHaHb), 3.67 (1H, dq, /  = 10.7, 7.2, CHaHb), 0.82 (3H, t, J = 7.2, CH3); 
&(100 MHz; CDCh) 190.0, 167.3, 133.4, 129.9, 128.8, 126.9, 85.5, 63.0, 62.5,
13.9.
The enantiomers of the syn-diastereomer were separated analytically by 
chiral HPLC using the conditions in the general experimental section; £r i = 9.0 
min. and ho = 10.8 min. The enantiomers of the anh'-diastereomer were 
separated analytically by chiral HPLC using the same conditions; £r i = 13.9 
min. and tm = 39.9 min.
Preparation of (4S,5.R)-5-(4-methoxyphenyl)-2-thioxo-oxazolidine-4- 
carboxylic acid ethyl ester syn-164
OMe
(4S,5R)-164 S
The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-methoxybenzaldehyde (92 pL, 0.76 mmol) to provide, in 
order of elution, the title compound and flnfz-diastereomer (133 mg, 69%), 
symanti = 85:15, eesyn = 86%, [ a ] D 21 = +49.0 (c = 1.0, DCM), eeanti = 53%; the 
oxazolidinethione syn-164 (109 mg, 56%) as white crystals; mp 80 °C (DCM- 
light petroleum (bp 40-60 °C)); Pf(Si02, DCM:EtOAc, 98:2) 0.19; Mnax(KBr)/cm_1 
3426 (NH), 2815 (CH), 1748 (C=0), 1614 (Ar), 1517 (Ar), 1486 (NHC=S), 1171 
(CO), 1032 (CO); <fc(400 MHz; CDCh) 7.71 (1H, s, NH), 7.34-7.32 (2H, m, 
ArH), 6.96-6.92 (2H, m, ArH), 5.90 (1H, d, /  = 6.2, ArCH), 4.47 (1H, d, /  = 6.2,
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EtO(CO)CH), 4.37-4.25 (2H, m, CH2), 3.82 (1H, s, OCHs), 1.34 (3H, t, J = 7.0, 
OCH2CH3); &(100 MHz; CDCh) 188.7, 167.7, 160.4, 128.5, 127.3, 114.4, 85.8,
64.4, 62.9, 55.4, 14.2; a n d  o x a z o lid in e th io n e  anti-164 (9 m g , 5%) a s  w h ite  
c ry s ta ls ; m p  87 °C (D C M -lig h t p e t ro le u m  (b p  40-60 °C)); Rf(SiC>2, 
D C M :E tO A c, 98:2) 0.11; vwCKBrycm1 3425 (NH), 2859 (C H ), 1747 (C=0), 
1614 (A r), 1517 (A r), 1487 (N H C = S), 1171 (C O ), 1032 (C O ); <5k(400 M H z; 
C D C h ) 7.51 (1H, s, NH), 7.25-7.21 (2H, m , A rH ), 6.90-6.86 (2H, m , A rH ), 6.04 
(1H, d , J = 9.8, A rC H ), 4.86 (1H, d , /  = 9.8, E tO (C O ) C H ) ,  3.84 (1H, d q , /  = 10.6,
7.2, CHaHb), 3.80 (3H, s, O C H s), 3.73 (1H, d q , /  10.6, 7.2, CHaHb), 0.88 (3H, t, /  
= 7.2, O CH2CH3); <5c(100 M H z ; C D C h ) 189.9, 167.1, 160.7, 128.3, 125.4, 114.1,
85.5, 63.0, 62.5, 55.7,14.0.
The enantiomers of the syn-diastereomer were separated analytically by 
chiral HPLC using the conditions in the general experimental section; fai = 
12.0 min. and ha = 13.3 min. The enantiomers of the *mfz-diastereomer were 
separated analytically using the same conditions; fa 1 = 15.9 min. and fa2 = 45.9 
min.
Preparation of (4S,5R)-5-(2-naphthyl)-2-thioxo-oxazolidine-4-carboxylic 




The reaction was carried out according to the experimental procedure above 
(Section III 4) with 2-naphthaldehyde (119 mg, 0.76 mmol) to provide, in 
order of elution, the title compound and <mh-diastereomer (133 mg, 64%, 
symanti = 72:28), eesyn = 85%, [ a ] D 21 = +46.0 (c = 1.0, DCM), eeanu = 71%;
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oxazolidinethione syn-165 (96 mg, 46%) as white crystals; 145 °C (DCM-light 
petroleum (bp 40-60 °Q); Rf(Si02, DCM:EtOAc, 98:2) 0.21; Mnax(KBr)/cm1 3426 
(NH), 2957 (CH), 1749 (C=0), 1582 (Ar), 1487 (NHC=S), 1180 (CO); <5h(400 
MHz; CDCh) 7.92-7.85 (5H, m, ArH & NH), 7.55-7.53 (2H, m, ArH), 7.48-7.46 
(1H, m, ArH), 6.14 (1H, d, /  = 6.2, ArCH), 4.56 (1H, d, /  = 6.2, EtO(CO)CH), 
4.42-4.29 (2H, m, CH2), 1.38 (3H, t, J = 72, CH3); <5c(100 MHz; CDCh) 189.1,
168.1, 134.1, 133.8, 133.1, 129.7, 128.5, 128.0, 127.3, 127.1, 125.6, 122.6, 86.1,
64.9, 63.4,14.6; and oxazolidinethione anti-165 (37 mg, 18%) as white crystals; 
mp 169 °C (DCM-light petroleum (bp 40-60 °C)); Rf(Si02, DCMrEtOAc, 98:2) 
0.11; Wnax(KBr)/cm’^ 3425 (NH), 2913 (CH), 1748 (C=0), 1603 (Ar), 1489 
(NHC=S), 1175 (CO); <5h(400 MHz; CDCh) 7.86-7.83 (4H, m, ArH), 7.55-7.50 
(3H, m, ArH & NH), 7.39-7.36 (1H, m, ArH), 6.26 (1H, d, J = 9.8, ArCH), 4.97 
(1H, d, /  = 9.8, EtO(CO)CH), 3.64 (1H, dq, /  = 10.7, 7.2, CHaHb), 3.48 (1H, dq, 
/  = 10.7, 7.2, CHaHb), 0.55 (3H, t, /  = 7.2, CHa); <5c(100 MHz; CDCh) 189.7,
166.7, 133.5, 132.5, 130.3, 128.4, 128.1, 127.6, 126.9, 126.7, 126.4, 123.3, 85.4,
62.8, 62.2,13.4; m/z (El) 301 (6 8 %, M+), 256 (8 %, M -  QHsO), 43 (57%, CHNO), 
29 (77%, C2H5); (Found: M+, 301.0763. C16H 15NO3S requires M, 301.0773).
The enantiomers of the syw-diastereomer were separated analytically by 
chiral HPLC using the conditions in the general experimental section; tm = 
11.8 min. and tm = 14.0 min. The enantiomers of the anh-diastereomer were 





carboxylic acid ethyl ester syn-162
The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-bromobenzaldehyde 192 (141 mg, 0.76 mmol) to 
provide, in order of elution, the title compound and zmfz-diastereomer (180
Data identical to that reported earlier. The enantiomers of the syn- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; fei = 10.2 min. and £r2 = 11.8 
min. The enantiomers of the an f z-diastereomer were separated analytically 
using the same conditions; fai = 14.3 min. and txi = 49.2 min.
Br
(4S,5R)-162 S




acid ethyl ester syn-159
CN
(4S,5K)-159 S
The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-cyanobenzaldehyde (100 mg, 0.76 mmol) to provide, in 
order of elution, the title compound and an h-diastereomer (135 mg, 71%), 
symanti = 66:34, eesyn = 3%, eeanti = 37%; oxazolidinethione syn-159 (91 mg, 47%) 
as white crystals; mp 132 °C (DCM-light petroleum (bp 40-60 °C)); Rf(SiC>2, 
DCM:EtOAc, 98:2) 0.09; unax(K B r)/cm 13425 (NH), 2946 (CH), 2233 (CN), 1750 
(CO ), 1613 (Ar), 1488 (NHC=S), 1171 (CO); <5k(400 MHz; CDCb) 8.09 (1H, s, 
NH), 7.75-7.54 (4H, m, ArH), 6.03 (1H, d, J = 6.1, ArCH), 4.44 (1H, d, /  = 6.1, 
(C=0)CH), 4.41-4.29 (2H, m, CH2), 1.37 (3H, t, J = 7.2, CHa); &(100 MHz; 
CDCb) 188.2, 167.2, 141.6, 132.8, 126.1, 117.9, 113.4, 84.0, 64.4, 63.4, 14.2; m/z 
(El) 276 (57%, M+), 69 (32%, CaHaNO), 29 (39%, C2H 5); (Found: M+, 276.0567. 
C13H 12N2O3S requires M, 276.0569) (Found: C, 56.6; H, 4.4; N, 10.2. 
C13H 12N2O3S requires C, 56.5; H, 4.38; N, 10.1%); and oxazolidinethione anti- 
159 (29 mg, 15%) as white crystals; mp 169 °C (DCM-light petroleum (bp 40- 
60 °C)); Rf(Si02, DCM:EtOAc, 98:2) 0.06; Mnax(KBr)/cm1 3423 (NH), 2950 (CH), 
2233 (CN), 1749 (CO ), 1485 (NHC=S); <5h(400 MHz; CDCb) 7.72-7.46 (4H, m, 
ArH), 7.36 (1H, s, NH), 6.12 (1H, d, } = 9.8, ArCH), 4.94 (1H, d, J = 9.8, 
(CO)CH), 3.85 (1H, dq, J = 10.7, 7.1, CHaHb), 3.72 (1H, dq, J = 10.7, 7.1, 
CFIaHb), 0.88 (3H, t, /  = 7.1, CHa); <5c(100 MHz; CDCla-CDaOD, 67:33) 189.7,
167.0, 138.9, 132.2, 127.5, 118.0, 113.1, 83.7, 63.0, 62.1, 13.6; HRMS (ES+): 
(Found: M+, 276.0570. C13H12N2O3S requires M, 276.0569).
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The enantiomers of the syn-diastereomer were separated analytically by 
chiral HPLC using the conditions in the general experimental section; tm = 
19.7 min. and tm = 2 1 . 2  min. The enantiomers of the anh'-diastereomer were 
separated analytically using the same conditions; tm = 23.0 min. and tm = 64.9 
min.
Preparation of (4S,5R)-2-thioxo-5-p-tolyl-oxazolidine-4-carboxylic acid 
ethyl ester syn-183
The reaction was carried out according to the experimental procedure above 
(Section III 4) with p-tolualdehyde 196 (90 pL, 0.76 mmol) to provide, in 
order of elution, the title compound and anfz-diastereomer (161 mg, 8 8 %),
identical to that reported earlier. The enantiomers of the syn-diastereomer 
were separated analytically by chiral HPLC using the conditions in the 
general experimental section; £r i = 9.0 min. and tm = 9.9 min. The enantiomers 
of the anh-diastereomer were separated analytically by chiral HPLC using 
the same conditions; £ri = 12.3 min. and tm = 38.2 min.
Me
(4S,5K)-183 S




carboxylic acid ethyl ester syn-187
The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-ethoxybenzaldehyde (106 pL, 0.76 mmol) to provide, in 
order of elution, the title compound and flnfz-diastereomer (174 mg, 85%),
identical to that reported earlier. The enantiomers of the syn-diastereomer 
were separated analytically by chiral HPLC using the conditions in the 
general experimental section; h .i = 20.0 min. and tm = 21.6 min. The 
enantiomers of the flnh'-diastereomer were separated analytically by chiral 
HPLC using the same conditions; fei = 26.9 min. and tm = 79.2 min.
Preparation of (4S,5R)-5-(4-methylsulfanyl-phenyl)-2-thioxo-oxazolidine-4- 
carboxylic acid ethyl ester syn-188
OEt
(4S,5K)-187 S
symanti = 87:13, eesyn = 93%, [ a ] D 21 = +46.0 (c = 1.0, DCM), eema = 62%. Data
SMe
(4S,5R)-188 S
The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-(methylthio)benzaldehyde (101 pL, 0.76 mmol) to 
provide, in order of elution, the title compound and arch-diastereomer (131
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mg, 64%), symanti = 85:15, eesyn = 94%, [ a ] D 21 = +40.0 (c = 1.0, DCM), eeami = 62%.
Data identical to that reported earlier. The enantiomers of the syn- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; fei = 13.1 min. and £r2 = 14.5 
min. The enantiomers of the flnh'-diastereomer were separated analytically by 
chiral HPLC using the same conditions; £r i  = 16.1 min. and fa2 = 48.9 min.
Preparation of (4S,5R)-2-thioxo-5-m-tolyl-oxazolidine-4-carboxylic acid 
ethyl ester syw-184
The reaction was carried out according to the experimental procedure above 
(Section III 4) with m-tolualdehyde (90 pL, 0.76 mmol) to provide, in order of 
elution, the title compound and atth-diastereomer (152 mg, 84%), symanti = 
82:18, eesyn = 85%, [ a ] D 21 = +25.0 (c = 1.0, DCM), eeami = 73%. Data identical to 
that reported earlier. The enantiomers of the syn-diastereomer were 
separated analytically by chiral HPLC using the conditions in the general 
experimental section; fai = 8.2 min. and ha = 9.7 min. The enantiomers of the 
anh-diastereomer were separated analytically by chiral HPLC using the same 









The reaction was carried out according to the experimental procedure above 
(Section III 4) with biphenyl-4-carboxaldehyde (138 mg, 0.76 mmol) to 
provide, in order of elution, the title compound and anfz-diastereomer (164 
mg, 73%), symanti = 71:29, eesyn = 85%, [ a ] D 21 = +26.0 (c = 1.0, DCM), eeanti = 61%. 
Data identical to that reported earlier. The enantiomers of the syn- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; fei = 14.7 min. and ha = 16.5 
min. The enantiomers of the zmfz-diastereomer were separated analytically by 
chiral HPLC using the same conditions; tm = 17.0 min. and ha = 52.9 min.
Preparation of (4S,5K)-5-(4-ethyl-phenyl)-2-thioxo-oxazolidine-4-carboxylic 





The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-ethylbenzaldehyde (104 pL, 0.76 mmol) to provide, in
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order of elution, the title compound and anf z-diastereomer (181 mg, 95%), 
symanti = 91:9, eesyn = 90%, [ a ] D 21 = +34.0 (c = 1.0, DCM), eeami = 6 6 %. Data 
identical to that reported earlier. The enantiomers of the syn-diastereomer 
were separated analytically by chiral HPLC using the conditions in the 
general experimental section; tm = 7A min. and tm = 9.6 min. The enantiomers 
of the zmf z-diastereomer were separated analytically by chiral HPLC using 
the same conditions; tm = 11.4 min. and tm = 36.6 min.
Preparation of (4S,5R)-2-thioxo-5-(4-trifluoromethoxy-phenyl)-oxazolidine- 
4-carboxylic acid ethyl ester syn-190
o c f 3
(4S,5R)-190 S
The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-(trifluoromethoxy)benzaldehyde (108 pL, 0.76 mmol) to 
provide, in order of elution, the title compound and ah f z-diastereomer (180 
mg, 78%), symanti = 74:26, eesyn = 52%, [a]d21 = +5.0 (c = 1.0, DCM), eeann = 63%. 
Data identical to that reported earlier. The enantiomers of the syn- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; tm = 7.7 min. and tm = 8.9 min. 
The enantiomers of the zmh-diastereomer were separated analytically by 
chiral HPLC using the same conditions; fei = 11.3 min. and tm = 36.1 min.
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Preparation of (4S/5R)-2-thioxo-5-o-tolyl-oxazolidine-4-carboxylic acid
ethyl ester syn-185
The reaction was carried out according to the experimental procedure above 
(Section III 4) with o-tolualdehyde ( 8 8  pL, 0.76 mmol) to provide, in order of 
elution, the title compound and flnfz-diastereomer (162 mg, 8 8 %), symanti =
1.0, DCM). Data identical to that reported earlier. The enantiomers of the syn- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; foi = 9.7 min. and fR2 = 11.7 
min. The enantiomers of the antz-diastereomer were separated analytically by 
chiral HPLC using the same conditions; foi = 14.9 min. and ftu = 42.8 min.
Ill 5 Preparation of (4S,5.R)-2-thioxo-5-p-tolyl-oxazolidine- 
4-carboxylic acid ethyl ester st/w-183 employing (S)-4-benzyl-3- 
(2-xsothiocyanatoacetyl)oxazolidin-2-one 193
(4S,5R)-185 s
50:50, eesyn = 62%, [a]o21 = +12.5 (c = 3.0, DCM), ee»* = 89%, [a]d21 = +163.8 (c =
Me










The reaction was carried out according to the experimental procedure above 
(Section III 4) with (S)-4-benzyl-3-(2-zsothiocyanatoacetyl)oxazolidin-2-one106 
193 and p-tolualdehyde 196 (90 pL, 0.76 mmol) to provide, in order of 
elution, the title compound and zmfz-diastereomer (161 mg, 8 8 %), symanti = 
91:9, eesyn = 90%. Data identical to that reported earlier. The enantiomers of 
the syzz-diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; £r i  = 9.0 min. and tm = 9.9 min.
Preparation of (4R,5S)-2-thioxo-5-p-tolyl-oxazolidine-4-carboxylic acid 
ethyl ester syzz-183 employing (R)-4-benzyl-3-(2-
zsothiocyanatoacetyl)oxazolidin-2-one 193
(Section III 4) with (P)-4-benzyl-3-(2-zsothiocyanatoacetyl)oxazolidin-2-one106 
193 and p-tolualdehyde 196 (90 pL, 0.76 mmol) to provide, in order of 
elution, the title compound and flzzfz-diastereomer (137 mg, 75%), symanti = 
81:19, eesyn = 64%. Data identical to that reported earlier. The enantiomers of 
the syzz-diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; fei = 9.0 min. and tm = 9.9 min.
Me
(4R,5S)-183
The reaction was carried out according to the experimental procedure above
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Preparation of (4S,5R)-2-thioxo-5-p-tolyl-oxazolidine-4-carboxylic acid 
ethyl ester syn-183 employing (S)-4-benzyl-3-(2-
isothiocyanatoacetyl)oxazolidin-2-one 193 and 2,6-bis-(4,5-dihydro-oxazol-
2-yl)-pyridine 195 as a ligand
Me
 /  (S)-193 196
/ = \  (4S,5R)-183
 ^ //
The reaction was carried out according to the experimental procedure above 
(Section III 4) with (S)-4-benzyl-3-(2-zsothiocyanatoacetyl)oxazolidin-2-one106 
193, 2,6-bis-(4/5-dihydro-oxazol-2-yl)-pyridine 195 (17 mg, 0.08 mmol) and p- 
tolualdehyde 196 (90 pL, 0.76 mmol) to provide, in order of elution, the title 
compound and anfi-diastereomer (160 mg, 87%), symanti = 81:19, eesyn -  83%. 
Data identical to that reported earlier. The enantiomers of the syn- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; tm = 9.0 min. and tm = 9.9 min.
Ill 6 Preparation of 2,6-bis-(4,5-dihydro-oxazol-2-yl)- 
pyridine 195
Pyridine-2,6 -dicarboxylie acid bis-[(2-hydroxy-ethyl)-amide] 194 (1.63 g, 3.95 
mmol) as prepared by Kumar et al109 was stirred in boron trifluoride diethyl-
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etherate (15 mL) for 4 h at 120 °C under a nitrogen atmosphere. The reaction 
mixture was cooled to ambient temperature and diluted with DCM (75 mL), 
then poured into chilled 2 M sodium hydroxide (75 mL). The organic layer 
was then concentrated under reduced pressure to yield the 
pyridinebisoxazoline 195 as a white solid (760 mg, 54%). An analytical sample 
of the title compound was prepared by recrystallisation from 
dimethylsulfoxide; mp 185 °C dec. (DMSO); Unax(KBr)/cm1 2874 (CH), 1660 
(C=N), 1569 (C=N); <5k(300 MHz; CDCh) 8.17 (2H, d, J = 5.7, ArH), 7.88 (1H, t, 
/  = 5.7, ArH), 4.54 (4H, t, /  = 7.2, CH2CH2), 4.12 (4H, t, /  = 7.2, CH2CH2); Sc(75 
MHz; CDCh) 163.8, 147.2, 137.8, 125.9, 68.7, 55.5; HRMS (ES+): C11H12N3O2, 
[M+H]+ requires 218.0924. Found 218.0924; C11H 11N3O2 requires C, 60.8; H, 
5.10; N, 19.34%. Found C, 60.5; H, 5.12; N, 19.2%.
Ill 7 Preparation of
bis(oxazolinyl)pyridine)2] (CIChh 201
+ Mg(cio<) 2 —
Ph 181 Ph
A mixture of Mg(C104)2 (137 mg, 0.62 mmol) and 2,6-bis((R)-4,5-dihydro-4- 
phenyl-2-oxazolyl)pyridine 181 (250 mg, 0.68 mmol) was stirred for 8 h in 
dry acetonitrile (50 mL) under a nitrogen atmosphere at reflux. The reaction 
mixture was then cooled to ambient temperature and concentrated under 
reduced pressure to furnish a pale pink foam. The foam was dissolved up in 
DCM (25 mL), filtered through a sintered funnel and chilled for several days
[Mg((2?,2?)-phenyl-




to afford the title compound as transparent lilac prisms. The crystals were
III 8 Preparation of O-protected analogues of 3-chloro-4- 
hydroxybenzaldehyde
Preparation of 4-(ferf-butyl-dimethyl-silanyloxy)-3-chloro-benzaldehyde 
300
3-Chloro-4-hydroxybenzaldehyde 298 (2.0 g, 12.8 mmol) was stirred in dry 
DMF (5 mL) under a nitrogen atmosphere at 0 °C. To the solution was added 
f-butyldimethylsilyl chloride 299 (2.02 g, 13.4 mmol) and imidazole (0.91 g,
13.4 mmol) portion-wise and the mixture was allowed to stir for 2 h to reach 
RT. The mixture was then diluted with light petroleum (bp 40-60 °C) and 
washed twice with water. The organic phase was filtered through a short 
plug of neutral alumina and concentrated under reduced pressure to provide 
the aldehyde146 300 as a pale yellow oil (2.78 g, 80%); <5h(300 MHz; CDCh)
stored under DCM until subjection to X-ray crystallography (Appendix B).
O
9.83 (1H, s, CHO), 7.90 (1H, d, /  = 2.2, ArH), 7.68 (1H, dd, /  = 8.2, 2.2, ArH),
6.99 (1H, d, /  = 8.2, ArH), 1.04 (9H, s, C(CH3)3), 0.28 (6H, s, Si(CH3)2); <5c(100 
MHz; CDCh) 190.2,157.5,132.3,131.3,130.1,127.3,121.0,25.9,18.8, -3.9.
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3-ChIoro-4-hydroxybenzaldehyde 298 (2.0 g, 12.8 mmol) was stirred in dry 
DCM (50 mL) under a nitrogen atmosphere at 0 °C. To the suspension was 
added 2-methoxyethoxymethyl chloride 301 (1.60 mL, 14.0 mmol) and 
di/sopropylethylamine (2.45 mL, 14.0 mmol) portion-wise and the mixture 
was allowed to stir for 2 h to reach RT. The mixture was then quenched with 
saturated aqueous ammonium chloride (5 mL) and diluted with DCM. The 
organic phase was separated and washed twice with water. The extract was 
filtered through a short plug of neutral alumina and concentrated under 
reduced pressure to provide the aldehyde147 302 as a pale yellow oil (2.50 g, 
80%); <5h(400 MHz; CDCh) 9.87 (1H, s, CHO), 7.92 (1H, s, ArH), 7.75 (1H, d, /  
= 8.0, ArH), 7.36 (1H, d, /  = 8.0, ArH), 5.44 (2H, s, OCH2O), 3.88 (2H, t, /  = 4.0, 
OCH2CH2O), 3.56 (2H, t, /  = 4.0, OCH2CH2O), 3.37 (3H, s, OCHa).
Preparation of 3-chloro-4-methylsulfanylmethoxy-benzaldehyde 304
O 0




3-Chloro-4-hydroxybenzaldehyde 298 (2.0 g, 12.8 mmol) was stirred in dry 
DMF (10 mL) under a nitrogen atmosphere at RT. To the solution was added 
chloromethyl methyl sulfide 303 (1.18 mL, 14.0 mmol) and anhydrous 
potassium carbonate (1.94 g, 14.0 mmol) portion-wise and the mixture was 
allowed to stir for 16 h at RT. The mixture was then diluted with DCM and
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washed twice with water. The extract was filtered through a short plug of 
neutral alumina and concentrated under reduced pressure to provide the 
aldehyde 304 as a pale yellow oil (2.35 g, 85%); vinaxfneatj/cm'1 2923 (CH), 1700 
(C=0), 1227 (CO), 1054 (CO); <5h(300 MHz; CDCh) 9.83 (1H, s, CHO), 7.88 
(1H, s, ArH), 7.73 (1H, d, /  = 9.0, ArH), 7.08 (1H, d, /  = 9.0, ArH), 5.29 (2H, s, 
SCH2O), 2.26 (3H, s, SCHa); Sc(75 MHz; CDCh) 189.8, 157.2, 131.4, 130.9,
130.0,125.0,114.7, 73.4,14.7; HRMS (ES+): C9Hi335ClN02S, [M+NH4]+ requires 
234.0350. Found 234.0352.
Preparation of 4-(4-methoxybenzyloxy)-3-chlorobenzaldehyde 233
clN p Y ^ H  + j f Y ' a
298 305 MeO' 233
H
3-Chloro-4-hydroxybenzaldehyde 298 (2.0 g, 12.8 mmol) was stirred in dry 
DMF (10 mL) under a nitrogen atmosphere at RT. To the solution was added 
p-methoxybenzyl chloride 305 (1.90 mL, 14.0 mmol), and anhydrous 
potassium carbonate (1.94 g, 14.0 mmol) portion-wise and the mixture was 
allowed to stir for 16 h at RT. The mixture was then diluted with water and 
the precipitate formed was filtered through a sinter funnel and washed with 
water and dried. The crude product was purified by recrystallisation from 
DCM-rc-hexane to provide the aldehyde 233 as a white crystalline solid (3.0 g, 
85%); mp 102-103 °C (DCM-n-hexane); ^(KBrJ/cm -11688 (C=0), 1273 (CO), 
1249 (CO), 1193 (CO), 1175 (CO); <5h (300 MHz; CDCh) 9.84 (1H, s, CHO), 7.93 
(1H, d, /  = 3.0, ArH), 7.74 (1H, dd, /  = 6.0, 3.0, ArH), 7.39 (2H, d, /  = 7.5, ArH), 
7.09 (1H, d, /  = 6.0, ArH), 6.94 (2H, d, /  = 7.5, ArH), 5.18 (2H, s, OCH2O), 3.82 
(3H, s, OCHa); &(75 MHz; CDCh) 189.9,159.8,159.2,131.4,130.5,130.4,129.0,
127.5, 124.4, 114.3, 113.3, 71.0, 55.4; HRMS (ES+): CisHi^ClNOs, [M+NH4]+
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requires 294.0891. Found 294.0889; C15H13CIO3 requires C, 65.1; H, 4.74%. 
Found C, 64.6; H, 4.68%.
Ill 9 Racemic preparation of derivatised syn- 
oxazolidinethione aldol adducts of O-protected 3-chloro-4- 
hydroxybenzaldehydes and 3-(2-xsothiocyanatoacetyl)- 
oxazolidin-2-one 154
Preparation of (4S*,5R*)-5-[4-(ferf-butyl-dimethyl-silanyloxy)-3-chloro- 
phenyl]-2-thioxo-oxazolidine-4-carboxylic acid ethyl ester 224
0 A n1 _ N C S  ♦ H-
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The reaction was carried out according to the experimental procedure above 
(Section III 3) with 4-(ferf-butyl-dimethyl-silanyloxy)-3-chloro-benzaldehyde 
300 (206 mg, 0.76 mmol). The resultant residue was purified by flash 
chromatography (SiC>2, DCM:EtOAc, 98:2) to provide the title compound syn- 
224 (180 mg, 63%) as a colourless oil; Rf(Si02, DCM:EtOAc, 98:2) 0.30; 
MnaxfneatJ/cm'1 3290 (NH), 1746 (CO), 1506 (NHC=S), 1173 (CO); <5k(300 
MHz; CDCh) 7.40 (1H, d, /  = 2.3, ArH), 7.32 (1H, s, NH), 7.18 (1H, dd, J = 8.4,
2.3, ArH), 6.97 (1H, d, /  = 8.4, ArH), 5.87 (1H, d, /  = 6.2, ArCH), 4.44 (1H, d, /  =
6.2, EtO(CO)CH), 4.25-4.40 (2H, m, (C=0)0CH2CH3), 1.35 (3H, t, /  = 7.1, 
(C=0)0CH2CH3), 1.03 (9H, s, C(CH3)3), 0.23 (6H, s, Si(CH3)2); &(100 MHz;
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CDCh) 189.2,168.1,153.2,130.7,128.4,126.9, 125.6,121.6, 85.3, 64.8, 63.5, 26.0, 
18.8, 14.5, -3.9; HRMS (ES+): Cista^ClNChSSi, [M+H]+ requires 416.1113. 
Found 416.1106. and oxazolidinethione anti-224 (11 mg, 4%), as a colourless oil; 
Rf(SiC>2, DCM:EtOAc, 98:2) 0.18; <5h(300 MHz; CDCh) 7.69 (1H, s, NH), 7.31 
(1H, d, /  = 2.3, ArH), 7.10 (1H, dd, J = 8.4, 2.3, ArH), 6.88 (1H, d, /  = 8.4, ArH),
5.99 (1H, d, /  = 9.7, ArCH), 4.87 (1H, d, /  = 9.7, EtO(CO)CH), 3.83 (2H, m, 
(C=0)0CH2CH3), 1.02 (9H, s, C(CH3)3), 0.94 (3H, t, /  = 7.1, (C=0)0CH2CH3), 
0.21 (6H, s, Si(CH3)2); HRMS (ES+): Cis^T^ClNChSSi, [M+H]+ requires 
416.1113. Found 416.1109.
Preparation of (4S*,5R*)-5-[3-chloro-4-(2-methoxy-ethoxymethoxy)-phenyl]- 




The reaction was carried out according to the experimental procedure above 
(Section III 3) with 3-chloro-4-(2-methoxy-ethoxymethoxy)-benzaldehyde 302 
(186 mg, 0.76 mmol). The resultant residue was purified by flash 
chromatography (SiO, DCM:EtOAc, 95:5) to provide the title compound syn- 
225 (174 mg, 65%) as a pale yellow oil; Rf(SiC>2, DCM:EtOAc, 95:5) 0.13; 
vinax(neat)/cm1 3404 (NH), 2934 (CH), 1734 (CO ), 1506 (NHC=S), 1188 (CO); 
<5h(400 M Hz; CDCh) 7.44 (1H, m, ArH), 7.39 (1H, s, NH), 7.24-7.30 (2H, m, 
ArH), 5.88 (1H, d, /  = 6.0, ArCH), 5.37 (2H, s, OCH2O), 4.44 (1H, d, /  = 6.0, 
EtO(CO)CH), 4.25-4.40 (2H, m, (CO)OCH2CH3), 3.87 (2H, t, /  = 4.0, 
CH2CH2), 3.56 (2H, t, /  = 4.0, CH2CH2), 3.38 (3H, s, OCH3), 1.36 (3H, t, /  = 6.8, 
(CO)OCH2CH3); &(100 MHz; CDCh) 188.7, 167.6, 153.8, 131.0, 127.8, 125.4,
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124.3, 116.6, 94.0, 84.7, 71.4, 68.2, 64.3, 63.1, 59.0, 14.1; HRMS (ES+): 
Ci6H2435ClN206S, [M+NH4]+ requires 407.1038. Found 407.1037. and
oxazolidinethione anti-225 (37 mg, 14%), as a colourless oil; <5h (400 MHz; 
CDCh) 7.86 (1H, s, NH), 7.35 (1H, s, ArH), 7.17-7.24 (2H, m, ArH), 6.02 (1H, 
d, /  = 8.0, ArCH), 5.35 (2H, s, OCH2O), 4.90 (1H, d, /  = 8.0, EtO(C=0)CH), 
3.77-3.93 (4H, m, OCH2CH2O & (C=0)0CH2CH3), 3.55 (2H, t, /  = 4.0, 
OCH2CH2O), 3.37 (3H, s, OCH3), 0.92 (3H, t,J  = 6.0, (CO)OCH2CH3).
Preparation of (4S*,5R*)-5-(3-chloro-4-methylsulfanylmethoxy-phenyl)-2- 




The reaction was carried out according to the experimental procedure above 
(Section III 3) with 3-chloro-4-methylsulfanylmethoxy-benzaldehyde 304 (165 
mg, 0.76 mmol). The resultant residue was purified by flash chromatography 
(SiC>2, DCM:EtOAc, 95:5) to provide the title compound syn-226 (148 mg, 
59%) as a yellow oil; Unax(neat)/cm1 3319 (NH), 2980 (CH), 2922 (CH), 1740 
(C=0), 1497 (NHC=S), 1225 (CO), 1177 (CO); <5h (300 MHz; CDCh) 7.50 (1H, s, 
NH), 7.46 (1H, d, /  = 2.3, ArH), 7.30 (1H, dd, J = 8.6, 2.3, ArH), 7.04 (1H, d, J =
8.6, ArH), 5.90 (1H, d, J = 6.0, ArCH), 5.27 (2H, s, SCH2O), 4.45 (1H, d, J = 6.0, 
EtO(CO)CH), 4.25-4.40 (2H, m, (C=0)0CH2CH3), 2.29 (3H, s, SCH3), 1.36 
(3H, t, 7 = 6.9, (C=0)0CH2CH3); &(75 MHz; CDCh) 189.1, 168.1, 153.6, 131.3,
128.5, 125.5, 125.4, 116.4, 85.0, 73.9, 64.8, 63.5, 15.0, 14.5; HRMS (ES+): 
Ci4Hi735ClN04S2, [M+H]+ requires 362.0282. Found 362.0284. and 
oxazolidinethione anti-226 (10 mg, 4%), as a yellow oil; viru^neatycm1 3161
168
Chapter III Experimental
(NH), 2989 (CH), 1734 (C=0), 1506 (NHC=S), 1226 (CO), 1184 (CO); <5b(300 
MHz; CDCla) 7.51 (1H, s, NH), 7.36 (1H, d, /  = 2.4, ArH), 7.20 (1H, dd, J = 8.4,
2.4, ArH), 6.99 (1H, d, /  = 8.4, ArH), 6.02 (1H, d, /  = 9.8, ArCH), 5.25 (2H, s, 
SCH2O), 4.89 (1H, d, J -  9.8, EtO(CO)CH), 3.75-3.94 (2H, m, 
(C=0)0CH2CH3), 2.26 (3H, s, SCHs), 0.92 (3H, t, /  = 7.2, (CO)OCH2CHi); 
<5c(100 MHz; CDCh) 189.7, 166.8, 153.3, 128.9, 127.4, 125.9, 124.5, 115.7, 84.1,
73.6, 62.6, 62.4, 14.5, 13.6; HRMS (ES+): Ci4Hi735ClN04S2, [M+H]+ requires 
362.0282. Found 362.0288.
Preparation of (4S*,5R*)-5-[3-chloro-4-(4-methoxy-benzyloxy)-phenyl]-2- 




The reaction was carried out according to the experimental procedure above 
(Section III 3) with 4-(4-methoxybenzyloxy)-3-chlorobenzaldehyde 233 (210 
mg, 0.76 mmol). The resultant residue was purified by flash chromatography 
(Si02, DCM:EtOAc, 98:2) to provide the title compound syn-227 (186 mg, 
64%) as a white foam; Rf(Si02, DCM:EtOAc, 98:2) 0.37; vw(KBr)/cm4 3376 
(NH), 1739 (CO ), 1515 (NHC=S), 1245 (CO), 1172 (CO); <5h(300 MHz; CDCh) 
7.55 (1H, s, NH), 7.43 (1H, m, ArH), 7.37 (2H, m, ArH), 7.24 (1H, m, ArH), 
7.00 (1H, m, ArH), 6.92 (2H, m, ArH), 5.87 (1H, d, J = 6.5, ArCH), 5.11 (2H, s, 
ArCHOAr), 4.43 (1H, d, J = 6.5, EtO(CO)CH), 4.27-4.38 (2H, m, 
(CO)OCH2CH3), 3.82 (3H, s, OCH3), 1.35 (3H, t, J = 7.2, (CO)OCH2CH3); 
Sc(75 MHz; CDCh) 188.7, 167.7, 159.6, 155.1, 129.8, 128.9, 127.9 x 2, 125.4,
124.0, 114.3, 114.1, 84.8, 70.8, 64.4, 63.1, 55.3, 14.1; HRMS (ES+):
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C2oH2i35ClN05S, [M+H]+ requires 422.0823. Found 422.0827. C2oH2o35C1N05S 
requires C, 56.9; H, 4.78; N, 3.32%. Found C, 56.8; H, 4.89; N, 3.26%. and 
oxazolidinethione anti-227 (37 mg, 13%), as a white solid; mp 112 °C (DCM- 
EtOAc); Mnaxtneatycm-1 3156 (NH), 1736 (CO ), 1516 (NHC=S), 1250 (CO), 
1179 (CO); <5k(300 MHz; CDCh) 7.32-7.37 (3H, m, ArH), 7.15 (1H, dd, J = 8.7,
2.1, ArH), 7.04 (1H, s, NH), 6.89-6.97 (3H, m, ArH), 5.98 (1H, d, /  = 9.5, 
ArCH), 5.10 (2H, s, ArCHO), 4.85 (1H, d, J = 9.5, EtO(CO)CH), 3.68-3.90 
(2H, m, (CO)OCH2CH3), 3.81 (3H, s, OCH3), 0.89 (3H, t, /  = 7.2, 
(C O P C H 2CH3); &(75 MHz; CDCh) 189.7, 166.7, 159.6, 155.1, 128.8 * 2,
127.9, 126.3, 126.1, 123.5, 114.0, 113.9, 84.2, 70.7, 62.5, 62.3, 55.3, 13.6; 
C2oH2o35C 1N05S requires C, 56.9; H, 4.78; N, 3.32%. Found C, 56.9; H, 4.81; N, 
3.30%.
Ill 10 Asymmetric preparation of derivatised syn-
oxazolidinethione aldol adducts of O-protected 3-chloro-4- 
hydroxybenzaldehydes and 3-(2-isothiocyanatoacetyl)- 
oxazolidin-2-one 154
Preparation of (4S,5R)-5-[4-(fer/-butyl-dimethyl-silanyloxy)-3-chloro- 
phenyl]-2-thioxo-oxazoiidine-4-carboxylic acid ethyl ester 224
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The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-(£erf-butyl-dimethyl-silanyloxy)-3-chloro-benzaldehyde 
300 (206 mg, 0.76 mmol). The resultant residue was purified by flash 
chromatography (SiCh, DCM:EtOAc, 98:2) to provide, in order of elution, the 
title compound and anh-diastereomer (228 mg, 79%), symanti = 75:25, eesyn = 
72%, [a]d21 = +17.9 (c = 6.0, DCM). Data identical to that reported earlier. The 
enantiomers of the syn-diastereomer were separated analytically by chiral 
HPLC using the conditions in the general experimental section; tm = 24.7 min. 
and tm = 31.8 min.
Preparation of (4S,5R)-5-[3-chloro-4-(2-methoxy-ethoxymethoxy)-phenyl]-2- 




The reaction was carried out according to the experimental procedure above 
(Section III 4) with 3-chloro-4-(2-methoxy-ethoxymethoxy)-benzaldehyde 302 
(186 mg, 0.76 mmol). The resultant residue was purified by flash 
chromatography (SiC>2, DCM:EtOAc, 95:5) to provide, in order of elution, the 
title compound and anh-diastereomer (211 mg, 79%), symanti = 77:23, eesyn = 
74%, [ a ] D 21 = +15.2 (c = 2.0, DCM). Data identical to that reported earlier. The 
enantiomers of the syrc-diastereomer were separated analytically by chiral 
HPLC using the conditions in the general experimental section; £ r i = 51.5 min. 









The reaction was carried out according to the experimental procedure above 
(Section III 4) with 3-chloro-4-methylsulfanylmethoxy-benzaldehyde 304 (165 
mg, 0.76 mmol). The resultant residue was purified by flash chromatography 
(SiC>2, DCM:EtOAc, 95:5) to provide, in order of elution, the title compound 
and fltth-diastereomer (158 mg, 63%), symanti = 93:7, eesyn = 82%, [ a ] D 21 = +92.0 
(c = 0.5, DCM). Data identical to that reported earlier. The enantiomers of the 
syn-diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; tei = 19.7 min. and tR2 = 22.6 
min.
Preparation of (4S,5K)-5-[3-chloro-4-(4-methoxy-benzyloxy)-phenyl]-2- 




The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-(4-methoxybenzyloxy)-3-chlorobenzaldehyde 233 (210
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mg, 0.76 mmol). The resultant residue was purified by flash chromatography 
(SiCh, DCM:EtOAc, 98:2) to provide, in order of elution, the title compound 
and <mh'-diastereomer (223 mg, 77%), symanti = 93:7, eesyn = 95%, [ c i] d 21 = +24.0 
(c = 1.0, DCM), eeanti = 71%. Data identical to that reported earlier. The 
enantiomers of the syn-diastereomer were separated analytically by chiral 
HPLC using the conditions in the general experimental section; tm = 28.8 min. 
and fR2 = 31.3 min. The enantiomers of the flnh-diastereomer were separated 
analytically by chiral HPLC using the conditions in the general experimental 
section; £ri = 22.8 min. and £r2 = 55.4 min. A single crystal of the syn- 
oxazolidinethione syn-227 was grown for X-ray crystallography from 'PrOH-rc- 
hexane as a colourless needle (Appendix A) over several days at RT; mp 114- 
115 °C ('PrOH-n-hexane).
Ill 11 Racemic preparation of (2S*,3R*)-2-amino-3-(tert- 
butyl-dimethyl-silanyloxy)-3-(3-chloro-4-hydroxy-phenyl)- 
propionic acid methyl ester 239; analogue of AA-6, a 
vancomycin building block
Preparation of (4S*,5R*)-5-[3-chloro-4-(4-methoxy-benzyloxy)-phenyl]-2- 




oxazolidine-4-carboxylic acid ethyl ester 227 (370 mg, 0.88 mmol) was stirred 
in dry DCM (10 mL) under a nitrogen atmosphere at RT. To this solution was 
added di-ferf-butyl dicarbonate (211 mg, 0.96 mmol) followed by 4- 
dimethylaminopyridine (5 mg, 0.04 mmol). The mixture effervesced and was 
allowed to stir for 45 min. The mixture was then cooled to 0 °C and 30 wt.% 
hydrogen peroxide (3.5 mL) was added portion-wise followed by formic acid 
(3.5 mL). The mixture was allowed to stir for 45 min. after which time the 
reaction was deemed complete. The reaction was quenched by the addition 
of the mixture to 1 M aqueous K2CO3 (75 mL). The organic layer was 
separated and the aqueous layer washed with DCM. The combined organic 
layers were dried (Na2S04) and concentrated under reduced pressure. The 
residue was purified by flash chromatography (SiC>2, DCM:EtOAc, 98:2) to, 
provide oxazolidinone syn-229 (324 mg, 73%), as a white foam; vtnax(KBr)/cm1 
3451 (NH), 2982 (CH), 1829 (C O ), 1750 (CO ), 1247 (CO), 1060 (CO); <5h (300 
MHz; CDCh) 7.34-7.41 (3H, m, ArH), 7.20 (1H, dd, J = 8.7, 2.4, ArH), 7.00 (1H, 
d, J = 8.7, ArH), 6.92 (2H, d, /  = 8.7, ArH), 5.27 (1H, d, /  = 4.5, ArCH), 5.11 (2H, 
s, OCH2Ar), 4.57 (1H, d, J = 4.5, EtO(CO)CH), 4.26-4.42 (2H, m, CH2CH3), 
3.82 (3H, s, OCHs), 1.51 (9H, s, C(CH3)3), 1.34 (3H, t, J = 7.2, CH2CH3); Sc(75 
MHz; CDCh) 168.3, 159.6, 155.0, 150.5, 148.4, 130.2, 128.9, 128.0, 127.3, 124.6,
124.2, 114.3, 114.1, 85.0, 75.2, 70.8, 63.7, 62.7, 55.3, 27.8, 14.2; HRMS (ES+): 
C25H3235C1N208, [M+NH4]+ requires 523.1842. Found 523.1844.
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Preparation of (2S*,3R*)-2-ferf-butoxycarbonylamino-3-[3-chloro-4-(4- 
methoxy-benzyloxy)-phenyl]-3-hydroxy-propionic acid ethyl ester 230
'O










3,4-dicarboxylic acid 3-ferf-butyl ester 4-ethyl ester 229 (225 mg, 0.45 mmol) 
was stirred in dry EtOH (7 mL) under a nitrogen atmosphere at 0 °C. To this 
solution was added cesium carbonate (59 mg, 0.18 mmol). The mixture was 
allowed to stir for 2 h after which time the reaction was deemed complete. 
The mixture was then concentrated under reduced pressure. The residue was 
taken up in EtO Ac and washed with water and brine and dried (Na2S04). 
After filtration the solvent was removed in vacuo and the residue was 
purified by flash chromatography (Si02, DCM:EtOAc, 98:2 then 90:10 and 
0:100) to provide hydroxycarbamate syn-230 (52 mg, 25%), as a white solid; mp 
104-105 °C (DCM-EtOAc); uI1ax(KBr)/cm-1 3405 (OH), 2978 (CH), 1746 (C=0), 
1671 (C=0), 1252 (CO), 1059 (CO); <5k(300 MHz; CDCh) 7.43 (1H, d, /  = 3.0, 
ArH), 7.38 (2H, d, /  = 9.0, ArH), 7.18 (1H, dd, J = 9.0, 3.0, ArH), 6.93 (3H, m, 
ArH), 5.29 (1H, d, /  = 9.0, ArCH), 5.13 (1H, t, /  = 3.0, NH), 5.08 (2H, s, 
OCH2Ar), 4.46 (1H, d, J = 9.0, EtO(CO)CH), 4.16-4.26 (2H, m, CH2CH3), 3.82 
(3H, s, OCHs), 2.68 (1H, s, OH), 1.37 (9H, s, (CH3)3), 1.25 (3H, t, J = 9.0, 
CH2CH3); <5c(75 MHz; CDCh) 170.8, 159.7, 155.9, 154.2, 133.5, 129.0, 128.6,
128.4, 125.6, 123.5, 114.2 * 2, 80.5, 73.5, 71.0, 62.0, 57.7, 55.5, 28.3, 14.3; HRMS 
(ES+): C24H3i35C1N07, [M+H]+ requires 480.1784. Found 480.1782; C24H30CINO7 




thioxo-oxazolidine-4-carboxylic acid methyl ester 234
A mixture of Mg(C104)2 (360 mg, 1.6 mmol) and 3-(2-zsothiocyanatoacetyl)- 
oxazolidin-2-one 154 (3.0 g, 16.1 mmol) was stirred in dry DCM (120 mL) 
under nitrogen at 0 °C. After 15 min, 4-(4-methoxybenzyloxy)-3- 
chlorobenzaldehyde 233 (4.90 g, 17.7 mmol) and di/sopropylethylamine (561 
pL, 3.2 mmol) were added and the mixture was stirred for a further 3 h. The 
reaction was quenched with saturated aqueous ammonium chloride. The 
organic layer was separated and the aqueous layer extracted with DCM. The 
combined organic layers were washed with brine, dried (MgSCh) and 
concentrated under reduced pressure. The resultant foam was dissolved in 
dry THF (120 mL) and cooled to 0 °C. A solution of methyl magnesium 
bromide (3 M in diethyl ether, 6.9 mL, 20.9 mmol) was added to methanol (46 
mL) at 0 °C and subsequently added to the previous solution via cannula 
transfer. After 3 min. of vigorous stirring the reaction was quenched by 
addition of an aqueous pH 7 phosphate buffer. The mixture was 
concentrated under reduced pressure, taken up in aqueous 1 M HC1 and 
extracted with DCM. The organic layer was separated and the aqueous layer 
extracted further with DCM. The organic portions were combined, dried 
(MgSCh) and concentrated under reduced pressure. The residue was purified 
by flash chromatography (SiC>2, DCM:EtOAc, 98:2) to provide the title 
compound syn-234 (4.9 g, 75%) as a white solid; mp 192-193 °C (DCM-
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EtOAc); MnaxCKBrVcm1 3177 (NH), 1741 (CO ), 1511 (NHC=S), 1246 (CO), 
1173 (CO); <5h(300 MHz; CDCh) 7.44 (1H, d, /  = 3.0, ArH), 7.38 (2H, d, /  = 9.0, 
ArH), 7.24 (1H, dd, J = 9.0, 3.0, ArH), 7.00 (1H, d, J = 9.0, ArH), 6.92 (2H, m, 
ArH), 5.88 (1H, d, J = 6.0, ArCH), 5.11 (2H, s, ArCFLOAr), 4.45 (1H, d, /  = 6.0, 
MeO(CO)CH), 3.88 (3H, s, (CO)OCH3), 3.82 (3H, s, OCHa); Sc{75 MHz; 
CDCh) 188.9, 168.3, 159.8, 155.4, 129.9, 129.0, 128.1, 128.0, 125.5, 124.4, 114.5,
114.3, 85.0, 71.0, 64.4, 55.5, 53.8; HRMS (ES+): CioHi^ClNOsS, [M+H]+ 
requires 408.0667. Found 408.0665; CwHisClNOsS requires C, 55.9; H, 4.45; N, 
3.43%. Found C, 55.7; H, 4.47; N, 3.40%.
Preparation of (4S*,5R*)-5-[3-chloro-4-(4-methoxy-benzyloxy)-phenyl]-2- 
oxo-oxazolidine-3,4-dicarboxylic acid 3-ferf-butyl ester 4-methyl ester 235
(4S*,5R*)-5-[3-Chloro-4-(4-methoxy-benzyloxy)-phenyl]-2-thioxo- 
oxazolidine-4-carboxylic acid methyl ester 234 (4.175 g, 10.24 mmol) was 
stirred in dry DCM (120 mL) under a nitrogen atmosphere at RT. To this 
solution was added di-ferf-butyl dicarbonate (2.46 g, 11.26 mmol) followed 
by 4-dimethylaminopyridine (63 mg, 0.52 mmol). The mixture effervesced 
and was allowed to stir 1 h. The mixture was then cooled to 0 °C and 30 wt.% 
hydrogen peroxide (39 mL) was added portion-wise followed by formic acid 
(39 mL). The mixture was allowed to stir for 1 h  after which time the reaction 
was deemed complete. The reaction was quenched by the addition of the 
mixture to 1 M aqueous K2CO3 (750 mL). The organic layer was separated
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and the aqueous layer washed with DCM. The combined organic layers were 
dried (Na2S04) and concentrated under reduced pressure. The residue was 
purified by flash chromatography (SiCh, DCM:EtOAc, 98:2) to provide 
oxazolidinone syn-235 (3.68 g, 73%), as a white foam; Mna^KBrycm*1 2980 (NH), 
1829 (C=0), 1756 (C=0), 1250 (CO), 1061 (CO); <5h(300 MHz; CDCh) 7.34-7.41 
(3H, m, ArH), 7.19 (1H, dd, J = 8.7, 2.4, ArH), 7.00 (1H, d, J = 8.4, ArH), 6.92 
(2H, d, /  = 8.7, ArH), 5.28 (1H, d, J = 4.5, ArCH), 5.10 (2H, s, OCH2Ar), 4.60 
(1H, d, /  = 4.5, MeO(GO)CH), 3.87 (3H, s, (C=0)OCH3), 3.81 (3H, s, OCHa), 
1.50 (9H, s, C(CH3)3); Sc(75 MHz; CDCh) 168.9, 159.7, 155.1, 150.6, 148.5,
130.1, 129.0, 128.0, 127.4, 124.8, 124.2, 114.4, 114.2, 85.2, 75.2, 70.9, 63.7, 55.4,
53.5, 27.9; HRMS (ES+): C24H3o35C1N208, [M+NH4]+ requires 509.1685. Found 
509.1684; C24H26CINO8 requires C, 58.6; H, 5.33; N, 2.85%. Found C, 58.4; H, 
5.35; N, 2.72%.
Preparation of (2S*,3R*)-2-ferf-butoxycarbonylamino-3-[3-chloro-4-(4- 
methoxy-benzyloxy)-phenyl]-3-hydroxy-propionic acid methyl ester 236
(4S*,5R*)-5-[3-Chloro-4-(4-methoxy-benzyloxy)-phenyl]-2-oxo-oxazolidine-
3,4-dicarboxylic acid 3-ferf-butyl ester 4-methyl ester 235 (3.29 g, 6.69 mmol) 
was stirred in dry MeOH (100 mL) under a nitrogen atmosphere at -20 °C. To 
this solution was added cesium carbonate (0.87 g, 2.67 mmol). The mixture 
was allowed to stir for 2 h after which time the reaction was deemed 
complete. The mixture was then concentrated under reduced pressure. The 






(Na2SC>4). After filtration the solvent was removed in vacuo and the residue 
was purified by flash chromatography (SiCb, DCM:EtOAc, 98:2 then 90:10 
and 0:100) to provide, in order of elution, (Z)-enamide 237 (by-product) (370 
mg, 12%), as a white solid; 113-114 °C (DCM-EtOAc); v^ax(KBr)/cm1 2944 
(CH), 1705 (C=0), 1250 (CO), 1160 (CO); <fc(300 MHz; CDCh) 7.63 (1H, d, /  =
2.4, ArH), 7.37 (3H, d, J = 8.7, ArH), 7.20 (1H, s, COH), 6.90-6.95 (3H, m, 
ArH), 6.26 (1H, s, NH), 5.11 (2H, s, OCHiAr), 3.84 (3H, s, (C=0)OCH3), 3.82 
(3H, s, OCHa), 1.42 (9H, s, (CH3)3); Sc{75 MHz; CDCh) 166.5, 160.0, 155.2,
153.0,131.8,130.5,129.6,129.5,128.5,128.2,123.6,114.4,113.7, 81.5, 71.0, 55.7,
53.1, 28.6; m/z (EI+) 447 (7%, M+); C^HieClNOe requires C, 61.6; H, 5.85; N, 
3.13%. Found C, 61.3; H, 5.85; N, 3.04%. Assignment of (E)-configuration was 
accomplished through NOESY experiment, coupling was observed between 
NH, 6.26 ppm and ArH, 7.63 ppm (Appendix F); and hydroxycarbamate syn- 
236 (1.87 g, 60%), as a white solid; mp 108-109 °C (DCM-EtOAc); 
unax(KBr)/cm1 3403 (OH), 2978 (CH), 1751 (CO ), 1670 (CO ), 1253 (CO), 1060 
(CO); <5h(300 MHz; CDCh) 7.42 (1H, m, ArH), 7.37 (2H, d, /  = 8.7, ArH), 7.17 
(1H, m, ArH), 6.90-6.94 (3H, m, ArH), 5.30 (1H, d, /  = 8.4, ArCH), 5.16 (1H, s, 
NH), 5.07 (2H, s, OCHiAr), 4.48 (1H, d, /  = 8.4, MeO(CO)CH), 3.81 (3H, s, 
(CO)OCH3), 3.76 (3H, s, OCHs), 2.66 (1H, s, OH), 1.35 (9H, s, (CH3)3); <5c(75 
MHz; CDCh) 169.6, 157.8, 154.0, 152.3, 131.7, 127.2, 126.8, 126.4, 123.8, 121.6,
112.4, 112.3, 78.7, 71.4, 69.1, 57.7, 53.7, 51.1, 26.5; HRMS (ES+): C 23H2935C 1 N 0 7, 
[M+H]+ requires 466.1627. Found 466.1630; C 23H28C1N07 requires C , 59.3; H, 
6.06; N, 3.01%. Found C , 59.3; H , 6.05; N, 3.13%.
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Preparation of (2S*,3R*)-2-amino-3-(fer£-butyl-dimethyl-silanyloxy)-3-[3- 
chloro-4-(4-methoxy-benzyloxy)-phenyl]-propionic acid methyl ester 238
(2S*,3R*)-2-terf-Butoxycarbonylamino-3-[3-chloro-4-(4-methoxy-benzyloxy)- 
phenyl]-3-hydroxy-propionic acid methyl ester 236 (392 mg, 0.84 mmol) was 
stirred in dry DCM (25 mL) under a nitrogen atmosphere at 0 °C. To this 
solution was added drop-wise, 2,6-lutidine (0.87 g, 2.67 mmol), followed by 
ferf-butyldimethylsilyl triflate (502 pL, 2.19 mmol). The mixture was allowed 
to warm to RT over 1 h after which time the reaction was deemed complete. 
The mixture was then concentrated under reduced pressure and the residue 
taken up in MeOH (6 mL) and treated with aqueous K2CO3 (117 mg, 0.84 
mmol in 2 mL H 2O). After 1 h DCM was added and the organic extract was 
washed with brine. The extract was then concentrated in vacuo and the 
resultant residue was purified by flash chromatography (SiCh, DCM:EtOAc, 
1:1) to provide the title compound, syn-amino-TBS ether 238 (402 mg, 100%), 
as a colourless oil; vinax(KBr)/cm1 3391 (NH), 3325 (NH), 2952 (CH), 2857 
(CH), 1746 (C=Q), 1250 (CO), 1059 (CO); <fc(300 MHz; DMSO) 7.36-7.41 (3H,
m, ArH), 7.16-7.26 (2H, m, ArH), 6.96 (2H, d, /  = 9.0, ArH), 5.09 (2H, s, 
OCLbAr), 5.00 (1H, d, /  = 3.0, ArCH), 3.76 (3H, s, OCH3), 3.61 (3H, s, 
(C=0)OCH3), 3.39 (1H, d, J = 3.0, MeO(CO)CH), 1.56 (2H, s, NH2), 0.83 (9H, 
s, (SiCH3)3), -0.04 (3H, s, SiCHs), -0.21 (3H, s, SiCHs); Sc{75 MHz; CDCh)
171.3, 159.9, 155.7, 135.5, 129.3, 128.9, 128.6, 125.8, 123.4, 114.4, 114.1, 74.4, 
71.2, 60.8, 55.7, 52.5, 26.1, 18.5, -4.2, -5.1; HRMS (ES+): C24H3535ClN05Si,
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[M+H]+ requires 480.1968. Found 480.1969; C24H34ClNOsSi requires C, 60.0; H,
Preparation of (2S*,3R*)-2-amino-3-(fert-butyl-dimethyl-silanyloxy)-3-(3- 
chloro-4-hydroxy-phenyl)-propionic acid methyl ester 239
(2S*,3R*)-2-Amino-3-(terf-butyl-dimethyl-silanyloxy)-3-[3-chloro-4-(4- 
methoxy-benzyloxy)-phenyl]-propionic acid methyl ester 238 (160 mg, 0.33 
mmol) was stirred in dry MeOH (4 mL) with 20% Pd(OH)2  on carbon (12 mg) 
under a hydrogen atmosphere at RT. The mixture was stirred for 30 min. 
after which time the reaction was deemed complete. After a nitrogen purge 
the mixture was filtered through celite and then concentrated under reduced 
pressure. The resultant white solid was purified by flash chromatography 
(SiCh, DCMrEtOAc, 1:1) to provide the title compound, phenol 239 (72 mg, 
60%), as a white solid; mp 116 °C (DCM-EtOAc); Mnax(KBr)/cm1 3352 (NH), 
3283 (NH), 2954 (CH), 2857 (CH), 1734 (C=0), 1292 (SiC), 1257 (CO), 1084 
(CO); <5h(400 MHz; DMSO) 10.07 (1H, s, ArOH), 7.29 (1H, d, /  = 2.0, ArH), 
7.08 (1H, dd, /  = 8.4, 2.0, ArH), 6.89 (1H, d, /  = 8.4, ArH), 4.93 (1H, d, /  = 3.2, 
ArCH), 3.61 (3H, s, (C=0)OCH3), 3.37 (1H, d, J = 3.2, MeO(CO)CH), 1.56 
(2H, s, NH2), 0.83 (9H, s, SiC(CH3)3), -0.04 (3H, s, SiCHs), -0.20 (3H, s, SiCH3); 
Sc(75 MHz; CDCh) 173.9, 151.9, 133.9, 127.2, 125.8, 120.7, 117.1, 74.4, 62.0,
52.7, 26.1, 18.5, -4.2, -5.2; HRMS (ES+): Ci6H2735ClN04Si, [M+H]+ requires 
360.1392. Found 360.1391; Ci6H26ClN04Si requires C, 53.3; H, 7.28; N, 3.89%. 
Found C, 53.0; H, 7.24; N, 3.82%.
7.14; N, 2.92%. Found C, 59.6; H, 7.27; N, 2.65%.
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III 12 Asymmetric preparation of (2S,3R)-2-amino-3-(terf- 
butyl-dimethyl-silanyloxy)-3-(3-chloro-4-hydroxy-phenyl)- 
propionic acid methyl ester 239; analogue of AA-6 building 
block of vancomycin
Preparation of (4S,5K)-5-[3-chloro-4-(4-methoxy-benzyloxy)-phenyl]-2- 
thioxo-oxazolidine-4-carboxylic acid methyl ester 234
(4S,5R)-234
The reaction was carried out according to the experimental procedure above 
(Section III 4) with 4-(4-methoxybenzyloxy)-3-chlorobenzaldehyde 233 (210 
mg, 0.76 mmol) and MeOH (5 mL). The resultant residue was purified by 
flash chromatography (SiCh, DCM:EtOAc, 95:5) to provide, in order of 
elution, the title compound and flnh'-diastereomer (220 mg, 78%), symanti = 
93:7, eesyn = 94%, [a]D20= +25.0 (c = 1.0, DCM). Data identical to that reported 
earlier. The enantiomers of the syn-diastereomer were separated analytically 
by chiral HPLC using the conditions in the general experimental section; fei = 




oxazolidine-3,4-dicarboxylic acid 3-ferf-butyl ester 4-methyl ester 235
The reaction was carried out according to the experimental procedure above 
(Section III 10) with (4S,5R)-5-[3-chloro-4-(4-methoxy-benzyloxy)-phenyl]-2- 
thioxo-oxazolidine-4-carboxylic acid methyl ester 234 (370 mg, 0.91 mmol). 
The resultant residue was purified by flash chromatography (SiCh, 
DCM:EtOAc, 98:2) to provide syn-oxazolidinone syn-235 (323 mg, 72%), [ a ] D 21 =  
+52.0 (c = 1.0, DCM). Data identical to that reported earlier.
Preparation of (2S,3R)-2-£crt-butoxycarbonylamino-3-[3-chloro-4-(4- 
methoxy-benzyloxy)-phenyl]-3-hydroxy-propionic acid methyl ester 236
The reaction was carried out according to the experimental procedure above 
(Section III 10) with (4S,5R)-5-[3-chloro-4-(4-methoxy-benzyloxy)-phenyl]-2- 
oxo-oxazolidine-3,4-dicarboxylic acid 3-ferf-butyl ester 4-methyl ester 235 
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chromatography (SiC>2, DCM:EtOAc, 95:5 then 0:100) to provide 
hydroxycarbamate syn-236 (130 mg, 60%) as a white solid, [a]d21 = -11.0 (c = 1.0, 
DCM). Data identical to that reported earlier.
Preparation of (2S,3R)-2-amino-3-(ferf-butyl-dimethyl-silanyloxy)-3-[3-
chloro-4-(4-methoxy-benzyloxy)-phenyl]-propionic acid methyl ester 238
Me










The reaction was carried out according to the experimental procedure above 
(Section III 10) with (2S,3R)-2-ferf-butoxycarbonylamino-3-[3-chloro-4-(4- 
methoxy-benzyloxy)-phenyl]-3-hydroxy-propionic acid methyl ester 236 (114 
mg, 0.25 mmol). The resultant residue was purified by flash chromatography 
(SiC>2, DCM:EtOAc, 1:1) to provide the title compound, amino-TBS ether syn- 
238 (117 mg, 100%) as a white solid, [ a ] D 21 = -23.0 (c = 1.0, DCM). Data 
identical to that reported earlier.
Preparation of (2S,3R)-2-amino-3-(tert-butyl-dimethyl-silanyloxy)-3-(3- 












The reaction was carried out according to the experimental procedure above 
(Section III 10) with (2S,3R)-2-amino-3-(fert-butyl-dimethyl-silanyloxy)-3-[3- 
chloro-4-(4-methoxy-benzyloxy)-phenyl]-propionic acid methyl ester 238 (33 
mg, 0.07 mmol), MeOH (1 mL) and 20% Pd(OH )2 on carbon (3 mg). The 
resultant residue was purified by flash chromatography (SiCh, DCMrEtOAc, 
1:1) to provide the title compound, phenol syn-239 (17 mg, 69%) as a white 
solid, [ a ] D 20 = -30.0 (c = 1.0, DCM). Data identical to that reported earlier.
Ill 13 Preparation of AM4-ferf-butyl-benzylidene)-4-methyl- 
benzenesulfonamide 308; to serve as a typical experimental 
procedure for the preparation of N-tosylbenzaldimines 
employed in the asymmetric Mannich-type reaction
To a refluxing solution of p-(f-butyl)benzaldehyde 306 (3.0 mL, 17.9 mmol) p- 
toluenesulfonamide 307 (3.07 g, 17.9 mmol) in toluene (50 mL) employing 
Dean and Stark apparatus was added portion-wise boron trifluoride-diethyl 
etherate (0.6 mL, 4.7 mmol). The mixture was refluxed for 4 h and then 
cooled and extracted with aqueous 2 M sodium hydroxide and washed with 
water. The organic phase was separated, dried over Na2SC>4 and concentrated 





60 °C) to provide the title compound as a white solid (4.8 g, 85%); mp 119 °C 
(DCM-light petroleum (bp 40-60 °C)); Mnax(KBr)/cm1 2968 (CH), 1596 (C=N), 
1321 (SOz), 1156 (SOz); <5h (300 MHz; CDCh) 9.01 (1H, s, (N=C)H), 7.85-7.89 
(4H, m, ArH), 7.50 (2H, d, /  = 8.7, ArH), 7.33 (2H, d, J = 8.1, ArH), 2.43 (3H, s, 
ArCHs), 1.33 (9H, s, C(CHs)3); Sc{75 MHz; CDCh) 170.4, 159.7, 144.8, 135.9,
131.7, 130.2, 130.1, 128.4, 126.6, 35.8, 31.4, 22.0; m/z (EI+) 315 (100%, M+); 
CisHziNOzS requires C, 68.5; H, 6.71; N, 4.44%. Found C, 68.5; H, 6.64; N, 
4.51%.
Ill 14 Preparation of (4S*,5S*)-3-[5-phenyl-2-thioxo-l- 
(toluene-4-sulfonyl)-imidazolidine-4-carbonyl]-oxazolidin-2- 
one anti-241 and (4S*,5.R*)-3-[5-phenyl-2-thioxo-l-(toluene-4- 
sulfonyl)-imidazolidine-4-carbonyl]-oxazolidin-2-one syn-241; 
to serve as a typical experimental procedure for the racemic 
preparation of adducts of N-tosylimines and 3-(2- 
isothiocyanatoacetyl)-oxazolidin-2-one 154
Me
A mixture of Mg(ClC>4)z (15 mg, 0.07 mmol) and 3-(2-zsothiocyanatoacetyl)- 
oxazolidin-2-one 154 (128 mg, 0.69 mmol) was stirred for 1 h in dry DCM (15 
mL) with activated powdered 4 A MS (200 mg) under nitrogen at RT. The
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temperature was then lowered to -78 °C. After 15 min, N-( 4- 
toluenesulfonyl)benzaldimine 240 (358 mg, 1.38 mmol) and
diz’sopropylethylamine (24 pL, 0.14 mmol) were added and the mixture was 
stirred for a further 24 h at -78 °C. The reaction was quenched with saturated 
aqueous ammonium chloride (5 mL). The organic layer was separated and 
the aqueous layer extracted with DCM (3  ^ 10 mL). The organic portions 
were combined, washed with brine (5 mL), dried (MgSCh) and concentrated 
under reduced pressure. The residue was purified by flash chromatography 
(SiCh, DCM:EtOAc, 90:10) to provide the title compounds, in order of elution, 
imidazolidinethione syn-241 (36 mg, 11%), as a white foam; Mnax(KBr)/cm1 3353 
(NH), 1777 (C=0), 1699 (CO ), 1491 (NHC=S), 1357 (SO2), 1164 (SO2); <5k(300 
MHz; CDCh) 7.58 (2H, d, /  = 8.3, ArH), 7.33-7.38 (5H, m, ArH & NH), 7.10- 
7.15 (3H, m, ArH), 6.34 (1H, d, /  = 1.2, ArCH), 4.87 (1H, d, J = 1.2, 
N(CO)CH), 4.50-4.61 (2H, m, OCH2), 4.04-4.18 (2H, m, NCH2) 2.37 (3H, s, 
ArCHs); <5c(75 MHz; DMSO) 178.7, 167.0, 152.7, 143.4, 140.9, 140.2, 138.5, 
134.3,128.31,127.8,127.7,127.6,125.7,124.6, 65.8, 62.3, 60.9, 41.7, 20.0; HRMS 
(ES+): C20H20N3O5S2, [M+H]+ requires 446.0839. Found 446.0830; and 
imidazolidinethione anti-241 (212 mg, 69%), as white crystals; mp 220-222 °C 
(CHCb); Unax(KBr)/cm*1 3338 (NH), 1776 (CO), 1704 (CO ), 1477 (NHC=S), 
1364 (SO2), 1169 (SO2); <5h(300 M Hz; CDCh) 7.42 (2H, d, /  = 8.3, ArH), 7.25- 
7.37 (4H, m, ArH & NH), 7.18 (2H, d, J = 7.2, ArH), 7.07 (2H, d, /  = 8.3, ArH), 
6.26 (1H, d, J = 9.9, ArCH), 5.74 (1H, d, J = 9.9, N(CO)CH), 4.30 (1H, app. dt, 
J = 6.0, 9.2, OCHaH b), 3.97 (1H, app. dt, /  = 6.0, 9.2, OCHaH b), 3.75 (1H, m, 
NCHcH d), 3.06 (1H, m, N CH cHd) 2.35 (3H, s, ArCHs); <5c(75 MHz; CDCh)
179.2.166.0.152.7.144.8.135.0.134.9.129.6.129.5.128.7.128.0, 66.2, 63.1, 62.3,












The reaction was carried out according to the experimental procedure above 
(Section III 14) with 4-methyl-N-naphthalen-2-ylmethylene- 
benzenesulfonamide 309 (427 mg, 1.38 mmol) to provide, in order of elution, 
syn-imidazolidinethione syn-216 (8 mg, 2%) which could not be purified from 
p-toluene sulfonamide and imidazolidinethione anti-216 (128 mg, 37%) as a 
white solid; mp 222-223 °C (DCM-EtOAc); nnax(KBr)/cm-1 3357 (NH), 1770 
(C=0), 1699 (C=0), 1476 (NHC=S), 1367 (SO2), 1168 (SO2); <5k(300 MHz; 
CDCh) 7.67-7.83 (4H, m, ArH), 7.48-7.57 (2H, m, ArH & NH), 7.38 (2H, d, /  =
8.3, ArH), 7.21 (1H, d, /  = 9.0, ArH), 6.87 (2H, d, /  = 8.3, ArH), 6.42 (1H, d, /  =
9.9, ArCH), 5.82 (1H, d, /  = 9.9, N(C=0)CH), 4.10-4.23 (1H, m, OCHaH b), 3.57- 
3.70 (2H, m, CH2), 2.76-2.90 (1H, m, N CH cHd), 2.26 (3H, s, ArCHs); Sc(75 
MHz; CDCh) 179.3, 166.0, 152.8, 144.8, 134.9, 133.4, 132.6, 132.0, 129.3, 128.6,
128.4, 127.7, 127.6, 127.2, 126.8, 124.7, 66.4, 63.0, 62.4, 42.0, 21.5; m/z (CI+) 496 
(10%, [M+HJ+); C24H21N3O5S2 requires C, 58.2; H, 4.27; N, 8.48%. Found C, 
58.1; H, 4.25; N, 8.63%.
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Preparation of (4S*,5S *)-3-[5-(4-bromo-phenyl)-2-thioxo-l-(toluene-4- 






The reaction was carried out according to the experimental procedure above 
(Section III 14) with N-(4-bromo-benzylidene)-4-methyl-benzenesulfonamide 
310 (467 mg, 1.38 mmol) to provide, in order of elution, the syn- 
imidazolidinethione syn-247 (11 mg, 3%) which could not be purified from p- 
toluene sulfonamide and imidazolidinethione anti-247 (80 mg, 21%) as a white 
solid; mp 233-235 °C (DCM-EtOAc); M.ax(KBr)/cm1 3341 (NH), 1771 (C=0), 
1698 (C=0), 1479 (NHC=S), 1367 (SO2), 1169 (SO2); <5h(300 MHz; CDCb) 7.50 
(2H, d, /  = 8.1, ArH), 7.41 (2H, d, /  = 8.3, ArH), 7.12 (2H, d, /  = 8.1, ArH), 7.07 
(2H, d, /  = 8.3, ArH), 6.25 (1H, d, J = 9.9, ArCH), 5.70 (1H, d, /  = 9.9, 
N(C=0)CH), 4.34 (1H, app. dt, /  = 6.0, 8.1, OCHaH b), 4.10 (1H, app. dt, /  = 6.0,
8.1, OCHaHb), 3.80 (1H, m, NCHcH d), 3.22 (1H, m, N CH cH d), 2.39 (3H, s, 
ArCHs); &(75 MHz; DMSO) 178.8, 166.1, 153.4, 145.0, 135.7, 135.6, 131.9,
129.3, 129.2, 129.1, 122.6, 65.2, 63.7, 62.3, 42.5, 21.5; HRMS (ES+): 
C2oHi979BrN30sS2, [M+H]+ requires 523.9944. Found 523.9943; C2oHi8BrN30sS2 
requires C, 45.8; H, 3.46; N, 8.01%. Found C, 45.7; H, 3.46; N, 8.10%.
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Preparation of (4S*,5S *)-3-[5-(4-fluoro-phenyl)-2-thioxo-l-(toluene-4- 












The reaction was carried out according to the experimental procedure above 
(Section III 14) with N-(4-fluoro-benzylidene)-4-methyl-benzenesulfonamide 
311 (383 mg, 1.38 mmol) to provide, in order of elution, syn- 
imidazolidinethione syn-248 which could not be purified from p-toluene 
sulfonamide and imidazolidinethione anti-248 (35 mg, 10%) as a white solid; 
mp 238 °C (DCM-EtOAc); vhnax(KBr)/cm1 3334 (NH), 1779 (C=0), 1706 (CO), 
1510 (NHC=S), 1395 (SO2), 1170 (SO); <5h(300 MHz; CDCla) 7.48 (2H, d, /  = 8.4, 
ArH), 7.16-7.21 (2H, m, ArH), 7.11 (2H, d, 7 = 8.1, ArH), 6.94-7.04 (3H, m, ArH 
& NH), 6.27 (1H, d, /  = 9.9, ArCH), 5.72 (1H, d, /  = 9.9, N(CO)CH), 4.35 (1H, 
app. dt, /  = 6.6, 9.3, OCHaHb), 4.09 (1H, app. dt, J = 6.6, 9.3, OCHaHb), 3.79- 
3.89 (1H, m, NCHcHd), 3.16-3.24 (1H, m, NCHcHd), 2.37 (3H, s, ArCHs); &(75 
MHz; DMSO) 179.1, 165.9, 163.1 (d, Vcf = 250.0), 152.7, 145.1, 135.0, 131.1 (d, 
47c f  =  3.3), 130.0 (d, 37c f  = 8.5), 129.4,128.8,115.7 (d, 2Jcf = 21.7), 65.5, 63.1, 62.3, 
42.1, 21.7; HRMS (ES+): C2oHi919FN305S2, [M+H]+ requires 464.0745. Found 




Preparation of (4S*,5S *)-3-[5-(4-ferf-butyl-phenyl)-2-thioxo-l-(toluene-4- 







The reaction was carried out according to the experimental procedure above 
(Section III 14) with N-(4-ferf-butyl-benzylidene)-4-methyl- 
benzenesulfonamide 308 (435 mg, 1.38 mmol) to provide, in order of elution, 
syn-imidazolidinethione syn-250 (17 mg, 5%) which could not be purified from 
p-toluene sulfonamide and imidazolidinethione anti-250 (132 mg, 38%) as a 
white foam; nnax(KBr)/cm1 3340 (NH), 2963 (CH), 1782 (CO ), 1709 (CO ), 
1476 (NHC=S), 1394 (SO2), 1170 (SO2); <5h(300 M Hz; CDCh) 7.40 (2H, d, /  = 8.4, 
ArH), 7.26 (2H, d, /  = 8.4, ArH), 7.08 (2H, d, /  = 8.4, ArH), 7.01 (2H, d, /  = 8.4, 
ArH), 6.89 (1H, s, NH), 6.24 (1H, d, /  = 9.9, ArCH), 5.71 (1H, d, /  = 9.9, 
N(CO)CH), 4.28 (1H, app. dt, /  = 6.6, 9.0, OCHaH b), 3.88 (1H, app. dt, /  = 6.6,
9.0, OCHaHb), 3.67-3.79 (1H, m, NCH cH d), 2.92-3.03 (1H, m, NCH cHd), 2.34 
(3H, s, ArCH3), 1.30 (9H, s, C(CH3)3); &(75 MHz; CDCh) 179.6, 166.6, 153.3,
153.0, 145.0, 135.5, 132.3, 129.8, 129.0, 128.1, 125.8, 66.5, 63.4, 62.7, 42.5, 35.2,
31.7, 22.0; HRMS (ES+): CmHmNsOsS ,^ [M+H]+ requires 502.1465. Found 




Preparation of (4S*,5S *)-3-[2-thioxo-l-(toluene-4-sulfonyl)-5-ra-tolyl-







The reaction was carried out according to the experimental procedure above 
(Section III 14) with 4-methyl-N-(3-methyl-benzylidene)-benzenesulfonamide 
312 (377 mg, 1.38 mmol) to provide, in order of elution, syn- 
imidazolidinethione syn-249 which could not be purified from p-toluene 
sulfonamide and imidazolidinethione anti-249 (101 mg, 31%) as a white foam; 
Unax(KBr)/cm1 3334 (NH), 1780 (CO), 1709 (CO), 1491 (NHC=S), 1394 (SO2), 
1170 (SO2); <5k(300 MHz; CDCls) 7.45 (2H, d, /  = 8.3, ArH), 7.11-7.20 (2H, m, 
ArH), 7.07 (2H, d, /  = 8.3, ArH), 6.95-7.03 (2H, m, ArH), 6.90 (1H, s, NH), 6.21 
(1H, d, /  = 9.9, ArCH), 5.73 (1H, d, /  = 9.9, N(CO)CH), 4.30 (1H, m, OCHaH b), 
3.94 (1H, m, OCHaHb), 3.69-3.80 (1H, m, NCHcH d), 2.99-3.10 (1H, m, 
NCH cH d), 2.36 (3H, s, ArCHs), 2.22 (3H, s, ArCHs); Sc(75 MHz; CDCh) 179.3,
166.1, 152.7, 144.8, 138.5, 135.0, 134.8, 130.2, 129.5, 128.6, 128.4, 125.1, 66.3,
63.1, 62.3, 42.1, 21.6, 21.2; H R M S (ES+): C21H22N3O5S2, [M +H ]+ requires 
460.0995. Found 460.1000; C21H21N3O5S2 requires C, 54.9; H, 4.61; N, 9.14%. 
Found C, 54.6; H, 4.71; N, 8.94%.
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Preparation of (4S*,5S *)-3-[5-styryl-2-thioxo-l-(toluene-4-sulfonyl)-











The reaction was carried out according to the experimental procedure above 
(Section III 14) with 4-methyl-N-(3-phenyl-allylidene)-benzenesulfonamide 
313 (395 mg, 1.38 mmol) to provide, in order of elution, syn- 
imidazolidinethione syn-253 (10 mg, 3%) which could not be purified from p- 
toluene sulfonamide and imidazolidinethione anti-253 (83 mg, 26%) as a white 
foam; unaxfK B rJ/cm -1 3332 (NH), 1782 (CO ), 1706 (CO ), 1477 (NHC=S), 1394 
(SO2), 1169 (SO2); <fc(300 MHz; CDCh) 7.92 (2H, d, /  = 8.3, ArH), 7.33 (5H, m, 
ArH), 7.14 (2H, d, /  = 8.3, ArH), 7.10 (1H, s, NH), 6.83 (1H, d, /  = 15.0, 
CHOHPh), 5.88-6.03 (2H, m, ArCH & CHOHPh), 5.65 (1H, d, /  = 8.7, 
N(CO)CH), 4.41 (1H, app. dt, /  = 6.6, 9.3, OCHaH b), 4.15 (1H, app. dt, /  = 6.6,
9.3, OCHaHb), 3.92-4.01 (1H, m, NCHcH d), 3.66-3.75 (1H, m, N CH cHd), 2.36 
(3H, s, ArCH3); Sc(75 MHz; CDCh) 178.7, 166.2, 152.8, 145.0, 137.1, 135.5, 
134.9, 129.8, 129.2, 129.0, 127.0, 120.8, 65.4, 63.3, 61.5, 42.4, 21.6; HRMS (ES+): 
C22H22N 3O5S2, [M+H]+ requires 472.0995. Found 472.0999; C22H21N3O5S2 
requires C, 56.0; H, 4.49; N, 8.91%. Found C, 55.7; H, 4.50; N, 8.61%.
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Preparation of (4S*,5S *)-3-[5-cyclohexyl-2-thioxo-l-(toluene-4-sulfonyl)- 
imidazolidine-4-carbonyl]-oxazolidin-2-one anti-251 and (4S*,5R*)-3-[5- 
cyclohexyl-2-thioxo-l-(toluene-4-sulfonyl)-imidazolidine-4-carbonyl]- 
oxazolidin-2-one syn-251
cA nA A  V  + JU l
°\ / ' /N v A  ° .N
Me
anti- 251 syn-251
The reaction was carried out according to the experimental procedure above 
(Section III 14) with N-cyclohexylmethylene-4-methyl-benzenesulfonamide 
314 (366 mg, 1.38 mmol) to provide, in order of elution, syn- 
imidazolidinethione syn-251 which could not be purified from p-toluene 
sulfonamide and imidazolidinethione anti-251 (61 mg, 19%) as white crystals; 
mp 239 °C (CHCh); vbiax(KBr)/cm1 3302 (NH), 2932 (CH), 1771 (C=0 ), 1712 
(C=0 ), 1517 (NHC=S), 1391 (SO2), 1167 (SO2); <5h(300 MHz; CDCh) 7.97 (2H, d, 
/  = 8.3, ArH), 7.32 (2H, d, /  = 8.3, ArH), 6.75 (1H, s, NH), 5.29 (2H, m, NCHCH 
& N(C=0 )CH), 4.50-4.64 (2H, m, OCH2CH2), 3.98-4.19 (2H, m, CH2CH2N), 
2.43 (3H, s, ArCHs), 1.70-1.90 (3H, m, CH & CH2), 1.40-1.70 (4H, m, CH2), 
1.02-1.24 (4H, m, CH2); <5c(75 MHz; CDCh) 180.0, 166.1, 152.6, 145.0, 135.6,
129.4, 129.1, 68.3, 63.1, 62.2, 42.8, 42.4, 29.4, 27.0, 26.5, 26.4, 25.8, 21.7; HRMS 
(ES+): C20H26N3O5S2, [M+H]+ requires 452.1308. Found 452.1308; C20H25N3O5S2 
requires C, 53.2; H, 5.58; N, 9.31%. Found C, 52.7; H, 5.47; N, 9.14%.
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Preparation of (4S*,5S *)-3-[5-pentyl-2-thioxo-l-(toluene-4-sulfonyl)-




-  0A NA "
Me
anti-252 syn-252
The reaction was carried out according to the experimental procedure above 
(Section III 14) with N-hexylidene-4-methyl-benzenesulfonamide 315 (350 
mg, 1.38 mmol) to provide, in order of elution, the syn-imidazolidinethione syn- 
252 which could not be purified from p-toluene sulfonamide and 
imidazolidinethione anti-252 (35 mg, 12%) as white crystals; mp 100-102 °C 
(CHCh); Unax(KBr)/cm1 3369 (NH), 2957 (CH), 1780 (CO ), 1707 (CO), 1477 
(NHC=S), 1394 (SO2), 1167 (SO2); <5h(300 MHz; CDCh) 8.01 (2H, d, /  = 8.3, 
ArH), 7.33 (2H, d, /  = 8.3, ArH), 6.61 (1H, s, NH), 5.34-5.45 (2H, m, NCHCH2 
& N(CO)CH), 4.56 (2H, t, /  = 8.1, OCH2CH2N), 3.98-4.18 (2H, m, 
OCH2CHaHbN), 2.36 (3H, s, ArCHa), 1.78-1.92 (1H, m, CHCHaHb), 1.58-1.67 
(1H, m, CHCHaHb), 1.15-1.48 (6H, m, CH2), 0.86 (3H, t, /  = 6.6, CH2CH3); Sc{75 
MHz; CDCh) 179.6,166.5,153.1,145.5,135.9,129.7,129.5, 64.1, 63.6, 62.3, 42.9, 
32.2, 32.1, 23.6, 22.7, 22.1, 14.3; C19H25N3O5S2 requires C, 51.9; H, 5.73; N, 
9.56%. Found C, 51.4; H, 5.71; N, 9.35%.
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III 15 Preparation of (4S*,5S*)-5-(4-methoxy-phenyl)-2- 
thioxo-l-(toIuene-4-sulfonyl)-imidazolidine-4-carboxylic acid 
ethyl ester anti-317; to serve as a typical experimental procedure 
for the racemic preparation of derivatised adducts of N- 
tosylimines and 3-(2-zsothiocyanatoacetyl)-oxazolidin-2-one 154
A mixture of Mg(ClC>4)2 (15 mg, 0.07 mmol) and 3-(2-zsothiocyanatoacetyl)- 
oxazolidin-2-one 154 (128 mg, 0.69 mmol) was stirred for 1 h in dry DCM (15 
mL) with activated powdered 4 A MS (200 mg) under nitrogen at RT. The 
temperature was then lowered to -78 °C. After 15 min, N-(4-methoxy- 
benzylidene)-4-methyl-benzenesulfonamide 316 (399 mg, 1.38 mmol) and 
dizsopropylethylamine (24 pL, 0.14 mmol) were added and the mixture was 
stirred for a further 24 h at -78 °C. The reaction was quenched with saturated 
aqueous ammonium chloride (5 mL). The organic layer was separated and 
the aqueous layer extracted with DCM (3 * 10 mL). The organic portions 
were combined, washed with brine (5 mL), dried (MgSCk) and concentrated 
under reduced pressure. The residue was purified by flash chromatography 
(SiCh, DCMiEtOAc, 90:10) to provide, in order of elution, syn- 
imidazolidinethione syn-257 which could not be purified from p-toluene 
sulfonamide and imidazolidinethione anti-257 (85 mg, 27%) of which 62 mg, 






methyl magnesium bromide (3 M in diethyl ether, 92 pL, 0.28 mmol) was 
added to ethanol (1.0 mL) at 0 °C and subsequently added to the previous 
solution via cannula transfer. After 40 min. the reaction was quenched by 
addition of an aqueous pH 7 phosphate buffer (5 mL). The mixture was 
concentrated under reduced pressure, taken up in aqueous HC1 (1 M, 10 mL) 
and DCM (10 mL). The organic layer was separated and the aqueous layer 
extracted with DCM (3 * 10 mL). The organic portions were combined, dried 
(MgSCh) and concentrated under reduced pressure. The residue was purified 
by flash chromatography (SiCh, DCM:EtOAc, 98:2) to provide the title 
compound anti-317 (28 mg, 51%) as a white foam; Mnax(KBr)/cm"1 3347 (NH), 
1750 (CO), 1479 (NHC=S), 1361 (SO2), 1168 (SO2); <5k(300 MHz; CDCh) 7.39 
(2H, d, /  = 8.3, ArH), 7.13 (2H, d, /  = 8.9, ArH), 7.04 (2H, d, /  = 8.3, ArH), 6.92 
(1H, s, NH), 6.76 (2H, d, /  = 8.9, ArH), 5.90 (1H, d, /  = 9.5, ArCH), 4.95 (1H, d, 
/  = 9.5, EtO(CO)CH), 3.80 (5H, m, CH2CH3 & OCHs), 2.35 (3H, s, ArCHs), 
0.87 (3H, t, /  = 7.2, CH2CH3); &(75 MHz; CDCh) 179.4, 166.1, 160.5, 144.7,
134.8, 129.6, 129.5, 128.6, 126.6, 113.9, 66.3, 62.0, 60.8, 55.4, 21.6, 13.6; HRMS 
(ES+): C20H23N2O5S2, [M+H]+ requires 435.1043. Found 435.1041.
Preparation of (4S*,5S*)-2-thioxo-l-(toluene-4-sulfonyl)-5-p-tolyl- 





The reaction was carried out according to the experimental procedure above 
(Section III 15) with 4-methyl-N-(4-methyl-benzylidene)-benzenesulfonamide
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318 (377 mg, 1.38 mmol) to provide, in order of elution, imidazolidinethione 
syn-256 which could not be purified from p-toluene sulfonamide and 
imidazolidinethione anti-256 (129 mg, 41%) of which 87 mg, 0.19 mmol was 
dissolved in dry THF (4 mL) and cooled to 0 °C. The reaction was carried out 
according to the experimental procedure above (Section III 15) with a 
solution of methyl magnesium bromide (3 M in diethyl ether, 126 pL, 0.38 
mmol) added to ethanol (1.4 mL) to provide the title compound anti-319 (48 
mg, 60%) as a white foam; Unax(KBr)/cm1 3355 (NH), 1752 (C=0), 1479 
(NHC=S), 1362 (SO2), 1168 (SO2); <5k(300 MHz; CDCh) 7.37 (2H, d, /  = 8.7, 
ArH), 7.00-7.10 (6H, m, ArH), 6.95 (1H, s, NH), 5.89 (1H, d, /  = 9.5, ArCH), 
4.96 (1H, d, /  = 9.5, EtO(CO)CH), 3.71-3.86 (2H, m, CH2CH3), 2.34 (3H, s, 
ArCH3), 2.34 (3H, s, ArCHa), 0.83 (3H, t, /  = 7.2, CH2CH3); Sc(75 MHz; CDCh)
179.9, 166.5.145.1,139.9,135.2,131.9, 130.0, 129.5, 128.9, 128.5, 66.9, 62.4, 61.2,
22.0, 21.6, 13.9; HRMS (ES+): C20H23N2O4S2, [M+H]+ requires 419.1094. Found 
419.1097.
Preparation of (4S*,5S *)-5-(4-cyano-phenyl)-2-thioxo-l-(toluene-4-sulfonyl)- 




The reaction was carried out according to the experimental procedure above 
(Section III 15) with N-(4-cyano-benzylidene)-4-methyl-benzenesulfonamide 
320 (392 mg, 1.38 mmol) to provide, in order of elution, imidazolidinethione 
syn-258 which could not be purified from p-toluene sulfonamide and
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imidazolidinethione anti-258 (91 mg, 28%) of which 65 mg, 0.14 mmol was 
dissolved in dry THF (3 mL) and cooled to 0 °C. The reaction was carried out 
according to the experimental procedure above (Section IE 15) with a 
solution of methyl magnesium bromide (3 M in diethyl ether, 92 pL, 0.28 
mmol) added to ethanol (1.0 mL) to provide the title compound anti-321 (24 
mg, 40%) as a white solid; mp 172 °C (DCM-n-hexane); MnaxfKBrJ/cnr1 3340 
(NH), 2229 (ArCN), 1748 (CO ), 1499 (NHC=S), 1338 (SO2), 1168 (SO2); <5h(300 
MHz; CDCh) 7.58 (2H, d, /  = 8.4, ArH), 7.47 (2H, d, /  = 8.4, ArH), 7.36 (2H, d, /  
= 8.4, ArH), 7.11 (2H, d, /  = 8.4, ArH), 6.69 (1H, s, NH), 5.98 (1H, d, /  = 9.6, 
ArCH), 5.00 (1H, d, /  = 9.6, EtO(CO)CH), 3.71-3.90 (2H, m, CH2CH3), 2.39 
(3H, s, ArCHs), 0.88 (3H, t, /=  7.2, CH2CH3); <5c(100 MHz; DMSO) 179.3,167.1,
145.5, 142.3, 135.6, 133.0, 129.7, 129.5, 129.0, 119.1, 112.2, 65.7, 62.0, 61.6, 22.0, 
14.2; HRMS (ES+): C20H20N3O4S2, [M+H]+ requires 430.0890. Found 430.0895.
Preparation of (4S*,5S *)-5-furan-2-yl-2-thioxo-l-(toluene-4-sulfonyl)-




The reaction was carried out according to the experimental procedure above 
(Section III 15) with N-furan-2-ylmethylene-4-methyl-benzenesulfonamide 
322 (344 mg, 1.38 mmol) to provide, in order of elution, imidazolidinethione 
syn-254 which could not be purified from p-toluene sulfonamide and 
imidazolidinethione anti-254 (161 mg, 54%) of which 100 mg, 0.23 mmol was 
dissolved in dry THF (5 mL) and cooled to 0 °C. The reaction was carried out 
according to the experimental procedure above (Section III 15) with a
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solution of methyl magnesium bromide (3 M in diethyl ether, 153 pL, 0.46 
mmol) added to ethanol (1.7 mL) to provide the title compound anti-323 (42 
mg, 46%) as a yellow oil; Mnax^ea^/cm1 3333 (NH), 1751 (C=0), 1492 
(NHC=S), 1365 (SO2), 1169 (SO2); <5k(300 MHz; CDCh) 7.47 (2H, d, /  = 8.4, 
ArH), 7.26 (1H, m, CH=CHO), 7.13 (2H, d, /  = 8.4, ArH), 6.79 (1H, s, NH), 6.51 
(1H, d, /  = 3.2, OC=CH), 6.37 (1H, app. dd, /  = 3.2, 1.5, CHCH=CHO), 6.05 
(1H, d, /  = 9.3, ArCH), 4.90 (1H, d, /  = 9.3, EtO(C=0)CH), 3.92-4.04 (2H, m, 
CH2CH3), 2.37 (3H, s, ArCH3), 1.02 (3H, t, /  = 7.2, CH2CH3); Sc(75 MHz; 
CDCh) 178.8, 165.6, 147.8, 144.9, 143.2, 134.6, 129.4, 128.8, 111.8, 110.7, 62.3,
59.7, 58.9, 21.7, 13.8; HRMS (ES+): C17H 19N2O5S2, [M+H]+ requires 395.0730. 
Found 395.0728.
Preparation of (4S*,5S *)-5-thiophen-2-yl-2-thioxo-l-(toluene-4-sulfonyl)- 




The reaction was carried out according to the experimental procedure above 
(Section III 15) with 4-methyl-N-thiophen-2-ylmethylene- 
benzenesulfonamide 324 (366 mg, 1.38 mmol) to provide, in order of elution, 
imidazolidinethione syn-253 which could not be purified from p-toluene 
sulfonamide and imidazolidinethione anti-255 (56 mg, 18%) of which 47 mg, 
0.10 mmol was dissolved in dry THF (2.5 mL) and cooled to 0 °C. The 
reaction was carried out according to the experimental procedure above 
(Section III 15) with a solution of methyl magnesium bromide (3 M in diethyl 
ether, 69 pL, 0.21 mmol) added to ethanol (0.8 mL) to provide the title
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compound anti-325 (28 mg, 65%) as a colourless oil; Unax(neat)/cm1 3332 
(NH), 1748 (C=0), 1474 (NHC=S), 1364 (SO2), 1169 (SO2); <5h(300 MHz; CDCh) 
7.41 (2H, d, /  = 8.4, ArH), 7.25 (1H, d, /  = 5.1, CH=CHS), 7.04-7.09 (3H, m, ArH 
& SC=CH), 6.92 (1H, app. dd, /  = 5.1, 3.6, CHCHCHS), 6.85 (1H, s, NH), 6.22 
(1H, d, /  = 8.7, ArCH) 4.96 (1H, d, /  = 8.7, EtO(CO)CH), 3.87-3.99 (2H, m, 
CH2CH3), 2.35 (3H, s, ArCH3), 0.94 (3H, t, /  = 7.2, CH2CH3); Sc(75 MHz; 
CDCh) 177.7, 164.5, 143.8, 134.8, 133.5, 128.5, 128.0, 127.6, 125.9, 125.7, 61.2,
61.0, 59.8, 20.6, 12.5; HRMS (ES+): C17H 19N2O4S3, [M+H]+ requires 411.0501. 
Found 411.0499.
Ill 16 Preparation of (4S,5S)-3-[5-phenyl-2-thioxo-l- 
(toluene-4-sulfonyl)-imidazolidine-4-carbonyl]-oxazolidin-2- 
one anti-241; to serve as a typical experimental procedure for 









A mixture of Mg(ClC>4)2 (15 mg, 0.07 mmol), (R,R)-4,6-dibenzofurandiyl-2,2'- 
bis(4-phenyloxazoline) 175 (37 mg, 0.08 mmol) and 3-(2-
zsothiocyanatoacetyl)-oxazolidin-2-one 154 (128 mg, 0.69 mmol) was stirred 
for 1 h in dry DCM (15 mL) with activated powdered 4 A MS (200 mg) under 
nitrogen at RT. The temperature was then lowered to -78 °C. After 15 min, N-
201
Chapter III Experimental
(4-toluenesulfonyl)benzaldimine 240 (358 mg, 1.38 mmol) and
dizsopropylethylamine (24 pL, 0.14 mmol) were added and the mixture was 
stirred for a further 24 h at -78 °C. The reaction was quenched with saturated 
aqueous ammonium chloride (5 mL). The organic layer was separated and 
the aqueous layer extracted with DCM (3 * 10 mL). The organic portions 
were combined, washed with brine (5 mL), dried (MgSCX) and concentrated 
under reduced pressure. The residue was purified by flash chromatography 
(SiCh, DCM:EtOAc, 90:10) to provide the title compound (289 mg, 94%, 
antiisyn = 87:13, eeanti = 96%, [ a ] D 30 = -52.0 (c = 0.5, CHCh)) as colourless 
crystals. Data identical to that reported earlier. The syn-imidazolidinethione 
could not be purified from p-toluene sulfonamide. The enantiomers of the 
an fz-diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; £r i  = 53.8 min. and tm = 81.0 
min. A single crystal of the anti-diastereomer was grown from CHCh for X- 
ray crystallographic experiment (Appendix C).
Preparation of (4S,5S)-3-[5-naphthalen-2-yl-2-thioxo-l-(toluene-4-sulfonyl)- 
imidazolidine-4-carbonyl]-oxazolidin-2-one anti-216
(4S,5S)-246
The reaction was carried out according to the experimental procedure above 
(Section III 16) with 4-methyl-N-naphthalen-2-ylmethylene- 
benzenesulfonamide 309 (427 mg, 1.38 mmol) to provide the title compound 
(342 mg, 100%, anti:syn = 93:7, eeanti = 98%, [ a ] D 30 = -46.0 (c = 0.5, CHCh)) as a
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white solid. Data identical to that reported earlier. The syn-imidazolidinethione 
could not be purified from p-toluene sulfonamide. The enantiomers of the 
Attfz-diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; fm = 59.0 min. and tzi = 113.9 
min.
Preparation of (4S,5S)-3-[5-(4-bromo-phenyl)-2-thioxo-l-(toluene-4- 
sulfonyl)-imidazolidine-4-carbonyl]-oxazolidin-2-one anti-247
The reaction was carried out according to the experimental procedure above 
(Section HI 16) with N-(4-bromo-benzylidene)-4-methyl-benzenesulfonamide 
310 (467 mg, 1.38 mmol) to provide the title compound (312 mg, 86%, antiisyn 
= 83:17, eeanti = 98%, [ cxJd 30 = -66.0 (c = 0.5, CHCh)) as a white solid. Data 
identical to that reported earlier. The syn-imidazolidinethione could not be 
purified from p-toluene sulfonamide. The enantiomers of the anti- 
diastereomer were separated analytically by chiral HPLC using the 







Preparation of (4S,5S)-3-[5-(4-fluoro-phenyl)-2-thioxo-l-(toluene-4- 
sulfonyl)-imidazolidine-4-carbonyl]-oxazolidin-2-one anti-218
F
The reaction was carried out according to the experimental procedure above 
(Section III 16) with N-(4-fluoro-benzylidene)-4-methyl-benzenesulfonamide 
311 (383 mg, 1.38 mmol) to provide the title compound (314 mg, 98%, antiisyn 
= 75:25, eeanti = 93%, [ o Jd 30 = -42.0 (c = 0.5, CHCh)) as a white solid. Data 
identical to that reported earlier. The syn-imidazolidinethione could not be 
purified from p-toluene sulfonamide. The enantiomers of the anti- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; tei = 57.0 min. and ho. = 11H 
min.








The reaction was carried out according to the experimental procedure above 
(Section III 16) with N-(4-ferf-butyl-benzylidene)-4-methyl- 
benzenesulfonamide 308 (435 mg, 1.38 mmol) to provide the title compound
white foam. Data identical to that reported earlier. The syn-imidazolidinethione 
could not be purified from p-toluene sulfonamide. The enantiomers of the 
an h-diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; tm = 31.9 min. and tm = 51.5 
min.
Preparation of (4S,5S)-3-[2-thioxo-l-(toluene-4-sulfonyl)-5-m-tolyl- 
imidazolidine-4-carbonyl]-oxazolidin-2-one anti-249
The reaction was carried out according to the experimental procedure above 
(Section III 16) with 4-methyl-N-(3-methyl-benzylidene)-benzenesulfonamide 
312 (377 mg, 1.38 mmol) to provide the title compound (290 mg, 91%, antiisyn 
= 86:14, eeanti = 99%, [ajD30 = -24.0 (c = 0.5, CHCh)) as a white foam. Data 
identical to that reported earlier. The syn-imidazolidinethione could not be 
purified from p-toluene sulfonamide. The enantiomers of the anti- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; fai = 45.8 min. and tm = 67.3 
min.









The reaction was carried out according to the experimental procedure above 
(Section III 16) with 4-methyl-N-(3-pheny 1-ally lidene)-benzenesulfonamide 
313 (395 mg, 1.38 mmol) to provide the title compound (314 mg, 97%, antiisyn 
= 78:22, eeanti = 97%, [ a ] D 30 = -81.0 (c = 0.98, CHCh)) as a white foam. Data 
identical to that reported earlier. The syn-imidazolidinethione could not be 
purified from p-toluene sulfonamide. The enantiomers of the anti- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; fai = 46.2 min. and fR2 = 86.2 
min.
Preparation of (4S,5S)-3-[5-cyclohexyl-2-thioxo-l-(toluene-4-sulfonyl)- 
imidazolidine-4-carbonyI]-oxazolidin-2-one anti-251
The reaction was carried out according to the experimental procedure above 





314 (366 mg, 1.38 mmol) to provide the title compound (306 mg, 98%, antiisyn 
= 67:33, eeanti = 99%, [ a ] D 30 = +40.0 (c = 0.65, CHCh)) as white crystals. Data 
identical to that reported earlier. The syn-imidazolidinethione could not be 
purified from p-toluene sulfonamide. The enantiomers of the anti- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; tm = 36.2 min. and tm = 85.6 
min. A single crystal of the anh-diastereomer was grown from CHCh for X- 
ray crystallographic experiment (Appendix D).
Preparation of (4S,5S)-3-[5-pentyl-2-thioxo-l-(toluene-4-sulfonyl)- 
imidazolidine-4-carbonyl]-oxazolidin-2-one anti-252
Me
(Section III 16) with N-hexylidene-4-methyl-benzenesulfonamide 315 (350 
mg, 1.38 mmol) to provide the title compound (120 mg, 40%, antiisyn = 67:33, 
eeanti = 84%, [a]D30= +26.1 (c = 0.65, CHCh)) as white crystals. Data identical to 
that reported earlier. The syn-imidazolidinethione could not be purified from p- 
toluene sulfonamide. The enantiomers of the anfz'-diastereomer were 
separated analytically by chiral HPLC using the conditions in the general 
experimental section; fei = 36.0 min. and tm = 64.1 min.
Me
(4S,5S)-252
The reaction was carried out according to the experimental procedure above
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III 17 Preparation of (4S,5S)-5-(4-methoxy-phenyl)-2- 
thioxo-l-(toluene-4-sulfonyl)-imidazolidine-4-carboxylic acid 
ethyl ester anti-317; to serve as a typical experimental procedure 
for the asymmetric preparation of derivatised adducts of N- 









A mixture of Mg(C104)2 (15 mg, 0.07 mmol), (R,R)-4,6-dibenzofurandiyl-2,2'- 
bis(4-phenyloxazoline) 175 (37 mg, 0.08 mmol) and 3-(2-
zsothiocyanatoacetyl)-oxazolidin-2-one 154 (128 mg, 0.69 mmol) was stirred 
for 1  h in dry DCM (15 mL) with activated powdered 4 A MS (200 mg) under 
nitrogen at RT. The temperature was then lowered to -78 °C. After 15 min, N- 
(4-methoxy-benzylidene)-4-methyl-benzenesulfonamide 316 (399 mg, 1.38 
mmol) and dizsopropylethylamine (24 pL, 0.14 mmol) were added and the 
mixture was stirred for a further 24 h at -78 °C. The reaction was quenched 
with saturated aqueous ammonium chloride (5 mL). The organic layer was 
separated and the aqueous layer extracted with DCM (3 * 10 mL). The 
organic portions were combined, washed with brine (5 mL), dried (MgSCh) 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography (SiCh, DCM:EtOAc, 90:10) to provide a mixture of syn and 
anti imidazolidinethiones (282 mg, 8 6 %, antiisyn = 76:24) of which 62 mg, 0.13 
mmol of anti-imidazolidinethione was dissolved in dry THF (3 mL) and cooled
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to 0 °C. A solution of methyl magnesium bromide (3 M in diethyl ether, 92 
pL, 0 .28 mmol) was added to ethanol (1.0 mL) at 0 °C and subsequently 
added to the previous solution via cannula transfer. After 40 min. the 
reaction was quenched by addition of an aqueous pH 7 phosphate buffer (5 
mL). The mixture was concentrated under reduced pressure, taken up in 
aqueous HC1 (1 M, 10 mL) and DCM (10 mL). The organic layer was 
separated and the aqueous layer extracted with DCM (3 * 10 mL). The 
organic portions were combined, dried (MgSOi) and concentrated under 
reduced pressure. The residue was purified by flash chromatography (SiC>2, 
DCM:EtOAc, 98:2) to provide the title compound anti-317 (28 mg, 51%, eeanti = 
97%, [ a ] D 30 = -36.3 (c = 0.8, CHCh)) as a white foam. Data identical to that 
reported earlier. The enantiomers of the flnh'-diastereomer were separated 
analytically by chiral HPLC using the conditions in the general experimental 
section; tei = 19.6 min. and fR2 = 29.7 min.
Preparation of (4S,5S)-2-thioxo-l-(toluene-4-sulfonyl)-5-p-tolyl- 
imidazolidine-4-carboxylic acid ethyl ester anti-319
Me
The reaction was carried out according to the experimental procedure above 
(Section III 17) with 4-methyl-N-(4-methyl-benzylidene)-benzenesulfonamide 
318 (377 mg, 1.38 mmol) to provide a mixture of syn and anti 
imidazolidinethiones (304 mg, 96%, antiisyn = 83:17) of which 87 mg, 0.19 mmol 





carried out according to the experimental procedure above (Seaction III 17) 
with a solution of methyl magnesium bromide (3 M in diethyl ether, 126 pL, 
0.38 mmol) added to ethanol (1.4 mL) to provide the title compound anti-319 
(48 mg, 60%, eeanti = 99%, [ a ] D 30 = -35.0 (c = 0.8, CHCh)) as a white foam. Data 
identical to that reported earlier. The enantiomers of the awh-diastereomer 
were separated analytically by chiral HPLC using the conditions in the 
general experimental section; fei = 14.8 min. and h i = 24.2 min.
Preparation of (4S,5S)-5-(4-cyano-phenyl)-2-thioxo-l-(toluene-4-sulfonyl)- 





The reaction was carried out according to the experimental procedure above 
(Section III 17) with N-(4-cyano-benzylidene)-4-methyl-benzenesulfonamide 
320 (392 mg, 1.38 mmol) to provide a mixture of syn and anti 
imidazolidinethiones (280 mg, 85%, antiisyn = 67:33) of which 65 mg, 0.14 mmol 
was dissolved in dry THF (3 mL) and cooled to 0 °C. The reaction was 
carried out according to the experimental procedure above (Section III 17) 
with a solution of methyl magnesium bromide (3 M in diethyl ether, 92 pL, 
0.28 mmol) added to ethanol (1.0 mL) to provide the title compound anti-321 
(24 mg, 40%, eeanti = 99%, [ a ] D 3 0 =  -34.3 (c = 0.35, CHCh)) as a white solid. Data 
identical to that reported earlier. The enantiomers of the anh-diastereomer 
were separated analytically by chiral HPLC using the conditions in the 




imidazolidine-4-carboxylic acid ethyl ester anti-323
The reaction was carried out according to the experimental procedure above 
(Seaction III 17) with N-furan-2-ylmethylene-4-methyl-benzenesulfonamide 
322 (344 mg, 1.38 mmol) to provide a mixture of syn and anti 
imidazolidinethiones (276 mg, 92%, antiisyn = 50:50) of which 100 mg, 0.46 
mmol was dissolved in dry THF (5 mL) and cooled to 0 °C. The reaction was 
carried out according to the experimental procedure above (Section III 17) 
with a solution of methyl magnesium bromide (3 M in diethyl ether, 153 pL, 
0.46 mmol) added to ethanol (1.7 mL) to provide the title compound anti-323 
(42 mg, 46%, eeanti = undetermined, [ajD30 = +7.2 (c = 0.97, CHCh) as a yellow 
oil. Data identical to that reported earlier. The enantiomers of the anti- 
diastereomer could not be separated analytically by chiral HPLC.
Preparation of (4S,5S)-5-thiophen-2-yl-2-thioxo-l-(toluene-4-sulfonyl)- 







The reaction was carried out according to the experimental procedure above 
(Section III 17) with 4-methyl-N-thiophen-2-ylmethylene-
benzenesulfonamide 324 (366 mg, 1.38 mmol) to provide a mixture of syn 
and anti imidazolidinethiones (294 mg, 94%, antiisyn = 50:50) of which 47 mg, 
0.1 mmol was dissolved in dry THF (2.5 mL) and cooled to 0 °C. The reaction 
was carried out according to the experimental procedure above (Section III 
17) with a solution of methyl magnesium bromide (3 M in diethyl ether, 69 
pL, 0.21 mmol) added to ethanol (0.8 mL) to provide the title compound anti- 
325 (28 mg, 65%, eeanti = 90%, [ a ] D 30 = -24.0 (c = 0.5, CHCh) as a colourless oil. 
Data identical to that reported earlier. The enantiomers of the anti- 
diastereomer were separated analytically by chiral HPLC using the 
conditions in the general experimental section; fRi = 20.9 min. and tm = 25.2 
min.
Ill 18 Preparation of phenacyl and naphthacyl carbonate 
analogues employed in the direct catalytic aldol addition to 
aromatic aldehydes
Preparation of carbonic acid ethyl ester 2-oxo-2-phenyl-ethyl ester 260
Ethyl chloroformate 326 (50 mL, 520 mmol) was added drop-wise to a stirred 
solution of 2-hydroxyacetophenone 71 (7.04 g, 51.7 mmol) in dry pyridine 
(100 mL) under a nitrogen atmosphere at 0 °C. After 2.5 h at 0 °C the reaction 
mixture was warmed to 50 °C for a further 30 min. The reaction mixture was
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then cooled to ambient temperature and poured into diethyl ether (500 mL) 
and quenched with cold 1 M H2SO4 (500 mL). The organic layer was washed 
with 1 M H2SO4 (2 x 250 mL), saturated NaHCCb (2 * 250 mL), and brine (2 * 
250 mL). The organic layer was dried over anhydrous magnesium sulfate 
and then concentrated in vacuo. The crude yellow oil (10.28 g) was purified 
by reduced pressure distillation. The carbonate 260 was obtained as a white 
crystalline solid (8.80 g, 82%) on cooling; mp 41 °C (lit.,129 41-43 °C); bp 104 °C 
at 0.1 mmHg; Rf(SiC>2, 20% EtOAc in light petroleum (bp 40-60 °C)) 0.39; 
6h (300 MHz; CDCb) 7.35-7.95 (5H, m, ArH), 5.35 (2H, s, (C=0)CH2), 4.26 (2H, 
q, /  = 7.2, CH2CH3), 1.35 (3H, t, /  = 7.2, CH2CH3); 6c(75 MHz; CDCb) 192.2,
155.3, 134.4, 134.4, 129.3, 128.1, 68.9, 65.1, 14.6. Analytical data for this 
compound is consistent with that in the literature.129
Preparation of carbonic acid methyl ester 2-oxo-2-phenyl-ethyl ester 259
O
259
Methyl chloroformate (28.4 mL, 367.3 mmol) was added drop-wise to a 
stirred solution of 2-hydroxyacetophenone 71 (10.0 g, 73.5 mmol) in dry 
pyridine (100 mL) under a nitrogen atmosphere at 0 °C. After 2 h at 0 °C the 
reaction was complete. The reaction mixture was then poured into diethyl 
ether (500 mL) and quenched with cold 1 M H2SO4 (500 mL). The organic 
layer was washed with 1 M H2SO4 (2 * 250 mL), saturated NaHCCb (250 mL), 
water (250 mL) and brine (250 mL). The organic layer was dried over 
anhydrous magnesium sulfate and then concentrated in vacuo. The resultant 
yellow oil was purified by flash column chromatography (SiCh (25:1), 10% 
EtOAc in light petroleum (bp 40-60 °C)) and the carbonate 259 was obtained 
as a white crystalline solid (11.89 g, 83%); mp 46-47 °C (EtOAc-light
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petroleum (bp 40-60 °C)), Rf(SiC>2, 50% EtOAc in light petroleum (bp 40-60 
°C)) 0.67; 5h (300 MHz; CDCla) 7.92 (2H, d, /  = 6.0, ArH), 7.46-7.62 (3H, m, 
ArH), 5.37 (2H, s, CH2), 3.87 (3H, s, CH3). Analytical data for this compound 
is consistent with that in the literature.129




Isopropenyl chloroformate (3.17 mL, 29.4 mmol) was added drop-wise to a 
stirred solution of 2-hydroxyacetophenone 71 (2.0 g, 14.7 mmol) in dry 
pyridine (30 mL) under a nitrogen atmosphere at 0 °C. After 1 h at 0 °C the 
reaction was complete. The reaction mixture was then poured into diethyl 
ether (150 mL) and quenched with cold 1 M H2SO4 (150 mL). The organic 
layer was washed with 1 M H2SO4 (75 mL), saturated NaHCCb (2 * 75 mL) 
and brine (2 * 75 mL). The organic layer was dried over anhydrous 
magnesium sulfate and then concentrated in vacuo. The resultant yellow oil 
was purified by flash column chromatography (SiChrproduct, 25:1), 5% 
EtOAc in light petroleum (bp 40-60 °C)) and recrystallisation from diethyl 
ether and layered n-heptane. The carbonate 261 was obtained as a white 
crystalline solid (1.93 g, 60%); mp 44-45 °C (diethyl ether-n-heptane); R^SiOi, 
20% EtOAc in light petroleum (bp 40-60 °C)) 0.55; Vmax(KBr)/cm1 1753 (C=0), 
1701 (C=0), 1677 (C=C), 1295 (CO), 1204 (CO); 6h (300 MHz; CDCla) 7.86-7.95 
(2H, m, ArH), 7.56-7.65 (1H, m, ArH), 7.44-7.54 (2H, m, ArH), 5.39 (2H, s, 
CH2), 4.88 (1H, s, (H)CH=C(CH3)0), 4.73 (1H, s, (H)CH=C(CH3)0), 2.01 (3H, 
s, CHa); 6c(100 MHz; CDCb) 191.8, 153.4, 153.1, 134.2, 129.8, 128.6, 127.7,
102.5, 69.2,19.4; m/z (EI+) 220 (9%, M+), 163 (96%, [M-C02C(CH3)=CH2]+), 105
214
Chapter III Experimental
(100%, PhC=0 +), 77 (89%, P h+), (CI+) 238 (100%, [M +N H 4]+); H R M S (ES+): 
C12H16NO4, [M +N H 4]+ requires 238.1074. Found 238.1068; C12H12O1 requires C, 
65.4; H, 5.49%. Found C, 65.40; H, 5.54%.
Preparation of carbonic acid 2-oxo-2-phenyl-ethyl ester phenyl ester 262
O
262
Phenyl chloroformate (3.46 mL, 27.5 mmol) was added drop-wise to a stirred 
solution of 2-hydroxyacetophenone 71 (2.5 g, 18.4 mmol), triethylamine (3.07 
mL, 22.0 mmol in dry THF (120 mL) under a nitrogen atmosphere at 0 °C. 
After 2.5 h at 0 °C the reaction was deemed complete. The reaction mixture 
was then poured into EtOAc (200 mL) and water (200 mL). The organic layer 
was washed with saturated NaHC03 (100 mL), and brine (100 mL). The 
organic layer was dried over anhydrous magnesium sulfate and then 
concentrated in vacuo. The resultant yellow oil was purified by flash column 
chromatography (Si02:product, 25:1), 10% EtOAc in light petroleum (bp 40- 
60 °C)). The carbonate 262 was obtained as a white crystalline solid (2.54 g, 
54%) and then recrystallised from diethyl ether and layered light petroleum 
(bp 40-60 °C); mp 70 °C (EtOAc-light petroleum (bp 40-60 °C)); R^SiOi, 20% 
EtOAc in light petroleum (bp 40-60 °C)) 0.45; Vmax(KBr)/cm11765 (C=0), 1703 
(GO), 1290 (CO), 1255 (CO); 6h (300 MHz; CDCh) 7.88-7.95 (2H, m, ArH), 
7.57-7.65 (1H, m, ArH), 7.44-7.53 (2H, m, ArH), 7.34-7.42 (2H, m, ArH), 7.21- 
7.28 (3H, m, ArH), 5.45 (2H, s, CH2); 6c(100 MHz; CDCh) 191.3, 153.6, 151.3,
134.3, 134.0, 129.7, 129.2, 128.0, 126.4, 121.2, 69.5; m/z (CI+) 274 (100%, 
[M+NH4]+); HRMS (ES+): Ci5Hi6N04, [M+NH4]+ requires 274.1074. Found 
274.1071; Ci5Hi20 4 requires C, 70.3; H, 4.72%. Found C, 70.2; H, 4.78%.
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Preparation of carbonic acid methyl ester 2-naphthalen-2-yl-2-oxo-ethyl
Methyl chloroformate (2.07 mL, 26.8 mmol) was added drop-wise to a stirred 
solution of 2-hydroxy-l-naphthalen-2-yl-ethanone141 327 (2.5 g, 13.4 mmol) in 
dry pyridine (20 mL) under a nitrogen atmosphere at 0 °C. After 1 h at 0 °C 
the reaction was complete. The reaction mixture was then diluted with 
EtOAc (100 mL) and quenched with cold 1 M H 2SO4 (100 mL). The organic 
layer was washed with 1 M H2SO4 (2 * 50 mL), saturated NaHCOs (50 mL), 
saturated copper sulfate (25 mL) water (50 mL), and brine (50 mL). The 
organic layer was dried over anhydrous magnesium sulfate and then 
concentrated in vacuo. The carbonate 274 was obtained as a yellow solid (3.35 
g, 100%); mp 82 °C (EtOAc), Rf(Si02,50% EtOAc in light petroleum (bp 40-60 
°Q) 0.81; Vmax(KBr)/cm.’1 1748 (CO ), 1694 (CO ), 1257 (CO); 6h (300 MHz; 
CDCh) 8.41 (1H, s, ArH), 7.87-7.99 (4H, m, ArH), 7.55-7.66 (2H, m, ArH), 5.51 
(2H, s, CH2), 3.89 (3H, s, CH3); 6c(100 MHz; CDCh) 192.1, 156.0, 136.4, 132.8,
131.7, 130.0, 129.9, 129.4 x 2, 128.3, 127.6, 123.6, 69.19, 55.85; m/z (CI+) 262 
(100%, [M+NH4]+); HRMS (ES+): C14H 16NO4, [M+NH4]+ requires 262.1074. 
Found 262.1073; C14H 12O4 requires C, 68.9; H, 4.95%. Found C, 68.9; H, 5.03%.









2-Bromo-l-(2-(methylthio)phenyl)ethanone142 280 (8.86 g, 36.1 mmol) and 
betaine (5.08 g, 43.4 mmol) were stirred in EtOH (120 mL) under a nitrogen 
atmosphere at 60 °C. After 3 h, the mixture was cooled to ambient 
temperature and concentrated under reduced pressure. The residue was 
titrated in EtOAc for 16 h and the resultant solid filtered, taken up in 
aqueous NaHC03 and DCM. The biphasic mixture was stirred until the 
yellow aqueous layer became colourless. The DCM layer was then separated, 
dried (Na2S04) and concentrated under reduced pressure to provide the title 
compound, alcohol 281 without further purification as a yellow oil (3.02 g, 
46%); Vmax(neat)/cm1 3447 (OH), 2919 (CH), 1675 (C=0); 6h (300 MHz; CDCh) 
7.72 (1H, dd, /  = 8.0, 1.2, ArH), 7.51-7.57 (1H, m, ArH), 7.37 (1H, d, /  = 8.0, 
ArH), 7.19-7.24 (1H, m, ArH), 4.83 (2H, d, /  = 4.5, CH2OH), 3.59 (3H, t, /  = 4.5, 
CHzOH), 2.47 (3H, s, SCHa); 6c(75 MHz; CDCh) 198.6, 144.0, 133.6, 130.0, 
129.8, 125.2, 123.7, 65.9, 15.8; HRMS (ES+): C9H11O2S, [M+H]+ requires 
183.0474. Found 183.0472; C9H 10O2S requires C, 59.3; H, 5.53%. Found C, 59.4; 
H, 5.60%.
Preparation of carbonic acid methyl ester 2-(2-methylsulfanyl-phenyl)-2- 
oxo-ethyl ester 282
MeS O
Methyl chloroformate (0.32 mL, 4.14 mmol) was added drop-wise to a stirred 
solution of 2-hydroxy-l-(2-methylsulfanyl-phenyl)-ethanone 281 (377 mg, 
2.07 mmol) in dry pyridine (10 mL) under a nitrogen atmosphere at 0 °C. 
After 2 h at RT the reaction mixture was poured into diethyl ether and 
quenched with cold 1 M H2SO4. The organic layer was washed with 1 M 
H2SO4, saturated NaHCCb and brine. The organic layer was dried over
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anhydrous magnesium sulfate and then concentrated in vacuo. The crude 
yellow oil was purified by flash column chromatography (25% EtOAc in n- 
hexane). The carbonate 282 was obtained as an orange crystalline solid (0.40 g, 
81%); mp 99 °C (EtOAc-w-hexane); vmax(KBr)/cm1 2959 (CH), 1755 (CO), 
1686 (CO ), 1265 (CO); 6h (300 MHz; CDCh) 7.70 (1H, dd, /  = 7.8, 1.5, ArH), 
7.48-7.54 (1H, m, ArH), 7.36 (1H, d, /  = 7.8, ArH), 7.18-7.23 (1H, m, ArH), 5.30 
(2H, s, (CO)CH2), 3.85 (3H, s, OCH3), 2.44 (3H, s, SCH3); 6c(75 MHz; CDCh)
192.5, 155.6, 143.5, 133.2, 131.3, 129.5, 127.7, 123.8, 69.2, 55.5, 16.1; HRMS 
(ES+): C11H13O4S, [M+H]+ requires 241.0529. Found 241.0526; C11H12O4S 
requires C, 55.0; H, 5.03%. Found C, 55.2; H, 5.13%.
Ill 19 Preparation of (4R*,5S*) and (4R*,5.R*)-4-benzoyl-5- 
phenyl-[l,3]dioxolan-2-one 263; to serve as a typical 
experimental procedure for the direct aldol addition of phenacyl 





2,2/-bipyridine (31 mg, 0.2 mmol), 4 A molecular sieves (200 mg), and 
magnesium perchlorate (45 mg, 0.2 mmol) were stirred for 30 minutes in dry 
THF (2.5 mL) under a nitrogen atmosphere at ambient temperature. The 
suspension formed was then treated with carbonic acid methyl ester 2-oxo-2- 
pheny 1-ethyl ester 259 (388 mg, 2 mmol) in THF (2.5 mL). After 10 minutes 
benzaldehyde 17 (102 pL, 1 mmol) and N-methylmorpholine (55 pL, 0.5
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mmol) were added drop-wise. The reaction was monitored by thin layer 
chromatography. After 24 h the reaction mixture was diluted with EtOAc (2 
x 30 mL), filtered through celite and subsequently quenched with a saturated 
aqueous solution of ammonium chloride (10 mL). The organic layers were 
washed with a saturated aqueous solution of copper sulfate (10 mL) followed 
by water (30 mL) and brine (30 mL). The organic layer was dried over 
anhydrous magnesium sulfate and concentrated in vacuo. The crude mixture 
of diastereomers (cisitrans, 1:10) was purified by flash column
chromatography (SiChiproduct, 50:1) to give an overall yield of 240 mg, 90%. 
1:1 DCM:light petroleum (bp 40-60 °C) provided the major diastereomer, 
tnms-dioxolan-2-one trans-263 as a white solid (220 mg, 82%); mp 98-99 °C 
(diethyl ether-light petroleum (bp 40-60 °C)); Rf(Si02, 30% diethyl ether in 
light petroleum (bp 40-60 °C)) 0.38; Vmax(KBr)/cm1 1841 (C=0), 1694 (C=0),
1224 (CO), 1163 (CO); 6h (300 MHz; CDCh) 7.94 (2H, d, /  = 7.2, ArH), 7.66 (1H, 
m, ArH), 7.26-7.52 (7H, m, ArH), 5.95 (1H, d, /  = 6.3, Ph(CO)CH), 5.61 (1H, 
d, /  = 6.3, PhCH); 6c(100 MHz; CDCh) 189.7, 151.8, 134.3, 133.6, 132.0, 128.6, 
128.0 x 2, 127.8, 124.6, 80.7, 77.8; m/z (CI+) 286 (91%, [M+NH4]+), 242 (100%, 
[M-C02+NH4]+), 105 (100%, PhC=0+); HRMS (ES+): Ci6Hi6N 0 4, [M+NH4]+ 
requires 286.1074. Found 286.1071; Ci6Hu04 requires C, 71.6; H, 4.51%. Found 
C, 71.9; H, 4.68%. Analytical data for this compound is consistent with that in 
the literature.148 2% EtOAc in DCM provided the minor diastereomer, cis- 
dioxolan-2-one cis-263 as a white solid (20 mg, 8%); mp 159-160 °C (diethyl 
ether-n-heptane); Rf(Si02, DCM) 0.38; Vmax(KBr)/cm1 1815 (C=0), 1682 (C=0),
1225 (CO), 1174 (CO); 6h (300 MHz; CDCh) 7.40-7.50 (2H, m, ArH), 7.25-7.35 
(2H, m, ArH), 7.05-7.15 (6H, m, ArH), 6.22 (1H, d, /  = 8.4, Ph(C=0)CH), 6.02 
(1H, d, /  = 8.4, PhCH); 6c(75 MHz; CDCh) 191.6, 153.9, 134.6, 134.1, 131.4,
129.7,128.6,128.5,127.9,126.7, 80.2, 79.1; m/z (CI+) 286 (100%, [M+NH4]+), 242 
(27%, [M-C02+NH4]+); HRMS (ES+): Ci6Hi6N 0 4, [M+NH4]+ requires 286.1074. 
Found 286.1073; Ci6Hi20 4 requires C, 71.6; H, 4.51%. Found C, 71.5; H, 4.60%.
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Preparation of (4R*,5S*) and (4R*,5R*)-4-benzoyl-5-p-tolyl-[l,3]dioxolan-2- 
one 265
Me Me
trans- 265 c/'s- 265
The reaction was carried out according to the experimental procedure above 
(Section III 19) with p-tolualdehyde 196 (118 pL, 1 mmol). The crude mixture 
of diastereomers (cis:trans, 1:16) was purified by flash column
chromatography (SiChiproduct, 50:1) to give an overall yield of 274 mg, 97%. 
1:1 DCM-light petroleum (bp 40-60 °C) provided the major diastereomer, 
trans-dioxolan-2-one trans-265 as a colourless oil (259 mg, 92%); R/(Si02, 30% 
diethyl ether in light petroleum (bp 40-60 °C)) 0.35; Vmax(neat)/cm1 1814 
(CO ), 1691 (C=0), 1225 (CO), 1161 (CO); 6h(300 MHz; CDCh) 7.92-7.99 (2H, 
m, ArH), 7.63-7.70 (1H, m, ArH), 7.47-7.55 (2H, m, ArH), 7.24-7.35 (4H, m, 
ArH), 5.92 (1H, d, /  = 6.3, Ph(C=0)CH), 5.59 (1H, d, /  = 6.3, ArCH), 2.40 (3H, s, 
CHs); 6c(75 MHz; CDCh) 191.2, 153.2, 140.1, 135.0, 133.4, 132.7, 130.0, 129.4,
129.1, 126.1, 82.0, 79.1, 21.3; m/z (CI+) 300 (100%, [M+NH4]+), 256 (14%, [M- 
C 02+NH4]+), 239 (34%, [M-C02+H]+); HRMS (ES+): Ci7Hi8N 04, [M+NH4]+ 
requires 300.1230. Found 300.1227; Ci7Hi40 4 requires C, 72.3; H, 5.00%. Found 
C, 72.4; H, 5.16%. 1% EtOAc in DCM provided the minor diastereomer, cis- 
dioxolan-2-one cis-265 as a white solid (14 mg, 5%); mp 133 °C (diethyl ether); 
Rf(Si02, DCM) 0.26; Vmax(KBr)/crn1 1794 (C=0), 1687 (CO ), 1225 (CO), 1172 
(CO); 6h(300 MHz; CDCh) 7.43-7.51 (3H, m, ArH), 7.27-7.33 (2H, m, ArH),
6.88-6.99 (4H, m, ArH), 6.18 (1H, d, /  = 8.4, Ph(CO)CH), 5.98 (1H, d, /  = 8.4, 
ArCH), 2.18 (3H, s, ArCHa); 6c(75 MHz; CDCh) 191.6, 153.9, 139.8, 134.7,
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134.0, 129.2, 128.6, 128.5, 128.0, 126.7, 80.3, 79.4, 21.1; m/z (CI+) 300 (85%, 
[M +N H 4]+), 256 (100%, [M -C0 2 + N H 4]*), 105 (32%, P h C O ); H R M S (ES+): 
C17H18NO4, [M +N H 4]+ requires 300.1230. Found 300.1238.
Preparation of (4R*,5S*) and (4R*,5R*)-4-benzoyl-5-(4-methoxy-phenyl)- 
[l,3]dioxolan-2-one 266
OM e OM e
trans-266 cis- 266
The reaction was carried out according to the experimental procedure above 
(Section III 19) with p-anisaldehyde (244 pL, 2 mmol). The crude mixture of 
diastereomers (cis:trans, 1:11) was purified by flash column chromatography 
(SiCh:product, 50:1) to give an overall yield of 508 mg, 85%. DCM provided 
the major diastereomer, trans-dioxolan-2-one trans-266 as a pale yellow oil (508 
mg, 85%); Rf(SiC>2, 30% diethyl ether in light petroleum (bp 40-60 °C)) 0.18; 
vmaxtneatycnr1 1813 (C=0), 1691 (C=0), 1254 (CO), 1224 (CO), 1163 (CO); 
6h(300 MHz; CDCh) 7.90-7.97 (2H, m, ArH), 7.62-7.70 (1H, m, ArH), 7.46-7.54 
(2H, m, ArH), 7.36 (2H, d, /  = 8.6, ArH), 6.97 (2H, d, /  = 8.6, ArH), 5.88 (1H, d, 
/  = 6.3, Ph(C=0)CH), 5.61 (1H, d, /  = 6.3, ArCH), 3.84 (3H, s, OCHa); 6c(75 
MHz; CDCh) 191.2, 160.9, 153.2, 134.9, 133.3, 129.3, 129.1, 127.9, 127.4, 114.8,
81.9, 79.2, 55.4; m/z (CI+) 316 (64%, [M+NH4]+); HRMS (ES+): C17H18NO5, 
[M+NHi]+ requires 316.1179. Found 316.1181; C17H 14O5 requires C, 68.4; H, 
4.73%. Found C, 68.2; H, 4.80%. 2% EtOAc in DCM provided the minor 
diastereomer, cis-dioxolan-2-one cis-266 as a white solid (7 mg, 1%); mp 104- 
105 °C (diethyl ether); V m ax(K B r)/c rn1 1794 (C=0), 1687 (C=0), 1225 (CO), 1172
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(CO); 6h(300 MHz; CDCh) 7.46-7.53 (3H, m, ArH), 7.28-7.35 (2H, m, ArH),
7.00 (2H, d, /  = 8.7, ArH), 6.63 (2H, d, /  = 8.7, ArH), 6.18 (1H, d, /  = 8.6, 
Ph(CO)CH), 5.97 (1H, d, /  = 8.6, ArCH), 3.68 (3H, s, OCHa); 6c(75 MHz; 
CDCh) 191.6, 160.5, 149.0, 134.6, 134.1, 128.7, 128.3, 128.0, 123.4, 114.0, 80.1,
79.4, 55.3; m/z (CI+) 316 (100%, [M+NH4]+); HRMS (ES+): C17H 18NO4, 
[M+NH4]+ requires 316.1179. Found 316.1179.




The reaction was carried out according to the experimental procedure above 
(Section III 19) with 4-(trifluoromethyl)benzaldehyde (137 pL, 1 mmol). The 
crude mixture of diastereomers (cisitmns, 1:8) was purified by flash column 
chromatography (Si02:product, 50:1) to provide an overall yield of 220 mg, 
65%. 1:1 DCM-light petroleum (bp 40-60 °C) provided the major 
diastereomer, trans-dioxolan-2-one trans-267 as a white solid (202 mg, 60%); 
mp 91-92 °C (DCM-light petroleum (bp 40-60 °C)) Rf(SiC>2, 30% diethyl ether 
in light petroleum (bp 40-60 °C)) 0.34; vmax(KBr)/cm-11792 (CO ), 1678 (CO ), 
1326 (CFa), 1233 (CO), 1178 (CO); 6h(400 MHz; CDCh) 7.97-8.04 (2H, m, ArH), 
7.65-7.77 (3H, m, ArH), 7.50-7.62 (4H, m, ArH), 6.16 (1H, d, /  = 6.5, 
Ph(CO)CH), 5.49 (1H, d, /  = 6.5, ArCH); 6c(75 MHz; CDCh) 191.0, 152.6,
139.7, 135.2, 133.9, 132.0 (q, 2J c f  = 32.9), 129.6 x 2, 129.2, 126.4 (q, 3/ c f  = 3.8),
123.6 (q, Vcf = 272.4), 81.9, 77.9; 5f(376 MHz; CDCh) -62.84; m/z (CI+) 354
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(48%, [M+NH4]+), 105 (100%, P hC O ); HRMS (ES+): C17H 15F3NO4, [M+NH4]+ 
requires 354.0948. Found 354.0945; Ci7HnF304 requires C, 60.7; H, 3.30%. 
Found C, 61.0; H, 3.35%. 1% EtOAc in DCM provided the minor 
diastereomer, cis-dioxolan-2-one cis-267 as a white solid (18 mg, 5%); mp 152- 
153 °C (diethyl ether); Rf(Si02, DCM) 0.41; Vmax(KBr)/cm1 1799 (CO), 1686 
(CO ), 1324 (CFs), 1167 (CO), 1069 (CO); £>h(300 MHz; CDCh) 7.42-7.54 (3H, 
m, ArH), 7.25-7.40 (4H, m, ArH), 7.18-7.23 (2H, m, Ar-H), 6.26 (1H, d, J = 8.6, 
Ph(CO)CH), 6.06 (1H, d, J = 8.6, ArCH); 6c(75 MHz; CDCh) 191.4, 153.5, 
135.5, 134.5, 134.4, 131.8 (q, 2/ c f  = 32.8), 128.9, 127.9, 127.0, 125.5 (q, 3/ c f  = 3.7), 
123.4 (q, Vcf = 272.3), 79.3, 78.7; m/z (CI+) 354 (21%, [M+NH4]+).




The reaction was carried out according to the experimental procedure above 
(Section III 19) with 4-cyanobenzaldehyde (144 mg, 1 mmol) in THF (2.5 mL). 
The crude mixture of diastereomers (cis:trans, 1:8) was purified by flash 
column chromatography (Si02:product, 50:1) to provide an overall yield of 
222 mg, 76%. DCM provided the major diastereomer, trans-dioxolan-2-one 
trans-268 as a white solid (201 mg, 69%); mp 111 °C (diethyl ether-light 
petroleum (bp 40-60 °C); Rf(Si02, 70% diethyl ether in light petroleum (bp 40- 
60 °C)) 0.58; Vmax^B^/crn1 2229 (C=N), 1810 (C=0), 1687 (C=0), 1227 (CO), 
1177 (CO); 6h(300 MHz; CDCh) 8.00-8.03 (2H, m, ArH), 7.68-7.79 (3H, m,
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ArH), 7.52-7.60 (4H, m, ArH), 6.18 (1H, d, J = 6.8, Ph(C=0)CH), 5.45 (1H, d, /  =
6.8, ArCH); 6c(75 MHz; CDCh) 190.9, 152.3, 140.7, 135.3, 133.2, 133.1, 129.6,
129.2, 126.4, 117.9, 113.7, 81.8, 77.6; m/z (CI+) 311 (100%, [M+NH4]+); HRMS 
(ES+): C17H 15N2O4, [M+NH4]+ requires 311.1026. Found 311.1027; Ci7H nN 04 
requires C, 69.6; H, 3.78, N, 4.78%. Found C, 69.5; H, 3.86, N, 4.75%. 2% 
EtOAc in DCM provided the minor diastereomer, cis-dioxolan-2-one cis-268 as 
a white solid (22 mg, 7%); mp 156-157 °C (diethyl ether-light petroleum (bp 
40-60 °C); Rf(Si02, DCM) 0.21; vmax(KBr)/crn1 2232 (ON), 1833 (CO), 1688 
(CO ), 1224 (CO), 1162 (CO); 6h(300 MHz; CDCh) 7.46-7.59 (3H, m, ArH), 
7.40-7.45 (2H, m, ArH), 7.31-7.39 (2H, m, ArH), 7.20-7.25 (2H, m, ArH), 6.29 
(1H, d, /  = 8.6, Ph(CO)CH), 6.07 (1H, d, /  = 8.6, ArCH); 6c(75 MHz; CDCh)
191.1, 153.2, 136.6, 134.8, 134.3, 132.2, 129.0, 127.9, 127.4, 117.7, 113.7, 79.0, 
78.4; m/z (CI+) 311 (100%, [M+NH4]+); HRMS (ES+): Ci7Hi5N20 4, [M+NH4]+ 
requires 311.1026. Found 311.1030.
Preparation of (4R*,5S*) and (4R*,5R*)-4-(naphthalene-2-carbonyl)-5- 
phenyl-[l,3]dioxolan-2-one 269
trans-269 cis- 269
The reaction was carried out according to the experimental procedure above 
(Section III 19) with benzaldehyde 17 (112 pL, 1.1 mmol). The crude mixture 
of diastereomers (cis:trans, 1:7) was purified by flash column
chromatography (Si02:product, 100:1) to give an overall yield of 252 mg, 
79%. 70% DCM in light petroleum (bp 40-60 °C) provided the major 
diastereomer, trans-dioxolan-2-one trans-269 as a white solid (228 mg, 72%);
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mp 127 °C (DCM-light petroleum (bp 40-60 °C); Rf(Si02, 30% diethyl ether in 
light petroleum (bp 40-60 °C)) 0.24; vmax(KBr)/cm1 1818 (C=0), 1680 (C=0), 
1148 (CO), 1089 (CO); 6h(400 MHz; CDCh) 8.41 (1H, s, ArH), 7.88-8.04 (4H, 
m, ArH), 7.56-7.69 (3H, m, ArH), 7.47-7.57 (4H, m, ArH), 6.05 (1H, d, /  = 6.2, 
Ar(CO)CH), 5.74 (1H, d, J = 6.2, PhCH); 6c(75 MHz; CDCh) 191.0, 153.2,
136.3, 135.8, 132.2 x 2, 130.7, 130.0, 129.9, 129.7, 129.4, 129.2, 128.0, 127.4,
126.1, 123.9, 82.2, 79.2; m/z (CI+) 336 (71%, [M+NH4]+), 292 (32%, [M- 
C0 2 +NH4]+); HRMS (ES+): C2oHi8N 04, [M+NH4]+ requires 336.1230. Found 
336.1236; QoHi40 4 requires C, 75.5; H, 4.43%. Found C, 75.3; H, 4.47%. 2% 
EtOAc in DCM provided the minor diastereomer, cis-dioxolan-2-one cis-269 as 
a white solid (24 mg, 7%); mp 138-139 °C (EtOAc-DCM); Rf(Si02, DCM) 0.30; 
Vmax(KBr)/cm1 1805 ( G O ) ,  1688 (C=0), 1177 (CO), 1088 (CO); 6h(300 MHz; 
CDCh) 8.04 (1H, s, ArH), 7.78-7.90 (2H, m, ArH), 7.68-7.74 (1H, m, ArH), 
7.52-7.65 (2H, m, ArH), 7.46-7.5Q (1H, m, ArH), 7.01-7.14 (5H, m, ArH), 6.37 
(1H, d, /  = 8.4, Ar(C=0)CH), 6.09 (1H, d, /  = 8.4, PhCH); 6c(75 MHz; CDCh)
191.4, 154.0, 135.7, 132.1, 131.9, 131.5, 130.1, 129.7, 129.6, 129.3, 128.8, 128.5,
127.9, 127.2, 126.7, 123.1, 80.4, 79.3; m/z (CI+) 336 (53%, [M+NH4]+), 292 (30%, 
[M-C02+NH4]+); HRMS (ES+): Ci7Hi5N20 4, [M+NH4]+ requires 336.1230. 
Found 336.1233.






The reaction was carried out according to the experimental procedure above 
(Section III 19) with p-tolualdehyde 196 (130 pL, 1.1 mmol). The crude 
mixture of diastereomers (cisitrans, 1:7) was purified by flash column 
chromatography (SiChiproduct, 100:1) to give an overall yield of 250 mg, 
75%. 70% DCM in light petroleum (bp 40-60 °C) provided the major 
diastereomer, trans-dioxolan-2-one trans-270 as a white solid (238 mg, 71%); 
mp 143-144 °C (DCM-light petroleum (bp 40-60 °C); Rf(SiCh, 30% diethyl 
ether in light petroleum (bp 40-60 °C)) 0.33; Vmax(KBr)/cm_1 1805 (C=0), 1682 
(0=0), 1172 (CO), 1068 (CO); 6h(300 MHz; CDCh) 8.40 (1H, s, ArH), 7.86-8.04 
(4H, m, ArH), 7.56-7.70 (2H, m, ArH), 7.27-7.38 (4H, m, ArH), 5.98 (1H, d, /  =
6.3, Ar(OO)CH), 5.73 (1H, d, /  = 6.3, ArCH), 2.41 (3H, s, ArCHs); 6c(75 MHz; 
CDCh) 191.0, 153.3, 140.1, 136.3, 132.7, 132.2, 132.1, 130.7, 130.1, 129.9, 129.7,
129.2, 127.9, 127.3, 126.2, 123.9, 82.2, 79.3, 21.3; m/z (CI+) 350 (100%, 
[M+NH4]+), 306 (41%, [M-CO2+NH4]+); HRMS (ES+): C21H20NO4, [M+NH4]+ 
requires 350.1387. Found 350.1384; C21H 16O4 requires C, 75.8; H, 4.85%. Found 
C, 75.5; H, 4.85%. 2% EtOAc in DCM provided the minor diastereomer cis- 
dioxolan-2-one cis-270 as a white solid (12 mg, 4%); mp 125 °C (diethyl ether); 
Rf(Si02, DCM) 0.28; vmax(KBr)/cm1 1813 (C=0), 1691 (0=0), 1168 (CO), 1090 
(CO); 5h(300 MHz; CDCh) 8.04 (1H, s, ArH), 7.78-7.90 (2H, m, ArH), 7.68-7.74 
(1H, m, ArH), 7.48-7.65 (3H, m, ArH), 6.98 (2H, d, /  = 7.8, ArH), 6.83 (2H, d, /  
= 7.8, ArH), 6.35 (1H, d, /  = 8.6, Ar(C=0)CH), 6.06 (1H, d, /=  8.6, ArCH), 2.07 
(3H, s, ArCHs); 6c(75 MHz; CDCh) 191.6, 154.1, 139.8, 135.7, 132.1, 132.0,
130.1, 129.6, 129.2 x 2, 128.7, 128.5, 127.8, 127.2, 126.6, 123.1, 80.4, 79.5, 21.0; 
m/z (CI+) 350 (46%, [M+NH4]+), 306 (26%, [M-C02+NH4]+); HRMS (ES+): 
C21H20NO4, [M+NH4]+ requires 350.1387. Found 350.1390.
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Preparation of (4R*,5S*) and (4R*,5R*)-4-(4-methoxy-phenyl)-5- 
(naphthalene-2-carbohyl)-[l,3]dioxolan-2-one 271
OMe OMe
trans- 271 cis- 271
The reaction was carried out according to the experimental procedure above 
(Section III 19) with p-anisaldehyde (134 pL, 1.1 mmol). The crude mixture of 
diastereomers {cis:trans, 1:14) was purified by flash column chromatography 
(SiChiproduct, 100:1) to give an overall yield of 252 mg, 72%. DCM provided 
the major diastereomer, trans-dioxolan-2-one trans-271 as a pale yellow solid 
(235 mg, 67%); mp 108 °C (DCM-light petroleum (bp 40-60 °C); Rf(Si02, 30% 
diethyl ether in light petroleum (bp 40-60 °C)) 0.18; Vmax(KBr)/cm1 1798 
(C=0), 1682 (C=0), 1249 (CO), 1173 (CO), 1066 (CO); 6h(300 MHz; CDCh) 
8.38 (1H, s, ArH), 7.86-8.04 (4H, m, ArH), 7.56-7.70 (2H, m, ArH), 7.36-7.42 
(2H, m, ArH), 6.96-7.02 (2H, m, ArH), 5.93 (1H, d, /  = 6.9, Ar(CO)CH), 5.75 
(1H, d, /  = 6.9, ArCH), 3.85 (3H, s, OCHa); 6c(75 MHz; CDCh) 191.0, 160.9,
153.3, 136.3, 132.2, 132.1, 130.7, 129.9, 129.7, 129.2, 128.0, 127.9, 127.4 x 2,
123.9, 114.8, 82.1, 79.4, 55.5; m/z (CI+) 366 (43%, [M+NH4]+), 322 (25%, [M- 
C02+NH4]+); HRMS (ES+): C21H20NO5, [M+NH4]+ requires 366.1336. Found 
366.1337; C21H 16O5 requires C, 72.4; H, 4.63%. Found C, 72.0; H, 4.65%. 2% 
EtOAc in DCM provided the minor diastereomer, cis-dioxolan-2-one cis-271 as 
a white solid (17 mg, 5%); mp 82-83 °C (diethyl ether); Rf(Si02, DCM) 0.22; 
Vmax(KBr)/cm1 1809 (C=0), 1699 (C=0), 1259 (CO), 1178 (CO), 1096 (CO); 
6h(300 MHz; CDCh) 8.05 (1H, s, ArH), 7.70-7.90 (3H, m, ArH), 7.50-7.64 (3H, 
m, ArH), 7.02 (2H, d, J = 8.7, ArH), 6.54 (2H, d, /  = 8.4, ArH), 6.36 (1H, d, /  =
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8.4, Ar(CO)CH), 6.07 (1H, d, J = 8.4, ArCH), 3.55 (3H, s, OCHs); 6c(75 MHz; 
CDCh) 191.7, 160.4, 154.1, 135.7, 132.0 x 2, 130.1, 129.6, 129.2, 128.7, 128.2,
127.8, 127.2, 123.4, 123.1, 113.9, 80.3, 79.5, 55.1; m/z (CI+) 366 (100%, 
[M+NHi]+); HRMS (ES+): C21H20NO5, [M+NH4]+ requires 366.1336. Found 
366.1341.
Preparation o f  (4R*,5S*) and (4R*,5R*)-4-(naphthalene-2-carbonyl)-5-(4- 
tr iflu orom eth y l-p h en y l)-[l,3 ]d ioxo lan -2 -on e  272
cf3 cf3
trans-272 cis- 272
The reaction was carried out according to the experimental procedure above 
(Section III 19) with 2,2'-bipyridine (63 mg, 0.4 mmol), 4 A molecular sieves 
(400 mg) and magnesium perchlorate (89 mg, 0.4 mmol) in dry THF (5 mL). 
The suspension formed was then treated with carbonic acid methyl ester 2- 
naphthalen-2-yl-2-oxo-ethyl ester 274 (733 mg, 3.0 mmol) in THF (5 mL). 4- 
(trifluoromethyl)benzaldehyde (273 pL, 2.0 mmol) and N-methylmorpholine 
(110 pL, 1 mmol) were added drop-wise. The crude mixture of diastereomers 
(cisitrans, 1:15) was purified by flash column chromatography (SiChiproduct, 
50:1) to give an overall yield of 746 mg, 97%. 70% DCM in light petroleum 
(bp 40-60 °C) provided the major diastereomer, trans-dioxolan-2-one trans-272 
as a white solid (669 mg, 87%); mp 133 °C (DCM-light petroleum (bp 40-60 
°C); Rf(SiCh, 30% diethyl ether in light petroleum (bp 40-60 °C)) 0.55; 
Vmax(KBr)/cm1 1777 (C=0), 1686 (C=0), 1330 (CF3), 1166 (CO), 1069 (CO); 
6h(300 MHz; CDCh) 8.50 (1H, s, ArH), 8.01-8.07 (1H, m, ArH), 7.88-7.98 (3H, 
m, ArH), 7.57-7.77 (6H, m, ArH), 6.22 (1H, d, /  = 6.5, Ar(C=0)CH), 5.64 (1H,
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d, /  = 6.5, ArCH); bc(75 MHz; CDCh) 190.8, 152.7, 139.7, 136.4, 132.4, 132.2,
132.0 (q, 2/ c f  = 32.9), 130.6, 130.0, 129.8, 129.2, 128.0, 127.5, 126.4 (q, 3J c f  = 3.7),
126.3, 123.9 (q, Vcf = 273.1), 123.7, 82.0, 78.1; m/z (CI+) 404 (76%, [M+NH4]+); 
HRMS (ES+): C21H17F3NO4, [M+NH4]+ requires 404.1104. Found 404.1100; 
C21H13F3O1 requires C, 65.3; H, 3.39%. Found C, 65,4; H, 3.42%. DCM 
provided the minor diastereomer, cis-dioxolan-2-one cis-272 as a white solid 
(77 mg, 10%); mp 135 °C (diethyl ether); Rf(SiC>2, DCM) 0.35; Vmax(KBr)/cm1 
1819 (CO ), 1701 (CO), 1328 (CFs), 1166 (CO), 1070 (CO); 6h(300 MHz; 
CDCh) 8.03 (1H, s, ArH), 7.80-7.90 (2H, m, ArH), 7.70-7.74 (1H, m, ArH), 
7.54-7.67 (2H, m, ArH), 7.40-7.45 (1H, m, ArH), 7.29 (2H, d, /  = 8.6, ArH), 7.21 
(2H, d, /  = 8.6, ArH), 6.43 (1H, d, /  = 8.4, Ar(CO)CH), 6.13 (1H, d, /  = 8.4, 
ArCH); 6c(75 MHz; CDCh) 191.3, 153.5,135.8,135.6,132.0,131.9, 131.8 (q, 2/ c f  
= 32.9), 130.1, 129.6, 129.5, 129.1, 127.9, 127.5, 127.0, 125.4 (q, 3/ c f  = 3.7), 123.3 
(q, Vcf = 272.3), 122.8, 79.4, 78.8; m/z (El) 386 (100%, M+), 342 (86%, [M-C02]+); 
HRMS (El): C2iHi3F304, M+ requires 386.0760. Found 386.0758.
Preparation o f  (4R*,5S*) and (4R*,5R*)-4-[5-(naphthalene-2-carbonyl)-2- 
oxo -[l,3 ]d ioxo lan -4 -y l]-b en zon itr ile  273
CN CN
trans-273 cis- 273
The reaction was carried out according to the experimental procedure above 
(Section III 19) with 2 ,2 /-bipyridine (63 mg, 0.4 mmol), 4 A molecular sieves 
(400 mg) and magnesium perchlorate (89 mg, 0.4 mmol) in dry THF (5 mL). 
The suspension formed was then treated with carbonic acid methyl ester 2-
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naphthalen-2-yl-2-oxo-ethyl ester 274 (733 mg, 3.0 mmol). 4-
cyanobenzaldehyde (262 mg, 2.0 mmol) in THF (5 mL) and N- 
methylmorpholine (110 pL, 1.0 mmol) were added drop-wise. The crude 
mixture of diastereomers (cisitrans, 1:16) was purified by flash column 
chromatography (SiChiproduct, 50:1) to give an overall yield of 467 mg, 68%. 
DCM provided the major diastereomer, trans-dioxolan-2-one trans-273 as a 
white foam; mp 147 °C (DCM); Rf(SiC>2, 70% diethyl ether in light petroleum 
(bp 40-60 °C)) 0.53; Vmax(KBr)/cm1 2229 (C=N), 1815 (CO), 1684 (CO ), 1165 
(CO), 1087 (CO); 6h(300 MHz; CDCh) 8.53 (1H, s, ArH), 7.89-8.07 (4H, m, 
ArH), 7.76-7.80 (2H, m, ArH), 7.66-7.72 (1H, m, ArH), 7.58-7.66 (3H, m, ArH), 
6.25 (1H, d, /  = 6.9, Ar(CO)CH), 5.59 (1H, d, /  = 6.9, ArCH); 6c(75 MHz; 
CDCh) 190.7,152.4,140.8,136.4,133.1,132.6,132.2,130.6,130 x 2,129.3,128.0,
127.5, 126.4, 123.9, 117.9, 113.8, 82.0, 77.7; m/z (CI+) 361 (100%, [M+NH4]+); 
HRMS (ES+): C21H 17N2O4, [M+NH4]+ requires 361.1183. Found 361.1184; 
C21H13N 0 4 requires C, 73.4; H, 3.82; N, 4.08%. Found C, 73.1; H, 3.78; N, 
4.14%. DCM provided the minor diastereomer, cis-dioxolan-2-one cis-273 as a 
white solid; mp 175 °C (diethyl ether); Rf(Si02, DCM) 0.20; Vmax(KBr)/cm1 
2231 (C=N), 1804 (CO ), 1684 (CO), 1174 (CO), 1076 (CO); 6h(300 MHz; 
CDCh) 8.08 (1H, s, ArH), 7.82-7.92 (2H, m, ArH), 7.74-7.79 (1H, m, ArH), 
7.57-7.70 (2H, m, ArH), 7.44-7.49 (1H, m, ArH), 7.35 (2H, d, /  = 8.6, ArH), 7.23 
(2H, d, /  = 8.6, ArH), 6.43 (1H, d, /  = 8.6, Ar(CO)CH), 6.12 (1H, d, J = 8.6, 
ArCH); 6c(75 MHz; CDCh) 190.9,153.3,136.8, 135.9,132.2, 131.9, 131.8,130.2,
129.8, 129.5, 129.3, 128.0, 127.7, 127.3, 122.7, 117.6, 113.6, 79.1, 78.5; m/z (CI+) 








The reaction was carried out according to the experimental procedure above 
(Section III 19) with carbonic acid methyl ester 2-(2-methylsulfanyl-phenyl)-
2-oxo-ethyl ester 282 (240 mg, 1 mmol). The crude mixture of diastereomers 
(cisitmns, 1:8) was purified by flash column chromatography (SiCh, 75% DCM 
in light petroleum (bp 40-60 °C)) to provide the major diastereomer, trans- 
dioxolan-2-one trans-283 as a white solid (235 mg, 75%); mp 131 °C (diethyl 
ether); vmax(KBr)/crn1 1813 (C=0), 1689 (CO), 1152 (CO), 1093 (CO); 6h(300 
MHz; CDCh) 7.76 (1H, dd, J = 8.1,1.5, ArH), 7.53-7.59 (1H, m, ArH), 7.38-7.49 
(6 H, m, ArH), 7.19-7.25 (1H, m, ArH), 6.05 (1H, d, /  = 6.3, Ar(CO)CH), 5.57 
(1H, d, /  = 6.3, ArCH), 2.49 (3H, t, SCHa); 6c(75 MHz; CDCla) 192.3, 153.5,
145.1, 136.2, 134.2, 131.9, 131.3, 130.2, 129.7, 126.3, 124.3, 82.8, 79.5, 16.5; 
HRMS (ES+): C17H15O4S, [M+H]+ requires 315.0686. Found 315.0685; C17H14O4S 
requires C, 64.9; H, 4.49%. Found C, 64.6; H, 4.52%.
In instances where benzaldehyde 17 and phenacyl carbonates 259, 260, 261 
and 262 were employed (section II 4.2) with greater loadings of Mg(C104)2 (50 
mol%) 1,2-dicarbonyl by-product 264 was also formed in the reactions and 








Rf(Si02, 25% EtOAc in light petroleum (bp 40-60 °C)) 0.56; Vmax(neat)/cm1 
1714 (C=0), 1672 (C=0); 6 h  (300 MHz; CDCh) 7.9-7.2 (10 H, m, ArH), 4.2 (2 H, 
s, CH2); enol tautomer 6 h  (300 MHz; CDCh) 7.85-7.2 (10 H, m, ArH), 6.4 (1 H, 
s, PhCH=C); m/z (EI+) 224 (100%, M+), 105 (100%, P h C O ), 77 (44%, Ph+), 
(CI+) 242 (100%, [M+NH4]+). Analytical data for this compound is consistent 
with that in the literature.149
Ill 20 Preparation of (lR*,2R*)-carbonic acid l-benzoyl-2- 
hydroxy-2-phenyl-ethyl ester methyl ester anti-328
0 > ^ .O M e  +
OH
259 17 328
The reaction was carried out according to the experimental procedure above 
(Section III 19) with benzaldehyde 17,1.1 equivalents (224 pL, 2.1 mmol) and 
trimethylsilyl chloride (252 pL, 2.0 mmol) (which were added in that order). 
The crude residue of diastereomeric silyl ethers {symanti, 67:33); (syn), 6h(300 
MHz; CDCh) 8.05-7.27 (10H, m, ArH), 6.04 (1H, d, /  = 5.7, Ph(C=0)CH), 4.85 
(1H, d, J = 5.7, PhCH), 3.70 (3H, s, OCHs), -0.07 (9H, s, OSi(CH3)3); {anti), 
5h(300 MHz; CDCh) 8.0-7.27 (10H, m, ArH), 5.91 (1H, d, /  = 6.9, Ph(CO)CH), 
5.12 (1H, d, /  = 6.9, PhCH), 3.67 (3H, s, OCH3), -0.12 (9H, s, OSi(CH3)3); was
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taken up in toluene (10 mL) and p-toluenesulfonic acid mono-hydrate (761 
mg, 4 mmol) was added. The mixture was stirred for 48 h at RT and then 
concentrated and purified by flash column chromatography (SiChiproduct, 
50:1) to give an overall yield of the fnms-dioxolan-2-one trans-263 and the 
title compound anti-328, 335 mg, 60%. 90% DCM in light petroleum (bp 40-60 
°C) provided the fnms-dioxolan-2-one trans-263 as a white solid (230 mg, 
43%); data identical to that reported earlier. DCM provided the title 
compound anti-328 as a colourless oil (105 mg, 17%); Rf(SiCh, DCM) 0.32; 
VnMo^neatJ/cm'1 3456 (OH), 1745 (C=0), 1684 (C=0), 1271 (CO); 6h(300 MHz; 
CDCh) 8.00-8.10 (2H, m, ArH), 7.65-7.75 (1H, m, ArH), 7.50-7.60 (2H, m, 
ArH), 7.20-7.35 (3H, m, ArH), 7.05-7.15 (2H, m, ArH), 5.99 (1H, d, /  = 2.9, 
Ph(C=0)CH), 5.67 (1H, dd, /=  7.7, 2.9, ArCH), 3.81 (3H, s, OCH3), 3.63 (1H, d, 
/  = 7.7, OH); 6c(75 MHz; CDCh) 197.6, 155.3, 134.5, 133.9, 133.3, 129.2, 128.9,
128.9, 128.1, 127.4, 80.4, 75.0, 55.1; HRMS (ES+): C17H 20NO5, [M+NH4]+ 
requires 318.1336. Found 318.1335.
Ill 21 Preparation of Baeyer-Villiger oxidation adducts of 
trans-d ioxolan-2-ones





To a stirred solution of phenyl ketone trans-263 (134 mg, 0.5 mmol) in DCM 
(7.5 mL) were added anhydrous NaFhPCh (360 mg, 3 mmol) and ra-CPBA 
(345 mg, 2 mmol). The resulting mixture was stirred vigorously at RT for 16 
h. The reaction mixture was then diluted with DCM and washed with 
saturated aqueous Na2S2C>3 solution, saturated aqueous NaHCCh solution, 
water, brine, and then dried over MgSCh. The solvent was removed under 
reduced pressure and the resultant residue was purified by flash silica-gel 
column chromatography (70% DCM in light petroleum (bp 40-60 °C)) to 
afford phenyl ester 276 (78 mg, 55%) as a colourless oil. An analytical sample 
was prepared via crystallisation from diethyl ether; mp 75 °C (diethyl ether); 
Rf(SiC>2, 30% diethyl ether in light petroleum (bp 40-60 °C)) 0.50; 
Vmax(neat)/cm1 1818 (C=0), 1762 (CO ), 1188 (CO), 1080 (CO); 6h(300 MHz; 
CDCh) 7.40-7.54 (7H, m, ArH), 7.28-7.35 (1H, m, ArH), 7.16-7.21 (2H, m, 
ArH), 5.83 (1H, d, J = 5.6, ArCH), 5.15 (1H, d, /  = 5.6, ArO(CO)CH); 6c(75 
MHz; CDCh) 165.4, 152.9, 149.7, 135.3, 130.1, 129.8, 129.5, 126.9, 125.5, 120.9, 
80.0, 79.2; m/z (CI+) 302 (100%, [M+NH4]+); HRMS (ES+): CieHieNOs, 
[M+NH4]+ requires 302.1023. Found 302.1026.
Preparation of (4R*,5S*)-naphthalen-2-yl 2-oxo-5-phenyl-l,3-dioxolane-4- 
carboxylate 277
trans- 269 trans-277
To a stirred solution of naphthyl ketone trans-269 (74 mg, 0.2 mmol) in DCM 
(3.5 mL), were added anhydrous NaH2P04(166 mg, 1.38 mmol) and ra-CPBA 
(159 mg, 0.9 mmol). The resulting mixture was stirred vigorously at RT for 5
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h. The reaction mixture was then diluted with DCM and washed with 
saturated aqueous Na2S2C>3 solution, saturated aqueous NaHCCte solution, 
water, brine, and then dried over MgSCh. The solvent was removed under 
reduced pressure and the resultant residue was purified by flash silica-gel 
column chromatography (70% DCM in light petroleum (bp 40-60 °C)) to 
afford naphthyl ester T i l  (67 mg, 87%) as an orange oil; Rf(Si02, 30% diethyl 
ether in light petroleum (bp 40-60 °C)) 0.55; Vmax(neat)/cm1 1792 (C=0), 1762 
(C=0), 1193 (CO), 1096 (CO); 6h(300 MHz; CDCh) 7.91 (1H, d, J = 9.0, ArH), 
7.83-7.89 (2H, m, ArH), 7.68 (1H, d, /  = 2.4, ArH), 7.36-7.48 (7H, m, ArH), 7.29 
(1H, dd, J = 9.0, 2.4, ArH), 5.88 (1H, d, /  = 5.7, ArCH), 5.20 (1H, d, /  = 5.7, 
ArO(CO)CH); 6c(75 MHz; CDCh) 165.6, 152.9, 147.3, 135.4, 139.6, 131.8,
130.2, 130.0, 129.5, 127.9, 127.8, 127.1, 126.4, 125.6, 119.8, 118.4, 80.0, 79.3; m/z 
(EI+) 334 (100%, [M]+); HRMS (El): C20H 14O3, [M]+ requires 334.0836. Found 
334.0833.
Ill 22 Preparation of (lR*,2R*)-carbonic acid l-benzoyl-2- 
phenyl-2-(toluene-4-sulfonylamino)-ethyl ester methyl ester 284; 
to serve as an experimental procedure for the direct Mannich 




2,2/-bipyridine (31 mg, 0.2 mmol), 4 A molecular sieves (200 mg), and 
magnesium perchlorate (45 mg, 0.2 mmol) were stirred for 30 min. in dry 
THF (2.5 mL) under a nitrogen atmosphere at ambient temperature. The 
suspension formed was then treated with carbonic acid methyl ester 2-oxo-2- 
phenyl-ethyl ester 259 (194 mg, 1 mmol) in THF (2.5 mL). After 10 min. N-(4- 
toluenesulfonyl)benzaldimine 240 (259 mg, 1 mmol) and N-
methylmorpholine (55 pL, 0.5 mmol) were added drop-wise. The reaction 
was monitored by thin-layer chromatography. After 24 h the reaction 
mixture was diluted with EtOAc (2 * 30 mL), filtered through celite and 
subsequently quenched with a saturated aqueous solution of ammonium 
chloride (10 mL). The organic layers were washed with a saturated aqueous 
solution of copper sulfate (10 mL) followed by water (30 mL) and brine (30 
mL). The organic layer was dried over anhydrous magnesium sulfate and 
concentrated in vacuo. The crude mixture of diastereomers (anthsyn, 5:1) was 
purified by flash column chromatography (SiChiproduct, 50:1) to give an 
overall yield of 314 mg, 70%. 95:5 DCM:EtOAc provided the major 
diastereomer, anti-carbonate 284 as a white solid (141 mg, 31%); mp 185-186 
°C (CHCb); Vmax(KBr)/cm1 3259 (NH), 1760 (CO ), 1702 (CO ), 1278 (CO), 
1168 (CO); 5h(300 MHz; CDCh) 7.73 (2H, m, ArH), 7.54-7.61 (3H, m, ArH), 
7.42 (2H, m, ArH), 7.05-7.14 (5H, m, ArH), 6.94 (2H, m, ArH), 6.11 (1H, d, /  =
4.2, Ph(CO)CH), 5.75 (1H, d, J = 8.4, NH), 5.01 (1H, d, /  = 8.4,4.2, PhCH), 3.75 
(3H, s, OCHs), 2.34 (3H, s, ArCHs); 6c(75 MHz; CDCh) 193.6, 155.0, 143.8,
137.5, 135.2, 134.8, 134.4, 129.9, 129.3, 128.8, 127.9, 127.5, 79.6, 58.4, 55.8, 21.9; 
C24H23NO6S requires C, 63.5; H, 5.11; N, 3.09%. Found C, 63.2; H, 5.08; N, 




III 23 Preparation of other acetyl analogues employed as 
substrates in the direct catalytic aldol addition to aromatic 
aldehydes
Preparation of 3-[2-(fcrf-butyl-dimethyl-silanyloxy)-acetyl]-oxazolidin-2- 
one 330
Oxalyl chloride (2.89 mL, 33.1 mmol) was added drop-wise to a stirred 
solution of tert-butyldimethylsilyl terf-butyldimethylsilyloxyacetate150 329 
(8.41 g, 27.6 mmol) and dry DMF (0.1 mL) in dry DCM (35 mL) under a 
nitrogen atmosphere at 0 °C. The reaction mixture was warmed to ambient 
temperature and after 3 h concentrated in vacuo. To the residue was added 
dry THF (50 mL) and this was stirred under a nitrogen atmosphere at 
ambient temperature. Meanwhile, 2-oxazolidinone 167 (2.0 g, 23 mmol) was 
stirred in THF (50 mL) under a nitrogen atmosphere at -78 °C. A 2.32 M 
solution of n-BuLi (9.91 mL, 23 mmol) in n-hexane was added drop-wise. 
Then the prepared solution of (ferf-butyl-dimethyl-silanyloxy)-acetyl 
chloride in THF (50 mL) was added drop-wise over 20 min. The reaction 
mixture was stirred at -78 °C for 30 min. and at ambient temperature for a 
further 30 min. The reaction mixture was quenched with a saturated aqueous 
solution of ammonium chloride (10 mL), volatiles were removed in vacuo and 
water was added. The reaction mixture extracted with EtOAc, dried over 





was obtained as a colourless oil (4.87 g, 82%). An analytical sample was 
prepared by recrystallisation from diethyl ether and n-heptane obtaining the 
product as a white crystalline solid; mp 59-60 °C (diethyl ether-n-heptane); Rf 
(SiC>2, 1:1 EtOAc-light petroleum (bp 40-60 °C)) 0.71; Vmax(KBr)/cm1 2926 
(CH), 2855 (CH), 1771 (C=0), 1714 (CO), 1399 (CO), 1297 (SiCHa), 1141 (CO); 
6h(300 MHz; CDCb) 4.84 (2H, s, CH2), 4.49 (2H, t, /  = 8.1, CH2O), 4.04 (2H, t, /  
= 8.1, CH2N), 0.94 (9H, s, C(CH3)3), 0.12 (6H, s, Si(CH3)2); 6c(75 MHz; CDCb)
172.2, 154.0, 64.5, 63.5, 42.5, 26.2, 18.8, -5.0; m/z (EI+) 259 (15%, M+), (CI+) 277 
(94%, [M+NH4]+), 260 (100%, [M+H]+), 202 (63%, [M-'Bu]+); HRMS (ES+): 
CnH25N204Si, [M+NH4]+ requires 277.1578. Found 277.1583; CnH2iN 04Si 
requires C, 50.9; H, 8.16; N, 5.40%. Found C, 50.7; H, 8.06; N, 5.34%.
Preparation of 3-(2-hydroxy-acetyl)-oxazolidin-2-one 331
O O Me O O
o-AMA ^ < X    nA  X^ OH
O N Si Me O N
\ _ J  Me Me ^
330 331
3-[2-(terf-Butyl-dimethyl-silanyloxy)-acetyl]-oxazolidin-2-one 330 (4.86 g, 18.7 
mmol) was added to a solution of THF (50 mL), and 3:1 HOAC-H2O (200 mL). 
The reaction mixture was stirred for 4 h at ambient temperature and then 
concentrated in vacuo to a white solid, which was triturated in dry diethyl 
ether for 16 h and filtered to provide the alcohol 331 as a white solid (2.47 g, 
91%). A sample was recrystallised from DCM as colourless needles for 
analysis; mp 129 °C (DCM); Rf(Si02, 1:1 EtOAc- light petroleum (bp 40-60 
°C)) 0.17; Vmax(KBr)/crn1 3494 (OH), 1788 (C=0), 1684 (C=0), 1314 (CO), 1221 
(CO), 1128 (CO); 5h(300 MHz; CDCb) 4.72 (2H, d, J = 5.4, CH2(C=0)), 4.54 
(2H, t, /  = 8.1, CH2O), 4.09 (2H, t, /  = 8.1, CH2N), 3.05 (1H, t, /  = 5.4, OH); 6c(75 
MHz; CDCb) 173.8, 153.6, 63.7, 63.4, 42.4; m/z (EI+) 146 (29%, [M+H]+), 128 
(100%, [M-OH]+), 87 (82%, [M-COCHbOH+H]"); HRMS (ES+): C5HnN20 4,
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[M+NH4]+ requires 163.0713. Found 163.0715; C5H7NO4 requires C, 41.4; H,
Preparation of carbonic acid tsopropenyl ester 2-oxo-2-(2-oxo-oxazolidin-3- 
yl)-ethyl ester 286f
/sopropenyl chloroformate (1.49 mL, 13.8 mmol) was added drop-wise to a 
stirred solution of 3-(2-hydroxy-acetyl)-oxazolidin-2-one 331 (1.0 g, 6.9 
mmol) in dry DCM (15 mL) and dry pyridine (15 mL) under a nitrogen 
atmosphere at 0 °C. After 1 h at 0 °C the reaction was deemed complete. The 
reaction mixture was poured into EtOAc (75 mL) and quenched with cold 1 
M H2SO4 (75 mL). The organic layer was washed with 1 M H 2SO4 (75 mL), 
saturated aqueous copper sulfate (75 mL), water (75 mL), saturated NaHCCb 
(75 mL) and brine (75 mL). The organic layer was dried over anhydrous 
magnesium sulfate and then concentrated in vacuo. The resultant yellow oil 
was purified by flash column chromatography (SiC)2:product, 20:1), 30% 
EtOAc in light petroleum (bp 40-60 °C)). The carbonate 286f was obtained as a 
white crystalline solid (1.43 g, 91%); Rf(Si02, 50% EtOAc in light petroleum 
(bp 40-60 °Q) 0.51; Vmax(KBr)/crn1 1775 (C=0), 1757 (C=0), 1720 (C=0), 1678
4.86; N, 9.65%. Found C, 41.2; H, 4.86; N, 9.55%.
331 286f
(C=C), 1204 (CO); 6h(300 MHz; CDCb) 5.25 (2H, s, (C=0)CH2), 4.87 (1H, d, /  =
1.5, (H)CH=C(CH3)0), 4.74 (1H, d, /  = 1.5, (H)CH=C(CH3)0), 4.54 (2H, t, /  =
8.1, CH2O), 4.07 (2H, t, /  = 8.1, CH2N), 2.01 (3H, s, CH3); 6c(75 MHz; CDCb)
167.1, 154.0, 153.3, 153.0, 102.6, 66.3, 63.9, 42.3, 19.4; C9H11NO6 requires C, 
47.2; H, 4.84; N, 6.11%. Found C, 47.2; H, 4.85; N, 6.07%.
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Preparation of methoxycarbonyloxy-acetic acid methyl ester 285e
O O
/OH ---------- ►
M e C T ^  MeO ^  Y
O
332 285e
Methyl chloroformate (2.11 mL, 27.3 mmol) was added drop-wise to a stirred 
solution of methyl glycolate 332 (2.46 g, 27.3 mmol) in dry diethyl ether (20 
mL) followed by dry pyridine (4.4 mL) under a nitrogen atmosphere at 0 °C. 
After 1 h at 0 °C the reaction was deemed complete. The reaction mixture 
was poured into diethyl ether and quenched with cold 1 M HC1. The organic 
layer was washed with 1 M HC1, saturated aqueous copper sulfate, water, 
saturated NaHCCb and brine. The organic layer was dried over anhydrous 
magnesium sulfate and then concentrated in vacuo. The resultant colourless 
oil was purified by flash column chromatography (SiChrproduct, 20:1), 10% 
EtOAc in light petroleum (bp 40-60 °C)). The carbonate 285e was obtained as a 
colourless oil (1.04 g, 26%); Rf(SiC>2, 50% EtOAc in light petroleum (bp 40-60 
°C)) 0.67; 6h(400 MHz; CDCb) 4.64 (2H, s, CH2), 3.83 (3H, s, CO2CH3), 3.79 
(3H, s, OCO2CH3); 5c(100 MHz; CDCb) 168.0, 155.4, 63.6, 55.7, 52.7; m/z (CI+) 
166 (100%, [M+NH4]+), 149 (3%, [M+H]+); HRMS (ES+): C5H 12NO5, [M+NH4]+ 
requires 166.0710. Found 166.0714.




Methyl chlorooxoacetate (1.77 mL, 19.3 mmol) was added drop-wise to a 
stirred solution of 2-hydroxyacetophenone 71 (2.5 g, 18.4 mmol), 
triethylamine (3.07 mL, 22.0 mmol) in dry THF (120 mL) under a nitrogen
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atmosphere at 0 °C. After 2 h at 0 °C the reaction was deemed complete. The 
reaction mixture was poured into EtOAc (200 mL) and water (200 mL). The 
organic layer was then washed with brine (100 mL). The organic layer was 
dried over anhydrous magnesium sulfate and then concentrated in vacuo. 
The resultant yellow oil was purified by flash column chromatography 
(Si02:product, 20:1), 15% EtOAc in light petroleum (bp 40-60 °C)). The oxalate 
287d was obtained as a very pale yellow crystalline solid (3.65 g, 89%); mp 
65-66 °C (EtOAc-light petroleum (bp 40-60 °C)); Rf(Si02, 30% EtOAc in light 
petroleum (bp 40-60 °C)) 0.48; Vmax(KBr)/cm1 1765 (C=0), 1696 (C=0) 1317 
(CO), 1210 (CO), 1162 (CO); 6h(300 MHz; CDCb) 7.88-7.95 (2H, m, ArH), 
7.60-7.68 (1H, m, ArH), 7.47-7.55 (2H, m, ArH), 5.56 (2H, s, CH2), 3.97 (3H, s, 
OCHa); 6c(75 MHz; CDCb) 190.1, 157.8, 157.1, 134.7, 134.0, 129.4, 128.2, 68.2, 
54.2; m/z (EI+) 222 (7%, M+), 163 (100%, [M-C02Me]+), 105 (100%, P hC O +), 77 
(86%, Ph+); HRMS (ES+): CuHmNOs, [M+NH4]+ requires 240.0866. Found 
240.0860; CnHioOs requires C, 59.5; H, 4.54%. Found C, 59.3; H, 4.49%.
Preparation of oxalic acid methyl ester 2-oxo-2-(2-oxo-oxazolidin-3-yl)- 
ethyl ester 286d
Methyl chlorooxoacetate (0.71 mL, 7.7 mmol) was added drop-wise to a 
stirred solution of 3-(2-hydroxy-acetyl)-oxazolidin-2-one 331 (1.07 g, 7.4 
mmol), triethylamine (1.23 mL, 8.8 mmol) in dry THF (50 mL) under a 
nitrogen atmosphere at 0 °C. After 2 h at 0 °C the reaction was deemed 
complete. The reaction mixture was poured into EtOAc (75 mL) and water 
(75 mL). The organic layer was then washed with brine (75 mL). The organic 
layer was dried over anhydrous magnesium sulfate and then concentrated in





vacuo to a white foam. The oxalate 286d was obtained without further 
purification (1.39 g, 81%); mp 102 °C (EtOAc); Rf(Si02, 1:1 EtOAcilight 
petroleum (bp 40-60 °C)) 0.44; vmax(KBr)/cm1 1791 (C O ), 1754 (C=0) 1704 
(C=0 ); 6h(300 MHz; CDCb) 5.40 (2H, s, (C O )C H 2), 4.55 (2H, t, /  = 7.8, OCH2),
4.06 (2H, t, /  = 7.8, NCH2), 3.96 (3H, s, OCH3); 5c(75 MHz; CDCla) 165.6,
157.7, 157.1, 154.0, 65.2, 63.9, 54.3, 42.3; HRMS (ES+): QH13N2O7, [M+NH4]+ 
requires 249.0717. Found 249.0721; C8H9NO7 requires C, 41.6; H, 3.92; N, 
6.06%. Found C, 41.8; H, 4.08; N, 5.80%.
Preparation of oxalic acid methyl ester 2-(2-methylsulfanyl-phenyl)-2-oxo- 
ethyl ester 288
MeS O MeS O O
281 288
Methyl chlorooxoacetate (0.55 mL, 5.9 mmol) was added drop-wise to a 
stirred solution of 2-hydroxy-l-(2-methylsulfanyl-phenyl)-ethanone 281 (1.03 
g, 5.7 mmol), and triethylamine (0.94 mL, 6.8 mmol) in dry THF (30 mL) 
under a nitrogen atmosphere at 0 °C. After 2 h at 0 °C the reaction was 
deemed complete. The reaction mixture was poured into EtOAc (100 mL) 
and water (100 mL). The organic layer was then washed with brine (100 mL). 
The organic layer was dried over anhydrous magnesium sulfate and then 
concentrated in vacuo. The oxalate 288 was purified by recrystallisation; 1:1 
EtOAcilight petroleum (bp 40-60 °C) affording yellow crystals (1.13 g, 75%); 
mp 100 °C (EtOAc-light petroleum (bp 40-60 °C)); Vmax(KBr)/cm1 1771 (C=0), 
1749 (C O ) 1682 (CO); 6h(300 MHz; CDCb) 7.74 (1H, d, J = 9.0, ArH), 7.54 
(1H, t, /  = 9.0, ArH), 7.38 (1H, d, /  = 6.0, ArH), 7.21-7.28 (1H, m, ArH), 5.52 
(2H, s, (CO)CH 2), 3.96 (3H, s, OCH3), 2.45 (3H, s, SCH3); 6c(75 MHz; CDCb)
190.6, 157.9, 157.1, 144.0, 133.6, 131.2, 129.9, 126.1, 124.1, 68.6, 54.2, 16.3;
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H R M S (ES+): C12H16NO5S, [M +N H 4]+ requires 286.0744. Found 286.0747; 
C12H12O5S requires C, 53.7; H, 4.51%. Found C, 53.6; H, 4.53%.
Preparation of imidazole-l-carboxylic acid 2-oxo-2-phenyl-ethyl ester 287b
O O
To a stirred solution of 2-hydroxyacetophenone 71 (1.0 g, 7.3 mmol) in dry 
DCM (30 mL) was added l,l'-carbonyldiimidazole (1.25 g, 7.7 mmol) under a 
nitrogen atmosphere at 0 °C. After 2 h the reaction mixture was washed with 
water and concentrated under reduced pressure. The crude phenyl ketone 
287b was crystallised from DCM-n-hexane to yield a pale orange solid (1.43 
g, 85%); 6h(300 MHz; CDCb) 8.24 (1H, s, ArH), 7.95 (2H, d, /  = 8.1, ArH), 7.67 
(1H, m, ArH), 7.51-7.56 (3H, m, ArH), 7.12 (1H, s, ArH), 5.63 (2H, s, 
(C=0)CH2); 6c(75 MHz; CDCb) 190.7, 148.8, 137.7, 134.8, 133.9, 131.2, 129.5,
128.1, 117.7, 68.9; C12H10N2O3 requires C, 62.6; H, 4.38; N, 12.17%. Found C, 
62.6; H, 4.45; N, 12.1%.
Preparation of imidazole-l-carboxylic acid 2-oxo-2-(2-oxo-oxazolidin-3-yl)- 
ethyl ester 286b
O O  O O  i==\
oA nX - oh ------- ► oA n^ ° Y n^
O
331 286b
To a stirred solution of 3-(2-hydroxy-acetyl)-oxazolidin-2-one 331 (1.0 g, 6.9 
mmol) in dry DCM (30 mL) was added l,r-carbonyldiimidazole (1.12 g, 6.9 
mmol) under a nitrogen atmosphere at 0 °C. After 3 h the reaction mixture 
was washed with water and concentrated under reduced pressure. The
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oxazolidinone 286b was obtained as a white solid and used as in further 
reactions (1.41 g, 86%); 6h(400 MHz; CDCb) 8.20 (1H, s, ImH), 7.48 (1H, s, 
ImH), 7.11 (1H, m, ImH), 5.49 (2H, s, CHi), 4.57 (2H, t, /  = 8.0, OCH2CH2), 4.09 
(2H, t, /  = 8.0, CH2CH2N); 6c(100 MHz; CDCb) 165.8,153.6,148.4,137.3,131.0,
117.3, 65.6, 63.6,41.9.
Preparation of sulfurous acid methyl ester 2-oxo-2-phenyl-ethyl ester 287i
O O
Methyl chorosulfinate151 (4.20 g, 36.7 mmol) was added drop-wise to a stirred 
solution of 2-hydroxyacetophenone 71 (5.0 g, 36.7 mmol) in dry pyridine (8.3 
mL) and diethyl ether (75 mL) under a nitrogen atmosphere at 0 °C. After 1 h 
at 0 °C the reaction was complete. The reaction mixture was diluted with 
diethyl ether (150 mL) and quenched with cold 1 M H2SO4 (50 mL). The 
organic layer was washed with 1 M H2SO4 (75 mL), saturated NaHCCb (2 x 75 
mL) and brine (2 x 75 mL). The organic layer was dried over anhydrous 
magnesium sulfate and then concentrated in vacuo. The resultant yellow oil 
was purified by flash column chromatography (SiChiproduct, 25:1), 100% 
DCM. The sulfite 287i was obtained as a colourless oil (4.62 g, 59%); 
Vmax(neat)/cm1 1701 (C=0), 1451 (S=0), 1208 (SO), 1059 (SO); 6h(300 MHz; 
CDCb) 7.90-7.93 (2H, m, ArH), 7.60-7,62 (1H, m, ArH), 7.47-7.52 (2H, m, 




III 24 Typical experimental procedure for the addition of 
phenacyl chloride to benzaldehyde




Magnesium perchlorate (322 mg, 1.0 mmol) was stirred for 20 minutes in dry 
THF (5 mL) under a nitrogen atmosphere at ambient temperature. The 
solution formed was then treated with 2-chloroacetophenone 124 (155 mg,
1.0 mmol). After 10 min. benzaldehyde 17 (112 pL, 1.1 mmol) and 
triethylamine (153 pL, 1.1 mmol) were added drop-wise. The reaction was 
monitored by thin-layer chromatography. After 48 h the reaction mixture 
was quenched with a saturated aqueous solution of ammonium chloride (20 
mL) and extracted with diethyl ether (2 * 20 mL). The organic layers were 
washed with a saturated aqueous solution of copper sulfate (5 mL) followed 
by water (20 mL) and brine (20 mL). The organic layer was dried over 
anhydrous magnesium sulfate and concentrated in vacuo. The pale yellow oil 
was purified by flash column chromatography (SiChiproduct, 50:1), 10% 
diethyl ether in light petroleum (bp 40-60 °C) afforded the two aldol 
diastereomers syn- and anti-333 (symanti, 67:33) as colourless oils (0.06 g, 
23%); major diastereomer (syn-333), 6h(300 MHz; CDCb) 8.02-7.25 (10 H, m, 
ArH), 5.23 (1 H, dd, /  = 8.0, 6.0, CHOH), 5.14 (1 H, d, /  = 8.0, CHC1), 3.31 (1H, 
d, /  = 6.0, OH); 6c(75 MHz; CDCb) 194.9, 139.5, 135.0, 134.7, 129.5, 129.2,
129.1, 128.9, 127.7, 75.2, 57.9; HRMS (ES+): C15H 17CINO2, [M+NH4]+ requires
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278.0948. Found 278.0947; minor diastereomer (anti-333), 6h(300 MHz; CDCb)
7.89-7.25 (10 H, m, ArH), 5.37 (1 H, dd, /  = 4.8, 4.0, C H O H ), 5.27 (1 H, d, /  =
4.8, C H C 1), 3.53 (1H , d, /  = 4.0, O H ); H R M S (ES+): C15H17CINO2, [M + N H 4]+ 
requires 278.0948. Found 278.0947. Analytical data for this compound is 
















































Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2cr(I)]
R indices (all data)
Absolute structure parameter 
Largest diff. peak and hole








a = 14.3028(3) A a = 90° 
b = 7.68010(10) A p = 100.7190(10)° 






0.20 x 0.12 x 0.10 mm 
3.93 to 27.46°
-18<=h<=18; -9<=k<=9; -23<=1<=23 
41516




Full-matrix least-squares on F2
8863/3/515
1.024
R1 = 0.0529 wR2 = 0.1250 
R1 = 0.0937 wR2 = 0.1420 
0.01(6)
0.571 and -0.400 eA3
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N otes: 2 m olecules in  th e  asym m etric  un it. Each m olecule in v o lv ed  in  1-d im ensional 
h y d ro g en -b o n d in g  as a  consequence of N -H * • »S in teractions.
H y d ro g en  b o n d s w ith  H ..A  < r(A) + 2.000 A n gstrom s and  < D H A  > 1 1 0  d eg .
D -H  d (D -H ) d (H ..A ) <D H A  d (D ..A ) A
N l - H l  0 .890 2.663 152.20 3.475 S l[ -x ,y - l /2 ,
-z+2]




Table 2 . Atomic coordinates (x 104) and equivalent isotropic
o
displacement parameters (A2 * 103) for (4S,5R)-227. U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor.
Atom X y z U(eq)
Cl(l) 2794(1) 6071(1) 6672(1) 49(1)
Cl(2) 2180(1) 119(1) 8300(1) 57(1)
S(l) -1059(1) 4027(1) 9793(1) 54(1)
S(2) 6067(1) 728(2) 5317(1) 71(1)
0 (1 ) 155(2) 5442(3) 9067(1) 45(1)
0 (2 ) 2332(2) 4858(3) 10780(1) 52(1)
0(3) 3045(2) 5700(5) 9842(2) 73(1)
0(4) 1280(1) 3929(3) 5934(1) 46(1)
0(5) 909(2) 4986(4) 2489(1) 60(1)
0 (6 ) 4693(2) 2144(4) 5868(2) 6 8 (1 )
0(7) 2817(2) 543(5) 4365(2) 84(1)
0 (8 ) 1824(2) -24(5) 5139(3) 107(1)
0(9) 3812(2) 1743(3) 9147(1) 47(1)
0 (1 0 ) 4018(2) 1283(4) 12605(1) 63(1)
N(l) 821(2) 3468(4) 9856(2) 45(1)
N(2) 4318(2) -391(4) 5382(2) 67(1)
C(l) 8 (2 ) 4266(4) 9584(2) 40(1)
0 (2 ) 1620(2) 4054(5) 9546(2) 43(1)
0(3) 1138(2) 5377(5) 8954(2) 42(1)
0(4) 2418(2) 4969(5) 10080(2) 48(1)
0(5) 3125(3) 5768(7) 11290(2) 69(1)
0 (6 ) 2896(3) 5694(10) 12027(3) 99(2)
0(7) 1153(2) 4889(5) 8147(2) 41(1)
0 (8 ) 1887(2) 5546(4) 7832(2) 39(1)
0(9) 1909(2) 5162(5) 7093(2) 38(1)
0 (1 0 ) 1209(2) 4152(5) 6661(2) 38(1)
C(ll) 472(2) 3844(5) 7730(2) 46(1)
C(12) 491(2) 3468(5) 6990(2) 46(1)
C(13) 453(2) 3331(5) 5426(2) 44(1)
0(14) 584(2) 3734(4) 4650(2) 40(1)
0(15) 1366(2) 4658(5) 4502(2) 49(1)
0(16) 1459(2) 5030(6) 3778(2) 55(1)
C(17) 752(2) 4481(5) 3186(2) 46(1)
C(18) -27(2) 3579(5) 3320(2) 43(1)
C(19) -1 1 1 (2 ) 3208(5) 4047(2) 43(1)
C(20) 371(3) 4125(8) 1854(2) 70(1)
0 (2 1 ) 4984(3) 801(6) 5511(2) 58(1)
C(22) 3458(3) 65(5) 5633(2) 55(1)
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C(23) 3740(3) 1819(5) 6022(2) 57(1)
C(24) 2598(3) 194(5) 5011(2) 56(1)
C(25) 2 0 1 2 (6 ) 562(14) 3743(4) 219(6)
C(26) 2135(3) -125(13) 3129(3) 132(3)
C(2 7) 3784(3) 1795(5) 6 8 6 8 (2 ) 50(1)
C(28) 3058(3) 1056(5) 7158(2) 49(1)
C(29) 3081(2) 1038(5) 7925(2) 47(1)
C(30) 3849(2) 1819(5) 8408(2) 43(1)
C(31) 4566(2) 2589(5) 8110(2) 51(1)
C(32) 4538(3) 2556(5) 7344(2) 53(1)
C(33) 4622(2) . 2360(5) 9666(2) 45(1)
C(34) 4464(2) 2040(5) 10437(2) 42(1)
C(35) 3658(2) 1219(5) 10593(2) 47(1)
C(36) 3533(2) 1012(5) 11318(2) 50(1)
C(37) 4211(2) 1558(5) 11908(2) 47(1)
C(38) 5036(2) 2351(5) 11768(2) 50(1)
C(39) 5152(2) 2570(5) 11038(2) 46(1)
C(40) 4618(3) 2050(8) 13229(2) 70(1)
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lengths [A] and 
angles [°] for (4S/5R)-227.
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Table 4. Anisotropic displacement parameters (A2 * 1 0 3) for (4S,5R)-227. 
The anisotropic displacement factor exponent takes the form: -2 gn 2 [h2 a* 2 
U ll + ... + 2hka*b*  U12].
Atom U ll U22 U33 U23 U13 U12
Cl(l) 39(1) 64(1) 45(1) -3(1) 7(1) -6 (1 )
Cl(2) 45(1) 60(1) 6 6 (1 ) -13(1) 6 (1 ) -8 (1 )
S(l) 47(1) 56(1) 55(1) 1 1 (1 ) 2 (1 ) -1 0 (1 )
S(2) 57(1) 73(1) 76(1) 3(1) -5(1) -1 (1 )
0 (1 ) 47(1) 45(1) 45(1) 1 1 (1 ) 1 2 (1 ) 9(1)
0 (2 ) 42(1) 62(2) 47(1) -1 2 (1 ) -4(1) 6 (1 )
0(3) 43(1) 92(2) 82(2) 3(2) 8 (1 ) -4(2)
0(4) 37(1) 60(2) 37(1) -1 1 (1 ) 0 (1 ) 1 (1 )
0(5) 55(2) 8 6 (2 ) 38(1) -9(1) 3(1) -15(2)
0 (6 ) 8 6 (2 ) 53(2) 6 6 (2 ) -3(1) 2 1 (2 ) -16(2)
0(7) 81(2) 124(3) 43(2) -1 1 (2 ) -1 (1 ) 56(2)
0 (8 ) 48(2) 89(3) 184(4) 17(3) 28(2) -3(2)
0(9) 43(1) 54(1) 40(1) -7(1) -2 (1 ) -6 (1 )
0 (1 0 ) 46(1) 93(2) 47(1) 3(1) 2 (1 ) -1 1 (1 )
N(l) 47(2) 42(2) 41(2) 6 (1 ) -7(1) -6 (1 )
N(2) 51(2) 53(2) 87(3) -14(2) -9(2) 1 0 (2 )
C(l) 47(2) 35(2) 34(2) -1 (1 ) -1 (1 ) -6 (2 )
0 (2 ) 51(2) 39(2) 37(2) -2 (1 ) 1 (1 ) 1 2 (2 )
0(3) 41(2) 45(2) 39(2) -1 (1 ) 5(1) 9(2)
0(4) 40(2) 50(2) 51(2) -6 (2 ) 2 (2 ) 1 2 (2 )
0(5) 45(2) 85(3) 68(3) -25(2) -1 1 (2 ) -3(2)
0 (6 ) 56(3) 167(6) 74(3) -47(4) 13(2) -30(3)
0(7) 41(2) 41(2) 38(2) -3(1) 4(1) 7(2)
0 (8 ) 37(2) 39(2) 37(2) -4(1) -3(1) 3(1)
0(9) 29(1) 40(2) 41(2) 4(2) 1 (1 ) 3(1)
0 (1 0 ) 38(2) 43(2) 32(2) -3(1) 0 (1 ) 4(2)
0 (1 1 ) 49(2) 48(2) 41(2) 1 (2 ) 9(1) -7(2)
C(12) 39(2) 49(2) 46(2) -5(2) 1 (1 ) -6 (2 )
C(13) 36(2) 49(2) 45(2) -7(2) 0 (1 ) -1 (2 )
0(14) 36(2) 40(2) 41(2) -1 2 (1 ) -2 (1 ) 5(1)
0(15) 39(2) 62(2) 43(2) -13(2) -1 (2 ) -8 (2 )
0(16) 42(2) 74(3) 47(2) -15(2) 4(2) -15(2)
0(17) 45(2) 52(2) 39(2) -5(2) 1 (2 ) 1 (2 )
C(18) 37(2) 49(2) 39(2) -1 1 (2 ) -4(1) 2 (2 )
C(19) 35(2) 48(2) 44(2) -1 2 (2 ) -2 (1 ) 0 (1 )
C(20) 53(2) 120(4) 36(2) -18(2) 5(2) -14(3)
C(21) 62(2) 51(2) 55(2) 8 (2 ) -5(2) 6 (2 )
C(22) 6 8 (2 ) 44(2) 51(2) 2 (2 ) 5(2) -3(2)
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C(23) 68(2) 43(2) 57(2) 6(2) 7(2) 3(2)
C(24) 43(2) 48(2) 74(3) -11(2) 4(2) 1(2)
C(25) 210(7) 298(11) 98(4) -127(6) -106(5) 216(8)
C(26) 60(3) 267(10) 74(3) -67(5) 24(2) -48(4)
C(2 7) 53(2) 48(2) 44(2) -2(2) 0(2) 8(2)
C(28) 49(2) 42(2) 51(2) -6(2) -5(2) 10(2)
C(29) 40(2) 45(2) 52(2) -7(2) 2(2) 2(2)
C(30) 43(2) 40(2) 43(2) -3(2) -1(1) 11(2)
C(31) 44(2) 52(2) 52(2) -1(2) -3(2) -4(2)
C(32) 51(2) 54(2) 51(2) 12(2) 4(2) 6(2)
C(33) 36(2) 46(2) 48(2) -8(2) -3(1) -5(2)
C(34) 35(2) 43(2) 47(2) -6(2) 2(1) 3(2)
C(35) 37(2) 49(2) 49(2) -8(2) -3(1) 4(2)
C(36) 37(2) 55(2) 57(2) 3(2) 5(2) -3(2)
C(3 7) 39(2) 55(2) 45(2) -4(2) 2(1) 0(2)
C(38) 38(2) 58(2) 50(2) -1(2) -4(2) -2(2)
C(39) 34(2) 50(2) 53(2) -4(2) 4(1) -3(2)
C(40) 54(2) 104(4) 49(2) -10(2) -1(2) -8(2)
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Table 5. Hydrogen coordinates (x 1 0 4) and isotropic displacement
parameters (A2 x 1 0 3) for (4S,5R)-227.
Atom X y z U(eq)
H(2A) 1886 3061 9296 52
H(3) 1438 6547 9063 50
H(5A) 3739 5177 11284 83
H(5B) 3175 6992 11133 83
H(6 A) 3397 6276 12383 148
H(6 B) 2848 4476 12175 148
H(6 C) 2287 6281 12025 148
H(8 ) 2368 6249 8118 47
H(ll) - 2 1 3371 7954 55
H(12) 15 2747 6711 55
H(13A) - 1 2 2 3924 5531 53
H(13B) 374 2062 5485 53
H(15) 1842 5039 4905 59
H(16) 1997 5653 3682 6 6
H(18) -506 3212 2917 52
H(19) -651 2583 4138 52
H(20A) 545 4596 1399 105
H(20B) -309 4314 1842 105
H(20C) 508 2874 1887 105
H(22) 3331 -806 6010 6 6
H(23) 3294 2752 5790 6 8
H(25A) 1474 -42 3904 263
H(25B) 1819 1789 3641 263
H(26A) 1545 -33 2758 198
H(26B) 2306 -1354 3211 198
H(26C) 2648 486 2946 198
H(28) 2533 552 6832 59
H(31) 5081 3143 8430 61
H(32) 5043 3063 7146 63
H(33A) 4711 3621 9590 54
H(33B) 5202 1743 9585 54
H(35) 3188 797 10195 56
H(36) 2967 481 11412 60
H(38) 5512 2737 12169 60
H(39) 5719 3098 10944 55
H(40A) 4389 1737 13686 106
H(40B) 4608 3319 13173 106
H(40C) 5270 1623 13260 106
H(l) 830(30) 2470(30) 10102(19) 64(12)




























Reflections observed (>2cr) 
Data Completeness 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2a (I)]
R indices (all data)
Absolute structure parameter
h04mcwl






a = 11.5000(1) A a = 90° 
b = 13.5120(1) A |3 = 90° 
c = 30.2080(3) A y  = 90°
4693.96(7) A3 
4
1.481 m g/m 3 
0.337 mm 1 
2160
0.40 x 0.40 x 0.40 mm 
3.56 to 27.49°
-14<=h<=14; -17<=k<=17; -38<=1<=39 
63575
10726 [R(int) = 0.0686]
6984
0.995
Semi-empirical from equivalents 
0.90 and 0.88
Full-matrix least-squares on F2
10726 / 0 / 651
0.990
R1 = 0.0476 wR2 = 0.1029 




Largest diff. peak and hole 0.353 and -0.343 eA'3
Notes: Asymmetric unit also contains 1 molecule of dichloromethane in which the 
chlorines are disordered over 2 sites, in a 60:40 ratio.
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Table 2 . Atomic coordinates (* 104) and equivalent isotropic
displacement parameters (A2 * 1 0 3) for (R,R)-2 0 1 . U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor.
Atom X y z U(eq)
Cl(l) 4446(1) 3763(1) 3872(1) 43(1)
Cl(2) 9304(1) 1487(1) 1296(1) 65(1)
Cl(3) 2237(3) 482(2) 2438(1) 60(1)
Cl(4) 2873(2) -128(2) 1634(1) 61(1)
Mg(l) 2962(1) 5052(1) 1246(1) 24(1)
0 (1 ) 3581(2) 2406(1) 509(1) 47(1)
0 (2 ) 2234(2) 7497(1) 398(1) 44(1)
0(3) 286(2) 4415(2) 2165(1) 39(1)
0(4) 6085(2) 6030(2) 1847(1) 38(1)
0(5) 4968(2) 3260(2) 3508(1) 61(1)
0 (6 ) 3219(2) 3691(2) 3833(1) 73(1)
0(7) 4768(2) 4772(2) 3879(1) 74(1)
0 (8 ) 4792(3) 3303(2) 4274(1) 81(1)
0(9) 9589(4) 1813(2) 1718(1) 114(1)
0 (1 0 ) 9083(3) 460(2) 1306(1) 109(1)
0 (1 1 ) 10223(4) 1674(3) 1009(1) 144(2)
0 (1 2 ) 8385(4) 2038(2) 1129(1) 1 2 1 (1 )
N(l) 3322(2) 3485(2) 1073(1) 31(1)
N(2) 2825(2) 4955(2) 544(1) 27(1)
N(3) 2454(2) 6566(2) 1 0 1 1 (1 ) 27(1)
N(4) 1339(2) 4593(2) 1543(1) 29(1)
N(5) 3185(2) 5176(2) 1952(1) 27(1)
N(8 ) 4726(2) 5579(2) 1349(1) 28(1)
C(l) 3514(3) 2498(2) 1294(1) 40(1)
0 (2 ) 3878(4) 1843(2) 904(1) 72(1)
0(3) 3340(2) 3313(2) 658(1) 33(1)
0(4) 3054(2) 4100(2) 336(1) 31(1)
0(5) 2987(3) 4011(2) -117(1) 40(1)
0 (6 ) 2666(3) 4838(2) -360(1) 48(1)
0(7) 2443(3) 5725(2) -153(1) 43(1)
0 (8 ) 2537(2) 5754(2) 306(1) 31(1)
0(9) 2393(2) 6624(2) 592(1) 30(1)
C(10) 2270(4) 8221(2) 761(1) 56(1)
C(ll) 2307(2) 7592(2) 1183(1) 34(1)
C(12) 4361(3) 2619(2) 1673(1) 36(1)
C(13) 5555(3) 2657(3) 1624(1) 59(1)
0(14) 6254(4) 2892(3) 2013(2) 83(2)
0(15) 5659(5) 3058(3) 2410(2) 75(1)
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C(16) 4534(5) 2978(3) 2454(1) 72(1)
C(17) 3896(4) 2777(2) 2091(1) 52(1)
C(18) 1263(2) 7654(2) 1488(1) 30(1)
C(19) 204(3) 8057(2) 1364(1) 43(1)
C(20) -718(3) 8081(3) 1646(2) 59(1)
C(21) -619(3) 7686(3) 2053(2) 64(1)
C(22) 432(4) 7288(2) 2 2 0 1 (1 ) 59(1)
C(23) 1382(3) 7284(2) 1914(1) 39(1)
C(24) 229(2) 4162(2) 1384(1) 33(1)
C(25) -532(3) 4221(3) 1803(1) 44(1)
C(26) 1280(2) 4662(2) 1962(1) 30(1)
C(27) 2302(2) 4975(2) 2 2 2 2 (1 ) 30(1)
C(28) 2404(3) 5049(2) 2681(1) 37(1)
C(29) 3482(3) 5333(2) 2846(1) 40(1)
C(30) 4399(3) 5539(2) 2571(1) 37(1)
C(31) 4213(2) 5463(2) 2116(1) 28(1)
C(32) 5033(2) 5689(2) 1752(1) 28(1) .
C(33) 6666(3) 6130(2) 1416(1) 45(1)
C(34) 5708(2) 5947(2) 1072(1) 33(1)
C(35) -205(2) 4700(2) 983(1) 36(1)
C(36) -254(3) 4227(3) 577(1) 60(1)
C(3 7) -572(4) 4736(4) 2 0 1 (1 ) 80(1)
C(38) -845(4) 5718(4) 228(1) 79(1)
C(39) -817(3) 6209(3) 628(1) 60(1)
C(40) -495(2) 5693(2) 1004(1) 41(1)
C(41) 5979(2) 5234(2) 704(1) 32(1)
C(42) 6460(3) 4315(2) 787(1) 45(1)
C(43) 6625(3) 3643(3) 448(1) 61(1)
C(44) 6308(3) 3872(3) 27(1) 59(1)
C(45) 5839(3) 4780(3) -67(1) 55(1)
C(46) 5676(3) 5474(2) 269(1) 42(1)
C(4 7) 1579(3) 58(3) 1962(1) 53(1)
C1(4A) 2330(4) 45(3) 1484(2) 8 8 (1 )
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Table 4. Anisotropic displacement parameters (A2 * 1 0 3) for (R,R)-2 0 1 . 
The anisotropic displacement factor exponent takes the form: -2 gn2 [h2 a* 2 
U ll + ... + 2h  k a*b* U12].
Atom U ll U22 U33 U23 U13 U12
0 (2 ) 119(1) 41(1) 34(1) 2 (1 ) -15(1) -6 (1 )
0(3) 50(2) 74(2) 56(1) 4(2) -6 (1 ) -2 0 (1 )
0(4) 65(1) 48(1) 70(2) -18(1) 24(1) -1 2 (1 )
Mg(l) 26(1) 27(1) 2 0 (1 ) 0 (1 ) -1 (1 ) -1 (1 )
0 (1 ) 74(2) 33(1) 35(1) -1 0 (1 ) -6 (1 ) 8 (1 )
0 (2 ) 65(1) 34(1) 33(1) 8 (1 ) -1 (1 ) 2 (1 )
0(3) 35(1) 48(1) 34(1) 9(1) 1 0 (1 ) -2 (1 )
0(4) 33(1) 44(1) 37(1) -1 (1 ) -1 0 (1 ) -6 (1 )
0(5) 63(2) 79(2) 42(1) -18(1) 1 (1 ) 15(1)
0 (6 ) 50(2) 99(2) 70(2) -31(2) 2 (1 ) -2 (1 )
0(7) 97(2) 42(1) 84(2) -6 (1 ) 4(2) -13(1)
0 (8 ) 145(3) 61(2) 37(1) -3(1) -29(2) 23(2)
0(9) 231(4) 71(2) 40(2) -1 2 (1 ) -45(2) 2 2 (2 )
0 (1 0 ) 194(4) 44(2) 90(2) 13(1) -56(2) -25(2)
0 (1 1 ) 230(5) 78(2) 123(3) -2 1 (2 ) 95(3) -15(3)
0 (1 2 ) 149(3) 89(2) 125(3) 14(2) -68(3) 17(2)
N(l) 37(1) 28(1) 28(1) -2 (1 ) -1 (1 ) 3(1)
N(2) 27(1) 33(1) 2 2 (1 ) -3(1) 0 (1 ) 0 (1 )
N(3) 25(1) 28(1) 30(1) -2 (1 ) 1 (1 ) 1 (1 )
N(4) 31(1) 29(1) 27(1) -2 (1 ) 4(1) 0 (1 )
N(5) 34(1) 25(1) 2 2 (1 ) -2 (1 ) -3(1) 2 (1 )
N(8 ) 26(1) 28(1) 29(1) -1 (1 ) -1 (1 ) -1 (1 )
C(l) 56(2) 25(2) 38(2) 1 (1 ) -2 (2 ) 4(1)
0 (2 ) 142(4) 36(2) 39(2) -7(2) -19(2) 30(2)
0(3) 35(2) 29(2) 35(2) -6 (1 ) -4(1) -1 (1 )
0(4) 31(2) 35(2) 28(2) -2 (1 ) 2 (1 ) -3(1)
0(5) 46(2) 44(2) 30(2) -1 0 (1 ) -3(1) -4(2)
0 (6 ) 62(2) 58(2) 2 2 (2 ) -4(2) -5(1) -1 (2 )
0(7) 55(2) 46(2) 27(2) 2 (1 ) -3(1) 1 (2 )
0 (8 ) 35(2) 35(2) 23(1) 6 (1 ) -2 (1 ) 0 (1 )
0(9) 30(2). 31(2) 30(2) 7(1) -4(1) -1 (1 )
0 (1 0 ) 90(3) 36(2) 43(2) -1 (2 ) 2 0 (2 ) 0 (2 )
C(ll) 41(2) 27(1) 36(2) 3(1) 4(1) -4(1)
C(12) 55(2) 2 1 (1 ) 31(2) 5(1) -2 (1 ) 2 (1 )
C(13) 55(2) 53(2) 69(2) 25(2) 4(2) 1 (2 )
0(14) 49(2) 48(2) 153(5) 53(3) -27(3) -16(2)
0(15) 117(4) 35(2) 72(3) 4(2) -27(3) -6 (2 )
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Appendix
Table 5. Hydrogen coordinates (x 104) and isotropic displacement 
parameters (A2 x 1 0 3) for (R,R)-2 0 1 .
Atom X y z U(eq)
H(2A) 4723 1706 913 87
H(2B) 3453 1206 909 87
H(5) 3155 3401 -260 48
H(6 ) 2599 4792 -672 57
H (7) 2233 6297 -317 51
H(10A) 1570 8647 757 67
H(10B) 2970 8644 738 67
H(H) 3018 7775 1355 41
H(13) 5910 2533 1345 71
H(14) 7078 2932 1997 1 0 0
H(15) 6101 3240 2663 89
H(16) 4175 3060 2735 87
H(17) 3076 2741 2123 62
H(19) 119 8324 1075 52
H(20) -1429 8375 1556 71
H(21) -1276 7677 2243 76
H(22) 499 7026 2492 71
H(23) 2108 7027 2 0 1 1 47
H(24) 358 3451 1307 40
H(25A) -1108 4763 1777 52
H(25B) -951 3590 1851 52
H(28) 1768 4912 2872 44
H(29) 3586 5385 3157 48
H(30) 5136 5726 2686 44
H(33A) 7297 5636 1385 54
H(33B) 7000 6801 1381 54
H(34) 5480 6596 939 39
H(36) -67 3543 558 71
H(3 7) -602 4405 -76 96
H(38) -1056 6068 -33 95
H(39) -1015 6890 645 72
H(40) -474 6026 1281 49
H(42) 6679 4144 1081 54
H(43) 6963 3016 510 73
H(44) 6412 3401 -203 71
H(45) 5623 4937 -362 6 6
H(46) 5361 6107 203 50
H(47A) 1054 558 1830 64






































Theta range for data collection 
Limiting indices 
Reflections collected / unique 
Completeness to theta = 35.01 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2cr(I)]
R indices (all data)
Absolute structure parameter 
Largest diff. peak and hole








a = 9.69500(10) A a  = 90° 
b = 9.64000(10) A (3 = 93.27° 




0.590 m m 1 
580
0.50 x 0.40 x 0.20 mm 
3.68 to 35.01°
-15<=h<=15, -15<=k<=15, -20<=1<=20 
31690 /10261 [R(int) = 0.0419] 
97.9%
0.8911 and 0.7568 
Full-matrix least-squares on F2 
10261/1/349 
1.036
R’ = 0.0321, wR2 = 0.0818 
RJ = 0.0338, wR2 = 0.0829 
0.01(3)
0.386 and -0.497 eA3
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Table 2 . Atomic coordinates (* 104) and equivalent isotropic
displacement parameters (A2 * 1 0 3) for (4S,5S)-241. U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor.
Atom X y z U(eq)
S(l) 6282(1) 6547(1) 2718(1) 19(1)
S(2) 8167(1) 3510(1) 2816(1) 29(1)
N(l) 5970(1) 5084(1) 3359(1) 19(1)
N(2) 6136(1) 3016(1) 4065(1) 2 2 (1 )
N(3) 2502(1) 2854(1) 4841(1) 2 0 (1 )
0 (1 ) 5348(1) 7517(1) 3143(1) 24(1)
0 (2 ) 7740(1) 6799(1) 2814(1) 27(1)
0(3) 3945(1) 1356(1) 4129(1) 25(1)
0(4) 2864(1) 5041(1) 5562(1) 28(1)
0(5) 814(1) 3981(1) 5575(1) 30(1)
C(l) 5766(1) 6280(1) 1418(1) 2 0 (1 )
0 (2 ) 6650(1) 5615(1) 768(1) 26(1)
0(3) 6192(1) 5377(1) -252(1) 30(1)
0(4) 4884(1) 5802(1) -631(1) 26(1)
0(5) 4382(2) 5496(2) -1728(1) 38(1)
0 (6 ) 4036(1) 6498(2) 33(1) 29(1)
0(7) 4463(1) 6734(1) 1058(1) 26(1)
0 (8 ) 6755(1) 3871(1) 3419(1) 2 0 (1 )
0(9) 4912(1) 3598(1) 4503(1) 19(1)
C(10) 3767(1) 2511(1) 4468(1) 19(1)
0 (1 1 ) 2143(1) 4054(1) 5350(1) 2 2 (1 )
C(12) 226(1) 2644(2) 5269(1) 31(1)
C(13) 1338(1) 1889(1) 4705(1) 28(1)
0(14) 4605(1) 4888(1) 3809(1) 18(1)
0(15) 3450(1) 4696(1) 2992(1) 19(1)
0(16) 3557(1) 3766(1) 2181(1) 26(1)
C(17) 2443(1) • 3593(2) 1464(1) 35(1)
C(18) 1227(1) 4327(2) 1572(1) 36(1)
C(19) 1118(1) 5249(1) 2375(1) 30(1)
C(20) 2229(1) 5445(1) 3081(1) 23(1)
C(30) 299(7) 9022(6) 1971(5) 38(1)
ci(i) 1843(3) 9125(2) 2709(2) 37(1)
0 1 (2 ) 560(2) 8091(2) 824(1) 52(1)
01(3) -457(3) 10592(3) 1744(5) 108(1)
C(30A) 80(13) 9230(14) 1854(10) 60(3)
C1(1A) 1677(6) 9237(5) 2584(4) 55(1)
C1(2A) 45(9) 7972(3) 862(3) 97(1)
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Table 5. Anisotropic displacement parameters (A2 * 103) for (4S,5S)-241. 
The anisotropic displacement factor exponent takes the form: -2 n 2 [h2 a* 2 U l l  
+ ... + 2 h k a* b* U12].
Atom U ll U22 U33 U23 U13 U12
S(l) 2 2 (1 ) 19(1) 17(1) 0 (1 ) 2 (1 ) -3(1)
S(2) 19(1) 33(1) 38(1) 7(1) 1 1 (1 ) 5(1)
N (l) 17(1) 19(1) 2 0 (1 ) 4(1) 4(1) 0 (1 )
N(2) 18(1) 2 2 (1 ) 28(1) 7(1) 6 (1 ) 3(1)
N(3) 18(1) 2 1 (1 ) 2 2 (1 ) -1 (1 ) 4(1) -2 (1 )
0 (1 ) 35(1) 19(1) 2 0 (1 ) -1 (1 ) 5(1) 1 (1 )
0 (2 ) 25(1) 30(1) 27(1) 2 (1 ) 2 (1 ) -1 0 (1 )
0(3) 25(1) 2 0 (1 ) 31(1) -1 (1 ) 4(1) 1 (1 )
0(4) 31(1) 23(1) 30(1) -6 (1 ) 1 1 (1 ) -4(1)
0(5) 2 2 (1 ) 33(1) 36(1) -1 (1 ) 1 1 (1 ) 2 (1 )
C(l) 24(1) 2 0 (1 ) 17(1) 0 (1 ) 3(1) -1 (1 )
0 (2 ) 26(1) 30(1) 23(1) 0 (1 ) 5(1) 4(1)
0(3) 37(1) 32(1) 2 1 (1 ) -3(1) 6 (1 ) 6 (1 )
0(4) 40(1) 2 1 (1 ) 18(1) 0 (1 ) 1 (1 ) 1 (1 )
0(5) 61(1) 33(1) 2 1 (1 ) -5(1) -5(1) 4(1)
0 (6 ) 33(1) 31(1) 2 2 (1 ) 0 (1 ) -2 (1 ) 6 (1 )
0(7) 29(1) 30(1) 2 0 (1 ) -2 (1 ) 2 (1 ) 7(1)
0 (8 ) 16(1) 23(1) 2 2 (1 ) 3(1) 2 (1 ) 1 (1 )
0(9) 17(1) 2 0 (1 ) 19(1) 3(1) 2 (1 ) -1 (1 )
C(10) 18(1) 2 1 (1 ) 18(1) 2 (1 ) 2 (1 ) 0 (1 )
0 (1 1 ) 2 2 (1 ) 24(1) 2 0 (1 ) 2 (1 ) 6 (1 ) 1 (1 )
C(12) 17(1) 40(1) 34(1) -1 (1 ) 3(1) -5(1)
C(13) 2 0 (1 ) 30(1) 35(1) -3(1) 4(1) -7(1)
0(14) 16(1) 19(1) 18(1) 1 (1 ) 3(1) 0 (1 )
0(15) 17(1) 19(1) 2 1 (1 ) 1 (1 ) 1 (1 ) 1 (1 )
0(16) 25(1) 25(1) 29(1) -6 (1 ) -3(1) 4(1)
0(17) 33(1) 36(1) 35(1) -U(l) -8 (1 ) 2 (1 )
C(18) 25(1) 40(1) 41(1) -5(1) -1 2 (1 ) 0 (1 )
C(19) 19(1) 33(1) 38(1) 4(1) -2 (1 ) 3(1)
C(20) 19(1) 24(1) 27(1) 2 (1 ) 3(1) 2 (1 )
C(30) 35(2) 33(1) 45(3) -8 (2 ) 1 1 (2 ) -1 (1 )
c i(i) 41(1) 35(1) 35(1) -2 (1 ) 9(1) -1 (1 )
0 1 (2 ) 73(1) 53(1) 30(1) -5(1) -6 (1 ) 14(1)
01(3) 65(1) 54(1) 202(4) -2 2 (1 ) -25(1) 31(1)
C(30A) 40(4) 98(8) 42(3) 18(4) 2(3) -21(5)
C1(1A) 58(2) 74(2) 34(1) 8 (1 ) 1 1 (1 ) 4(1)
C1(2A) 170(4) 53(1) 60(1) 2 0 (1 ) -56(2) -31(2)
C1(3A) 91(2) 51(1) 82(1) 6 (1 ) 15(1) 35(1)
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Table 6 . Hydrogen coordinates (* 104) and isotropic displacement 
parameters (A2 * 103) for (4S,5S)-241.
Atom X y z U(eq)
H(2A) 6410(20) 2160(20) 4140(16) 38(5)
H(2) 7547 5330 1015 31
H(3) 6783 4914 -700 36
H(5A) 3918 4593 -1757 58
H(5B) 5170 5479 -2168 58
H(5C) 3731 6219 -1972 58
H(6 ) 3153 6816 - 2 2 0 35
H (7) 3874 7199 1506 31
H(9) 5135 3896 5232 2 2
H(12A) -614 2773 4808 37
H(12B) -24 2 1 1 1 5883 37
H(13A) 1559 9 77 5025 33
H(13B) 1058 1754 3966 33
H(14) 4400 5705 4250 2 1
H(16) 4383 3252 2115 32
H(17) 2515 2973 901 42
H(18) 466 4193 1089 43
H(19) 284 5748 2445 36
H(20) 2159 6092 3627 28
H(30) -351 8463 2375 45























Theta range for data collection 
Limiting indices 
Reflections collected / unique 
Completeness to theta = 30.49 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2a(I)]
R indices (all data)
Absolute structure parameter 
Largest diff. peak and hole







P 2i 2i 2i
a = 9.63500(10) A a = 90° 
b = 12.01400(10) A j3 = 90° 
c = 18.9670(2) A y = 90°
2195.52(4) A3 
4,1.366 mg/m3 
0.279 mm 1 
952
0.38 x 0.30 x 0.25 mm 
4.00 to 30.49°
-13<=h<=13, -17<=k<=17, -27<=1<=27 
39701 / 6643 [R(int) = 0.0476]
99.6%
0.9335 and 0.9014 
Full-matrix least-squares on F2 
6643/0/276 
1.031
Rl = 0.0314, wR2 = 0.0744 
Rl = 0.0361, wR2 = 0.0768 
-0.01(4)
0.262 and -0.356 e.A3
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Table 2. Atomic coordinates (* 104) and equivalent isotropic displacement 
parameters (A2 x 103) for (4S,5S)-251. U(eq) is defined as one third of the trace 
of the orthogonalized Uij tensor.
Atom X y z U(eq)
S(l) 5119(1) -552(1) 9158(1) 20(1)
S(2) 4400(1) -2178(1) 10551(1) 27(1)
0(1) 6439(1) -583(1) 9507(1) 26(1)
0(2) 5090(1) -166(1) 8442(1) 24(1)
0(3) 2443(1) -4956(1) 8758(1) 33(1)
0(4) 1311(1) -2268(1) 7484(1) 37(1)
0(5) 745(1) -3654(1) 6747(1) 35(1)
N(l) 4441(1) -1823(1) 9124(1) 20(1)
N(2) 2985(1) -3101(1) 9496(1) 26(1)
N(3) 1664(1) -4125(1) 7778(1) 24(1)
C(l) 3966(2) 242(1) 9668(1) 26(1)
0(2) 4447(2) 770(1) 10268(1) 32(1)
0(3) 3531(2) 1439(1) 10644(1) 43(1)
0(4) 2174(2) 1572(2) 10433(1) 50(1)
0(5) 1197(4) 2281(2) 10864(1) 85(1)
0(6) 1728(2) 1037(2) 9826(1) 58(1)
0(7) 2620(2) 372(2) 9438(1) 43(1)
0(8) 3931(1) -2385(1) 9720(1) 22(1)
0(9) 2613(1) -2964(1) 8759(1) 21(1)
0(10) 2265(1) -4093(1) 8444(1) 23(1)
0(11) 1253(2) -3245(1) 7355(1) 27(1)
C(12) 954(2) -4849(2) 6713(1) 36(1)
C(13) 1286(2) -5197(1) 7466(1) 32(1)
0(14) 3891(1) -2331(1) 8459(1) 20(1)
0(15) 4970(1) -3051(1) 8078(1) 21(1)
0(16) 5715(2) -3906(1) 8550(1) 26(1)
C(17) 6668(2) -4640(1) 8102(1) 32(1)
C(18) 7709(2) -3958(2) 7678(1) 36(1)
C(19) 6999(2) -3063(1) 7237(1) 32(1)
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Table 5. Anisotropic displacement parameters (A2 * 103) for (4S,5S)-251. The 
anisotropic displacement factor exponent takes the form: -2 n 2 [h2 a*2 U ll + 
... + 2 h k a* b* U12].
Atom U ll U22 U33 U23 U13 U12
S(l) 22(1) 18(1) 19(1) 1(1) -1(1) 0(1)
S(2) 27(1) 35(1) 18(1) 3(1) -1(1) -4(1)
0 (1) 23(1) 26(1) 29(1) 5(1) -4(1) -2(1)
0 (2) 32(1) 21(1) 20(1) 3(1) 1(1) 0(1)
0(3) 36(1) 26(1) 37(1) 8(1) -6(1) -2(1)
0(4) 48(1) 28(1) 36(1) 6(1) -12(1) -1(1)
0(5) 37(1) 42(1) 26(1) -1(1) -7(1) -3(1)
N (l) 24(1) 20(1) 17(1) 1(1) 2(1) -3(1)
N(2) 24(1) 34(1) 19(1) 6(1) 1(1) -8(1)
N(3) 20(1) 23(1) 28(1) -2(1) -2(1) 1(1)
C(l) 33(1) 23(1) 21(1) 1(1) 2(1) 7(1)
0 (2) 45(1) 25(1) 26(1) -3(1) 1(1) 1(1)
0(3) 74(1) 28(1) 28(1) -3(1) 8(1) 11(1)
, 0(4) 78(1) 43(1) 30(1) 5(1) 11(1) 35(1)
0(5) 125(2) 89(2) 41(1) 4(1) 17(1) 79(2)
0 (6) 51(1) 86(2) 37(1) -3(1) 0(1) 42(1)
0(7) 37(1) 62(1) 29(1) -9(1) -4(1) 21(1)
0 (8) 20(1) 24(1) 21(1) 4(1) 2(1) 1(1)
0(9) 19(1) 26(1) 19(1) 2(1) 1(1) -2(1)
0 (10) 18(1) 26(1) 26(1) 1(1) 1(1) -2(1)
C (ll) 24(1) 33(1) 25(1) 3(1) -2(1) -1(1)
0 (12) 30(1) 44(1) 35(1) -14(1) -1(1) 3(1)
C(13) 30(1) 27(1) 40(1) -10(1) -6(1) 3(1)
0(14) 20(1) 22(1) 18(1) 1(1) -1(1) -2(1)
0(15) 20(1) 23(1) 19(1) -1(1) 1(1) -2(1)
0(16) 25(1) 30(1) 23(1) 1(1) -1(1) 4(1)
C(17) 30(1) 35(1) 31(1) -3(1) -2(1) 11(1)
C(18) 23(1) 49(1) 36(1) -14(1) 3(1) 4(1)
C(19) 30(1) 34(1) 31(1) -9(1) 13(1) -8(1)
C(20) 27(1) 25(1) 27(1) -4(1) 9(1) -5(1)
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Table 6. Hydrogen coordinates (* 104) and isotropic displacement 
parameters (A2 * 103) for (4S,5S)-251.
Atom X y z U(eq)
H(2) 5379 677 10420 39
H(3) 3849 1813 11055 52
H(5A) 1365 2150 11367 127
H(5B) 236 2084 10750 127
H(5C) 1355 3068 10756 127
H(6) 795 1128 9674 69
H (7) 2308 12 9021 51
H(9) 1778 -2472 8726 26
H(12A) 1732 -5034 6393 44
H(12B) 105 -5228 6543 44
H(13A) 468 -5527 7703 39
H(13B) 2068 -5731 7483 39
H(14) 3567 -1728 8135 24
H(15) 4464 -3481 7707 25
H(16A) 6269 -3513 8912 31
H(16B) 5021 -4375 8794 31
H(17A) 7177 -5160 8414 38
H(17B) 6096 -5089 7774 38
H(18A) 8375 -3602 8005 43
H(18B) 8237 -4460 7363 43
H(19A) 6441 -3419 6862 38
H(19B) 7711 -2590 7010 38
H(20A) 6624 -1938 8051 32
H(20B) 5582 -1779 7401 32




(lR*,2R*)-Carbonic acid l-benzoyl-2-phenyl-2-(toluene-4- 













Unit cell dimensions a = 25.3750(2) A a = 90°
Volume
b = 10.34100 A [3 = 111.2770° 
c = 18.0450(2) A y  = 90° 
4412.30(7) A3
Z, Calculated density 8,1.365 mg/m3
Absorption coefficient 0.188 mm-1
F(000) 1904
Crystal size 0.45 x 0.35 x 0.35 mm
Theta range for data collection 3.78 to 27.47°
Limiting indices -32<=h<=32, -13<=k<=13, -23<=1<=23
Reflections collected / unique 35865 / 5011 [R(int) = 0.0334]
Completeness to theta = 27.47 99.2%
Max. and min. transmission 0.9371 and 0.9202
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 5011/0/294
Goodness-of-fit on F2 1.030
Final R indices [I>2cr(I)] Rl= 0.0329, wR2 = 0.0862
R indices (all data) Rl = 0.0352, wR2 = 0.0879
Largest diff. peak and hole 0.382 and -0.501 e.A*3
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Table 2. Atomic coordinates (* 104) and equivalent isotropic
o
displacement parameters (A2 * 103) for anti-284. U(eq) is defined as one third 
of the trace of the orthogonalized Uij tensor.
Atom X y z U(eq)
S 5032(1) 2117(1) 221(1) 19(1)
0(1) 4944(1) 3276(1) 592(1) 26(1)
0(2) 4567(1) 1230(1) -112(1) 25(1)
0(3) 6461(1) -278(1) 1483(1) 21(1)
0(4) 6781(1) -1289(1) 614(1) 28(1)
0(5) 6509(1) -2354(1) 1509(1) 28(1)
0(6) 7483(1) 822(1) 1964(1) 30(1)
N(l) 5517(1) 1276(1) 877(1) 20(1)
C(l) 5291(1) 2563(1) -527(1) 20(1)
0(2) 5366(1) 3862(1) -652(1) 25(1)
0(3) 5561(1) 4223(1) -1249(1) 28(1)
0(4) 5688(1) 3298(1) -1719(1) 27(1)
0(5) 5902(1) 3702(2) -2361(1) 37(1)
0(6) 5618(1) 1995(1) -1575(1) 29(1)
0(7) 5419(1) 1615(1) -987(1) 26(1)
0(8) 6081(1) 1848(1) 1286(1) 19(1)
0(9) 6195(1) 2101(1) 2163(1) 21(1)
0(10) 5851(1) 1590(1) 2541(1) 28(1)
C(ll) 5965(1) 1853(1) 3342(1) 35(1)
C(12) 6423(1) 2615(1) 3771(1) 34(1)
0(13) 6763(1) 3137(1) 3398(1) 33(1)
0(14) 6646(1) 2894(1) 2594(1) 27(1)
0(15) 6509(1) 933(1) 1129(1) 19(1)
0(16) 6603(1) -1317(1) 1145(1) 21(1)
C(17) 6618(1) -3573(1) 1198(1) 39(1)
C(18) 7123(1) 1411(1) 1443(1) 21(1)
C(19) 7252(1) 2609(1) 1079(1) 21(1)
C(20) 7729(1) 3324(1) 1527(1) 26(1)
C(21) 7875(1) 4429(1) 1213(1) 31(1)
C(22) 7556(1) 4819(1) 444(1) 29(1)
C(23) 7081(1) 4119(1) -4(1) 28(1)
0(24) 6925(1) 3020(1) 312(1) 24(1)
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Table 5. Anisotropic displacement parameters (A2 * 103) for anti-284. 
The anisotropic displacement factor exponent takes the form: -2 n 2 [h2 a*2 
U ll + ... + 2 h k a *  b* U12].
Atom U ll U22 U33 U23 U13 U12
S 19(1) 15(1) 23(1) 0(1) 7(1) 2(1)
0 (1) 33(1) 18(1) 31(1) -1(1) 17(1) 3(1)
0 (2) 18(1) 21(1) 33(1) -1(1) 6(1) -1(1)
0(3) 26(1) 17(1) 20(1) 1(1) 11(1) 2(1)
0(4) 33(1) 29(1) 28(1) -2(1) 18(1) 1(1)
0(5) 42(1) 19(1) 25(1) 2(1) 16(1) 5(1)
0 (6) 25(1) 31(1) 29(1) 5(1) 3(1) 2(1)
N(l) 20(1) 15(1) 23(1) 1(1) 5(1) -1(1)
C(l) 20(1) 20(1) 20(1) 0(1) 6(1) 2(1)
0 (2) 30(1) 20(1) 29(1) 1(1) 13(1) 4(1)
0(3) 31(1) 24(1) 32(1) 5(1) 14(1) 2(1)
0(4) 22(1) 36(1) 22(1) 2(1) 7(1) 2(1)
0(5) 34(1) 51(1) 30(1) 3(1) 16(1) 0(1)
0 (6) 31(1) 33(1) 26(1) -8(1) 12(1) 1(1)
0(7) 30(1) 21(1) 27(1) -4(1) 10(1) 0(1)
0 (8) 18(1) 17(1) 20(1) 1(1) 7(1) -1(1)
0(9) 23(1) 19(1) 21(1) 1(1) 9(1) 5(1)
0 (10) 31(1) 28(1) 28(1) 1(1) 14(1) -1(1)
C(ll) 47(1) 34(1) 32(1) 5(1) 25(1) 4(1)
0 (12) 49(1) 34(1) 21(1) -1(1) 14(1) 13(1)
0(13) 33(1) 35(1) 27(1) -10(1) 8(1) 2(1)
0(14) 28(1) 28(1) 26(1) -6(1) 12(1) -2(1)
0(15) 22(1) 19(1) 18(1) 2(1) 8(1) 0(1)
0(16) 20(1) 22(1) 19(1) -1(1) 6(1) 2(1)
C(17) 64(1) 21(1) 36(1) -1(1) 23(1) 9(1)
C(18) 22(1) 24(1) 19(1) -2(1) 8(1) 1(1)
0(19) 20(1) 25(1) 22(1) -2(1) 10(1) 0(1)
C(20) 22(1) 32(1) 24(1) -2(1) 7(1) -2(1)
C(21) 27(1) 32(1) 35(1) -6(1) 12(1) -9(1)
C(22) 32(1) 28(1) 35(1) 0(1) 20(1) -4(1)
C(23) 30(1) 32(1) 25(1) 4(1) 13(1) -1(1)
0(24) 21(1) 29(1) 22(1) -1(1) 8(1) -3(1)
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Table 6. Hydrogen coordinates (x 104) and isotropic displacement 
parameters (A2 * 103) for anti-284.
Atom X y z U(eq)
H(l) 5514(6) 498(17) 724(9) 28(4)
H(2) 5285 4501 -330 30
H(3) 5609 5114 -1337 34
H(5A) 5738 4541 -2577 56
H(5B) 5792 3054 -2786 56
H(5C) 6315 3772 -2136 56
H(6) 5708 1354 -1887 35
H (7) 5370 724 -899 31
H(8) 6093 2697 1027 22
H(10) 5539 1059 2252 34
H(ll) 5727 1507 3595 42
H(12) 6503 2778 4319 41
H(13) 7077 3662 3690 39
H(14) 6876 3272 2337 32
H(15) 6390 803 542 23
H(17A) 6538 -4285 1500 58
H(17B) 7014 -3609 1246 58
H(17C) 6373 -3650 637 58
H(20) 7954 3051 2049 32
H(21) 8195 4922 1524 37
H(22) 7663 5565 225 35
H(23) 6862 4390 -528 34




NOESY spectrum of (Z)-2-tert-butoxycarbonylamino-3-[3- 













Supply and Synthesis of Ligands
2,2'-Bipyridine 157: purchased from Aldrich
(3ajR,8aS)-8,8a-Dihydro-2-(2-((3aR/8aS)-8,8a-dihydro-3aH-indeno[l,2- 
d]oxazol-2-yl)propan-2-yl)-3aH-indeno[l,2-d]oxazole,153 (4R,5S)-172: 
provided by V. J.-D. Piccio
(3aR,8aS)-8,8a-Dihydro-2-(l-((3aP/8aS)-8,8a-dihydro-3aH-indeno[l,2- 
d]oxazol-2-yl)cyclopropyl)-3aH-indeno[l/2-d]oxazole/154(4P,5S)-152: provided 




dihydrooxazole, (R,R)-242: purchased from Aldrich
(S)-4-terf-Butyl-2-(l-((S)-4-terf-butyl-4,5-dihydrooxazol-2-yl)cyclopropyl)-4,5- 






Et20 , RT, 20 h SOCI2 f ^ \  / ^ \
C 02> -78 °C CHCl3






2,6-Bis((S)-4-benzyl-4,5-dihydrooxazol-2-yl)pyridine,135 (S,S)-178: provided 
by V. J.-D. Piccio
2/6-Bis((S)-4-ter£-butyl-4/5-dihydrooxazol-2-yl)pyridine/155 (S,S)-180: provided 
by V. J.-D. Piccio
Me y r -M e  
^  MeMe Me
2,6-Bis((4R/5P)-4/5-dihydro-4-methyl-5-phenyloxazol-2-yl)pyridine, (4R,5S)- 
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